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Abstract 
AP-2 transcription factors are crucial regulators of embryonic development and also 
play important roles in human neoplasia.  Over-expression of AP-2α and AP-2γ in 
primary breast cancer (BC) correlates with expression of two major breast markers, 
ERBB2 and oestrogen receptor.  High AP-2γ expression is associated with reduced 
survival in BC patients, including those treated with hormone therapy.  Our aim is to 
define the pathways regulated by AP-2 factors in breast epithelial cells. Data from 
AP-2γ depleted MCF-7 cells suggested a role in cell cycle control.  Here, regulation 
by AP-2α and AP-2γ in additional breast cancer cell lines with differing genetic 
background is investigated. Cell cycle analysis of synchronized T47D cells, which 
express both AP-2 isoforms but mutant p53, showed a reduction in G1 but increased 
S and G2/M-phase populations when AP-2α and AP-2γ were silenced either 
independently or together. Despite the lack of growth arrest, p21cip protein levels 
increased following AP-2 silencing. ChIP analysis showed AP-2α and AP-2γ binding 
at the p21cip/CDKN1A promoter.   In addition, cyclin D3 protein levels increased 
following AP-2 silencing and ChIP analysis showed AP-2α and AP-2γ binding to its 
promoter. Luciferase reporter constructs carrying CCND3 promoter sequences were 
repressed when co-transfected with AP-2α or AP-2γ expression constructs. These 
findings demonstrate the importance of AP-2 factors in the control of cell cycle 
regulation but illustrate cell-type differences in their mode of action. Further work 
focused on MCF10A immortalised breast epithelial cells, which express both AP-2 
isoforms and wild-type p53. AP-2 silenced MCF10A cells adopted a more rounded 
phenotype suggestive of changes in cell adhesion which was also supported by 
microarray analysis of their gene expression profile. 
 
KIAA1324, a protein of unknown function with features of a membrane-bound 
growth factor receptor, was found to be significantly down-regulated following AP-
2γ silencing in MCF-7 cells.  Functional assays using i) inducible knock down of 
KIAA1324 in MCF-7 cells, and ii) stable KIAA1324 overexpression in MCF10A 
investigated if altering KIAA1324 expression level could affect cell growth. 
KIAA1324 did not affect breast epithelial cell proliferation on plastic but may 
contribute to the ability of MCF-7 cells to display anchorage-independent growth.  
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1. INTRODUCTION 
The Activator Protein-2 (AP-2) family of transcription factors are crucial regulators 
of embryonic development and have been shown to play an important role in human 
neoplasia.  Many studies have contributed to understanding how AP-2 proteins are 
able to control both transcriptional activation and repression of their target genes.  
The roles of AP-2α and AP-2γ have been best characterized in breast cancer.  Over-
expression of AP-2α and AP-2γ in primary breast cancer correlated with the 
expression of two major breast markers, ERBB2 and the oestrogen receptor ERα.  
High AP-2γ expression is associated with reduced survival in breast cancer patients 
and therefore, represents a marker of poor prognosis in breast cancer.  In contrast, 
expression of AP-2α was lost in invasive breast carcinomas.  Research presented 
herein will focus on the roles of both AP-2α and AP-2γ transcription factors in the 
growth of breast cancer cells. 
 
1.1. The AP-2 family of transcription factors 
The Activator protein-2 (AP-2) was first identified by its ability to bind enhancer 
regions of simian virus 40 (SV40) and the human metallothionein IIA gene and 
stimulate RNA synthesis from these promoters in vitro (Mitchell et al., 1987).  The 
AP-2 transcription factor family consists of five members identified as AP-2α, AP-
2β, AP-2γ, AP-2δ and AP-2ε in humans and mice (Bosher et al., 1995; Cheng et al., 
2002; Feng and Williams, 2003; Moser et al., 1995; Williams et al., 1988; Zhao et 
al., 2001).  AP-2 transcription factors share a multidomain structure composed of a 
highly conserved helix-span-helix dimerization domain at the carboxyl terminus 
which allows the proteins to form homo- and heterodimers, preceded by a central 
basic domain which mediates DNA-binding; and a less conserved proline and 
glutamine rich transactivation domain at the amino-terminus (Eckert et al., 2005; 
Mohibullah et al., 1999).  Within this region there are a number of highly conserved 
residues and a PY (XPPXY) motif in AP-2α, AP-2β and AP-2γ but not AP-2δ, that 
are critical for modulation of AP-2 activity.  This suggests that AP-2δ might 
transactivate genes by a different mechanism.  All AP-2 factors, except for AP-2 δ 
are encoded by seven exons and share a characteristic domain structure (Hilger-
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Eversheim et al., 2000).  However, recently in our lab we identified alternative first 
exons for AP-2α (Dr Chiara Berlato, personal communication).  These closely 
related AP-2 family members are transcribed from different genes and each factor 
has a molecular weight of approximately 50 kDa.  A schematic diagram of AP-2 
protein structure is outlined in Figure 1, and the chromosomal locations and 
accession numbers for AP-2 transcription factors in humans are given in Table 1. 
 
 
 
Figure 1 A representation of AP-2 protein structure.  AP-2 proteins share highly conserved 
approximately 80 amino acides C-terminal helix-span-helix motif (blue) which is responsible for 
dimerisation of the proteins and mediates DNA binding together with the basic domains (green).  The 
less conserved proline-and glutamine (P/Q) rich transactivation domain (orange) is located at the N-
terminus.   
 
AP-2 Family 
Member 
Gene Names Chromosomal 
Locations 
Accession 
Numbers 
AP-2α TFAP2A 6p24 NP_003211 
AP-2β TFAP2B 6p12 NP_003212 
AP-2γ TFAP2C 20q13.2 NP_003213 
AP-2δ TFAP2D 6p12.1 NP_758438 
AP-2ε TFAP2E 1p34.3 NP_848643 
 
Table 1.  Gene names, chromosomal locations and accession numbers of AP-2 transcription 
factors in humans.  Table adapted from (Eckert et al., 2005). 
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AP-2 family members are remarkably conserved throughout evolution.  There are 
homologues in Chicken (Gallus gallus), Frog (Xenopus laevis), Fruit Fly 
(Drosophila melanogaster), Zebrafish (Danio rerio) and even in the invertebrate 
Caenorhabditis elegans (Bauer et al., 1998; Cheng et al., 2002; Li and Cornell, 
2007; Li et al., 2008; Shen et al., 1997; Zhang et al., 2006).  Eckert and colleagues 
aligned the amino acid sequences among these species to generate a phylogenetic 
tree and revealed that the vertebrate AP-2 proteins are grouped together and divided 
into five groups according to their isoforms (Eckert et al., 2005).  As illustrated in 
the phylogenetic tree (see Figure 2), AP-2δ genes are separated from the rest of the 
family which suggests that this gene might have evolved separately.  Given that no 
AP-2 genes have been identified in yeast, and that the AP-2 proteins of C. elegans 
and D. melanogaster formed an outgroup to other vertebrate and protochordate AP-2 
transcription factors, it has been proposed that AP-2 proteins originated at this stage 
in evolution and subsequently expanded to give rise to the five members identified in 
vertebrates. 
 
1.2. Localisation and Function of AP-2 Transcription Factors 
AP-2 transcription factors are localised predominantly in the nucleus where they bind 
to target sequences and regulate transcription of target genes.  AP-2 homo- and 
heterodimers recognise and bind to consensus palindromic sequences 5’-GCCN3-
4GGC-3’ within the promoters and enhancers of their target genes resulting in both 
activating and repressing stimuli.  Target genes containing AP-2 binding sites in their 
promoter sequences are involved in biological processes such as cell growth and 
differentiation, for example, the cell cycle inhibitor p21cip/CDKN1A, oestrogen 
receptor-α (ERα), and ERBB2 (or HER2) (Bosher et al., 1995; McPherson et al., 
1997; Zeng et al., 1997).   
 
Several studies have shown that the activity of AP-2 proteins can be controlled at 
multiple levels such as their transactivation potential; DNA binding; subcellular 
localisation and degradation (Aqeilan et al., 2004; Mazina et al., 2001; Nyormoi et 
al., 2001; Pellikainen et al., 2004).  For example, the WW domain protein encoded 
by the WWOX gene has been reported to interact with the PY motif of AP-2α and 
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AP-2γ and that interaction caused AP-2 to localise to the cytoplasm and suppressed 
the transcriptional activity of AP-2 (Aqeilan et al., 2004).  Another study has 
demonstrated that AP-2α can be cleaved by caspases, destroying its DNA binding 
activity and leading to subsequent degradation by the proteasome (Nyormoi et al., 
2001).  Since the nature of AP-2 as transcription factors is to stimulate and repress 
their target genes, these studies suggest that the activity of AP-2 is also regulated by 
other mechanisms in order to determine the fate of the cells. 
 
AP-2 transcription factors also play an important role in embryogenesis.  Among the 
five isoforms, AP-2α, AP-2β and AP-2γ are the best characterised genes in 
embryonic development and are expressed in distinct but overlapping patterns.  The 
roles of AP-2 transcription factors, in particular, AP-2α and AP-2γ, in 
embryogenesis, the mechanism for transcription regulation by AP-2 and their 
involvement in tumourigenesis will be described in more detail in the following 
sections. 
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Figure 2. A phylogenetic tree of the AP-2 family.  This phylogentetic tree is based on amino acid 
sequence alignments. The scale bar indicates the number of residue changes and asterisks indicate 
where predicted proteins have been included.  Diagram taken from (Eckert et al., 2005). 
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1.3. Gene Transcription 
In eukaryotic cells, the expression of protein-coding genes is regulated at several 
steps: transcription initiation and elongation, mRNA processing, transport, 
translation and stability.  Gene transcription is performed by RNA polymerase II, and 
genes that are transcribed by RNA polymerase II typically have two types of cis-
acting transcriptional regulatory DNA elements: 1) a promoter, which includes a core 
promoter and proximal regulatory elements; and 2) distal regulatory elements 
including enhancers (increase transcription), silencers (repress transcription), 
insulator (prevent genes from being affected by the transcriptional activity of 
neighbouring genes) and locus control regions (regulate the entire locus or gene 
cluster).  The cis-acting transcriptional regulatory elements contain recognition sites 
for trans-acting DNA-binding transcription factors which can either enhance or 
repress transcription.  The typical gene transcriptional regulatory elements are shown 
in Figure 3. 
 
Factors that are involved in gene transcription by RNA polymerase II can be 
classified into three groups: 1) general transcription factors (GTFs) including RNA 
polymerase II and six other protein complexes known as TFIIA, TFIIB, TFIID, 
TFIIE TFIIF and TFIIH; 2) promoter-specific activator proteins, known as activators; 
and 3) coactivators, which lack intrinsic sequence-specific DNA binding themselves 
but function as a link between activators and GTFs.  GTFs assemble on the core 
promoter in a specific order to form a preinitiation complex (PIC) and direct RNA 
polymerase II to the transcription start site (TSS).  Activators can bind to upstream 
regulatory elements to facilitate formation of PIC (Maston et al., 2006).  All of these 
constitute the transcriptional machinery and are summarised in a schematic diagram 
in Figure 4. 
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Figure 3.  A schematic diagram of a gene transcriptional regulatory region.  The promoter, 
comprising a core promoter and proximal promoter elements, typically 100 bp apart from each other.  
Distal regulatory elements located up to 1 Mb upstream of the promoter which can include enhancers, 
silencers, insulators and locus control regions.  These distal elements may contact the promoter by 
looping out the intervening DNA.  Diagram taken from (Maston et al., 2006). 
 
 
 
 
Figure 4.  The eukaryotic transcriptional machinery.  General transcription factors (GTFs) 
including RNA polymerase II and six auxiliary components, activators and coactivators assembled on 
the core promoter that contains a TATA box to form a preinitiation complex (PIC) and direct RNA 
polymerase II to the TSS.  Activators consist of DNA-binding domain (DBD) and activation domain 
(AD) required for transcription stimulation. Diagram taken from (Maston et al., 2006). 
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Genomic DNA is closely associated with histones, a special class of proteins that 
form tightly packed chromosomes.  There are five major types: H1, and the core 
histones: H2A, H2B H3 and H4.  All these histones carry positively charged amino 
acids which attract and hold the negative charges on the phosphates of DNA.  
Approximately 147 bp of DNA is wrapped around an octamer of the core histones 
forming a nucleosome.  The linker histone (H1) and other nonhistone chromosomal 
proteins bind directly to the nucleosomes and join the adjacent nucleosomes together 
to facilitate higher organisation and further compaction of the chromatin fibre within 
the nucleus.  The complex of DNA and histones is termed chromatin.  The packaging 
of the DNA in this manner results in a stable chromatin structure, where DNA is 
inaccessible to the transcriptional machinery.  There are two types of chromatin: 
transcriptionally active euchromatin and transcriptionally inactive heterochromatin.  
In order for a gene to be transcribed, transcription factors, activators and RNA 
polymerase must bind to DNA, therefore the chromatin structure must change to 
allow DNA to become more accessible to the transcriptional machinery.  There are 
multiple mechanisms that affect chromatin structure including histone modification 
and chromatin remodelling.   
 
1.3.1. Histone Modifications 
Many histone modifications occur at the positively charged histone tails (N-terminal 
domains) where they interact with the negatively charged phosphate groups on the 
DNA.  The most studied histone modifications are acetylation and methylation of 
lysine residues.   
 
Acetylation is a process which results in the addition of an acetyl group to histone 
proteins at multiple lysine residues by histone acetyltransferase (HAT) enzyme.  The 
acetyl groups destabilize the nucleosome structure, perhaps by neutralizing the 
positive charges on the histone tail, thereby reducing the affinity between histones 
and DNA (“opening the chromatin”), giving RNA polymerase and transcription 
factors easier access to the promoter region and thus facilitating gene transcription.  
Histone deacetylatases (HDACs) can reverse this process and their activity is 
therefore associated with transcriptional repression (Chan and La Thangue, 2001; 
Luo and Dean, 1999).   
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Methylation refers to an addition of a methyl group to lysine or arginine residues of a 
histone protein.  Methylation can occur several times on one lysine, thus termed as 
mono-, di- or trimethylation.  Methylation on different residues may have different 
outcomes, for example, acetylation and methylation of lysine 4 of histone 3 (H3K4ac 
and H3K4me) and acetylation of lysine 9 in histone 3 (H3K9ac) tend to be associated 
with transcriptional activation.  In contrast, methylation of lysines 9 and 27 in histone 
3 (H3K9me3 and H3K27me), which occurs at the centromere of hererochromatin, is 
associated with gene silencing (Berger, 2007).  A study has shown that the a histone 
lysine methyltransferase known as Ash21, interacts exclusively with AP-2δ, which 
leads to H3K4 trimethylation resulting in gene activation (Tan et al., 2008). 
 
In addition, another mechanism for transcriptional repression is DNA methylation.  
This occurs on cytosine bases adjacent to guanine nucleotides on the same strand 
(CpG), when methyl groups are added to yield 5-methylcytosine.  DNA regions with 
many CpG sequences are called CpG islands and these are commonly found over 
gene TSS (Nan et al., 1998a).  Evidence has shown that a protein called MeCP2 
which specifically binds to methylated CpG, can silence gene transcription by 
recruiting histone deacetylases.  MeCP2 may also repress transcription by facilitating 
the methylation of lysine 9 of histone 3 (Batsche et al., 1998; Fuks et al., 2003; Nan 
et al., 1998a; Nan et al., 1998b). 
 
1.3.2. Chromatin Remodelling 
Chromatin remodelling complexes have the ability to alter chromatin structure 
independent of histone acetylation.  They are ATP-dependent and utilise ATP energy 
to alter nucleosome structure and position.  These complexes bind directly to DNA 
and nucleosomes at particular sites with high affinity and disrupt nucleosome 
conformation.  Other models of chromatin remodelling include 1) nucleosome 
sliding, which refers to the sliding of nucleosomes along the DNA; 2) 
phosphorylation of chromatin remodelling complex subunits by cell cycle regulators, 
which regulate the activity and function of the chromatin remodelling complexes; 
and 3) through recruitment by gene specific activators to promoters.  The 
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consequence of chromatin remodelling allows transcription factors to bind to 
promoters and initiate transcription (Chioda and Becker, 2010; Vignali et al., 2000) 
 
1.4. The Role of AP-2 Factors as Transcription Activators 
Transcription factors tightly regulate gene expression in response to intra- and 
extracellular stimuli and play a central role in determining cell fate by controlling the 
pattern of gene expression.  AP-2, like other DNA binding transcription factors, 
binds within promoter or enhancer regions of their target genes and recruit cofactors 
to alter the localised chromatin structure, gain access to the transcriptional machinery 
and ultimately effect changes in their target genes at the transcriptional level.  AP-2 
proteins were initially considered as weak activators of transcription when analysed 
in reporter gene assays.  However, it has been shown that AP-2 proteins can be 
coactivated by the recruitment of the CREB-binding protein (CBP) and that 
recruitment is mediated by members of the CITED (CBP/p300 interacting 
transactivators with ED-rich termini), family of adaptor proteins (Bamforth et al., 
2001; Braganca et al., 2003; Braganca et al., 2002).  CBP and p300 belong to a 
protein family which is ubiquitously expressed and was first identified by their 
interaction with CREB (cyclic adenosine monophosphate response element binding 
protein) and adenoviral E1A protein respectively (Lundblad et al., 1995).  They 
function as transcriptional coactivators and have intrinsic HAT activity which can 
acetylate the histone N-terminal tails to “open” chromatin (Kalkhoven, 2004).  CBP 
and p300 are key regulators of gene expression by acting as protein bridges 
connecting different sequence-specific transcription factors including AP-2 family 
members to the general transcription machinery of their target genes.   
 
Unlike many DNA binding transcription factors that bind to p300/CBP directly, AP-
2 factors require the CITED adaptor protein.  Members of this family include 
CITED1, CITED2 and CITED4.  The function of CITED proteins is to act as 
transcription coactivators and, in this example, bring CBP/p300 to the AP-2 
complex.  AP-2 transcription factors were first linked to CITED proteins when 
CITED2 was identified in a screen for AP-2 interacting proteins.  The functional 
importance of the interaction was shown by comparing the activity of an AP-2 
reporter construct after transfection into embryonic fibroblasts derived from CITED2 
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knock out mice.  The activation of the reporter was minimal in CITED2-/- cells, but 
addition of exogenous CITED2 restored reporter activity, demonstrating that 
CITED2 is essential for full activation by AP-2.  In addition, similarities in 
phenotype between knockout mice for CITED2,p300 or AP-2α (described later) 
strongly suggested that the interaction between these factors is biologically 
significant and they act on a common subset of target genes (Bamforth et al., 2001).  
The physical interaction between CBP/p300, AP-2α and CITED involves the first 
cysteine-histidine-rich (CH1) region of p300/CBP, the C-terminus of CITED 
proteins and the first helix of the helix-span-helix motif of AP-2 transcription factors.  
AP-2α has been shown to interact with certain p300 domains independently of 
CITED2, however, full transcriptional activation by AP-2α-CBP/p300 complexes 
can only be achieved in the presence of CITED2 and when the HAT activity of p300 
is intact (Braganca et al., 2003; Chan and La Thangue, 2001).  Additionally, another 
member of the CITED family, CITED4, was also shown to physically interact with 
all AP-2 proteins and function as a coactivator for AP-2 with lower efficiency 
compared to CITED2 (Braganca et al., 2002).  A schematic diagram demonstrating 
the complex of AP-2, p300/CBP and CITED 2 proteins as transcription activator is 
shown in Figure 5. 
 
AP-2 factors have also been widely reported to interact with other DNA binding 
factors and alter transcription rates.  Many of these studies appear in the literature as 
single publications and are difficult to evaluate, however, there is a significant 
literature describing associations between AP-2 factors and specificity protein 1 
(Sp1).  Similar to AP-2, Sp1 also binds to GC-rich sequences but through its zinc 
finger DNA binding domain.  Studies have demonstrated that AP-2 and Sp1 form a 
protein-protein complex and bind directly to the promoters of their target genes and 
activate gene transcription (Mitchell et al., 2006; Pena et al., 1999).  Another study 
showed that pRb and c-Myc interact with AP-2 transcription factor to form a 
complex in order to activate E-cadherin by binding to the E-cadherin promoter in 
epithelial cells (Batsche et al., 1998).   
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Figure 5.  A schematic diagram showing the AP-2-p300/CBP/CITED2 complex.  AP-2 
transcription factors use CITED as an adaptor to recruit p300/CBP to activate gene transcription. 
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1.5. The Role of AP-2 Factors as Transcription Repressors 
As well as activating gene transcription, AP-2 factors have also been reported to act 
as repressors of transcription, particularly during cellular differentiation but the 
molecular mechanism behind this is not clear.  Sumoylation is one of the 
mechanisms of post-translational protein modification.  Similar to ubiquitination, 
sumoylation uses a small polypeptide, small ubiquitin-like modifier (SUMO), to alter 
the structure of its target proteins and rapidly change their function or subcellular 
localisation.  In sumoylation, SUMO is covalently conjugated to lysine residues of 
the target proteins by the E2-conjugating enzyme, UBC9 (Verger et al., 2003).  Due 
to the fact that sumoylation is able to alter the function of a protein, it has been, 
suggested that SUMO is a negative regulator of gene transcription.  Indeed, work in 
our lab has shown that the SUMO-specific UBC9 was capable of interacting with 
AP-2α, AP-2β and AP-2γ.  The conjugation of SUMO was shown to occur at the 
conserved lysine residue (lys 10) in the N-terminal region of AP-2γ and resulted in 
reduced transcription activation potential when analysed in reporter gene assays 
(Eloranta and Hurst, 2002).  This study demonstrated for the first time that AP-2 
transcription activity can be repressed by sumoylation, however it is not clear this 
was true repression or just reduced activation activity.  In addition, CBP and p300 
can also be SUMO-modified allowing them to recruit HDAC, leading to 
transcriptional repression (Girdwood et al., 2003).  Figure 6A summarises the known 
events which may contribute to gene transcription repression by AP-2 factors, with a 
dotted arrow to show that sumoylated AP-2 may recruit co-repressors as shown for 
CBP.   
 
Another study suggested that AP-2 represses liver-specific gene expression, hence its 
expression is very low liver cells (Ren and Liao, 2001).  These authors identified two 
AP-2 binding sites within the promoter of serum amyloid A (SAA, one of the major 
acute-phase proteins induced by cytokines during inflammation and expressed 
exclusively in liver hepatocytes).  It was shown that binding of AP-2 to both regions 
of the SAA promoter resulted in inhibition of SAA promoter activity, and mutation 
of these sites de-repressed SAA promoter activity.  The proximal binding site 
overlaps with the binding site of nuclear factor-kB (NFkB) (a key transcription factor 
in the induction of genes involved in inflammatory responses, which in this case, 
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induce SAA) on the SAA promoter, and showed that AP-2 binds to this site with 
higher affinity.  AP-2 may mediate repression by antagonizing the function of NFkB.  
Furthermore, this study also demonstrated that stable expression of AP-2 exerted an 
inhibitory effect on other endogenous liver genes such as human complement 3, 
albumin and α-Fetoprotein expression at the transcriptional level.  This study 
suggested that AP-2 activity as a transcription repressor is tissue-specific. 
 
An early study investigated the transcriptional regulation of the AP-2α promoter and 
identified a cis-regulatory element composed of a consensus AP-2 binding site 
overlapping a basal transcription element (Imhof et al., 1999).  This study also 
identified two transcription factors, called BTEB-1 and AP-2rep, which can interact 
with the AP-2α protein in a mutually exclusive manner at the AP-2 site.  They found 
that AP-2α expression was positively regulated by BTEB-1 but negatively regulated 
by AP-2rep, which is a novel zinc finger protein.  Interaction with AP-2rep on AP-
2α promoter caused a significant transcriptional repression of AP-2α expression.  
This finding implies that AP-2α expression can be auto-regulated with other 
transcription factors binding to its promoter, which in turn, indirectly regulate its 
own target genes. 
 
Furthermore, a few studies have proposed that AP-2 mediates transcriptional 
repression via recruitment of a co-repressor on the promoters of its regulated genes.  
One study showed that both AP-2α and nucleophosmin (NPM) are targets of retinoic 
acid (RA) during cell differentiation, and are associated with down-regulation of 
certain RA-responsive genes that have AP-2 binding sites within their promoters (Liu 
et al., 2007).  During RA treatment, AP-2α recruits NPM to the promoters of these 
genes resulting in their down-regulation, while knockdown of NPM resulted in up-
regulation of these genes.  It was suggested that NPM acts as an AP-2α co-repressor 
and is required for chromatin remodeling.  In a separate study, Wu and Lee examined 
the cis-regulatory elements important for cell cycle control of the replication-
dependent hamster histone H3.2 gene, and identified an AP-2 binding site within the 
H3.2 promoter.  They discovered AP-2α and AP-2β could physically interact with 
the retinoblastoma protein (pRb) both in vitro and in vivo, and co-expression of 
either AP-2α or AP-2β with pRb expression plasmids resulted in repression of H3.2 
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promoter activity (Wu and Lee, 1998).  Later these authors focused on the CCAAT 
repeats within the hamster histone H3.2 promoter and found CCAAT displacement 
protein (CDP), which acts as a repressor of the H3.2 promoter, physically interacts 
with AP-2α and AP-2β (Wu and Lee, 2002).  H3.2 promoter activity was reduced 
significantly on co-transfection of AP-2β and CDP expression vectors compared to 
CDP alone.  They proposed AP-2 proteins may act as a bridge between pRB and 
CDP in mediating transcription repression.  A schematic diagram in Figure 6B shows 
the proposed role of AP-2 as transcription repressor and directly recruiting a co-
repressor. 
 
 
 
 
 
Figure 6.  A schematic diagram showing the SUMO modification of AP-2 and p300/CBP.  (A) 
Sumoylation of AP-2 and p300/CBP transcription factors reduces their activation potential and, in the 
case of p300/CBP recruits HDACs associated with  transcriptional repression. Corepressor complexes 
may also be recruited by sumoylated AP-2 factors to modulate their activity.  (B)  Corepressor may 
interact with AP-2 factors and modulate their activity. 
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Although it has been demonstrated by some authors that AP-2 can form a complex 
with Sp1 and bind to Sp1 binding sites on Sp1-dependent target genes to mediate 
gene transcription, other studies have proposed an opposite role for AP-2.  That is, 
AP-2 can mediate transcription repression either by 1) interacting with Sp1 and 
thereby repressing Sp1-mediated transcriptional activation; or 2) by competition with 
Sp1 transcription activator for a GC-rich promoter binding site (Chen et al., 1997; 
Liu et al., 2009; Xu et al., 2002).  The role of AP-2 in terms of transcription 
activation or repression via interaction with Sp1 is not yet clear.  A model of AP-2 as 
either transcription activator or repressor via interaction with Sp1 is summarised 
in Figure 7. 
 
 
 
 
 
 
 
Figure 7.  A schematic diagram shows three proposed models of AP-2 association with Sp1.  (A)  
AP-2 associates with Sp1 to form a transcriptional activator complex and transactivate their target 
genes by binding to Sp1 binding sites.  (B)  AP-2 forms a complex with Sp1 and inhibits its 
transactivation activity. (C)  AP-2 competes with Sp1 for Sp1 binding sites to inhibit Sp1-dependent 
gene transcription. 
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1.6. AP-2 and Development 
AP-2 family members are widely expressed during vertebrate embryogenesis, 
showing overlapping and distinct patterns of expression.  In particular, AP-2 proteins 
are expressed in neural crest, neural tube and epidermal structures which all develop 
from the primitive ectoderm during embryogenesis.   
 
1.6.1. AP-2α 
Two early studies examined the expression pattern of AP-2α in mouse 
embryogenesis and found that AP-2α is predominantly expressed between 8.5 and 
12.5 days of gestation, its major sites of expression occur in the neural tube, the 
migratory neural crest and their major derivatives including cranial and spinal 
sensory ganglia and facial mesenchyme (Chazaud et al., 1996; Mitchell et al., 1991).  
AP-2α knockout mice died perinatally with multiple defects in body wall closure, 
failure of cranial neural-tube closure and severe dismorphogenesis of skull, sensory 
organs, and defects in cranial ganglia development (Schorle et al., 1996).  AP-2α is 
important in regulating bone and cartilage development during embryogenesis since 
severe skeletal defects in the head and truck region, where bones were deformed or 
absent, were observed in the knockout mice (Zhang et al., 1996). Defects in skeletal 
myogenesis was also obsereved when the regulatory function of AP-2α is impaired 
(Mitchell and DiMario, 2010; Wenke and Bosserhoff, 2010).  Defects in eye 
formation were also observed in AP-2α knockout mice (Nottoli et al., 1998).  A 
recent study found that optic nerve morphogenesis was defective in AP-2α knockout 
mice.  These mice had eyes embedded inside the head with absent cornea and 
eyelids, defective lens induction and abnormalities in the optic cup (Bassett et al., 
2010).  Similarly, a study in lockjaw zebrafish, in which a truncated form of AP-2α 
lacking the DNA binding domain was overexpressed, displayed similar defects to the 
mice described above (Holzschuh et al., 2003; Knight et al., 2003).  Since AP-2α 
expression occurs within the neural crest lineage which is required for normal 
cardiac morphogenesis, AP-2α-deficient mice embryos showed severe cardiac 
outflow tract malformations (Brewer et al., 2002) similar to those seen in cited2-
deficient mice (Bamforth et al., 2001).   AP-2α, however, is not required for neural 
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crest cell migration, and instead might be involved in an interaction between neural 
crest and surrounding tissue to promote normal outflow tract morphogenesis.  AP-2α 
was also shown to be expressed in mammary glands of virgin and pregnant mice 
(Zhang et al., 2003).  Most recently, AP-2α was found to be associated with 
branchio-oculo-facial syndrome (BOFS), a rare dominant genetic disorder 
characterized by distinctive craniofacial, oral, ear, ocular, ectodermal and renal 
anomalies (Gestri et al., 2009; Milunsky et al., 2008; Stoetzel et al., 2009).  These 
studies identified that all these BOFS patients either had a deletion in chromosome 6, 
including the TFAP2A gene, or mutations within the DNA-binding domain.   
 
1.6.2. AP-2β 
AP-2β is essential for kidney development, and AP-2β-null mice die shortly after 
birth because of renal failure due to apoptosis of epithelial cells in collecting ducts 
and distal tubules (Moser et al., 2003; Moser et al., 1997).  AP-2β also plays a role in 
Char syndrome, an autosomal dominant disorder characterised by the heart defect, 
patent ductus arteriosus (PDA), plus facial dysmorphism and an abnormal fifth digit 
of the hand.  Mutations within the TFAP2B gene that affected DNA binding or 
activation function were found in patients suffering from Char syndrome (Satoda et 
al., 2000).   
 
1.6.3. AP-2γ 
AP-2γ expression is present in all cells of preimplantation embryos and later 
becomes restricted to the extra-embryonic lineages at the time of implantation.  A 
study conducted on AP-2γ-deficient mice showed these mice died at 7 to 9 days post 
coitum (d.p.c) due to failure of the cells derived from trophoectoderm, the first 
specialised cells which arise from the fertilised egg, and the ectoplacental cone to 
proliferate.  From chimera studies performed by injecting tfap2c-null embryonic 
stem cells into wild type blastocysts, it was observed that development of the embryo 
proper could be rescued to term by the presence of wild-type cells in the extra-
embryonic lineages.  This demonstrated that AP-2γ is required for the establishment 
and/or maintenance of the extra embryonic membrane for the subsequent normal 
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development of the placenta and therefore for survival of the mouse embryos 
(Auman et al., 2002).  Similar findings were observed in another study in which AP-
2γ knockout mice displayed severe growth retardation and died at days 7 to 9 of 
embryonic development, and AP-2γ mutant embryos were reduced in size and failed 
to gastrulate (Werling and Schorle, 2002).  Immunohistochemical analysis in this 
study showed that trophectodermal cells (which later give rise to extra embryonic 
tissues) derived from AP-2γ knockout mice failed to proliferate leading to a reduced 
number of giant cells and a failure of labyrinth layer formation.  This subsequently 
lead to failure of extra embryonic tissue development and the embryo suffered from 
malnutrition resulting in growth retardation and death.   
 
1.6.4. AP-2δ and AP-2ε 
AP-2δ and AP-2ε genes seem be more temporally and spatially restricted in their 
expression patterns.  AP-2δ is specially expressed in the central nervous system, 
retina, and the developing heart (Zhao et al., 2003b; Zhao et al., 2001).  AP-2ε is 
expressed in the developing olfactory bulb, neural tissue in the midbrain and 
hindbrain (Feng and Williams, 2003).  Compared to the other family members these 
expression patterns are distinct and non-overlapping.  This is perhaps reflective of 
the reduced sequence homology between AP-2δ and AP-2ε and the other members.  
 
1.7. Redundant Activities of AP-2 Factors 
As described above, AP-2α to AP-2γ family members play an important role during 
embryogenesis and it seems that they can all act redundantly in development.  For 
instance, both AP-2α and AP-2γ are co-expressed in extra-embryonic tissues, 
however, mutant AP-2γ knockout mice died at 8.5 days d.p.c due to abnormal 
placental function (Auman et al., 2002; Werling and Schorle, 2002), whereas mutant 
AP-2α knockout mice lived until shortly after birth (Schorle et al., 1996; Zhang et 
al., 1996).  Double mutant mice, with both AP-2α and AP-2γ knockout died at 3.5 
d.p.c, that is earlier than AP-2γ mutants suggesting there is redundant activity of AP-
2α and AP-2γ within extra embryonic membranes during murine development.  Both 
AP-2α and AP-2β were also found to play redundant roles in the ectoderm that 
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controls the induction of skeletogenesis in neural crest cells in zebrafish and both are 
required for craniofacial development.  Targeting AP-2β expression alone did not 
obviously perturb development of the hindbrain but severe craniofacial defects were 
observed in AP-2α/β knockouts (Knight et al., 2005).  Moreover, a study 
demonstrated that both AP-2α and AP-2γ deficient zebrafish embryos showed 
complete failure of neural crest induction, but this observation was not seen when 
either of these proteins were knocked down singly.  This suggested that they can 
compensate for each other, thus, further supporting the conclusion that there are 
redundant activities for these two proteins (Li and Cornell, 2007). 
 
1.8. Role of AP-2 factors in Cell Differentiation and Proliferation 
AP-2α and AP-2γ have been implicated in governing cell fate by controlling cell 
differentiation and proliferation.  A good example to demonstrate the role of AP-2α 
and AP-2γ in differentiation and proliferation is during skin epidermal development.  
Development of the skin epidermis involves a complex network of molecular events.  
It begins from a single layer of cells which eventually forms the basal layer in 
developed skin and subsequently commitment to stratification.  This process of 
epidermal differentiation is tightly controlled by p63 transcription factor isoforms, 
and results in multiple layers of supra-basal differentiated epithelial cells 
characterised by the expression of specific keratins (Koster and Roop, 2004a).  
Keratins are major structural proteins in epithelial cells where they form a 
cytoplasmic network of filaments to protect epithelial cells from cell rupture and 
death (Gu and Coulombe, 2007).  Studies in p63 null mice have shown that the 
transactivating (TA) isoforms of p63 are required for the commitment to initiate 
epithelial stratification in surface ectoderm (Koster and Roop, 2004a; Koster and 
Roop, 2004b).  AP-2 family members are important regulators of epidermal 
development and differentiation.  All the AP-2 family members, with the exception 
of AP-2δ, were detected in normal mouse skin epidermis.  In particular, AP-2α was 
expressed at high levels in the supra-basal nuclei and to a lesser extent in the basal 
nuclei of skin epidermis, whereas high levels of AP-2γ were restricted to basal nuclei 
(Wang et al., 2006).   
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A role for AP-2γ in epidermal development has been identified in a several studies.  
When commitment to stratification occurs, TAp63α induced AP-2γ levels by binding 
directly to the AP-2γ promoter region, whereas ΔNp63α, which does not contain the 
transactivation domain and acts to inhibit transcription activation, failed to induce 
AP-2γ expression.  Clearly ΔNp63α isoforms can still activate gene expression, 
notably K5 and K14 (Candi et al., 2006; Romano et al., 2007; Romano et al., 2009).  
In the case of AP-2γ, ΔNp63α appears to act exclusively as an inhibitor.  In the 
absence of AP-2γ, TAp63 failed to induce Keratin 14 gene transcription, thus, 
highlighting a role for AP-2γ in the transcription of this early epidermal marker 
(Koster et al., 2006).  As epidermis differentiates, the levels of ΔNp63α isoforms 
increase with respect to TAp63 isoforms.  This p63 isoform balance has been 
suggested to be important for commitment to terminal differentiation in the 
epidermis (Koster and Roop, 2004b).  ΔNp63 was shown to inhibit AP-2γ 
expression, suggesting this may be important for the progressive loss of AP-2γ 
expression observed in the differentiated supra-basal cells of the epidermis (Koster et 
al., 2006).  The findings of Koster and colleagues were supported by another study 
using an AP-2γ conditional ablation mouse model, and showed abnormal epidermal 
stratification in these mutant mice. The expression of both p63 and K14 and other 
keratin proteins was delayed in the skin of AP-2γ mutant embryos and showed 
decreased expression of late epidermal differentiation markers which suggests AP-2γ 
induces p63 expression (Guttormsen et al., 2008).  Figure 8 shows the proposed role 
for AP-2α and AP-2γ during skin epidermis development. 
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Figure 8.  A proposed role for AP-2α and AP-2γ in the proliferation and differentiation of skin 
epidermis.  AP-2γ is highly expressed in the basal epidermal layer where cells are proliferating.  The 
expression is gradually decreased as differentiation progresses.  AP-2α expression is required in 
differentiating cells to prevent proliferation.  Picture is adapted from (Koster et al., 2006). 
 
Epidermal growth factor receptors (EFGR) also play an important role in regulating 
the development of the epidermis.  EFGR is predominantly expressed in the basal 
epidermal layer and is down-regulated as cells commit to terminal differentiation.  
EFGR expression was elevated upon targeted ablation of AP-2α gene expression in 
the skin epidermis, resulting in hyperproliferation of the differentiating suprabasal 
cells (Wang et al., 2006).  Furthermore, AP-2α has been shown to mediate repression 
of the EFGR by direct interaction with the EGFR promoter, which suggested that 
AP-2α functions in the epidermis by repressing EGFR gene transcription as cells exit 
the basal layer and commit to terminal differentiation.  Although AP-2α is highly 
expressed in the suprabasal cells that are not proliferating, its expression also 
appeared to be higher in those basal cells that are not actively cycling.  This suggests 
that the role of AP-2 factors is critical in determining the balance between 
proliferation and differentiation in the epidermis.   
 
When the expression of both AP-2α and AP-2γ were ablated in the skin, the mice 
died within 24 hours after birth and displayed morphological and physiological 
defects in their epidermis (Wang et al., 2008).  Examination of the epidermis of these 
double knockout mice found no sign of terminal differentiation and no differentiation 
markers were detected.  The basal layer of these mice appeared to be normal, 
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however, a reduction in cell proliferation of the basal layer was detected compared to 
the wild-type control mice.  In summary, AP-2α is important for the control of 
signalling in proliferation and differentiating suprabasal cells of the skin epidermis.  
AP-2γ is required for proliferation in the basal layer but has to be down-regulated to 
allow differentiation and migration upwards to take place.  Together these studies 
suggest the presence of a control loop between AP-2α, AP-2γ and p63 during 
epidermis development.  
 
Another example of the role of AP-2γ in particular in the control of cell proliferation 
and differentiation is in gonocyte (germ cell) development.  AP-2γ is highly 
expressed in gonocytes during foetal testis development from 10 until roughly 22 
weeks of gestation and the levels decline rapidly and are gradually lost when 
differentiation of the gonocytes takes place (Hoei-Hansen et al., 2004; Pauls et al., 
2005).  AP-2γ expression is also found in oogonia (immature ovum, cells that go 
through the process of oogenesis to become an ovum) at high levels in early 
gestational ages in foetal ovaries but is decreased when cells enter meiosis.  Hoei-
Hansen et al induced proliferation in germ tumour cells by RA treatment and found 
that AP-2γ is highly expressed in these proliferating cells but not in the differentiated 
cells (Hoei-Hansen et al., 2004).  Moreover, similar observations were seen in 
another study (Pauls et al., 2005), and gradual down regulation of AP-2γ was 
observed with increasing differentiation of foetal testis.  These authors proposed that 
AP-2γ expression might be required for the suppression of differentiation and the 
promotion of proliferation in germ cells.  In agreement with this, AP-2γ expression 
was found at high levels in germ cell tumours which share characteristics with early 
germ cells.  Furthermore, mice with AP-2γ targeted deficiency in their embryonic 
germ cells failed to reproduce, and their testes and ovaries were significantly reduced 
in size compared to the wild-type due to impaired germ cell production (Weber et 
al.).  This study proposed that AP-2γ represses a set of genes involved in 
mesodermal differentiation and that loss of AP-2γ leads to up-regulation of somatic 
differentiation and exit from the proliferation phase. 
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1.9. Mammary Gland Development 
The mammary gland is a complex secretory organ that consists of a number of 
different cell types: epithelial cells that form the ductal network of the gland; 
adipocytes that constitute the fat pad where the ductal network is embedded; vascular 
endothelial cells which form the blood vessels and stromal cells, including 
fibroblasts and a variety of immune cells.  There are two main types of epithelium in 
the mammary gland: luminal and basal.  The luminal epithelial cells form the ducts 
and the secretory alveoli, whereas the basal epithelium consists of contractile 
myoepithelial cells.  There are three main stages of mammary gland development in 
rodents and humans: embryonic, puberty and adult.  The prenatal stage of mammary 
development is hormone independent and is regulated by sequential and reciprocal 
signalling between the epithelium and the mesenchyme.  The process involves cell 
specification, proliferation and migration.  Briefly, around mouse embryonic day E11 
to 13.5 the placode, a layer of embryonic epithelial cells where some organs begin to 
develop, protrudes from the body wall and grows into bulb-shaped buds which 
invaginate into the underlying dermis mesenchyme.  This becomes the mammary 
bud and is driven by cell migration from the epidermis.  Cell proliferation continues 
at the base of the bud which later sprouts and branches leading to the formation of an 
elongated duct known as the primary sprout, and eventually grows toward the fat pad 
from E15 to E16.5.  These processes result in the formation of a small ductal tree at 
birth which is connected to the skin and the outside through the nipple 
(Hennighausen and Robinson, 2001; Robinson, 2004; Watson and Khaled, 2008).  
The whole process is summarised in Figure 9. 
 
 
 
Figure 9.  Schematic diagram of prenatal mammary gland development.  b, bud; ec, ectoderm; 
ep, epidermis; n, nipple; p, placode; ps, primary sprout.  This diagram is taken from (Robinson, 2004). 
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The majority of mammary gland development occurs during puberty and pregnancy 
in response to changes in hormone levels.  During embryogenesis, the progenitor 
cells give rise to the formation of the structure described above.  After birth, 
mammary gland development is arrested until puberty when oestrogen and 
progesterone produced by the ovaries facilitate the outgrowth and elongation of the 
ducts.  Terminal end buds (TEBs) appear at the tips of the ducts comprising an outer 
layer of cap cells, which are the myoepithelial progenitors, and a multilayered inner 
layer of body cells, which are the luminal progenitors.  The TEBs begin to invade the 
fat pad.  Proliferation of TEBs results in the formation of secondary ductal branching 
which is regulated by oestrogen.  During pregnancy, the mammary gland undergoes 
further development to prepare for lactation.  Progesterone stimulates cell 
proliferation and induces extensive side-branching, and together with prolactin 
promotes differentiation and expansion of the alveoli.  Lactation begins when 
progesterone levels drop and, in the presence of prolactin, milk is synthesised by the 
mature alveoli and transported through the ducts that connect to the nipple.  Upon 
cessation of feeding and reduction in the prolactin level, the secretory duct epithelial 
cells undergo apoptosis and the surrounding stroma is remodelled to replace the 
apoptosed cells. This stage is known as involution. The whole cycle repeats when the 
production of ovarian oestrogen and progesterone returns (Andrechek et al., 2008; 
Hennighausen and Robinson, 2001; Robinson, 2004; Watson and Khaled, 2008).  
These stages are summarised in Figure 10. 
 
 
Figure 10.  Schematic diagram illustrating the mammary gland development and the hormones 
that control the development.  This diagram is taken from (Andrechek et al., 2008) 
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1.10. AP-2 and their role in mammary development 
Immunohistochemical expression of both AP-2α and AP-2γ was observed in the 
developing mammary gland.  AP-2α was found in the inner glandular cell layer and 
body cells (ductal epithelia), whereas AP-2γ was expressed in the cap cells 
(myoepithelial) of the basal ductal and lobular epithelia (Friedrichs et al., 2005; 
Friedrichs et al., 2007).  Later, AP-2 factors were examined throughout breast 
development to the postnatal period in order to determine the expression patterns of 
these factors and their functional role in more detail (Friedrichs et al., 2007).  This 
study illustrated that, intense AP-2α expression was detected in the basal cell layer at 
14 weeks of gestation and continued to be expressed during the primary breast 
outgrowth, budding and branching of the secondary outgrowths.  AP-2α expression 
appeared earlier than cytokeratin 5 (CK5), an immunohistochemical marker that 
distinguishes the progenitor cells of breast epithelium which have the potential to 
differentiate into glandular or myoepithelial cells (Boecker and Buerger, 2003).  This 
observation suggested that AP-2α is responsible for cell differentiation in the 
primary outgrowth by inducing CK5 progenitor cells.  AP-2γ expression appeared 
after AP-2α at 19 weeks of gestation, the earliest stages of budding and branching.  
The expression of AP-2γ was strictly confined to the cells which form the invading 
front line of the secondary outgrowths, and later on differentiated into 
myoepithelium which was characterised by the expression of smooth muscle actin 
(SMA), a marker of myoepithelial cells.  This suggested that AP-2γ might be 
involved in initiation of the ductal growth and branching morphogenesis.  Figure 11 
shows the AP-2γ expression pattern in normal human breast tissue. 
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Figure 11.  Immunohistochemical staining patterns for AP-2γ in normal breast tissue.  AP-2γ is 
strongly expressed in myoepithelial (M) cells and more weakly in the luminal layer (L) of normal duct 
tissue.  Picture is taken from (Gee et al., 2009). 
 
 
AP-2α has been shown to be involved in the transcriptional regulation of a gene 
known as Connexin 26 (Cx26).  Cx26 encodes the main gap junction protein which 
forms a channel that allows the passage of molecules for intercellular communication 
and is up-regulated in mammary epithelial cells during pregnancy and lactation (Tu 
et al., 2001).  AP-2 interacts at the proximal promoter region of Cx26 and the 
enrichment of AP-2 in this region was markedly increased during pregnancy and 
lactation, implying that AP-2 plays an important role in controlling milk production. 
 
1.11. AP-2 expression in transgenic mouse mammary gland studies 
Two separate transgenic mouse studies targeted AP-2α or AP-2γ over expression to 
the mouse mammary gland using the transgene under the control of the long terminal 
repeat (LTR) of mouse mammary tumour virus (MMTV) (Jager et al., 2003; Zhang 
et al., 2003).  It was found that AP-2α, AP-2β and AP-2γ were endogenously 
expressed in the early virgin mammary tissue, and their RNA and protein expression 
levels continued to increase as the mammary gland matured.  High levels were 
observed in pregnant mammary tissue and declined in lactating mammary tissue.  
Both AP-2α and AP-2γ were localised in the nuclei of the ductal epithelium as well 
as in the terminal end buds.  In AP-2α over-expressing mice, the initial embryonic 
development of the mammary gland was unaffected and the outgrowth and branching 
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of ducts during puberty appeared normal.  However, a significant decrease in cell 
proliferation in the alveolar bud during pregnancy was observed, coupled with an 
increase in apoptosis.  No mammary tumours were detected.  AP-2α therefore 
suppressed the growth and development of the ductal network within the developing 
breast.  This implied that AP-2α expression has to be lost or reduced in alveolar bud 
development for proliferation of these structures during pregnancy (Zhang et al., 
2003). 
 
Similarly, in AP-2γ over-expressing transgenic mice the embryonic and puberty 
stages appeared normal.  However, in AP-2γ over-expressing pregnant mice the 
number of alveolar cells was reduced as alveolar buds were unable to develop into 
mature alveoli resulting in lactation failure.  Impaired alveolar development in AP-2γ 
transgenic mice was due to hyperproliferation of these cells counterbalanced by 
enhanced apoptosis leading to the impairment of proper tissue-specific 
differentiation.  Indeed, analysis using differentiation markers suggested that over-
expression of AP-2γ resulted in suppression of differentiation (Jager et al., 2003).  
This implies that AP-2γ expression has to be down-regulated in later stages of 
alveolar bud development in order to stop proliferation and induce differentiation.  A 
recent study examined the mammary gland development in mice in which AP-2γ 
expression was conditionally knocked out in the myoepithelial compartment.  
Consistent with earlier studies in which AP-2γ was strongly expressed in the nuclei 
of cap cells and in myoepithelial cells lining the ducts by immunostaining, the 
staining in these sections was lost in AP-2γ-deficient mice (Jager et al., 2010).  Loss 
of AP-2γ did not result in a total lack of myoepithelial differentiation, and ductal 
network was still able to pervade the fat pad completely, however, the degree of 
branching and ductal elongation was significantly reduced in the AP-2γ-/- mammary 
glands.  It was concluded that impaired branching morphogenesis in these AP-2γ-
deficient mice was due to a huge reduction in cellular proliferation in the TEBs but 
this was not due to reduced levels of oestrogen or progesterone, because re-
administration of these hormones failed to rescue the phenotype.   
 
All together, these studies have demonstrated that both AP-2α and AP-2γ play an 
essential role during breast morphogenesis.  Over-expression of either AP-2α or AP-
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2γ inhibited alveolar bud formation in virgin mouse mammary glands and caused 
defects in lobuloalveolar development in pregnant and lactating mice.  This 
emphasises the role of AP-2α and AP-2γ in regulating the proliferation and 
differentiation of mammary gland epithelial cells and shows close similarities with 
the observations made in skin and germ cell development described in the previous 
section.  The recent study by Jager and colleagues further demonstrated that AP-2γ is 
essential for branching morphogenesis of the mammary epithelium which is 
consistent with an earlier study (Boecker and Buerger, 2003), which AP-2γ might 
control mammary gland development downstream of ovarian hormones in both mice 
and man. 
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1.12. Cancer and Cell Cycle Regulation  
Tumorigenesis in humans is a highly complex process involving genetic alterations 
that drive normal cells into highly malignant derivatives, and specific interactions 
between cancer cells and surrounding tissues giving rise to tumour angiogenesis, 
invasion and metastasis (Hanahan and Weinberg, 2000).  Over-expression or 
continuous activation of growth promoting signals, by so called oncogenes is a 
significant process in promoting a cancerous state.  In contrast, defects in, or loss of 
tumour suppressor genes can also lead to tumourigenesis (Sherr, 2004).  The proteins 
that tumour suppressor genes encode have a repressive effect on the regulation of the 
cell cycle thus inhibiting proliferation, and promoting cell cycle arrest and apoptosis 
if there is DNA damage in the cell that cannot be repaired.  Thus, failure of these cell 
cycle checkpoints to arrest the cell is a hallmark of cancer.  The following section 
will summarise cell cycle regulation, in particular the role of cell proliferation 
regulators at each cell cycle checkpoint and in apoptosis.   
 
1.12.1. Cyclins and Cyclin-Dependent-Kinases 
The cell cycle is a set of events responsible for cell division and under a series of 
strict controls to ensure that the genetic information from one cell generation is 
passed to the next correctly, thus maintaining genetic stability.  Eukaryotic cell 
division occurs in four phases of the cell cycle: G1, S, G2 and M-phase.  The cell is 
prepared for DNA replication during the gap period called G1-phase, genome 
replication then takes place during S-phase.  Duplicated chromosomes enter a second 
gap period G2-phase where they prepare for chromosome segregation and 
cytokinesis in M-phase (mitosis).  When a cell undergoes differentiation, or growth 
factor deprivation, it exits from G1-phase of the cell cycle to enter a quiescent state 
referred to as G0.  Cell cycle checkpoints occur at the G1/S boundary, S-phase, and 
G2/M and M-phase (Elledge, 1996; Nigg, 1995).  During mitosis, spindle assemblye 
checkpoint takes place in order to ensure all chromosomes are attached on the 
spindle and sister kinetochores are attached to opposite spindle poles (De Souza and 
Osmani, 2007).  These checkpoints are activated when cells encounter DNA damage 
or when chromosomes misalign at the mitotic spindle.   
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Progression through the four phases of the cell cycle is driven by a sequential 
activation and inactivation of cyclin-dependent-kinases (cdk): cdk2, cdk4 and cdk6.  
They belong to a well conserved family of serine/threonine kinases, and their kinase 
activity is dependent on their partner cyclins.  The concentration of the cdk remains 
constant throughout the cell cycle.  Cyclins, on the other hand, accumulate and then 
degrade at distinct points during the cell cycle.  There are four classes of cyclins: A, 
B, D and E.  The D-type cyclins (D1, D2 and D3) are induced in response to 
mitogenic signals (e.g. growth factors) and interact with and activate cdk4 and 6 
during early G1, whereas E-type cyclins activate cdk2 during the G1- to S-phase 
transition (Pucci et al., 2000; Sherr and Roberts, 1999; Swanton, 2004).  Upon 
mitogenic stimulation, cyclin D is activated and associates with ckd4 and cdk6.  
Assembled cyclin D-cdk4/6 complexes enter the nucleus where their activity is 
positively regulated by cdk-activating kinase (CAK) via phosphorylation of a central 
threonine residue and dephosphorylation of the threoine and tyrosine residures by the 
cdc25 phosphatase.  In early G1, a tumour suppressor protein known as 
retinoblastoma protein (pRb) is in its hypophosphorylated transcriptionally 
repressive form.  The family members of pRb include p130 and p107 (Paggi et al., 
1996).  They are referred to as ‘pocket proteins’ due to the structure of their 
functional domain.  pRb represses the activity of the E2F family of transcription 
factors which are necessary for transcription of genes essential for entry into S-phase.  
The cyclin D-cdk4/6 complexes phosphorylate pRb leading to partial inactivation of 
pRb and release of E2F.  E2F then subsequently activates the expression of cyclin E 
which binds and activates cdk2.  The cyclin E-cdk2 complex further phosphorylates 
the pRb protein, resulting in complete inactivation of pRb.  Phosphorylation of pRb 
relieves its repression of E2F, thus, allowing gene transcription required for S-phase.  
The hyperphosphorylation state of pRb is maintained by cyclin A-cdk and cyclin B-
cdk complexes during S- and G2-phases respectively until cells exit mitosis, and pRb 
returns to a hypophosphylated state at the start of the next G1-phase (Adams and 
Kaelin, 1995; Pucci et al., 2000).  The cell cycle progression is summarised in Figure 
12. 
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Figure 12.  Cell cycle progression is regulated by cyclin-cdk complexes.  This diagram summarises 
the events and checkpoints in each phase of the cell cycle.  Diagram is adapted from (Abukhdeir and 
Park, 2008; Pucci et al., 2000; Swanton, 2004). 
 
 
1.12.2. Cyclin-Dependent-Kinase Inhibitors 
Given the roles of cyclin/cdk complexes and pRb in cell cycle progression, 
dysfunction during any of these stages due to DNA damage could lead to abnormal 
proliferation and thus, tumour formation.  Inhibitors of cyclin-cdk complexes play a 
crucial part in regulating the activity of cyclin/cdk complexes, and are therefore 
central to restriction checkpoints.  There are two classes of cyclin-cdk inhibitors 
(CDKI).   
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1.12.3. INK4 Family 
This first class was originally identified as the cdk4 inhibitor termed INK4, but later 
was also found to be able to inhibit cdk6.  INK4 consists of four family members: 
p15, p16, p18 and p19 according to their molecular weights.  They inhibit cyclin 
D/cdk4 and cyclin D/cdk6 complexes by interacting only with cdk4 or cdk6 and not 
with cyclins.  Once INK4 proteins are bound to cyclin D-cdk4/6 complexes, their 
ability to phosphoylate pRb is inhibited, hence they are specific for early G1-phase 
(Canepa et al., 2007; Roussel, 1999).   
 
1.12.4. Cip/Kip Family 
The second class of cyclin/cdk complex inhibitor is classified as kinase inhibitor 
(Cip/Kip) proteins, which comprise p21cip, p27kip (Harper et al., 1993; Toyoshima 
and Hunter, 1994) and p57kip2 (Lee et al., 1995).  Unlike the INK4 proteins, the 
Cip/Kip family proteins are not specific for a particular phase because they can 
interact with both the cyclin and cdk subunits to prevent the cyclin-cdk complexes 
from phosphorylating their substrates.  
 
1.12.5. p21cip 
p21cip has been demonstrated to mediate growth inhibition by directly interacting 
with cyclin A- and cyclin E-cdk2 (Gu et al., 1993) and cyclin D-cdk4 complexes 
(Harper et al., 1993).  Early studies identified p21cip as a downstream target of the 
tumour suppressor p53 since p21cip was up-regulated following p53 activation (el-
Deiry et al., 1993).  The level of p21cip in cells with wild-type p53 was found to be 
elevated after exposure to DNA damaging agents and led to cells undergoing G1 
arrest and apoptosis (el-Deiry et al., 1994).  Cyclin-cdk activity is down-regulated 
following p21cip induction. As a consequence, pRb proteins remain 
hypophosphorylated and inactivate E2F thus resulting in transcriptional repression.  
p21cip can also inhibit DNA replication directly via association with the proliferating 
nuclear antigen (PCNA), a subunit of DNA polymerase δ.  This inhibits the function 
of PCNA without affecting DNA repair (Chen et al., 1995).  Prolonged expression of 
p21cip has been to shown to decrease PCNA expression leading to G1 arrest.  The 
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level of PCNA expression is restored upon p21cip knockdown, resulting in reduced 
numbers of cells in G1 and an increased cell population in S-phase (Gehen et al., 
2007).  cDNA microarray analysis of the effect of p21cip induction on gene 
expression showed that most de-regulated genes were involved in cell cycle 
progression, DNA repair and senescence (Chang et al., 2000).  Furthermore, p21cip 
can cause transcriptional repression through its interaction with transcription factors.  
For example, p21cip directly binds to E2F transcription factors and modulates their 
function in a manner that is independent of its involvement with cyclin-cdk 
complexes (Delavaine and La Thangue, 1999).  Besides E2F, p21cip also binds to c-
Myc, blocking cMyc-Max complex formation and suppressing c-Myc dependent 
transcription (Kitaura et al., 2000).  
 
In addition to its role as a CDKI, p21cip can also function as a transcriptional 
activator as it has been shown to be able to induce gene expression (Chang et al., 
2000).  A study identified a transcriptional repression domain on p300 that can 
repress transcription, and the repressive effect of this domain was relieved upon 
p21cip binding (Snowden et al., 2000).  Co-expression of both p300/CBP and p21cip 
stimulate the transcriptional activation by p300/CBP.  Taken together, these 
observations suggest that p21cip1 can function as a transcriptional repressor as well 
as coactivator and exerts effects via a variety of protein-protein interactions. 
 
1.12.6. p27kip1 
p27kip1 was also found to be associated with cyclin D-cdk4 and cyclin E-cdk2 
complexes, thereby causing G1 arrest (Toyoshima and Hunter, 1994).  In normal 
cycling cells, p27kip1 proteins are marked for proteolytic degradation which is 
mediated via phosphorylation of Thr 187 by cyclin E-cdk2 (Pagano et al., 1995).  
This phosphorylation happens during late G1 and early S-phase where cyclin E-cdk2 
levels are increasing which further phosphorylate p27kip1.  Phosphorylation of 
p27kip1 at Thr 187 leads to re-localisation from the nucleus to the cytoplasm, 
therefore, preventing the function of p27kip1 as a CDKI.  Moreover, phosphorylation 
of p27kip1 at Thr 157 has also been shown to regulate its localisation to the 
cytoplasm (Larrea et al., 2008).  In response to DNA damage, p21cip1 protein levels 
increase, this lowers cyclin D-cdk4/6 activity and fails to trigger cyclin E-cdk2 
 51
activity, which in turn prevents p27kip1 from being phosphorylated at Thr 187 thus 
stabilizing p27kip1 protein leading to an increase in levels.  In contrast to p21cip1, 
the role of p27kip1 as a CDKI is less clear.   
 
1.13. The Role of p21cip and p21kip as Cell Cycle Enhancer 
In total contrast to their role as a CDKI as described above, low levels of both p21cip 
and p27kip proteins have also been shown to facilitate the assembly of cyclin-cdk 
complexes and initiate their activity (LaBaer et al., 1997).  In another study which 
used primary mouse embryo fibroblast strains deficient in p21cip and p27kip, it was 
found that cyclin D-cdk4 activity was undetectable based on pRb phosphorylation 
status.  Cyclin D-cdk4 complex formation was restored upon exogenous expression 
of both p21cip and p27kip in the cells (Cheng et al., 1999).  This suggests that both 
p21cip and p27kip can stimulate cell cycle progression.  It has been proposed that 
p21cip and p27kip proteins promote the activation of cyclin D-cdk complexes via 
two mechanisms: translocation of the cyclin D-cdk complexes to the nucleus and by 
increasing the stability of cyclin D.  As described above, p27kip proteins are subject 
to ubiquitination and degradation.  p21cip proteins also undergo post-translational 
modification including phosphorylation of Thr 145 by Akt that leads to cytoplasmic 
re-localisation and a reduction in the growth suppression activity of p21cip (Zhou et 
al., 2001).  In addition, cytoplasmic levels of p21cip and p27kip have also been 
found in certain tumour types (Abukhdeir and Park, 2008; Alkarain et al., 2004; Chu 
et al., 2008; Holland et al., 2001; Winters et al., 2001).  Therefore, both the level and 
the localisation of cip/kip proteins may be important factors in determining their 
roles during cell cycle progression as well as in cell transformation (Larrea et al., 
2008; Zhou et al., 2001).   
 
1.14. The Role of p21cip in Apoptosis  
Apoptosis is a series of cellular events that lead to programmed cell death.  It is 
controlled by the activation of the caspase and p38 family members (Budihardjo et 
al., 1999).  p21cip is well known to play a key role apoptosis because it has been 
found to associate with and control these molecules.  Of the 10 caspases that have 
been identified, caspase 3 has been shown to be involved in Fas-mediated apoptosis.  
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Fas is a cell surface protein that triggers apoptosis following ligand binding.  In 
normal cells, caspase 3 is present in the cytoplasm in its inactive form as procaspase 
3, and its activity is suppressed by p21cip through physical interaction to resist Fas-
mediated apoptosis (Suzuki et al., 2000; Suzuki et al., 1998).  DNA damage can 
induce release of Fas ligand leading to activation of Fas and procaspase 3 becomes 
activated by proteolysis.  Active caspase 3 dissociates from p21cip and free p21cip 
re-localises from the cytoplasm into the nucleus where it exerts its growth 
suppressive effect by inhibiting cyclin-cdk activity resulting in growth arrest.  
However, if the DNA damage can not be repaired, cells undergo apoptosis, and 
p21cip becomes a substrate for caspase 3 cleavage (Zhang et al., 1999).  This reduces 
p21cip in the cytoplasm to an extremely low level so it is no longer able to promote 
cyclin-cdk complex formation, and thus, p21cip mediated cell growth as well as cell 
cycle arrest are impaired (see schematic diagram in Figure 12). 
 
1.14.1. p53 
p53 is a tumour suppressor protein that is involved in cell cycle arrest, apoptosis, 
DNA repair and the control of genome integrity (Levine, 1997).  It is a transcription 
factor that can activate and repress the transcription of target genes involved in a 
variety of cellular functions including growth arrest and apoptosis.  The p53 family 
consists of three members: p53, p63 and p73.  They share a certain degree of 
structural homology.  Unlike p63, whose function in epidermal differentiation has 
been described in section 1.8, both p53 and p73 have a role in controlling cell 
proliferation by exerting growth inhibitory effects during G1-phase of the cell cycle.  
p53 protein contains a transactivation domain (TA), a DNA binding domain (DBD) 
and an oligomerization domain (OD).  In unstressed cells, the level of p53 protein is 
tightly controlled by proteolytic degradation (Brooks and Gu, 2004; Brooks and Gu, 
2006; Levine, 1997).  DNA damage activates p53 and induces a G1 arrest in order to 
allow DNA repair by inducing p21cip expression resulting in inhibition of cyclin-cdk 
activity as described above.  p53 also plays an important role in triggering apoptosis 
if the damage is too extensive to be repaired (Levine, 1997). The TP53 gene is 
commonly found to be mutated or deleted in over 50% of human tumours (Olivier et 
al., 2002; Petitjean et al., 2007; Soussi, 2007).  The mutations that occur in the p53 
gene are classified into two categories: 1) DNA contact in which the mutations occur 
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at the DNA binding domain and 2) conformational in which mutations cause 
structural changes in p53 proteins.  The first class of mutation is commonly known as 
‘dominant negative’ meaning these mutations confer the mutant protein with a 
dominant negative activity over the remaining wild type allele.  Growth studies on 
cells carrying p53 mutations have shown that mutant p53 proteins also acquire 
additional functions independent of wild-type p53, known as ‘gain of function’ 
(Brosh and Rotter, 2009; Yan and Chen).  There is a vast literature on the biology of 
p53 therefore only aspects directly relevant to my thesis are discussed here. 
 
1.15. p53-dependent and independent regulation of p21cip 
expression 
p21cip is known to be directly regulated by p53 and is considered to be the most 
important and potent effector molecule of p53.  p53 proteins have been shown to 
activate p21cip expression by binding to the p21 promoter region and mediate 
nucleosome acetylation by recruitment of HATs in response to stress (Espinosa and 
Emerson, 2001; Kaeser and Iggo, 2004).  A later study demonstrated that the inactive 
form of p53 is required to form the PIC before stress induction.  After DNA damage, 
p53 is activated and increased p53 activity stimulates the elongation of RNA 
polymerase II resulting in transcription of p21cip (Espinosa et al., 2003).  This 
suggests that p53 plays an important role in preparing the p21cip gene for expression 
prior to cellular stress. 
 
Despite p21cip being a p53 target gene, a number of studies have demonstrated that 
p21cip can also be regulated via p53-independent pathways (Gartel and 
Radhakrishnan, 2005).  For example, microarray analysis showed that p21cip was 
transcriptionally repressed following activation of c-MYC (Coller et al., 2000).  Of 
particular relevance to this thesis is the involvement of AP-2 factors, which is 
discussed in more detail later in this chapter. 
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1.16. AP-2 and Cancer  
AP-2α and AP-2γ have been studied extensively and their importance has been 
highlighted not only in development, but also in the regulation of cell proliferation, 
differentiation, apoptosis and in carcinogenesis.  AP-2 factors while important during 
development, are not expressed in most adult tissues.  As described in the following 
sections, the most extensive studies concerning AP-2 factors and cancer have been 
done in breast cancer.  However, important insights into AP-2 biology have also 
come from studies in other solid tumours, as summarised below. 
 
1.16.1. AP-2α 
AP-2α is thought to possess tumour suppressor-like activity, as supported by strong 
evidence coming from studies using melanoma cell lines, in which loss of AP-2α has 
been associated with increased invasion and metastasis (Baldi et al., 2001; Bar-Eli, 
1999; Bar-Eli, 2001).  AP-2α was shown to be an important regulator of the genes 
for the tyrosine kinase receptor c-KIT and the adhesion molecule MCAM/MUC18 in 
promoter analysis (Bar-Eli, 1999).  AP-2α levels directly correlated with c-KIT and 
E-cadherin expression but were inversely correlated with MCAM/MUC18 
expression.  MCAM/MUC18 is known to promote tumour cell adhesion to 
endothelial cells in blood vessels and support migration to metastatic sites, while E-
cadherin is important for cell-cell adhesion in epithelial tissue.  Re-expression of AP-
2α in highly metastatic melanoma cells restored c-KIT expression and down-
regulated MCAM/MUC18, and inhibited tumour growth and metastatic potential.  
The role of AP-2α loss in melanoma metastasis was further supported by the 
observation that AP-2α dominant-negative transfected cell lines injected into nude 
mice increased their tumourigenicity and displayed increased Matrix 
Metalloproteinase MMP-2 expression compared to control, untransfected cells 
(Gershenwald et al., 2001).  MMP-2 type IV collagenase, has been shown to 
correlate with metastatic potential in melanoma. 
 
A study on a prostate cancer cell line also suggested a role for AP-2α as a tumour 
suppressor.  Expression of AP-2α is present in normal prostatic epithelium but it is 
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lost in high-grade prostatic intraepithelial neoplasia.  Vascular endothelial growth 
factor (VEGF) that positively regulates embryonic vasculogenesis and tumour 
angiogenesis, is highly expressed in prostate cancer.  Re-expression of AP-2α in AP-
2α-negative prostate cancer cells significantly reduced their VEGF expression and 
tumorigenicity. AP-2α was shown to mediate transcriptional repression of the VEGF 
gene via direct interaction with its promoter (Ruiz et al., 2004). 
 
Reduced cell proliferation following induction of AP-2α expression was also 
observed in other studies in AP-2α negative colon and ovarian cancer cells.  Nude 
mice intraperitoneally injected with AP-2α over-expressing cells showed reduced 
tumorgenicity and invasiveness and the mice survived longer than those with 
untransfected cells.  In these studies, AP-2α was found to up-regulate E-cadherin but 
down-regulate MMP-2, and MMP-9 through direct interaction at their promoters.  
Effects of AP-2α were reversed when AP-2α expression was depleted mediated by 
RNAi in a colon cancer cell line study, which further supports its tumour suppressor 
role (Schwartz et al., 2007; Sumigama et al., 2004).  
 
1.16.2. AP-2γ 
In contrast to AP-2α, high levels of AP-2γ have often been found in tumours and 
shown to be correlated with increased disease progression.  Research showed that 
AP-2γ expression is up-regulated in advanced stage ovarian carcinoma compared to 
early stage carcinomas, borderline tumours and the ovarian surface epithelium 
(Odegaard et al., 2006).  Immunohistochemical analysis showed abundant AP-2γ 
was detected in patients diagnosed with testicular carcinoma in situ and in testicular 
germ cell tumours (Hoei-Hansen et al., 2004; Hoei-Hansen et al., 2005; Pauls et al., 
2005), and thus AP-2γ expression was identified as a useful tool in the detection of 
testicular cancer.    
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1.17. Breast Cancer 
Aberrant AP-2α and AP-2γ expression is not only associated with the cancer types 
described above, but also with breast carcinoma.  Cancer research UK indicates that 
breast cancer is now the most common cancer in the UK, and in the past decade 
breast cancer incidence has increased by 5%.  Statistical analysis shows that the most 
common cancer in females is breast cancer (31%), compared to the second most 
common colorectal (12%), followed by lung (11%) and ovarian (5%).  About 90% of 
breast cancer is sporadic and 10% is thought to result from inherited mutations in 
genes such as BRCA1and BRCA2, thus leading to the malfunction of DNA damage 
checkpoints (Uyei et al., 2006).   
 
Breast cancer is a very heterogeneous disease.  Breast tumours are mainly divided 
into two major groups: In situ cancers, refer to when the tumour cells remain at the 
primary site, i.e. within the ducts or lobules of the breast and have not yet invaded 
into the surrounding breast tissue, and is termed ductal carcinoma in situ (DCIS) and 
lobule carcinoma in situ (LCIS), respectively.  Invasive cancers, on the other hand, 
refer to tumour cells that have invaded through the breast ducts or lobules into the 
surrounding breast tissue, and hence is called invasive ductal carcinoma and invasive 
lobular carcinoma, respectively (Beckmann et al., 1997).  
 
1.17.1. Prognostic Factors in Breast Cancer 
Pathologists determine the grade of a tumour according to their appearance, and the 
proliferation rate of the tumour cells.  Well-differentiated tumour cells which 
resemble normal tissue is termed grade 1 (low).  Moderately differentiated is termed 
as grade 2 (intermediate), whereas poorly differentiated tumour cells which appear as 
scattered or disorganised cells is termed as grade 3 (high).  The stage of a tumour can 
also be determined based on the size of the tumour, the degree of involvement of 
lymph nodes and the appearance of metastatic disease to other organs.  This is known 
as TNM stage (Sainsbury et al., 2000).   
 
Another key feature of breast tumours in relation to prognosis and treatment options 
is hormone receptor status.  These hormone receptors are: oestrogen receptor (ERα) 
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and progesterone receptor (PgR).  They are considered as key breast cancer 
prognostic markers because, as mentioned above, breast development and cell 
proliferation are regulated by oestrogen and progesterone acting on their 
corresponding receptors (Sutherland et al., 1998).  Note, there are two types of ER: 
ERα and ERβ, although ERβ is expressed in human breast cancer, its function and 
potential role in cancer progression is not yet clearly defined.  A number of 
oestrogen-responsive genes have been documented to be involved in cell adhesion, 
migration, cell proliferation and transcriptional regulation (Sabbah et al., 1999; 
Soulez and Parker, 2001; Wilson et al., 2006).  Since ERα is responsible for the 
majority of the effects of oestrogen on breast tissues, and sustained exposure of 
oestrogen is a well-established cause of breast cancer (Colditz, 1998; McDonnell and 
Norris, 2002), determining ERα status helps decide the type of treatment.  
Immunohistochemical positive staining for both receptors indicates that tumour 
growth is more likely driven by oestrogen, whereas differentiation is driven by 
progesterone, and these patients normally respond well to anti-hormone therapy.   
 
In addition, patients that are negative for ERα and PgR are tested for the presence of 
the receptor tyrosine kinase (ErbB2), which is another biomarker of breast cancer 
because over-expression of ErbB2 has been found in 15 – 20% of cases and is 
associated with amplification of the gene (Ross and Fletcher, 1998).  ErbB2 is a 
member of the epidermal growth factor (EGF) family of receptor tyrosine kinases, 
also called the HER family.  It consists of four members: ErbB1, ErbB2, ErbB3 and 
ErbB4.  ErbB proteins have an extracellular ligand-binding domain, single 
membrane-spanning region and a cytoplasmic protein tyrosine kinase domain.  EGF-
ligand binding to ErbB receptors induces homo- and heterodimerization that leads to 
activation of the intrinsic kinase domain and subsequent phosphorylation on tyrosine 
residues within the cytoplasmic domain.  This results in activation of intracellular 
pathways including the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol-3 kinase (PI-3k) pathways, which lead to cell proliferation.  
Given the role of ErbB receptors in promoting cell proliferation, ERBB2 is therefore 
considered as a proto-oncogene and is implicated in numerous types of human 
cancer, including breast cancer (Abd El-Rehim et al., 2004; Holbro et al., 2003; 
Olayioye, 2001; Ross and Fletcher, 1998).  Over-expression of ErbB2 protein can be 
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detected by IHC and amplification of ERBB2 gene can be detected using fluorescent 
in situ hybridization (FISH) (Ross and Fletcher, 1998).  ErbB2-positive patients can 
be given ‘HER-2 based therapy’.  Treatment for breast cancer is discussed further 
later in this section. 
 
1.17.2. Molecular Classification of Breast Cancer 
The development of high-throughput microarray technologies has recently been used 
to define better the underlying molecular differences between different subtypes of 
breast cancer (Cianfrocca and Gradishar, 2009; Weigelt et al., 2010).  Perou et al 
used complementary DNA (cDNA) microarrays to examine gene expression patterns 
in a set of 65 surgical specimens of human breast tumours and identified four 
different molecular subtypes of breast cancer: ER-positive/luminal-like; basal-like; 
ErbB2-positive and normal breast-like; (Perou et al., 2000).  Subsequent study 
showed the ER-positive/luminal-like group could be divided into three subgroups: 
Luminal A which has the highest expression of the ERα gene; Luminal B and C 
which have lower ERα expression than A and a worse prognosis (Sorlie et al., 2001).  
Furthermore, the ‘basal-like’ subtype has been further sub-divided into four distinct 
subgroups based on differences in their gene expression profile: EGFR over-
expression; cytokine receptor or c-kit positive; cytokeratin positive and BRCA1 
deficiency (Kreike et al., 2007; Nielsen et al., 2004).  ERα-positive tumours account 
for 70 - 80% of breast cancer cases.  The classification of breast cancers at the 
molecular level is summarised in Figure 13.   
 
1.17.3. Breast Cancer Treatment 
Sorlie et al (2001) further found that the different subtypes could be associated with 
different clinical outcomes.  Targeted therapy for breast cancer patients that has been 
approved or is in clinical development based on three groups: 1) agents directed 
against specific subtypes of breast cancer such as anti-oestrogen and anti-ErbB2; 2) 
drugs targeting the tumour microenvironment such as anti-angiogenic agents; and 3) 
inhibitors of specific signalling pathways such as EGFR, MEK and PI3K (Normanno 
et al., 2009).   
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Luminal subtypes generally express ERα, therefore, the best treatment for these 
patients is to use ‘selective oestrogen receptor modulators’ (SERMs) such as 
tamoxifen.  SERMs can be agonistic or antagonistic depending on the tissue type.  
They compete with the naturally occurring oestrogen and either mimic the biological 
response (agonist) or they antagonise oestrogen activity (antagonist) upon binding to 
the receptor (Lebowitz and Zujewski, 2003).  ERα is a DNA-binding transcription 
factor, which is able to regulate the transcription of oestrogen-responsive genes by 
binding to ‘oestrogen response elements’ (EREs) in the promoters of these genes 
(McDonnell and Norris, 2002).  Ovarian oestrogen (17β-oestradiol) binds to ERα 
and causes a conformational change which allows ERα to interact with other 
transcription coactivators or corepressors and results in the activation or repression of 
oestrogen-responsive genes (Schwabe et al., 1993).  ERα has two activation 
domains, called AF1 and AF2 that are responsible for mediating transcription, and a 
DNA-binding domain (Ali and Coombes, 2002; Ellmann et al., 2009; Kong et al., 
2003).  There are three mechanisms for ERα-mediated gene activation:  
 
1. ERα is activated upon oestrogen binding to its AF2 domain leading to 
interaction with transcription co-factors including HATs leading to chromatin 
opening and gene activation. 
2. ERα can also be activated in a ligand-independent manner, such as 
phosphorylation within its AF1 domain as a consequence of a downstream 
signalling event of receptor tyrosine kinases (RTKs). 
3. ERα can be localized at the cytoplasmic side of the cell membrane and be 
activated via interactions with other signaling molecules to induce an 
intracellular signalling cascade that is independent of ERα binding to DNA 
(Lebowitz and Zujewski, 2003).   
 
Tamoxifen has the properties of both agonist and antagonist, but it mainly acts as an 
antagonist in breast epithelium (Lebowitz and Zujewski, 2003).  Tamoxifen mediates 
its anti-oestrogenic effect on ERα by binding to the AF2 domain and thus preventing 
ERα from recruiting its co-activators and activating its target genes (Ali and 
Coombes, 2002).  A pure ERα antagonist called faslodex has also been shown to be 
effective in down-regulating ERα activity by binding to ERα, preventing the 
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activation of both AF1 and AF2, and inhibiting DNA binding.  It also promotes the 
rapid degradation of ERα resulting in a loss of ERα cellular levels (Fawell et al., 
1990; Gradishar, 2004).  The anti-oestrogenic action of tamoxifen and faslodex in 
breast cancer cells leads to G1 arrest and apoptosis (Abukhdeir et al., 2008; Cariou et 
al., 2000; Doisneau-Sixou et al., 2003; Ichikawa et al., 2008; Sutherland et al., 1998; 
Varshochi et al., 2005), thus, they are considered as one of the most effective anti-
tumour therapies.  The efficacy of tamoxifen was tested and found to reduce the 
incidence of recurrancies in ERα-positive breast cancer compared to the placebo 
group (Cuzick et al.; Radmacher and Simon, 2000)}.  ERα/PgR-positive patients 
generally respond well and have a good prognosis.  However, prolonged SERM 
treatment is associated with the recurrence of hormone-independent tumours thus 
these patients often acquire therapy resistance.  It has been reported that tamoxifen-
resistant breast tumours are characterised by elevated ERBB2 levels, and over-
expressing ERBB2 in ERα-positive breast cancer cell lines lead to acquired 
resistance to tamoxifen (Osborne and Schiff, 2003; Shou et al., 2004).  Furthermore, 
aromatase inhibitors (drugs that block the enzyme aromatase from converting 
androgens to oestrogen in tissues) are used to inhibit local oestrogen synthesis and 
may help reduce resistance to therapy (Musgrove and Sutherland, 2009).   
 
The ‘normal breast-like’ group showed similarity to adipose-enriched and basal 
mammary epithelial cells and have an intermediate prognosis.  Tumours of this 
subtype are still poorly characterised and their clinical outcome is not yet clear 
(Weigelt et al., 2010).  ErbB2-positive, ERα-negative tumours used to be the worst 
prognosis group because they are resistant to SERMs treatment.  However, new 
developments have shown that ErbB2-positive tumours may respond to trastuzumab 
(or Herceptin), a humanised monoclonal antibody that directly binds to the 
extracellular domain of the ErbB2 receptor and inhibits the activation of the 
intracellular tyrosine kinase and the subsequent proliferative signalling (Chen and 
Russo, 2009; Hudis, 2007; Normanno et al., 2009).  A newer fully humanised 
monoclonal antibody called pertuzumab binds to ErbB2 receptors in the dimerization 
domain.  Pertuzumab appears to be more efficient than trastuzumab because of 
increased inhibition of heterodimerization with other ErbB receptors (Agus et al., 
2005).  Moreover, as mentioned above, there is evidence suggesting that ‘cross-talk’ 
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between ER and the downstream signalling pathways mediated by growth factor 
receptors, including ErbB2, contribute to the development of resistance to endocrine 
therapy.  One proposed resistance mechanism is through the ‘ligand-independent’’ 
activation of ERα by the signalling cascade induced by RTKs, in which ERα is 
activated by ErbB2 signalling due to ErbB2 over-expression in such tumours 
(Knowlden et al., 2003).  Over-expression of the ERα coactivator AIB1 together 
with ErbB2 has also been suggested to contribute to tamoxifen resistance (Shou et 
al., 2004). 
 
The basal-like breast cancer subtype originates from the basal myoepithelial layer.   
Breast tumours within this subtype express very low levels of ERα, PgR or ErbB2, 
and are often termed ‘triple-negative’ breast cancer (TNBC). They are associated 
with EGFR over-expression and BRCA1 and TP53 mutation, thus, this is considered 
to be the most aggressive disease with the very poor patient prognosis (Dent et al., 
2007; Nielsen et al., 2004; Sorlie et al., 2003).  Due to the lack of receptor 
expression, this subgroup can not be treated with SERMs or ErbB2-targeted 
therapies, therefore the main treatment for TNBC is surgical removal of tumours 
follow by radiotherapy or chemotherapy.  Studies indicated tumours with BRCA1 
mutation often have defects in double-stranded DNA break repair (known as 
homologous recombination repair, HR).  Two of the most common chemotherapy 
regiments for basal-like breast cancers are AC (adriamycin and cytoxan) and FEC 
(fluorouracil, epirubicin and cyclophosphamide).  Both AC and FEC are also 
effective for ERα and ErbB2 double positive breast cancers.  Normally, DNA 
damage is repaired via HR, however, deficiency in either BRCA1 or BRCA2 leads to, 
double-strand DNA breaks being repaired by Poly ADP-ribose polymerase 1 (PARP-
1), an essential enzyme important for repairing single-strand breaks.  Therefore, 
tumour cells with BRCA1 or BRCA2 mutation are sensitive to PARP-1 inhibition, 
resulting in cell death/apoptosis.  PARP-1 inhibitors are currently in clinical 
development (Anders and Carey, 2008).  Other approaches of treating TNBC include 
targeting VEGF that required for blood vessel growth, to prevent angiogenesis and 
EGFR to prevent signalling events (Bartsch et al., 2010; Oakman et al.).  The 
molecular classification of breast cancers and potential target-based therapy is 
summarised in Figure 13. 
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Figure 13.  Representation of breast cancer subtypes and possible treatments.  Microarray gene 
expression data identified five subtypes of breast cancer.  Eighty percent of breast cancers are ERα-
positive and this group is further divided into Luminal A, B and C.  The remaining ERα-negative 
group is subdivided into Basal-like; ErbB2-positive and Normal-like (Perou et al., 2000; Sorlie et al., 
2001). 
 
1.18. The Role of AP-2 in Regulating ERBB2 and ERα Expression 
1.18.1. AP-2 and ErbB2 
The work of our lab has focused on the regulation of breast tumour cell growth and 
survival by AP-2α and AP-2γ.  AP-2 transcription factors were first linked to breast 
cancer when they were shown to be involved in the de-regulation of ERBB2 
transcription (Hollywood and Hurst, 1993).  The ERBB2 promoter was more active 
in over-expressing cells and this was shown to be mediated by a positively acting 
DNA-binding transcription factor initially named OB2-1 (Hollywood and Hurst, 
1993), but later identified as AP-2 (Bosher et al., 1995).  A following study 
examined expression of the closely related ERBB3 and showed ERBB3 promoter 
activity was also enhanced due to the binding of AP-2 transcription factors (Skinner 
and Hurst, 1993).  Further studies showed that AP-2 was a family of related factors 
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and that both AP-2α and AP-2γ can activate the transcription of ERBB2 and ERBB3 
genes and that both AP-2 factors are expressed at elevated levels in the majority of 
ERBB2 over-expressing mammary tumour lines (Bosher et al., 1996; Bosher et al., 
1995; Li et al., 2002; Turner et al., 1998).  Another study demonstrated that higher 
levels of ERBB3 expression are strongly positively associated with AP-2γ in a panel 
of human mammary epithelial and fibroblast cell lines, and ERBB3 expression was 
repressed when over-expressing cell lines were transfected with a dominant negative 
form of AP-2 protein (Zhu and Domann, 2002).  This study, however, did not find 
any correlation between the expression of ERBB3 and AP-2α or AP-2β suggesting 
that AP-2γ may be more important for the regulation of ERBB3 expression.  Several 
IHC studies on breast cancer patients also demonstrated ErbB2 expression is 
positively associated with AP-2 expression in both the nucleus and cytoplasm 
(Allouche et al., 2008; Pellikainen et al., 2004; Turner et al., 1998).  Examining 
expression of ErbB2 and AP-2α showed that patients who were ErbB2-negative/PA-
2-positive had the best prognosis while those with the worst outlook were ErbB2-
positive/AP-2α-negative (Pellikainen et al., 2004) 
 
Several of these studies identified functional AP-2 consensus binding sequences in 
the ERBB2 proximal promoter that might be responsible for ERBB2 over-expression.   
Two studies showed that AP-2 transcription factors, mainly AP-2α and AP-2γ, bind 
to a sequence located -218 bp upstream of the transcription initiation site (Bosher et 
al., 1996; Hollywood and Hurst, 1993).  A later study found an additional AP-2 
binding site located at -501 from the transcription initiation site (Vernimmen et al., 
2003).  Moreover, two studies mapped AP-2 binding sites to enhancer regions: a 
distal enhancer region located -4500 bp upstream of the TSS and an enhancer located 
within the first intron (Delacroix et al., 2005; Newman et al., 2000).  Recently, a 
study suggested that AP-2α protein was degraded by ubiquitination in normal 
mammary cells, but the stability of AP-2α protein was extended in ERBB2-positive 
breast cancer cell lines (Li et al., 2006c).  This implies that over-expression of 
ERBB2 is not just due to increased AP-2α expression, but can also result from 
defects in AP-2 protein degradation leading to over-abundance of AP-2α protein.  In 
contrast, a different study suggested that AP-2-mediated ERBB2 expression may also 
involve additional molecules and pathways.  AP-2α mRNA expression level was 
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found to be up-regulated upon p53 inactivation in mouse mammary epithelial cells, 
due to increased signalling by the protein kinase A pathway, which in turn lead to 
over-expression of ERBB2 (Yang et al., 2006).   
 
Putting all the evidence together, it seems different AP-2 family members may 
control ERBB2 expression in a variety of ways and in response to different stimuli.  
The precise interplay of all these pathways in normal breast epithelia and in tumours 
is not yet understood but it is clear that AP-2 transcription factors directly bind to the 
ERBB2 promoter and other regulatory regions and activate ERBB2 transcription.   
 
1.18.2. AP-2, ERBB2 and ERα 
AP-2 proteins have also been shown to be involved in the interplay between ErbB2 
and ERα in breast carcinoma.  ERα and ErbB2 expression are inversely correlated in 
breast cancer.  When ERα is activated by oestrogen, ErbB2 levels are reduced, and 
conversely, when ErbB2 is over-expressed oestrogen dependent signalling is 
bypassed.  Two elements in the ERBB2 locus have been shown to be oestrogen 
responsive in two independent studies (Bates and Hurst, 1997; Perissi et al., 2000).  
Bates and Hurst’s study showed that oestrogen repression of ERBB2 transcription 
was mediated by an enhancer that maps within the first intron of the gene, whereas, 
Perissi and colleagues suggested that the most proximal region (+1 to -218 bp) of the 
ERBB2 promoter was negatively regulated by oestrogen in breast cancer cells 
(see Figure 14).  It appeared that both regions are functionally identical to AP-2 
mediated transcriptional activation sites that are essential for ERBB2 over-expression 
(as discussed above) indicating that AP-2 factors are involved in the regulation of 
ERBB2 transcription by oestrogen.  The repression of ERBB2 by ERα can be 
relieved using anti-oestrogens such as tamoxifen or fasolodex (Bates and Hurst, 
1997; Orso et al., 2004; Perissi et al., 2000).  
 65
 
 
 
Figure 14.  A schematic diagram showing oestrogen responsive elements within the ERBB2 
locus.   The first oestrogen responsive element mapped to the first intron of the ERBB2 gene was 
identified (Bates and Hurst., 1997).  The -218bp region upstream from the major transcriptional start 
site of ERBB2 gene promoter was also shown to be repressed by oestrogen in a later study (Perissi et 
al., 2000).  Both regions are bound by AP-2 transcription factors. 
 
 
Oestrogen treatment of ERα positive cell lines was found to increase AP-2γ mRNA 
expression but conversely reduced AP-2α expression (Orso et al., 2004).  Chromatin 
Immuno Precipitation (ChIP) and EMSA assays over the AP-2γ promoter showed 
ERα occupancy indicating that AP-2γ expression is directly regulated by oestrogen 
through the binding of ERα to a conserved site within the gene.  This implies that 
changes in the balance of AP-2 proteins could affect the expression of genes such as 
ERBB2 in response to oestrogen.  In addition, an earlier study showed that both AP-
2α and AP-2γ were able to transactivate the cloned human ERα promoter in ER-
negative breast cancer cells by binding to an AP-2 consensus site within the first 
exon of the ER gene (McPherson and Weigel, 1999).   
 
A recent study examined the effect of AP-2α and AP-2γ silencing on the expression 
of ERα in three ERα-positive human mammary carcinoma cell lines (Woodfield et 
al., 2007).  It was found that the ERα mRNA levels reduced in all three cell lines 
upon AP-2γ silencing but not AP-2α silencing, and a direct interaction between AP-
2γ and ERα promoter was confirmed by ChIP assay.  Moreover, microarray data 
showed silencing AP-2γ altered the expression pattern of ERα-regulated genes as 
well as genes that are known to regulate ERα expression in breast cancer.  A 
reduction in cell proliferation and tumour growth of breast cancer xenografts 
following AP-2γ knockdown was observed in response to oestrogen exposure.  This 
study demonstrated that AP-2γ can control ERα expression both directly and 
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indirectly which implies AP-2γ may represent a novel therapeutic target for breast 
cancer treatment. 
 
Furthermore, it has been proposed that epigenetic changes in the chromatin structure 
of the ERα gene such as DNA demethylation and histone acetylation must take place 
in order to allow AP-2-mediated transcriptional activation.  Indeed, functional 
analysis identified a site located +200 bp downstream of the untranslated exon 1 of 
the ERα gene to be sensitive to structural changes and to contain high affinity 
binding sites for AP-2 transcription factors (Schuur et al., 2001).  Reduced CpG 
methylation after treatment with 5-aza-2’-deoxycytidine (AZA) and increased DNA 
accessibility after trichostatin A (TSA) treatment allowed AP-2γ and RNA 
polymerase II to bind to the ERα promoter in an ERα-negative breast carcinoma cell 
line, as shown by ChIP assay, which resulted in increased ERα expression 
(Woodfield et al., 2009).   
 
Overall, these findings described above have suggested the presence of a possible 
control loop between AP-2 factors and ERα in breast epithelial cells in vitro 
although again the precise mechanism of action is not yet clear. 
 
1.19. AP-2, ErbB2 and ERα in Human Breast Cancer 
Most of the studies described above looking at the interplay between AP-2 factors, 
ERα and ErbB2 have used in vitro experiments on established cell lines.  In parallel, 
there have been a number of IHC studies looking at AP-2α and AP-2γ expression in 
human breast cancer specimens in order to examine if the same associations also play 
a role in breast cancer. 
 
1.19.1. Expression Pattern of AP-2α 
An early study examining AP-2α expression in early-stage (DCIS) breast tumours 
found expression increased in proportion with ERα levels (Turner et al., 1998).  
Later, another study found that only 17% of the tumours showed very high 
expression levels of AP-2α/β, and this was correlated significantly with expression 
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of both ERα and p21cip, strongly suggesting that AP-2α/β are required for 
expression of these genes (Gee et al., 1999).  AP-2α expression, however, was 
inversely related to the levels of ErbB2.  The staining of AP-2α was found to be 
highest in normal breast epithelia but the level of staining declined in samples of 
DCIS and was significantly reduced in samples of invasive cancer.  High AP-2α/β 
expression also correlated with a lower proliferation rate with significantly reduced 
mitotic count, and these patients were more likely to have only low-grade tumours 
(Gee et al., 1999).  Note that, the Gee et al study used an antibody that recognised 
both AP-2α and AP-2β but not AP-2γ, however, since AP-2α has more expression in 
breast cancer, it was believed that the expression pattern detected in this study was 
mainly due to AP-2α.  Nonetheless, the Gee et al study indicated that AP-2α 
expression in breast cancer is associated with favourable prognostic markers: ERα 
positivity and ErbB2 negativity and reduced proliferation.  In other studies, reduced 
AP-2α nuclear staining was associated with more aggressive, high grade breast 
cancers and TFAP2A mRNA expression was inversely correlated with increased 
tumour grade and shorter recurrence-free survival (Pellikainen et al., 2002; Sotiriou 
et al., 2006).  Together these studies suggest that AP-2α plays a tumour suppressive 
role, not only in the other tumour types discussed above, but also in breast cancer.   
 
1.19.2. Expression Pattern of AP-2γ 
In contrast to AP-2α, elevated AP-2γ expression has been found in various cancers 
as described previously.  Our lab successfully generated a specific monoclonal 
antibody against human AP-2γ to examine expression in the same series of primary 
tumours obtained previously studied for AP-2α/β expression (Gee et al., 2009).  
Interestingly, AP-2γ epithelial expression was found to be significantly lower in the 
invasive tumours and DCIS tissue than in pure normal breast epithelial cells.  The 
expression pattern of AP-2γ in samples of normal breast tissue, pure DCIS, and 
invasive ductal carcinoma is shown in Figure 15.  This finding was in contrast to 
other cancers types, where AP-2γ expression was often found positively correlated to 
disease progression.  However, this was consistent with earlier microarray studies 
where AP-2γ was found to be expressed at significantly higher levels in samples of 
normal tissue or benign disease than those of ductal carcinoma (Ramaswamy et al., 
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2001; Sorlie et al., 2001).  Furthermore, there was no association between AP-2γ and 
ERα level which contrasts with some of the cell line studies described in the 
previous sections. 
 
 
 
Figure 15.  Immunohistochemical staining patterns for AP-2γ in breast tumours.  Top Panel: 
AP-2γ staining is positive in DCIS indicated by the arrow, and Bottom Panel: invasive ductal 
carcinoma characterised by a loss of recognisable morphology.  Pictures were taken from (Gee et al., 
2009). 
 
 
A closer investigation was carried out on the correlation between the expression of 
ERα, ErbB2 and AP-2γ and patient survival.  Figure 16A shows that there was 
reduced survival in those patients whose tumours had high levels of AP-2γ nuclear 
staining.  When separating patients into two subgroups: ERα positive and ErbB2 
negative, the survival curve separation was even more pronounced.  ERα positivity 
or ErbB2 negativity are generally considered to be markers of good prognosis in 
breast cancer because of tumour responsiveness to hormone therapy.  Again, higher 
AP-2γ expression in ERα positive or ErbB2 negative patients correlated with 
shortened survival time, as shown in Figure 16B and C respectively.  The association 
of high levels of AP-2γ expression and poor disease-free survival was also 
demonstrated in another study (Zhao et al., 2003a), and gene expression profiling 
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studies showed TFAP2C mRNA expression was associated with advanced clinical 
grade (Sorlie et al., 2001; Sotiriou et al., 2006).  Overall, high AP-2γ expression has 
been linked to poor patient survival, both independently and in the context of the 
generally considered indicators of good prognosis: ERα positivity and ErbB2 
negativity.   
 
All the patients in the series studied by Gee et al (2009) received anti-hormone 
therapy, and a significant reduction in the time to disease progression was observed 
in those with elevated AP-2γ.  Similar observations have also been made in an 
independent study (Guler et al., 2007).  Since AP-2γ transcription is activated by 
oestrogen-bound-ERα and anti-oestrogen abrogates ERα-mediated AP-2γ 
transcriptional activation (Orso et al., 2004), a reduction in AP-γ levels would be 
expected in ERα positive tumours undergoing anti-oestrogen therapy.  Therefore, 
high levels of AP-2γ expression might be a sign of resistance to anti-oestrogen 
therapy.  Indeed, an ERα-positive but ErbB2-negative mammary carcinoma cell line, 
MCF-7, was used to explore the relationship between AP-2γ levels and response 
versus resistance to anti-hormone therapy (Gee et al., 2009).  It was found that AP2γ 
levels were reduced in tamoxifen-treated MCF-7 cells compared to cells grown in 
oestrogen-containing media, however the level of AP-2γ was fully restored in cells 
that had become tamoxifen-resistant.   
 
One key gene which plays a critical role in tamoxifen-mediated growth inhibition is 
p21cip.  As discussed previously, p21cip is a cell cycle inhibitor, which acts at the 
G1 checkpoint, preventing cell cycle progression into S-phase when it is over-
expressed.  Several studies have demonstrated, tamoxifen and faslodex treatment in 
ERα-positive breast carcinoma cell lines induce p21cip expression and silencing 
p21cip abrogates the antioestrogen-mediated growth inhibition (Abukhdeir et al., 
2008; Cariou et al., 2000; Ichikawa et al., 2008; Kim et al., 2007a; Varshochi et al., 
2005).  In cycling MCF-7 cells, p21cip expression was shown to be repressed by 
ERα, via recruitment of HDAC and Sp1 at the proximal region of p21cip promoter, 
and treatment with faslodex dissociated the ERα-Sp1-HDAC complex, thus de-
repressed p21cip expression (Varshochi et al., 2005).  In another study, it was shown 
that, tamoxifen induced transcriptional activation of p21cip indirectly and 
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independently of p53 (Kim et al., 2007a).  First, tamoxifen-bound ERα stimulated a 
signalling pathway which induced the expression of a transcription factor called Egr-
1.  Egr-1 protein then bound to the proximal region of the p21cip promoter and 
activated p21cip transcription.  As discussed in the next section, p21cip is repressed 
by AP-2γ, thus, tumour cells with high levels of AP-2γ may block the induction of 
growth arrest via p21cip in the presence of tamoxifen or faslodex, which implies that 
over-expression of AP-2γ may lead to antioestrogen drug-resistance.  In addition, a 
study demonstrated that p21cip was phosphorylated via the Akt signalling pathway 
and re-localised to cytoplasm in ERBB2 over-expressing fibroblasts and breast 
cancer cells, and cytoplasmic localisation of p21cip retarded its inhibition of cell 
growth (Zhou et al., 2001).  Since AP-2 has been shown to be able to induce ERBB2 
expression, the findings of this study led us to speculate that over-expression of AP-
2γ in breast cancer cells could also indirectly reduce the growth inhibitory function 
of p21cip.  Based upon these findings, AP-2γ may be a useful prognostic indicator in 
breast cancer, and target genes in addition to ERα and ERBB2 regulated by AP-2γ 
could also be important.   
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Figure 16. Correlation between AP-2γ expression and poor prognosis in invasive breast 
tumours.  Seventy-five cases of formalin-fixed, paraffin-embedded primary tumours from patients 
were stained for AP-2γ expression.  Each sample was assigned a histopathology score (H-score) from 
1-300 based on the intensity of the staining and the percentage of tumour cells stained.  A statistically 
defined cut-off point, the median (H-score > 120) was used to define “positivity” for subsequent 
analysis.  Kaplan-Meier survival curves for patients show AP-2γ expression greater than (High γ) or 
less then (low γ) the median H-score value of 120.  Curves are shown for (A) all patients in the series, 
and (B) after subdivision for ER positivity or (C) for ErbB2 negativity.  Data obtained from (Gee et 
al., 2009). 
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1.20. The interplay between AP-2, p21cip and p53 during cell 
proliferation and cell cycle regulation 
Since AP-2α has been reported to be down-regulated in various cancers, its 
involvement in tumorigenesis has been investigated further in several studies.  One 
possible mechanism could be that AP-2α is normally able to induce growth arrest 
and apoptosis.  An early study in HepG2 hepatoblastoma cells and SW480 colon 
carcinoma cells showed that exogenous AP-2α expression inhibited growth and was 
accompanied by activation of CDKN1A expression (Zeng et al., 1997).  As discussed 
above, the gene CDKNIA encodes a potent cyclin-dependent kinase inhibitor, p21cip, 
that binds to and inhibits the activity of cyclin-cdk complexes.  Its expression is 
tightly controlled by p53 and it functions as a negative regulator of cell cycle 
progression during G1 phase.  Zeng et al generated a p21cip promoter reporter 
construct and showed that mutation between -101 and -71 bp upstream of the 
transcription initiation site of CDKN1A gene abrogated p21cip activation by AP-2α.  
A later study suggested that AP-2α activated p21cip expression via the p53 binding 
sites at -2250 bp upstream of the transcription initiation site (McPherson et al., 
2002).  Furthermore, McPherson et al showed a direct protein-protein interaction 
between AP-2α and p53 within the nucleus of MCF-7 breast carcinoma cells and 
HCT116 colon carcinoma cells.  However, a drawback with this study is that MCF-7 
cells express barely detectable levels of AP-2α, whereas AP-2γ is predominant in 
this cell line.  Unfortunately, the antibody used against AP-2 does not discriminate 
between AP-2α, AP-2β and AP-2γ.  Nonetheless, this study showed AP-2α (or AP-
2γ) interacting with p53 resulted in an augmentation of p53-mediated transcriptional 
activation of the CDKN1A gene.  A ChIP assay on the p21cip promoter suggested 
that AP-2 was brought to the p53 binding site through interaction with p53 and this 
resulted in cell cycle arrest.  Recently, unpublished data obtained from EMSA assays 
performed in our lab have identified a different AP-2 binding site, to which both AP-
2α and AP-2γ bind, between - 121 to -91 bp within the p21cip proximal promoter 
region and not to the -101 to -71 bp site suggested in the Zeng et al (1997) study (Dr 
Angelo G Scibetta, Personal communication).  A schematic diagram in Figure 17 
summarises the different AP-2 binding sites within the p21cip promoter region 
identified in these studies. 
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Figure 17.  A schematic diagram showing the CDKN1A promoter region.  The location of the p53 
binding sites and potential AP-2α and AP-2γ occupancy within the CDKN1A promoter region is 
indicated.  AP-2α regulates CDKN1A expression directly or via interaction with p53 (McPherson et 
al., 2002; Zeng et al., 1997), whereas AP-2γ suppresses CDKN1A expression (Williams et al., 2009; 
Zeng et al., 1997) . 
 
 
Over-expression of functional AP-2α mediated by adenovirus in a lung carcinoma 
cell line also induced p21cip activation, inhibited cellular DNA synthesis and 
induced apoptosis compared to a LacZ-expressing control virus (Wajapeyee and 
Somasundaram, 2003).  The growth inhibition by AP-2α over-expression was less 
efficient in p21cip null than wild-type cells, suggesting that p21cip is required for 
AP-2α to inhibit cell growth efficiently.  In addition, different cancer cell lines with 
varying p53 status (wild-type versus mutant) were used to examine whether p53 was 
essential for AP-2α-mediated growth inhibition.  It was found that AP-2α efficiently 
inhibited the growth of cancer cells independent of their p53 status.  However, when 
AP-2α was over-expressed in p53 null cells the p21cip induction was much lower 
compared to cells with wild-type p53.  This suggested that AP-2α can exert growth 
inhibition via the p21cip pathway using both p53 dependent and independent 
mechanisms.  Interestingly, a separate study demonstrated that forced expression of 
not only AP-2α but also AP-2γ in the non-expressing MDA MB-231 breast 
adenocarcinoma cell line significantly reduced the fraction of cells in S-phase and 
increased the number arrested in G1/G0 phase (Li et al., 2006a).  Up-regulation of 
p21cip mRNA and protein levels was observed following over-expression of either 
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AP-2α or AP-2γ, and a ChIP assay showed that both AP-2α and AP-2γ bind to the 
p21cip proximal promoter region in vivo.  Cell cycle arrest at G1 phase and reduced 
DNA synthesis in S-phase mediated by AP-2α or AP-2γ over-expression were not as 
pronounced as in p21cip-negative HCT116 cells compared to p21cip-positive cells 
indicating the importance of p21cip as an AP-2 downstream target in cell cycle 
modulation.  However, the drawback of this study is that the expression levels of AP-
2α and AP-2γ in these experiments were achieved using adenovirus vectors which 
are highly efficient and lead to very high levels of protein.  This can lead to non-
physiological effects as suggested by the control virus (expressing adenovirus 
backbone) which also induced significant p21cip expression in this study.  In 
addition to p21cip up-regulation, this study also showed that AP-2α and AP-2γ over-
expression significantly decreased cyclin D1 mRNA and protein levels and 
decreased Rb phosphorylation, resulting in cell cycle arrest.  Based upon these 
findings, the authors proposed a model in which AP-2α and AP-2γ can both mediate 
cell cycle arrest by upregulating p21cip expression and repressing cyclin D1, Rb is 
therefore hypophosphorylated leading to E2F inactivation.  This conclusion however 
does not agree with tumour expression data for AP-2γ discussed above, or with 
studies on the activity of AP-2γ at the p21cip promoter discussed below. 
 
As mentioned earlier, AP-2α has been suggested to interact with p53, and a study 
demonstrated that AP-2α can form a stable complex with p53 in vitro by GST 
pulldown assay where the AP-2α-binding region of p53 was localised to residues 
305-375 and involved the tetramerization domain (Stabach et al., 2006).  The 
interaction between AP-2α and p53 was also investigated in vivo by co-
immunoprecipitation, but again used an antibody which can not distinguish between 
AP-2α, AP-2β and AP-2γ proteins.  When co-transfecting expression vectors 
carrying various p53 mutations or wild-type p53 with a p53 luciferase reporter either 
with or without an expression vector for AP-2α, it was found that coactivation by 
AP-2α required the presence of p53 proteins with an ability to activate transcription 
that is comparable to wild-type p53.  This study also looked at the ability of AP-2α 
to induce endogenous p21cip expression in HCT116 cells with different p53 status: 
wild-type, mutant and non-expressing.  It was found that the ability of AP-2α  to 
bind to the p53-binding site at -2250 of the p21cip promoter and to induce p21cip 
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expression required the presence of wild-type p53.  However, these authors also 
reported that over-expression of AP-2α reduced the stability of p53 protein.  These 
results indicate that the role of AP-2α in the regulation of p21cip through interaction 
with p53 is complex, and may involve two competing mechanisms: 1) a direct 
transcriptional coactivation of p53 by AP-2 and; 2) a negative regulation of the levels 
of p53 expression by altering the stability of p53.  These authors also proposed three 
models for the partnership between AP-2 and p53 during gene transactivation:   
 
1. p53 binds to its regulatory site on the p21cip promoter where the interaction 
with AP-2 occurs, allowing the association of AP-2 with p21cip promoter to 
increase transcriptional signalling to the basal transcriptional complex (BTC).   
2. p53 binding to its regulatory site on the p21cip promoter induces chromatin 
changes, allowing AP-2 to bind to its regulatory site.   
3. both p53 and AP-2 factors bind to their own regulatory sites on the p21cip 
promoter and the interaction between AP-2 and p53 exerts a transcriptional 
signal to the BTC.  Diagram in Figure 18 summarises these three proposed 
models. 
 
 
 
Figure 18.  Models for AP-2 coactivation of p53-mediated.  BTC – basal transcriptional complex 
located at the transcriptional start site.  This diagram is taken from (Stabach et al., 2006) 
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Moreover, both AP-2α and AP-2γ expression have been shown to be elevated at the 
mRNA and protein levels upon p53 over-expression (Li et al., 2006b).  p53 has been 
suggested to up-regulate the expression of AP-2α and AP-2γ by binding to their 
promoter regions and inducing chromatin remodelling.  Although the expression of 
AP-2α and AP-2γ were increased, their mRNA stability was shortened after 
adenovirus-mediated p53 infection compared to the control.  This study proposed 
there may be a feedback loop between AP-2 and p53, such that when AP-2 
expression is low, it induces p53, and vice versa.   
 
Overall, although several lines of evidence have demonstrated that AP-2α can 
activate p21cip via direct binding to the proximal promoter site, or through 
interaction with p53 on the p21cip promoter, the role for p53 in the regulation of 
p21cip expression by AP-2 family members and the interplay between AP-2 and p53 
remains unclear. 
1.21. AP-2 and Apoptosis 
Several studies have suggested AP-2 transcription factors play a role during 
apoptosis.  Over-expressing AP-2α in lung carcinoma cells has been shown to induce 
cell cycle arrest and apoptosis due to an activation of the mitochondrial pathway 
(Wajapeyee et al., 2006).  Over-expression of AP-2α resulted in activation of 
caspases 3, 8 and 9 and also coincided with PARP cleavage.  AP-2α-induced 
apoptosis was inhibited by the addition of a caspase-9 inhibitor, indicating that AP-
2α induced apoptosis through the intrinsic pathway.  Mitochondrial membrane 
potential was reduced in AP-2α over-expressing cells compared to control cells, 
resulting in the release of mitochondrial intramembrane proteins such as cytochrome 
c into the cytosol.  Moreover, it was suggested that AP-2α induced apoptosis through 
transcriptional repression of the anti-apopototic protein Bcl-2 in colon carcinoma 
cells.  Apoptosis was accompanied by exogenous AP-2α occupancy of the proximal 
promoter region of BCL2.  Ectopic expression of Bcl-2 inhibited AP-2-induced 
apoptosis suggesting that the repression of Bcl-2 gene expression is essential for AP-
2α-mediated apoptosis.  An earlier study showed that over-expression of AP-2α not 
only inhibited the growth of cancer cells but also enhanced their chemosensitivity to 
the anticancer drugs adriamycin and cisplatin compared to control cells (Wajapeyee 
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and Somasundaram, 2003).  This suggested that AP-2α expression is intrinsic to the 
chemosensitivity of these cells.   
 
In contrast to the findings of Wajapeyee and colleagues, AP-2α expression was 
shown to be down-regulated by tumour necrosis factor-α (TNF-α) during TNF-α-
induced apoptosis in breast cancer cells (Nyormoi et al., 2001).  Apoptosis was 
accompanied by caspase-6 mediated AP-2α cleavage which resulted in loss of AP-
2α transcription activity.  These observations suggest that AP-2 proteins might be 
involved in different apoptotic pathways but the exact mechanism is not completely 
clear to date.  Nonetheless, over-expression of AP-2α in the mammary gland in 
transgenic mice resulted in inhibition of mammary gland growth and morphogenesis 
(Zhang et al., 2003) whereas over-expression of AP-2α and AP-2γ in the mouse 
mammary gland resulted in increased apoptosis (Jager et al., 2003). 
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1.22. Work leading up to this project 
1.22.1. AP-2γ and MCF-7 cells 
As discussed above, our previous studies indicated that AP-2γ in particular may be a 
useful prognostic marker in breast cancer and we set out to define the pathways 
activated by AP-2γ by determining its target genes in breast epithelial cells.  The 
ERα positive MCF-7 breast carcinoma cell line was used as a model because it 
exclusively expresses AP-2γ (Williams et al., 2009).  The RNAi technique was used 
to knockdown AP2-γ levels and samples were analysed using Affymetrix 
microarrays to determine the AP-2γ dependent transcription profile.  These 
experiments identified a total of 254 highly significant gene expression changes 
(p<0.01).  Of these, a large proportion of the significantly down-regulated genes 
were cell cycle related, as shown in Figure 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Distribution of functional classes of significantly regulated genes following AP-2γ 
silencing in MCF-7cells.  The numbers of genes are indicated adjacent to the pie chart or with the 
text.  Down-regulated genes are represented in green and up-regulated genes are in red.  Data taken 
from Christopher Williams, PhD Thesis, 2007. 
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In parallel to the microarray experiments, changes in cell cycle regulation were 
observed in AP-2γ silenced MCF-7 cells.  Using flow cytometry, elevated G1 and 
reduced S-phase populations were observed indicating that AP-2γ plays a role in the 
control of cell proliferation, particularly at the G1/S transition, as shown in Figure 
20.  Additional assays were performed to examine if loss of AP-2γ induced apoptosis 
in these cells and it was concluded that there was no evidence of increased apoptosis 
in silenced cells (Williams et al., 2009). 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 20.  Cell cycle and BrdU FACS analysis show cell cycle arrest at G1/S-phase in AP-2γ 
silenced MCF-7 cells.  MCF-7 cells were transiently transfected with AP-2γ specific siRNA and were 
harvested and fixed 72 hours post-transfection. (A) Cell cycle analysis for DNA content. (B) FACS 
analysis for BrdU incorporation.  (C) Whole cell lysates were separated by SDS/PAGE and blotted to 
a membrane.  Blots were probed with primary antibody against AP-2γ.  Ku-70 was used as loading 
control.  Data taken from Christopher Williams, PhD Thesis, 2007. 
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Furthermore, elevated p21cip mRNA and protein levels were observed in AP-2γ 
depleted MCF-7 cells, as shown in Figure 21.  ChIP assays showed AP-2γ occupancy 
at the proximal promoter region of the CDKN1A gene in cycling MCF-7 cells, but 
occupancy decreased in silenced cells, as shown in Figure 22.  This suggested that 
transcriptional repression of p21cip by AP-2γ could be part of its role in cell cycle 
control in breast carcinoma.   
 
 
 
Figure 21. Elevated p21 mRNA and protein are observed following transient transfection with 
AP-2γ targeting siRNA in cycling MCF-7 cells. Cells were transfected with AP-2γ specific siRNA 
for 72 hours and RNA was extracted to make cDNA. (A) Quantitative PCR analysis of CDKN1A 
mRNA levels.  Data were normalied to GAPDH mRNA levels and mock control values were set at 1 
to generate relative mRNA levels.  (B) Whole cell lysates were separated by SDS/PAGE and blotted 
to a membrane.  Blots were probed with primary antibody against AP-2γ.  Ku-70 was used as loading 
control.  Data taken from Christopher Williams, PhD Thesis, 2007. 
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Figure 22. ChIP assay showing reduced AP-2γ and p300 occupancy and increased AcH4 levels 
at the -21/+44 CDKN1A promoter region in AP-2γ silenced MCF-7 cells. (A) MCF-7 cells were 
transfected with non-silencing siRNA and AP-2γ specific siRNA for 72 hours before harvested for 
ChIP assay for AP-2γ, p300 and H4 acetylation (AcH4).  Chromatin samples were analysed by qPCR 
using the -21/+44 primers, data averaged from three PCR replicates, ± standard error.  Results were 
normalised to a no antibody control and expressed relative to the total input chromatin.  (B) CDKN1A 
levels were analysed by qPCR and normalised to GAPDH mRNA levels. The non-silencing control 
value was set at 1 to generate relative mRNA levels.  The graph represents data averaged from three 
PCR replicates, ± standard error.  Whole Cell extracts (5µg/lane) were separated by SDS/PAGE and 
blotted to a membrane. Blots were probed with primary antibodies against Ku-70, p21, and AP-2γ.  
Data taken from Dr Christopher Williams, PhD Thesis, 2007. 
 
 
Since MCF-7 cells predominantly express AP-2γ and carry wild-type p53, it is 
interesting, given the conflicting published data reviewed above, to investigate 
further the interplay between AP-2α and AP-2γ on the one hand and the role of p53.  
In particular, will silencing either AP-2α or AP-2γ or both in breast cancer cell lines 
that express both factors induce similar changes in the cell cycle and will the p53 
status (wild-type or mutant) alter the outcome.   
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1.22.2. KIAA1324 
The Affymetrix microarray data showed that KIAA1324 was the most significantly 
down-regulated gene following AP-2γ-silencing in MCF-7 cells.  Analysis of 
published literature has shown that the function of KIAA1324 has not yet been 
identified but its structure has features of a membrane-bound receptor so it may be 
involved in promoting cell growth.  Immunohistochemical staining showed 
KIAA1324 to be present at the cell membrane and in the cytoplasm of endometrial 
tissues (Deng et al., 2005) and these authors also suggested that KIAA1324 may be 
regulated by oestrogen and associated with more aggressive forms of endometrial 
cancer.  A ChIP assay showed that AP-2γ interacts with the proximal promoter of 
KIAA1324 and this interaction was reduced upon AP-2γ silencing in MCF-7 cells.  In 
addition, histone 4 acetylation was also decreased, concurrent with decreased 
transcriptional activity upon AP-2γ silencing, as shown in Figure 23.  This strongly 
suggested that KIAA1234 is directly regulated by AP-2γ.  
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Figure 23.  AP-2γ occupancy at the proximal region of the KIAA1324 promoter is reduced in 
AP-2γ silenced MCF-7 cells.  Top: Cells were transfected with non-silencing control siRNA or AP-
2γ specific siRNA for 72 hours, and then harvested for ChIP assay.  Chromatin samples were 
precipitated for either AP-2γ or acetylated histone 4 (AcH4) and were analysed by qPCR using 2321F 
/ 2191R primer set which amplifies at -110 bp upstream of the TSS of KIAA1324. Results were 
normalised to a no antibody control and expressed relative to the total input. Bottom:  The schematic 
diagram shows 15 potential AP-2 binding sites (vertical lines) at the KIAA1324 promoter region.  
Previous analysis of ChIP samples using the 1508 / 1571 and 2312 / 2391 primer sets suggested that 
AP-2 binding was confirmed to the -110 region of the promoter.  Data derived from Dr Karsten 
Friedrich, personal communication. 
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1.23. Project Aims  
1.23.1. AP-2 Study 
MCF-7 cells have wild-type p53 and only express AP-2γ and, given the published 
data reviewed above that suggest AP-2 regulation of p21cip may involve p53, we 
hypothesised that breast cell lines with AP-2α expression and/or mutant p53 would 
respond differently to AP-2 silencing.  To study this I aimed to  
• Determine if silencing of AP-2 transcription factors in cells expressing both 
AP-2α and AP-2γ with wild-type and/or mutant p53 have different effects on 
the cell cycle?   
• To investigate further gene regulation by AP-2 proteins and their role in 
breast cancer using expression arrays. 
 
Three AP-2α and AP-2γ expressing breast cell lines were chosen for this study: 
o T47D mammary carcinoma cells (mutant p53) 
o H3396 mammary carcinoma cells (wild-type p53) 
o MCF10A non-tumourigenic cells (wild-type p53) 
 
With these aims, I performed: 
• RNAi to knock down transiently AP-2α and AP-2γ independently and both 
together to achieve single and double knock down in these cells. 
• SubG1 and apoptosis analysis to determine if cells become apoptotic 
following AP-2 knockdown. 
• FACS analysis to generate cell cycle profiles to observe the effect of 
silencing AP-2α and AP-2γ alone or together on cell cycle progression. 
• BrdU analysis to determine if AP-2α or AP-2γ or both are required for cell 
proliferation. 
• Affymetrix GeneChip oligonucleotide microarrays to define AP-α and AP-2γ 
dependent transcriptional changes in MCF10A cells. 
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1.23.2. KIAA1324 Study 
KIAA1324 has been shown to be the most significant down-regulated gene in MCF-
7 cells following AP-2γ silencing, therefore, it is interesting to examine if this novel 
protein may play a role in breast tumourigenesis, for example by altering cell growth.  
To study this I aimed to: 
 
• Generate a KIAA1324 antibody to check protein expression in a panel of 
breast cell lines by western blotting. 
• Generate a KIAA1324 expression clone and stably transfect into non-
expressing immortalised mammary epithelial MCF10A cells. 
• Generate shRNA constructs to inducibly knock-down KIAA1324 expression 
in MCF-7 cells. 
• Examine MCF10A KIAA1324 expressing clones and MCF-7 KIAA1324 
silenced cells for altered growth compared to control cells using cell count 
assays, MTS assays, FACS analysis and soft agar growth assays. 
• Determine of KIAA1324 is an oestrogen regulated gene in ER-positive breast 
tumour lines. 
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Chapter 2 
Materials and Methods 
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2. Tissue Culture 
2.1. Culture Media and Cell Lines 
All cell lines used in this study were obtained from ATCC except for the ERα 
positive breast cancer cell line H3396 which was established from a malignant 
pleural effusion at the Bristol-Myers Squibb Pharmaceutical Research Institute 
(LaBaer et al., 1997).  All cell lines were maintained at 37oC.  Cells were changed 
with fresh media every 2 days and passaged regularly to maintain exponential 
growth.  Table 2 summarises the conditions for culturing these cell lines. 
 
Cell line Cell type Media Supplements Incubation 
condition 
MCF-7 Mammary 
Carcinoma 
DMEM 10% FCS, 
10μg/ml insulin 
10% CO2  
T47D Mammary 
Carcinoma 
DMEM 10% FCS 10% CO2 
MCF10A Immortalised 
Mammary 
myo-epithelial 
DMEM: 
HAMS 
F12 (1:1) 
5% Horse serum, 10μg/ml 
insulin, 5μg/ml 
hydrocortisone, 100ng/ml 
choleratoxin, 20ng/ml 
epidermal growth factor 
5% CO2  
H3396 Mammary 
Carcinoma 
RPMI 10% FCS 10% CO2 
HepG2 Hepatocellular 
carcinoma 
DMEM 10% FCS 10% CO2 
 
Table 2.  Culture condition of all cell lines used in this study. 
 
2.2. RNA Interference (RNAi) 
2.2.1. siRNA Selection 
Seven interfering RNAs (siRNA) specific to AP-2γ and three siRNA 
oligonucleotides specific to AP-2α were used in this study.  Two non-specific 
random sequences were tested for a non-silencing control (Qiagen).  Each siRNA 
obtained consisted of 21 nucleotides on both sense and antisense strands forming a 
siRNA duplex with 2 nucleotides overhang on each 3’end.  siRNA to DNA target 
sequences beginning with AA had dTdT ovehangs on both strands, whereas, siRNA 
to DNA target sequences beginning with any 2 bases (dXdY), the sense strand had a 
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dTdT overhang but the antisense strand had a dXdY overhang corresponding to the 
first 2 bases of the target.  siRNAs were diluted with RNAase-free siRNA suspension 
buffer according to the manufacturer’s protocol to obtain a 20μM stock solution and 
stored at -20oC.  The details are summarised below.    
 
AP-2γ specific siRNAs 
Company Name    Target Sequence 5’ – 3’ 
Qiagen  AP-2γ_1   AATGAGATGGCAGCTAGGAAG 
AP-2γ_2   GCGGCCCAGCAACTGTGTAAA 
AP-2γ_3   CCACACTGGAGTCGCCGAATA 
 
Dharmacon J-005238-05   AACCGATAATGTCAAGTACGA 
  J-005238-06   GGACACTGGAGTCGCCGAATA 
J-005238-07   TAGTAAACCAGTGGCAGAATA 
J-005238-08   TTGGACAAGATTGGGTTGAAT 
 
AP-2α specific siRNAs 
Company Name    Target Sequence 5’ – 3’ 
Qiagen  AP-2α_1   AACATCCCAGATCAAACTGTA 
  AP-2α_3   ATGTACCTCAGCAACAACC 
Dharmacon AP-2α_2   GTAGAAGACCCGGGTATTA 
 
KIAA1324 specific siRNAs 
Company Name    Target Sequence 5’ – 3’ 
Dharmacon J-010726-05   GCAAAGAGTCTGAGTACCATT 
  J-010726-06   GGAGCTAAATCGAGGCAATTT 
J-010726-07   CTGCAAACCTGGCACGTATTT 
J-010726-08   GGATCAACTTCGAGTACAATT 
 
Non Silencing Control siRNA 
Company Name    Target Sequence 5’ – 3’ 
Qiagen  Negative Control siRNA  AATTCTCCGAACGTGTCACGT 
AllStar Negative Control siRNA Proprietary 
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2.3. Transient Transfection of siRNA in T47D, H3396, MCF-7, 
MCF10A and HepG2 cells 
All siRNA transfection experiments were carried out in a 6-well format.  All 
amounts and volumes below are given on a per well basis.  Cells were seeded a day 
prior to transfection to obtain 30 – 40% confluency on the following day.  All siRNA 
transfection was performed 24 hours later using INTERFERin transfection reagent 
(PolyPlus) according to the manufacturer’s instructions.  Cells were incubated at 
37oC and were harvested at 48, 72 and 96 hours post-transfection for AP-2α and AP-
2γ knock-down assay and monitored for knockdown efficiency by western blotting.  
The table below summarises the transfection conditions of all these cell lines. 
 
Cell line Plating Density Final Concentration of 
siRNA per well 
MCF-7 2 × 105 cells/ml 25nM 
T47D 1.5 × 105 cells/ml 15nM 
MCF10A 1 × 105 cells/ml 15nM 
H3396 1.5 × 105 cells/ml 20nM 
HepG2 1.5 × 105 cells/ml 20nM 
 
Table 3.  This table summerises the transfection conditions of all cell lines used in this study. 
 
2.4. Western Blotting 
2.4.1. Whole cell extracts 
Cells were washed twice with ice-cold PBS and lysed on the plate in Urea whole cell 
lysis buffer (8M Urea, 1M Thiourea, 0.5% CHAPS, 24mM Spermine, 50mM DTT). 
Extracts were collected using cell scrapers. Alternatively, cells were trypsinised and 
collected with complete medium and centrifuged at 10,000 rpm for 5 minutes to 
collect cell pellets.  Cells were washed with ice-cold PBS and centrifuged again 
before being lysed with Urea buffer.  The cell lysates were stored at -20oC. 
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2.4.2. Determination of Protein Concentration 
The approximate protein content of each extract was determined using the Bradford 
Assay (Biorad Reagent) and a Bovine Serum Albumin (BSA) standard curve ranging 
from 0 – 10mg/ml. Briefly, Biorad protein assay 5× dye reagent was diluted with 
distilled water to obtain 1× concentration, and 200μl was aliquoted to each well of a 
96-well plate.  One μl of protein sample was added to each well in duplicates.  
Protein standards were prepared by diluting 10mg/ml BSA with distilled water to 
obtain solutions of a concentration of 0, 0.5, 1, 1.5, 2 to 10 mg/ml.  Protein 
concentrations were read on a Dynex Revelation 4.04 spectrophotometer set at a 
560nm wavelength.  Typically 10μg of whole cell extract were used in SDS PAGE. 
 
2.4.3. SDS PAGE and Western Blotting 
Samples were separated on a 7 - 12% SDS PAGE gels (National Diagnostics) 
prepared with a BioRad Mini Protean system.  Full range molecular weight Rainbow 
Markers (Amersham) were loaded to allow size determination of detected proteins.  
Separated proteins were transferred onto polyvinylidene difluoride membrane 
(PVDF) using a semi-dry blotting apparatus (Biorad) immersed in transfer buffer 
(700ml distilled water, 200ml Methanol and 100ml Tris-Glycine) at 25V for 45 mins 
to 1 hour.  The membrane was blocked (5% Marvel 0.1% Tween-20 in PBS) for an 
hour at room temperature or overnight at 4oC.  The primary antibody was diluted in 
blocking solution and incubated with the membrane for an hour at room temperature 
or overnight at 4oC.  Excess primary antibody was removed by 3 times 10-minute 
washes with blocking solution before incubation with the appropriate secondary for 1 
hour at room temperature.  The membranes were washed in blocking solution 3 times 
and a further two times in PBS / 0.1% Tween-20 to remove excess secondary 
antibody. Supersignal WestFemto reagents (Pierce) were used for 
chemiluminescence and the membrane was exposed to Kodak BMR autoradiograph 
film.  Where necessary, membranes were then stripped for 15 minutes at 55˚C in 
strip buffer (1M Tris HCl pH6.7, 2% SDS, 100mM β-Mercaptoethanol), re-blocked 
for 1 hour at RT and finally re-probed for Ku-70, PCNA or HSC 70 as a loading 
control.  A summary of the antibodies used and the appropriate dilutions is shown 
in Table 4. 
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Antigen Animal origin Source Dilution 
Molecular 
Weight 
(KDa) 
Gel 
percentage 
AP-2γ 
(6E4/4) Mouse  Lab Reagent 1:1000 
50 12% 
AP-2α (3B5) Mouse  Santa Cruz 1:1000 50 12% 
CDK2 Mouse Santa Cruz 1:500 36 12% 
CDK4(DCS1
56) Mouse 
Cell 
Signalling 1:1000 
36 12% 
Cyclin D1 
(DCS6) Mouse 
Cell 
Signalling 1:1000 
36 12% 
Cyclin D3 
(DCS22) Mouse 
Cell 
Signalling 1:1000 
36 12% 
Cyclin E2 
(HE12) Mouse Santa Cruz 1:1000 
36 12% 
Caspase Mouse 
Alexis 
Biochemical
s 
1:1000 
30 
uncleaved 
17/12 
cleaved 
Invitrogen 
gradient gel 
ERα (HC-20) Rabbit Santa Cruz 1:500 66 12% 
KIAA1324 Rabbit Ka Yi Chan 1:1000 121 7% 
Ku-70 (C19) Goat  Santa Cruz 1:1000 70 12% 
p21 (DCS60) Mouse Cell Signalling 1:1000 
21 12% 
p27 (# 2552) Rabbit Cell Signalling 1:1000 
27 12% 
p53 (DO1) Mouse  Santa Cruz 1:1000 53 12% 
phospho-p27 
(thr187) 
(2B10B7) 
Mouse Invitrogen 1:1000 
27 12% 
phospho-Rb 
(ser807/811) Rabbit 
Cell 
Signalling 1:1000 
110 7.5% 
phospho-Rb 
(ser795) Rabbit 
Cell 
Signalling 1:1000 
10 7.5% 
PARP-1 Mouse Santa Cruz 1:250 
116 
uncleaved 
85 cleaved 
Invitrogen 
gradient gel 
PCNA Mouse Santa Cruz 1:10,000 30 12% 
HSC 70 Mouse Santa Cruz 1:10,000 70 12% 
Table 4. List of antibodies and their dilutions for western blotting. 
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2.5. Flow Cytometry 
Flow cytometry analysis was performed with the assistance of Dr Derek Davies and 
colleagues at the CRUK FACS Laboratory, London Research Institute, Lincoln’s Inn 
Fields.  All protocols were obtained from CRUK FACS intranet. 
 
2.5.1. Propidium Iodide staining for Sub-G1 apoptosis analysis 
Culture media containing ‘floating’ dead cells were collected in Falcon tubes.  Cells 
were washed with PBS prior to trypsinisation then collected with complete media 
and placed with the dead cells in Falcon tubes.   Cells were centrifuged at 2000 rpm 
and cell pellets were further washed with PBS containing 0.1% BSA and 1mM 
EDTA to remove traces of media before being fixed in ice cold 70% ethanol which 
was added dropwise while vortexing to prevent excess clumping.  Cells were 
incubated on ice for at least 30 minutes.  Ethanol was discarded after centrifugation 
at 2000rpm and cells were washed twice with phosphate-citrate buffer (0.2M 
Na2HPO4 / 0.1M Citric acid).  Treatment with 50μl of RNase (100μg/ml) for 5 
minutes at room temperature ensured only DNA would be stained.  Propidium Iodide 
(PI) (50μg/ml) was then added to the cells and left for 30 minutes at room 
temperature in the dark before samples were analysed by flow cytometry.   
 
2.5.2. Propidium Iodide staining for cell cycle analysis 
An identical procedure as the PI staining for Sub-G1 apoptosis analysis was followed 
except cells were washed with PBS instead of phosphate-citrate buffer. Same 
acquisition was applied as in SubG1 analysis. 
 
2.5.3. Bromodeoxyuridine Staining 
Culture media were supplemented with 10μM BrdU for 30 minutes before cell 
harvest.  Cells were harvested, washed and fixed with 70% ice cold ethanol as 
described above.  Ethanol was discarded and cells were washed twice with PBS.  
After centrifugation at 2000rpm cells were treated with 2M hydrochloric acid (HCl) 
for 30 minutes at room temperature.  Cells were then washed twice in PBS and once 
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in PBS-T (PBS containing 0.1% BSA and 0.2% Tween-20 at pH 7.4) to ensure 
complete removal of hydrochloric acid as any free acid may denature the BrdU 
antibody.  Two μl of anti-BrdU antibody (Becton Dickinson) was added directly to 
the cell pellet and incubated in the dark for 20 minutes at room temperature.  Cells 
were then washed twice in PBS-T.  Cells were stained with 50μl of FITC-conjugated 
rabbit anti-mouse F(ab')2 fragments (DAKO) and incubated for 20 minutes at room 
temperature in the dark, followed by one wash in PBS.  Treatment with 50μl of 
RNase (100μg/ml) for 15 minutes at room temperature ensured only DNA would be 
stained.  PI (50μg/ml) was then added to the cells and left for 30 minutes at room 
temperature before samples were analysed by flow cytometry. 
 
2.5.4. TMRE Assay 
Cells were harvested and washed as described above 48 hours post-transfection.  
Cells were collected in a FACS tubes and incubated with PBS containing 40nM 
tetramethylrhodamine ethyl ester (TMRE), a cell permeable cationic fluorescent dye, 
in the dark at 37oC for 20 minutes.  After incubation, cells were washed once with 
PBS and left on ice.  DAPI (200μg/ml) was added to samples to gate out dead cells 
shortly before acquisition. 
  
2.5.5. Acquisition Using CellQuest 
Flow cytometry was performed using a FACS Calibur (Becton Dickinson).  
Fluorochromes were excited by a 488nm laser and fluorescence was collected 
between 515 and 545nm for FITC and above 580nm for PI.  Data acquisition was 
performed using the CellQuest programme.  An acquisition dot plot was drawn with 
the X-parameter as forward scatter (FSC-H) and Y-parameter as side scatter (SSC-
H).  Both FSC-H and SSC-H define the cellular population, in which FSC-H 
measures cell size whereas SSC-H measures cell granularity or general shape.  Pulse 
processing of the PI signal was used to distinguish true G2 cells from G1 doublets 
which are shown in another acquisition dot plot with X-parameter as FL3-W (width) 
and Y-parameter as FL3-A (area).  An individual fluorescence channel can be 
monitored independently by using a histogram plot with cell count (Y-parameter) 
against fluorescence channel (X-parameter).  For SubG1 analysis that only used a 
 94
single flurochrome, PI, which was detected by FL3-H fluorescence channel and 
shown on X-parameter in a histogram (see Figure 24).  Cells in G2 phase have 
double the amount of DNA to G1 phase, thus by setting the G1 peak at 200 on the 
linear scale on the histogram and by adjusting FL3 Detectors/Amps thus can give a 
more accurate measurement of the percentage of cells in each phase.   
 
 
Figure 24.  A histogram plot showing the DNA content of the cells.  M1 = SubG1; M2 = G1; M3 = 
S-phase and M4 = G2/M-phase. 
 
BrdU analysis used 2 flurochromes, BrdU and PI, which are detected by FL1-H and 
FL3-H, and shown on the Y and X axis on dot plot respectively.  BrdU-positive cells 
would have an increase in FL1-H which can be quantitated by gating during data 
analysis.  Histograms were also applied during acquisition to measure the percentage 
of cells in G1, S and G2 phase by setting the G1 peak at 200 on FL3-H scale 
(see Figure 25).   
 
Figure 25. A dot plot showing BrdU analysis results. 
 
The TMRE assay also used 2 flurochromes, TMRE and DAPI, detected by FL2-H 
and FL4-H respectively (see Figure 26).  Normally 10,000 events were acquired for 
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SubG1 and BrdU assays, and 20,000 events for the TMRE assay.  Gating was 
applied to dot plots during or after acquisition to exclude cell debris and doublets.  
Regions were used to obtain the percentage of cells in each phase i.e. live, dead, 
BrdU and TMRE positive, during analysis in both BrdU and TMRE assays. 
 
 
 
Figure 26.  A dot plot showing TMRE analysis results.  Top region – Dead cells, Left region – 
apoptotic cells and right region – live cells. 
 
2.5.6. Caspase Assay 
siRNA transfection was performed on T47D cells as described above.  Cells were 
harvested 48 hours post-transfection and floating cells were collected in 1 ml 
complete media per well at 48 hours.  Cells were then transferred into eppendorf 
tubes.  As the Caspase-Glo 3/7 Assay kit (Promega) is designed for use with 96, 384 
and 1536-well formats, collected cells were transferred to a 96-well plate in order to 
be read for caspase activity in a luminometer.  One well of a 6-well plate is 
equivalent to 16 wells of a 96-well plate, therefore, cells from each well were divided 
between 16 wells in order to be plated at the correct proportion onto a 96-well plate 
(1 ml ÷ 16 = 62.5μl).  For accurate reading, 3 different portions of cells were 
aliquoted to eppendorf tubes in duplicate (1 portion = 62.5μl cells; 2 portions = 
62.5μl cells × 2, and 3 portions = 62.5μl cells × 3) before centrifugation at 3,000 rpm 
to collect cell pellets.  Cells were resuspended in 100μl complete media, and 50μl 
was aliquoted per well of a white-walled 96-well plate.  Caspase-Glo 3/7 substrate 
and buffer, which had equilibrated to room temperature, were mixed together, and 
equal volumes of mixture were added to each sample.  The plate was incubated at 
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room temperature in the dark and caspase activity (that is proportional to luminescent 
signal) was measured by luminometer every 30 minutes from 0 to 3 hours.  Caspase 
mixture and complete media were used as blanks for background correction. 
 
2.6. MTS Assay 
Cell proliferation assays were carried out using the CellTiter 96 Aqueous One Solution 
Reagent (Promega) that contains the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) known as MTS, 
which is used in conjunction with the electron coupling reagent phenazine 
methosulfate (PMS).  Mitochondrial enzymatic activity in viable cells reduces MTS 
to the water-soluble product formazan and this reduction is facilitated by PMS.  The 
ratio of MTS to PMS is 20:1 and stored at -20oC.  The number of living cells is 
directly proportional to the concentration of formazan in the sample and is 
determined by the absorbance at 490nm.  Briefly, cells were seeded at 100,000 
cells/well in a 96 well plate one day prior to MTS assay.  At the time of analysis, 
MTS/PMS reagent was diluted in serum free DMEM media in 1:5 ratio.  Media was 
removed from the plates and replaced by DMEM containing MTS/PMS reagent.  
Cells were incubated at 37oC and absorbance values were read between 2 to 6 hours 
after the addition of the reagents.  Absorbance values for wells containing medium 
only was used as background control. 
 
2.7. Soft Agar Assay 
The soft agar assay for testing anchorage independent growth assay was carried out 
by dissolving 1.25 and 0.65 grams of agar powder (BDH, VMR International Ltd) in 
100 ml distilled water to obtain 1.25% and 0.65% agar respectively.  The agar was 
autoclaved before use.  On the day of seeding cells, agar was melted in a microwave 
and the temperature was maintained at 50oC.  2x media for MCF10A and MCF-7 
cells were pre-warmed at 37oC.  For the bottom layer, 1 ml of 2x media was mixed 
with 1 ml of 1.25% agar per well of a 6-well plate format.  Agar was left to solidify.  
Meanwhile, cells were washed once with PBS before being trypsinised and counted 
and the volume was adjusted to obtain 30,000 cells per ml.  For the top layer, 1 ml of 
0.65% agar was mixed with 1 ml of 2x media containing 30,000 cells and plated 
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evenly on top of the bottom layer.  Agar was left to harden before incubating at 37oC.  
Cells were allowed to grow and form colonies in soft agar for 30 days before staining 
them with 500 μl of 0.005% crystal violet for an hour.  The numbers of stained 
colonies were counted manually. 
 
2.8. Immunostaining 
Sterile coverslips were stored in 70% ethanol prior to use.  On the day of seeding 
cells, coverslips were rinsed in PBS to remove ethanol completely.  Two coverslips 
were placed in each well of a 6-well plate before cells were plated on top.  
Transfection was performed as described above on the following day, and samples 
were analysed at time points thereafter.  Cells were washed twice with cold PBS and 
fixed with 2% paraformaldehyde in PBS for 10 minutes at room temperature.  Cells 
were permeabilized with PBS + 0.5% triton-X 100 for 5 minutes at 4oC, followed by 
3 times 5-minute PBS + 100mM glycine washes.  Cells were blocked in filtered 
immunofluorescence (IF) buffer (PBS, 7.7mM NaN3, 1% BSA, 0.2% triton-X 100, 
0.05% Tween-20) with 10% goat serum for 1 hour at room temperature.  Primary 
antibody was diluted in IF buffer + 10% goat serum and centrifuged at top speed for 
30 minutes to remove the pellet that forms.  After 1 hour blocking, cells were probed 
with primary antibody for 1 hour at room temperature, followed by 3 times 5-minute 
washes with IF buffer to remove excess antibody.  Secondary antibody was also 
diluted in IF buffer + 10% goat serum and centrifuged at top speed for 30 minutes 
followed by incubation for 1 hour.  After 3 times 5-minute washes with IF buffer, 
coverslips were rinsed in distilled water to eliminate salt traces.  Coverslips were 
mounted upside-down on a glass slide using permafluor mounting solution 
containing 2μg/ml DAPI, allowed to dry overnight at room temperature in the dark, 
and stored at 4oC before confocal microscopy examination.   Cells without primary 
and secondary antibody staining were used as double negative controls and cells with 
secondary antibody staining only were used for background correction.  The amount 
of antibody used for immunostaining is summarised in Table 5. 
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Target Primary 
Antibody 
Concentration of 
Primary 
Antibody 
Secondary 
Antibody 
Concentration 
of Secondary 
Antibody 
AP-2γ AP-2γ 
(6E4/4) 
1 in 200 AlexaFluor 546 
goat anti-mouse 
IgG 
1 in 500 
KIAA1324 KIAA1324 1 in 500 AlexaFluor 488 
goat-anti-rabbit 
IgG 
1 in 500 
 
Table 5. A list of antibodies used and their dilutions for immunostaining 
 
2.9. RNA extraction 
Cells were washed twice with ice cold PBS and collected by scraping or 
trypsinisation in 200μl PBS per well.  Cell suspensions from each well of a six well 
plate was pooled and centrifuged at 10,000g for 5 mins at 4oC.  1.2ml of TRIZOL 
reagent (Invitrogen) was added to the cell pellets and homogenised by piptteing 
gently.  At this stage, samples were stored at -80oC until they were confirmed to have 
good AP-2 knockdown by western blotting of parallel wells before proceeding.  
TRIZOL extracts were thawed completely at room temperature and 240μl 
chloroform was added per 1.2ml TRIZOL (1:5 ratio, chloroform:TRIZOL), vortexed 
for 15 seconds, and then incubated for 2-3 minutes at room temperature. Samples 
were then centrifuged at 12,000g for 15 minutes at 4˚C and the aqueous upper phase 
was transferred to new eppendorf tubes.  An equal volume of 70% ethanol was added 
and mixed by pipetting.  RNA extraction was carried out using RNeasy Mini column 
(QIAGEN) using the manufacture protocol, including the DNAse I digestion step for 
DNA removal.  RNA concentration was estimated by NanoDrop spectrophotometer 
(NanoDrop Technologies) and RNA quality and integrity was confirmed by Agilent 
2100 Bioanalyzer (Agilent Technologies) electrophoresis. 
 
2.10. Reverse Transcription Reaction  
Reverse transcription (RT) reactions were performed using TaqMan Reverse 
Transcription Kit or High Capacity cDNA Reverse Transcription Kit (Applied 
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Biosystems), and were prepared using sterile plasticware throughout and aerosol 
filter tips to reduce contamination.  One μg of total RNA was used to generate cDNA 
per reaction mix, which contained 5.5mM MgCl2, 2.5mM dNTP mix, 2.5μM 
Random Hexamers, RNase Inhibitor (0.4U/μl), MultiScribe Reverse Transcriptase 
(1.25U/μl) and RNAse free water to make the reaction volume up to 100μl.  
Reaction mixes were prepared on ice.  Samples were then transferred to a 
thermocycler and reactions incubated at 25oC for 10 minutes, 48oC for 30 minutes 
followed by 95oC for 5 minutes to inactivate the enzyme.  After the RT reaction it 
was assumed that 1μg of total RNA corresponded to 1μg of cDNA.  cDNA was 
stored at -20oC. 
 
2.11. Quantitative ‘Real Time’ PCR Reaction (qPCR) 
Prior to qPCR reaction, stock cDNAs (10ng/μl) were diluted in distilled water to 
obtain a final concentration of 15ng in 10μl.  A total volume of 25μl of qPCR 
reactions were prepared using 2X Universal PCR master mix (Applied Biosystems) 
in triplicate on a 96-well plate, containing 20× primer-probe mix, diluted cDNA and 
distilled water.  In order to assess qPCR reaction efficiency and allow relative 
quantification, an endogenous housekeeping gene (GAPDH) was detected at the 
same time as target gene in a single reaction mix.  In addition to the samples, a no 
template control (distilled water only) was included to control for DNA 
contamination of the samples.  The qPCR reaction was carried out on the Applied 
Biosystems StepOnePlusTM using the following cycling conditions: 50oC for 2 
minutes (AmpErase UNG step), 95oC for 10 minutes to activate the AmpliTaq Gold, 
then 40 cycles of 95oC for 15 seconds, 60oC for 1 minute.  Pre-designed transcript-
specific primer-probe sets for use in qPCR reactions were purchased from Applied 
Biosystems, the details of these are outlined in Table 6.  Briefly, a probe binds the 
DNA between the two primers and is dye labelled at the 5’ end whose fluorescence is 
controlled by a quencher at the 3’ end. As the reaction proceeds, the dye is cleaved 
from the probe and thus released from the quencher and fluorescent emission from 
the dye increases proportionally as the amplification progresses, allowing accurate 
quantification of the target sequence. 
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Transcript Assay ID Probe Dye 
Layer 
TFAP2C  Hs00231476_m1 FAM 
TFAP2A Hs00231461_m1 FAM 
KIAA1324 Hs00331399_m1 FAM 
CDKN1A Hs00355782_m1 FAM 
GAPDH 4319413E VIC 
 
Table 6. Details of primer-probe sets used in qPCR analyses 
 
Data were initially analysed using Applied Biosystems StepOnePlusTM software, 
which uses the exponential phase of qPCR for quantification.  The amplification 
plots were observed in both linear and semi-log plots, with the background corrected 
and the threshold cycles (Ct) determined.  PCR efficiency and the correlation 
coefficient were determined by plotting the slope of the standard curve.  A 100% 
efficiency corresponds to a slope of -3.32.  This means every 3.2 cycles the amount 
of amplification is 10-fold higher in a 10× dilution.  The PCR efficiency was 
considered satisfactory above 98% and only if all the samples fell within the points 
of the standard curve. Data were analysed according to the Standard Curve Method 
for relative quantification (Applied Biosystems, url).  Endogenous control gene 
(GAPDH) were used to standardise the amount of cDNA, to normalise the results of 
a variable target gene and to correct for sample-sample variations.  For each 
experimental sample, the relative quantity of target and endogenous reference levels 
were determined from the appropriate standard curve.  The target amount was then 
divided by the endogenous reference amount to obtain a normalised target value.  
The transfection control sample was used as a calibrator and each of the normalised 
target values was divided by the calibrator normalised target value to generate the 
relative expression levels.  Triplicate samples were used to generate standard errors.   
 
2.12. Gene Expression Microarrays 
2.12.1. Sample Preparation 
AP-2α and AP-2γ expression were knocked down in MCF10A cells individually and 
together as described in section 2.3.  RNA extraction was carried out as described 
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above.  The RNA concentration and purity were assessed using the Nanodrop 
spectrophotometer (see Figure 27).   
 
 
 
Figure 27. An example of RNA concentration and purity measured by Nanodrop 
spectrophotometer.   The ratio A260 / A280 gives an indication of protein contamination levels in a 
sample. A value of 1.8 upwards is generally considered pure. The ratio A260 / A230 indicates 
contamination with phenol and similar organic compounds. A value of 1.9 is generally considered 
completely pure. 
 
After establishing that all the RNA samples were sufficiently concentrated and pure, 
the RNA’s integrity was assessed using Agilent Bioanalyzer 2100 and RNA 6000 
LabChip kit (Agilent Technologies, Palo Alto, CA, USA), which allows visual 
examination of both 18S and 28S rRNA bands as a measure of RNA integrity.  The 
integrity of total RNA measured by Agilent Bioanalyzer 2100 software is given as 
the score of RNA Integrity Number (RIN) in a range from 10 (intact) to 1 (totally 
degraded).  This was performed as follows: a mini gel was prepared by placing 550μl 
of RNA 6000 Nano gel matrix into the top receptacle of a spin filter and spun for 10 
min at 15,000g. Gel dye mixture was prepared by adding 65μl filtered gel to 1 μl of 
RNA 6000 Nio dye and centrifuged for 10 mins at room temperature at 13,000g.  A 
new RNA Nano chip was placed on the Chip Priming Station and 9 μl of the gel-dye 
mix was pipetted at the bottom of each well.  Five μl of RNA 6000 Nano marker was 
loaded and each of the 12 sample wells. A total of 250ng of each RNA sample was 
loaded per well.  All the RNA samples and the ladder were denatured at 70oC for 2 
mins and loaded onto each of the 13 wells.  The Chip was vortexed for 1 min at 
3,500g and placed in the receptacle of the Bioanalyzer; the RNA assay was run for 
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approximately 30 mins. A representative example of good RNA quality with RIN 
scored as 10 is given as an electropherogram in Figure 28.   
 
 
 
Figure 28.  An example of Agilent Bioanalyzer Electropherogram from one of the total RNA 
samples showing a high intact total RNA with two clear peaks at 18S and 28S and RIN = 10.  x-
axis indicates Time and y-axis indicates Fluorescence. 
 
2.13. Affymetrix  GeneChip 
Preparation of samples for the microarray analysis followed the protocol of 
GeneChip®3’ IVT Express Kit supplied by Affymetrix.  The chips used were Human 
Genome U133 Plus 2.0 high-density oligonucleotide arrays (Affymetrix, url).  
Oligonucleotides of 25 base pairs in length are used to probe message levels in the 
samples.  Each gene of interest is represented by a set of oligonucleotides comprised 
of 11 probe pairs.  Each probe pair is composed of a perfect match (PM) probe 
against a section of the mRNA molecule of interest, and a mismatch (MM) probe that 
is created by changing the middle (13th) base of the PM with the intention of 
measuring non-specific binding. The HG-U133 Plus 2.0 array contains 54,000 probe 
sets, representing an estimated 47,000 human transcripts.  An overview of this 
procedure is shown in Figure 31.  Briefly, the protocol involved the reverse 
transcription of total RNA (100ng) using a T7-Oligo(dT) promoter primer in the 
first-strand cDNA synthesis.  A second strand of DNA was then synthesised, giving 
double-stranded cDNA.  After cleaning, this double-stranded cDNA was used as a 
template for in vitro transcription with biotinylated UTP and CTP, resulting in the 
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synthesis of “cRNA” incorporating biotin-labelled nucleotide analogues.  After 
cleaning, the quality and quantity of the unfragmented biotinylated aRNA were 
checked using the Nanodrop spectrophotometer and the Agilent Bioanalyzer 2100 
(see Figure 29) before fragmentation.  Fifteen μg of biotinylated aRNA was 
fragmented to produce RNA fragments ranging from 3 to 200bp (see Figure 30).   
 
 
  
 
Figure 29. Expected profile for a good quality biotin-labelled aRNA on the Agilent Bioanalyzer 
2100 
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Figure 30. Expected profile of a good quality fragmented aRNA on the Agilent Bioanalyer 2100. 
 
The labelled cRNA was hybridised to “probe” DNA sequences embedded on a 
microchip. The level of hybridisation to each probe was measured by scanning the 
chip for fluorescence produced by the biotin labels background (scanning and image 
analysis was performed by Tracy Chaplin, Institute of Cancer, Charterhouse Square).  
These fluorescence data were recorded as an image file, which was then processed to 
quantify the level of binding to each probe. The final check for hybridisation 
efficiency and integrity of the sample is by comparison of binding intensities of 3’ 
and 5’ ends of control RNAs. 
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Figure 31. Affymetrix GeneChip Eukaryotic Sample and Array Processing. A more detailed 
description of this procedure can be found in Section 3: Eukaryotic Sample and Array Processing of 
the GeneChip Expression Analysis Technical Manual (Affymetrix, url).   
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2.14. Microarray Data Analysis 
The data analysis and bioinformatics protocol employed in this thesis was designed 
and carried out by Dr. Claude Chelala (Institute of Cancer, Molecular Oncology and 
Imaging Centre) who very kindly gave her time and expertise to this section of the 
project. 
 
Data analysis was performed in the ‘R’ platform using the Bioconductor software 
packages (http://wwww.bioconductor.org). Bioconductor is an open source 
environment for statistical analysis of genomic data (Gentleman et al., 2004).  Figure 
32 below summarises the steps of microarray analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Four different steps in the Affymetrix data analysis 
 
 
2.14.1. Quality control assessment 
The expression data were read from the .CEL raw data files using the ‘affy’ package. 
As quality control is a crucial step for successful microarray data analysis, scanned 
images were first analysed using Simpleaffy, a Bioconductor package dedicated to 
Quality control (Simpleaffy) 
Normalization (RMA) 
Statistical analysis (LIMMA) 
Identification of differentially 
expressed genes 
Annotations (Affymetrix) 
            ‘R’ packages 
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Affymetrix quality control.  It uses a number of assessments including: scaling 
factor, the percentage of probe sets declared ‘present’ (% P) by the detection call 
algorithm, and the 3'/5' ratios of the signal intensity values for two house keeping 
genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin 
(ACTB).  
 
2.14.2. Normalization 
Gene expression data were normalized for each tissue type by computing the Robust 
Multichip Average (RMA) directly from the Affymetrix .CEL files. RMA consists of 
three steps: a background adjustment, quantile normalization and finally 
summarization.  After summarization using the median polishing, we applied a filter 
using the standard deviation of gene expression values to select the top 2500 genes 
on Human Genome U133 Plus 2.0.  
 
2.14.3. Identification of differentially expressed genes 
using LIMMA 
To identify differentially expressed genes we used LIMMA, a Bioconductor package 
designed for the differential expression analysis of microarray data (Smyth et al., 
2005).  LIMMA fits a linear model to the expression data for each gene and uses an 
empirical Bayes method to moderate the standard errors of the estimated log-fold 
changes.  It has been shown that LIMMA is particularly useful for analysis of 
experiments with small numbers of samples (Kooperberg et al., 2005). Gene 
annotations were obtained from R packages called plus2.  A double cutoff of False 
Discovery Rate (FDR) < 0.01 and a fold change ≥ 2 were selected. 
 
2.14.4. Unsupervised hierarchical Clustering 
In order to reveal the relationship between the specimens analyzed, unsupervised 
hierarchical clustering of samples and gene expression values was performed using 
the average linkage method and Euclidean distance measurements in R ‘hclust’ 
package. Average linkage clustering uses the average similarity of observations to 
compare two groups. This is a multivariate technique that puts samples into unknown 
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groups or clusters suggested by the data itself (and not defined a priori). The samples 
in a given cluster tend to be more similar then samples in different clusters. 
 
2.14.5. Ingenuity Pathway Analysis (IPA) 
The genes shown to be de-regulated in the Affymetrix analysis were subjected to 
Ingenuity Pathway Analysis (IPA, version 4.0). IPA is a web-based analysis software 
(www.Ingenuity.com) that can identify biological mechanisms, pathways and 
functions relative to a set of genes. The software is based on the IPKB (Knowledge 
Base database) which is one of the largest curated databases that contains millions of 
computable relationships between genes, proteins, drugs and diseases. 
 
IPA builds networks from the deregulated genes/proteins entered by the user by 
searching IPKB for interactions between focus genes or proteins (shows a direct 
interaction with other genes within the knowledge base) and all other gene objects 
present in the knowledge base. A set of networks is then generated with a list of the 
genes involved. A score indicating the likelihood that the gene was placed in a 
network due to random chance is also included.  A score of 2 would give 99% 
confidence that the focus genes are not there by chance and therefore this will be 
used as a cut-off in our analysis.  Functions associated with the deregulated 
gene/protein set can also be generated. The right-tailed Fisher’s Exact test is used to 
calculate significant functions with a p value <0.05 being significant. Using its own 
curation in conjunction with KEGG (Kyoto Encyclopaedia of Genes and Genomes) 
IPA can also generate a list of any canonical pathways affected by the deregulated 
data set. This provides information on the signalling and metabolic pathways 
altered.   
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2.15. Chromatin ImmunoPrecipitation Assays (ChIP) 
The conditions of all the ChIP assays presented in this thesis were previously 
optimised by Dr Karsten Friedrich in our laboratory (Williams et al., 2009). 
 
2.15.1. Preparation of soluble chromatin 
For analysing AP-2α and AP-2γ occupancy at the p21 promoter in T47D cells, AP-2 
factors were knocked down as described above in one 6-well plate per condition.  
Forty-eight hours later, chromatin was cross-linked by the addition of formaldehyde 
to a final concentration of 1% and incubated at 37oC for 10 minutes. Cross-linking 
was stopped by the addition of glycine to a final concentration of 0.125M and 
incubation at RT for 5 minutes with gentle rocking. Cells were washed twice with ice 
cold PBS then all 6 wells from each condition were detached using a cell scraper in 
PBS with Complete Proteinase Inhibitors (Roche) and pooled together before being 
pelleted at 3,000g for 5 minutes at 4oC.  The supernatant was removed and the 
resultant cell pellet was gently resuspended in 1ml of cell lysis buffer (5mM PIPES 
pH 8.0, 85mM KCl, 0.5% NP40, and Complete Proteinase Inhibitors from sigma).  
Cell lysis was performed on ice for 10 minutes followed by centrifugation to pellet 
the crude nuclei fraction (5,000g for 5 minutes, 4 ºC).  The pellets from each 6-well 
plate were resuspended in 500μl of nuclei lysis buffer (1% SDS, 10 mM EDTA, 50 
mM Tris-HCl pH 8.1) and incubated for 10 minutes at 0-4 ºC (care was taken to 
prevent SDS precipitation).  The chromatin was sheared to an average length of 
500bp by sonication. This was achieved using a 10 second pulse followed by a 30 
second rest for a total of 20 cycles at 30% amplitude on the Sonics Vibracell 
VCX500 using a 0.3cm tip. Sonications were performed on ice and a multiple tipped 
probe allowed simultaneous sonication of up to four microfuge tubes, maximising 
the homogeneity of sonication between experimental conditions.  Debris was pelleted 
by centrifugation at 14,000g for 10 minutes at 10oC and the supernatant transferred 
to a clean tube. 
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2.15.2. Immunoprecipitation 
After sonication, chromatin was diluted 10 fold in IP buffer (0.01% SDS, 1.1 % 
Titron X100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 167 mM NaCl) containing 
1x Complete and 0.2mM AEBSF protease inhibitors and blocker (0.1 mg/ml salmon 
sperm DNA (Sigma B8894) and 0.5 mg/ml BSA (Invitrogen 15634-017)) before 
being bulk pre-cleared using 50% (w/v) blocked Protein A Sepharose (PSA) for 1h 
with gentle rotation at 4oC, in order to reduce the level of background in IPs.  After 
pre-clearing, PSA was removed by centrifugation at 500g for 5 minutes and the 
supernatant transferred to a clean tube. 
 
For the ChIP experiments documented in this thesis looking at the differences in 
promoter occupancy after AP-2α and AP-2γ were knocked down singly or together 
compared to controls, it was important to ensure that the amount of starting 
chromatin was kept consistent between experimental conditions.  Therefore, at this 
stage a 125μl aliquot of the pre-cleared chromatin was taken for DNA isolation and 
quantification.  This sample was used as the total input chromatin.  The total input 
was precipitated in 2.5 volumes of ice-cold 100% ethanol and1/10 volume Na 
Acetate at -80oC overnight then washed in 70% ethanol.  The pellet was air-dried 
before proceeding. 
 
Equivalent amounts of chromatin, as determined by DNA concentration, were then 
aliquoted for each IP reaction.  A “no antibody control” was included as a 
background comparator for IP experiments.  The details of the antibodies used in 
ChIP are shown in Table 7.  IP reactions were incubated over night at 4oC with 
gentle mixing. 
 
Antibody Animal Origin 
Concentration to 
use per reaction 
 
Cat # Provider 
AP-2γ (H77) Rabbit 2 μg Sc-8977 Santa Cruz 
AP-2α Rabbit 2.5 μg 39001 Active Motif 
 
Table 7. Antibodies used in ChIP assays in this study. The amounts of AP-2α and AP-2γ 
antibodies were determined by Dr Karsten Friedrich.   
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The immune complexes were collected by adding 50 μl of blocked 50 % (w/v) PSA 
to each sample and incubating on a rotating platform at 4ºC for 1 hr.  The PSA beads 
were pelleted by centrifugation at 2,000g for 3 minutes at RT and the supernatant 
discarded.  PSA beads were washed for three minutes on a rotating platform using 
1.25 ml of wash solution and then centrifuged for 3 minutes at 2,000g at RT using 
the following wash conditions: 
 
• Wash Buffer 1: 2 mM EDTA , 20 mM Tris-HCl [pH 8.0], 0.1 % SDS, 1 % Triton 
X100, 150 mM NaCl 
• Wash Buffer 2: 2 mM EDTA , 20 mM Tris-HCl [pH 8.0], 0.1 % SDS, 1 % Triton 
X100, 500 mM NaCl  
• Wash Buffer 3: 1 mM EDTA , 10 mM Tris-HCl [pH 8.0], 1 % NP-40,  1 % 
Deoxycholate, 0.25 M LiCl 
• Wash Buffer 4: 1 mM EDTA , 10 mM Tris-HCl [pH 8.0],  
 
After the centrifugation, as much of the remaining TE as possible was removed 
without disrupting the PSA beads.  The antibody/chromatin complexes were eluted 
from the PSA using Chelex 100 beads based on the protocol described by Nelson and 
colleagues (Nelson et al., 2006).  The PSA beads were resuspended in 100μl of a 
10% (w/v) Chelex 100 suspension and boiled for 10 minutes.  After cooling, 2μl of 
proteinase K (10 mg/ml) and RNAse were added and incubated on a thermal mixer at 
55oC for 30mins (1100rpm).  Samples were boiled for a further 10 minutes to 
inactivate the proteinase K and then centrifuged at 12,000g for 1 minute (4oC).  The 
DNA supernatant (approximately 80μl) was then transferred to a new tube. A further 
120μl of water was added to the Chelex beads, vortex mixed and then centrifuged at 
12,000g for 1 minute (4oC).  The 120μl supernatant was then pooled with the 
previous supernatant.  Five μl of isolated DNA was used per reaction in a 
quantitative real time PCR reaction described below.  
 
2.16. Quantitative PCR for ChIP  
Quantitative “real time” PCR for ChIP was performed using promoter specific 
primer pairs and measured using the fluorescent SYBR Green dye as a detector.  
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Briefly, SYBR Green intercalates into double-stranded DNA and produces a 
fluorescent signal. The intensity of the signal is proportional to the amount of 
dsDNA present in the reaction.  Therefore, at each step of the PCR reaction, the 
signal intensity increases as the amount of specific product increases.   
 
Promoter specific primer pairs for CDKN1A promoter have been designed previously 
in the lab and the primer concentration has been optimised for each primer pair under 
standard PCR conditions.  For CCND3 promoter, a titration of primer concentration 
was performed.  Combinations of the final primer concentrations: 50nM, 300nM, 
900nM, were assessed for each primer pair.  All PCR products were visualised by 
agarose gel electrophoresis in order to confirm the presence of a single specific 
product.  Details of the primers used in ChIP are shown in Table 8.  PCR reactions 
(25μl) were prepared in triplicate on a 96-well plate using 5μl of eluted DNA per 
reaction. 2X SYBR green master mix (Applied Biosystems) was combined with the 
primers to the indicated concentration (see Table 8).  In addition to the samples, a 
“no template control” was included to look at DNA contamination of the buffers.  In 
order to assess the efficiency of the PCR reaction and to allow relative quantification, 
a standard curve was run alongside the samples. The standard curve used four 
separate dilutions of input chromatin and was prepared in duplicate; 10-5, 10-6, 10-7, 
10-8, 10-9 and 10-10.  The PCR reaction and initial data analysis were carried out as 
described in section 2.11.  The relative quantities of each PCR reaction were 
calculated from the standard dilution of input chromatin.  All samples including the 
“no antibody control” was normalised to the total input and the fold change to “no 
antibody control” of each specific IP was obtained by setting the “no antibody 
control” as 1. 
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Genomic 
Region 
Amplicon 
Location 
Primer Pairs 5’ – 3’ 
Final Primer 
Concentrations 
CDKN1A 
Promoter 
-21 +44 
TTGTATATCAGGGCCGCGCT 
CGAATCCGCGCCCAGCTC 
300nM 
300nM 
-4005 -
3931 
TGGCCCCTCTGTGAAAACAT 
TTCCTGTTCCTGGCTCTAACAAC 
300nM 
300nM 
CCND3 
Promoter 
+642 +740 
CGCGAAAGACACAGGAACC 
GGCTTCTCACAGCGTCTCC 
300nM 
300nM 
-107 -8  
CCTCGCGACGATGTAGCA 
GGAGAGCGCTCAGCCAAC 
300nM 
300nM 
-3307 -
3199  
AGGAGAGATACTTCTGCCTCACC 
CTCACCTGCCTCCCCAGT 
300nM 
300nM 
 
Table 8. Primers used for SYBR Green Quantitative PCR for analysis of ChIP elutes.  Amplicon 
Locations are relative to the start of transcription at +1. 
 
2.17. Luciferase Reporter assays 
2.17.1. Generation of Cyclin D3 Luciferase Reporter 
Constructs 
Three forward upstream primers and one reverse primer within Cyclin D3 5’ UTR 
region were designed to generate PCR fragments with an XhoI restriction site at the 
5’ end and a HindIII restriction site at the 3’ end (See Table 9).  These PCR 
fragments were cloned into a TA vector and then sequenced to confirm they were 
correct before being excised using Xhol/HinddIII digestion and were subsequently 
sub-cloned into a luciferase reporter plasmid, pGL3 basic (Promega).   
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Primer Name Primer Sequence 5’ to 3’ 
CyclinD3 (1) For ACTCGAGGGAGAGCGCTCAGCCAAC 
CyclinD3 (2) For ACTCGAGGAAAGTTCTCTGCACCCGGT 
CyclinD3 (3) For ACTCGAGGTCCGAGAAGCAAAATGGGA 
CyclinD3 Rev TAAGCTTATACTCGGGCAGCGAACAGGCA 
 
Table 9. Primers used to generate Cyclin D3 reporter constructs.  See Figure 54 in Chapter 3 for 
precise localisation of primers with respect to the CCND3 gene sequence. 
 
2.18. Transient Co-Transfection of Cyclin D3 Luciferase 
Reporter Constructs with AP-2 Expression Constructs in 
HEPG2 cells 
HepG2 cells were seeded in 24-well plates at 80,000 cells per well and were 
transfected in triplicate the following day using FuGENE 6 (Roche Molecular 
Biochemicals) or GeneJuice (Merck).  Initial transfection assays were used to 
optimise the CCND3-reporter concentration and subsequent assays incorporated 
increasing concentrations of expression plasmids for either AP-2α or AP-2γ 
(Bamforth et al., 2001).  Appropriate plasmid vectors (pGL3-basic or pcDNA3) were 
used as makeweight to ensure all cells were transfected with equal amounts of DNA 
within any one experiment.  To accurately show changes in luciferase reporter 
activity, cells were transfected with both the luciferase reporter construct and 0.25μg 
phRG-TK Renilla plasmid (Promega). The phRG-TK Renilla utilises a constitutively 
active promoter to drive the expression of Renilla luciferase, therefore allowing 
luciferase levels to be normalised between reactions.  After transfection cells were 
incubated for 48 hours before being assessed for luciferase reporter activity. Cells 
were washed twice with ice cold PBS, then lysed with 100μl in 1x passive lysis 
buffer (Promega) at RT for 15 minutes with shaking.  Thirty μl of cell lysates were 
transferred onto a white 96-well plate. Luciferase levels were determined using 
Promega’s Dual Luciferase kit according to the manufacturer’s instructions on the 
Luminoskan Ascent (Thermo Labsystems) luminometer.  Relative luciferase activity 
generated from each sample was normalised to the Renilla luciferase activity, and 
cells transfected with the CCND3 promoter luciferase reporter alone were set at 1 to 
generate fold change. 
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2.19. Generation of KIAA1324 expression clones 
An IMAGE clone carrying the complete KIAA1324 cDNA sequence (Clone ID 
5297393) was ordered from the I.M.A.G.E Consortium.  The vector was 
pBluescriptR and the cloning orientation was 5’ SalI/XhoI and BamHI 3’. 
 
2.19.1. Standard PCR reaction 
A total volume of 50μl PCR reaction was prepared using Promega GoTaq Flexi 
DNA Polymerase kit, each reaction containing 1x Colourless Flexi buffer, 2mM 
MgCl2, 0.2mM each dNTP, 0.2μM forward and reverse primers (sigma), 1.25U 
GoTaq DNA polymerase and 0.8μg KIAA1324 IMAGE clone.  The PCR reaction 
was carried out in a PTC-200 Peltier Thermal Cycler (MJ Research) with the cycling 
condition as follows: 2 minutes at 95oC for initial denaturation, then 25 cycles of 30 
seconds at 95oC denaturation, 45 seconds at 67oC annealing, 45 seconds at 72oC 
elongation, then 72oC for 10 minutes final extension.  PCR products were confirmed 
by gel electrophoresis analysis.  Table 10 shows the sequences of primers used in the 
PCR reactions: 
 
Primers Sequence 
KIAA1324 Xhol For 5’  ACT CGA GGC ACC TGA GCC GCT ACT G  3’ 
KIAA1324 BstEII Rev 5’  CTG GGT CAC CTG GAA GGC G  3’ 
 
Table 10.  The sequences of primers used in the PCR reactions. 
 
2.19.2. Restriction Enzyme Digestion and cloning 
procedures 
All restriction enzymes (RE) used in this study were supplied by New England 
Biolabs (NEB). Digested fragments and PCR products required for further cloning 
and ligation steps were excised from agarose gels and purified using QIAquick Gel 
Extraction kit (Qiagen). 
 
Prior to ligation, RE digested plasmid was dephosphorylated to remove 5’ phosphate 
group to reduce self-ligation.  One μg plasmid DNA was incubated with 1 Unit of 
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Shrimp Alkaline Phosphatase (USB) in 1x RX SAP buffer in a total volume of 40μl 
at 37oC for 30 minutes followed by enzyme deactivation at 65oC for 15 minutes.   
 
Standard ligation reactions were performed at 16oC overnight. A 30μl reaction mix 
contained 1μl T4 DNA ligase (400,000U/ml, NEB) and 10% v/v 10X DNA ligase 
buffer with 1:1 ratio of vector to insert.  Competent cells JM109 (E.coli) were used 
for transformation.  Cells were thawed slowly on ice and 10μl of ligations were 
added to 50μl of cells per reaction.  After 15 – 20 minutes incubation on ice, cells 
were heat-shocked (42oC for 45 seconds) then 1ml LB medium was added and cells 
were incubated at 37oC for 1 – 1.5 hours. Bacteria were pelleted then resuspended in 
100μl LB medium, and 20 - 200μl was plated on LB agar plates enriched with 
ampicillin (50μg/ml).  Colonies were grown overnight at 37oC. Plasmid DNA was 
purified from minipreps of individual colonies using QIAprep Spin Miniprep kits 
(Qiagen) according to manufacturers’ instructions.  Constructs confirmed by 
restriction digest and sequencing analysis were further amplified by QIAprep 
Maxiprep kit (Qiagen).  DNA concentration and purity were determined using 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies).  Purified 
plasmids are stored at -20oC. 
 
2.19.3. Couple In vitro Transcription/Translation 
IVT was carried out with the KIAA1324 expression clone, using Promega TnT 
Coupled Reticulocyte Lysate System following the manufacturers’ instructions.  A 
control luciferase expression plasmid (provided) was used as positive control to 
ensure the viability of reagents which was confirmed by luciferase assay performed 
in a luminometer.  Protein production was assessed by Western Blotting. 
 
2.20. Short Hairpin RNA Vector Construction 
Short hairpin RNA expressing constructs were based on the pRetroSuper vector and 
details are shown in Figure 33 (Brummelkamp et al., 2002).  pRetroSuper constructs 
were made for KIAA1324 using 2 target sequences from Dharmacon siRNA 
sequences (J-010726-06 and J-010726-07)  Empty pRetroSuper was used as control 
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vector.  The correct sequence of inserts was confirmed before use.  The resulting 
siRNAs were identical to the RNA oligonucleotides used for transient transfection.  
 
2.21. Generation of shRNA Stable Lines  
2.21.1. Via Transfection 
KIAA1324 targeting constructs (shRNA #06 and shRNA #07), and an empty 
pRetroSuper vector were transfected into MCF-7 tet-inducible cells using FuGENE 6 
following the manufacturer’s instructions. Forty-Eight hours after transfection, cells 
were split one in three into selection medium containing 2.5μg/ml puromycin. 
Medium was changed every 2-3 days, and cells were maintained until all cells in the 
untransfected control had died. Single colonies of sufficient cell numbers were 
transferred onto 24-well plates using cloning cylinders.  Single cell clones were then 
expanded.  One μg of doxycycline was added to clones for 24, 48, 72h and western 
blots were performed to determine the knock down efficiency of each individual 
clone. 
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Dharmacon 06 siRNA sequence (Cat No. J-010726-06) 
 
Sense Sequence – GGA GCT AAA TCG AGG CAA TTT 
Anti-Sense Sequence – AAA TTG CCT CGA TTT AGC TCC 
 
(BglII)  Target Sense  (Hairpin)  Target Antisense 
5’ GATCCCCGGAGCTAAATCGAGGCAATTTTTCAAGAGAAAATTGCCTCGATTTAGCTCCTTTTTGGAAA  3’ 
3’ GGGCCTCGATTTAGCTCCGTTAAAAAGTTCTCTTTTAACGGAGCTAAATCGAGGAAAAACCTTTTCGA 5’ 
          (HindIII) 
 
Dharmacon 07 siRNA sequence (Cat No. J-010726-07) 
 
Sense Sequence – CTG CAA ACC TGG CAC GTA T 
Anti-Sense Sequence – A TAC GTG CCA GGT TTG CAG 
 
(BglII)  Target Sense         (Hairpin)       Target Antisense 
5’ GATCCCCCTGCAAACCTGGCACGTATTTCAAGAGAATACGTGCCAGGTTTGCAGTTTTTGGAAA 3’ 
 3’ GGGGACGTTTGGACCGTGCATAAAGTTCTCTTATGCACGGTCCAAACGTCAAAAACCTTTTCGA 5’  
                (HindIII) 
 
Figure 33. The pRetroSuper vector for expression of short interfering RNA.  Custom 
oligonucleotide pairs were annealed then ligated into the BglII/HindIII sites of the vector.  Each 
inserted region contained a 19nt sequence derived from the target sequence, separated by a short 
spacer from the reverse complement of the same 19nt sequence.  The H1 promoter transcribes a short 
RNA hairpin, which is cleaved to give a siRNA.  
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2.22. Generating KIAA1324 Antibodies 
2.22.1. Generation of a KIAA1324 peptide 
A 16 amino acid peptide sequence: TSKRTPDGFDSVPLKT which maps just in 
front of the KIAA1324 C-terminus was recommended for antibody geration by Dr R. 
Broaduss (Deng et al., 2005).  The peptide was synthesised and purified by the 
CRUK Peptide Synthesis Laboratory.  The peptide was synthesised as a 17mer with 
a C-terminal cystine residue to allow coupling in a maleimide chemistry. 
 
2.22.2. Peptide coupling with KLH carrier protein 
The KIAA1324 peptide equilibrated to room temperature prior to coupling to 
Mariculture Keyhole Limpet Hemocyanin (mcKLH) carrier protein (Imject 
Maleimide Activated mcKLH, Pierce).  6.5mg of KIAA1324 peptide was weighted 
out and dissolved in 130μl distilled water to give 50μg/ml.  Two vials of 2mg pre-
activated mcKLH carrier protein were reconstituted with distilled water to give 
10mg/ml solution, mixed well.  Forty μl KIAA1324 peptide solution was mixed with 
each vial of the activated mcKLH carrier protein (1:6 ratio of KIAA1324 peptide 
solution to carrier protein) and incubated for 2 hours at room temperature to allow 
conjugation i.e. linking KLH to sulfhydryl group.   
 
2.22.3. Purification of the Conjugate by Gel Filtration 
Sulfolink Gel Column was washed with 5 column volumes of Purification Buffer 
salts (provided by Pierce kit).  After 2 hours incubation, 2 vials of KIAA1324 
peptide-KLH conjugate were pooled together, and centrifuged at high speed for 1 
minute.  The supernatant was transferred to a new eppendorf and 20μl of conjugate 
was saved for later quantitation.  Insoluble KLH was formed as pellet (known as 
precipitate) was saved for later use (see section ‘Purification of the Conjugate by 
Dialysis’) in order to to ensure highest titre of immune response.  The remainder was 
applied directly to the column and fractions were collected in a new eppendorf tube, 
labelled as no. 1.  Purification buffer was added to the column and collected in 500μl 
in a separate tube for 19 times, labelled no. 2 to 20.  Absorbance values of all 20 
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fractions were measured at A280nm using NanoDrop to find the fractions containing 
the conjugate.  All conjugate-containing fractions were pooled together and kept on 
ice. 
 
2.22.4. Quantitation of Conjugation 
Ellman’s assay was performed (Pierce) for quantifying sulfhydrl groups by 
comparison to a standard curve prepared using a sulfhydryl-containing compound, 
Cysteine.  One mg of Ellman’s reagent was dissolved in 1ml of reaction buffer (0.1M 
Phosphate buffer, pH 8.0 with 1mM EDTA) to give 1mg/ml of Ellman’s reagent 
solution.  Cysteine was also dissolved to give 1M stock, and then a serial dilution 
was made to create a standard curve from 1000, 750, 500, 250, 100, 50 and 10μM in 
Ellman’s reaction buffer.  Absorbance measurement at 405nm was carried out on a 
96-well plate, and Ellman’s reaction buffer and Ellman’s reagent solution mix were 
used as blanks.  Cysteine standard curve and samples were added to wells followed 
by the addition of Ellman’s reagent solution.  In order to determine the amount of 
KIAA1324 peptide that had been coupled to KLH carrier protein, the absorbance 
value of non-conjugated KIAA1324 peptide was also included in the measurement 
along with KIAA1324 peptide-KLH.  Absorbance readings entered into an excel file 
was used to calculate the concentration and molar amount of sulfhydryl groups in 
KIAA1324 peptide-mcKLH conjugate and non-conjugate.  The free sulfhydryl 
groups were determined by subtracting the sulfhydryl concentration of KIAA peptde-
mcKLH conjugate from non-conjugated KIAA1324 peptide. The resulting value 
represented the amount of KIAA1324 peptide which has not been conjugated.  
 
2.22.5. Purification of the Conjugate by Dialysis 
Dialysis (Slide-A-Lyzer, Pierce) was used to remove the reducing agent e.g. DTT, 
which was used to make sulfhydryl groups available for coupling, unreacted peptide 
and EDTA from the peptide-mcKLH conjugate.  Dialysis also helps to prevent 
sample loss and clogging of the desalting column.  Dialysis was against PBS for 16 
hours at 4oC with one change of buffer.  In order to maximise the immune response, 
the precipitate saved previously (see section ‘Purification of the Conjugate by Gel 
Filtration’) was added to the purified KIAA1324 peptide-mcKLH conjugate, known 
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as immunogen.  This allows a certain amount of immunogen to bind to the insoluble 
KLH fraction, because the more immunogen coupled with KLH, the higher the 
immune response produced.   Immunogen was aliquoted into 6 tubes.  Tube 1 
contained 1.2ml immunogen, and tube 2 to 6 each contained 600μl immunogen + 
600μl PBS.  All were stored at 4oC. 
 
2.22.6. Antisera production – Rabbit polyclonal 
All 6 aliquots of immunogen were sent off to Clare Hall for injection into 2 rabbits to 
raise antisera.  Over the next 3 months, 1 pre-bleed, 3 test-bleeds and 1 terminal 
bleed from each rabbit were sent from Clare Hall and each was tested by western 
blotting for their specificity to KIAA1324 protein.   
 
2.22.7. Affinity Purification of KIAA1324 Antibodies 
An affinity column was generated by coupling KIAA1324 peptide to a SulfoLink 
Coupling Gel Column (Pierce).  The column was washed twice with 5ml coupling 
buffer.  KIAA1324 peptide was dissolved in coupling buffer to give 2.5mg/ml 
solution, and 800μl was applied to the column (closed cap).  The sulfhydryl group on 
the peptide is coupled with the iodoacetyl group on the gel during constant rotation 
for 15 minutes at room temperature.  The column was positioned upright for 30 
minutes before collecting eluate for assessing coupling efficiency.  The column was 
washed twice with 5ml coupling buffer.  50mM cysteine in 2ml coupling buffer was 
applied to the column to block unreacted iodoacetyl groups (15 minutes rotating and 
30 minutes upright position).  The column was then washed 3 times with 5ml 1M 
NaCl.  Ellman’s assay was performed to determine sulfhydryl concentration in the 
eluate and starting peptide solution, using the cysteine standard curve ranging from 
1000, 500, 100, 50, 10, 1, 0.5 and 0.1μM.  Coupling buffer was used as blank and 
absorbance was measured at 405nm.  SulfoLink Coupling Gel linked to KIAA1324 
peptide was removed from column and transferred to a 15ml Falcon tube and washed 
3 times with 5ml PBS.  The column was wrapped with parafilm and stored at 4oC.   
 
5ml of terminal bleed (serum) was applied to affinity gel in the Falcon and left 
tumbling at 4oC overnight.  The affinity gel was collected by centrifugation at 200g 
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at 4oC for 5 minutes.  Depleted serum (supernatant) was removed and stored at 4oC.  
The affinity gel was washed 3 times with 10ml 0.1M NaP buffer (4.63ml of 1M 
Na2HPO4 and 5.37ml of 1M NaH2PO4 and 90ml distilled water, pH 6.8) at 4oC.  The 
affinity gel was loaded into a column and further washed with 0.1M NaP buffer.  To 
elute bound antibody, 50mM Glycine (pH 2.2) was applied ti the column and 20 1ml 
fractions were collected.  1M Na2HPO2 was immediately added to each fraction to 
neutralise the pH to prevent degradation of antibodies. Absorbance at OD280 of all 
fractions were measured by NanoDrop and peak fractions were combined and 
dialyzed against PBS using Slide-A-Lyzer Dialysis Cassette overnight (see section 
above).  Purified antibodies were stored at 4oC.  The column was stored at 4oC with 
1ml PBS + 0.05% sodium azide after washing twice with 5ml 0.1M NaP followed by 
single wash with PBS.   
 
2.22.8. Concentrating Purified Antibodies 
Centricon Centrifugal Filter Device (Millipore) was used to concentrate KIAA1324 
antibodies by ultrafiltration through an anisotropic membrane.  Two ml of dialysed 
affinity purified antibody were applied to the sample reservoire and centrifuged at 
6500g for 1 hour.  Centrifugation steps were repeated until all concentrated and 
purified are pool together.  KIAA1324 antibodies can be stored at 4oC or -20oC with 
and without 30% glycerol or 0.05% sodium azide.  The optimal conditions for 
purified KIAA1324 antibodies in western blotting were tested on extracts from the 
KIAA1324 expressing cell line, MCF-7, using western blotting.  A dilution of 1:1000 
dilution KIAA1324 antibody and 1:10,000 anti-rabbit secondary antibody was found 
to be optimal. 
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3. Assessment of AP-2α and AP-2γ Expressing Breast Cell 
Lines 
Previous work from the lab had focused on the MCF-7 mammary carcinoma cell line 
and had shown that it predominantly expresses AP-2γ but not AP-2α.  With the aim 
to establish further which cellular pathways are regulated not only by AP-2γ but also 
by AP-2α, therefore, it was important to confirm the expression level of both AP-2α 
and AP-2γ in other breast cell lines prior to choosing which to use in this 
study.  Table 11 summarises the status of AP-2 proteins, the most important markers 
in breast cancer, ERα and ERBB2 as well as their p53 status.  This information was 
obtained from Professor Louise Jones (Institute of Cancer, Centre for Tumour 
Biology, personal communication).  These cells were paraffin embedded and stained 
for AP-2α, AP-2γ, ERα, and ERBB2 antibodies against these proteins by 
immunohistochemistry.  
 
 Cell Type AP-2α AP-2γ ERα ERBB2 p53 
MCF-7 Mammary 
Carinoma 
+/- +++ +++ -/+ Wt 
T47D Mammary 
Carinoma 
++ ++ ++ + Mut 
H3396 Mammary 
Carinoma 
++ ++ ++ nd Wt 
MCF10A Immortalised  
myoepithelial 
cells 
+++ + - + Wt 
 
Table 11  Summary of AP-2 and the status of key cancer related proteins in MCF-7, T47D, 
H3396 and MCF10A cell lines.  Key: +/- barely detectable; + low expression; ++ expression readily 
detectable; +++ very high level of expression; nd not determined. p53 status from (Bartek et al., 1990; 
Tait et al., 1990). 
 
T47D cells were chosen initially to look at the effects on cell cycle following AP-2 
silencing because it expresses both AP-2α and AP-2γ at a similar level, and also 
carries mutant p53.  Our lab had previously attempted to establish stable AP-2γ 
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silenced T47D cells, however, AP-2γ re-expressed with increasing passage number, 
suggesting that expression of AP-2γ at least is essential for continued proliferation of 
T47D cells.  As shown in the previous MCF-7 study, the cell cycle changes in AP-2γ 
silenced MCF-7 cells (see Figure 20) without stabilisation of p53 (Williams et al., 
2009), therefore, it was hypothesised that silencing AP-2 in T47D cells would lead to 
a similar observation as in the MCF-7 study.  The mutation of p53 in T47D cells 
occurs at codon 194 causing an amino acid change from leu to phe, which lies within 
the DNA binding domain, and thus, impairs the ability of p53 to bind to its target 
genes (Nigro et al., 1989).  Later on I also studied changes in cell growth in H3396, 
which carries both AP-2α and AP-2γ  with wild-type p53; and MCF10A, which 
predominantly expresses AP-2α, were also studied.  This will be described in the 
following sections.   
 
3.1. AP-2α and AP-2γ RNAi Interference 
3.1.1. Transient Knockdown of AP-2 in T47D cells by 
RNAi  
Three small interfering RNAs (siRNA) specific to AP-2γ (AP-2γ_1, AP-2γ_2 and 
AP-2γ_3) had been characterised by previous study in the lab (Williams et al., 2009) 
and four additional sequences specific to AP-2γ were ordered from Dharmacon (#05, 
06, 07 and 08) and recommended for use in SmartPool transfections.  In previous 
studies using MCF-7 cells, AP-2γ_1, AP-2γ_2 and AP-2γ_3 and Dharmacon siRNA 
#07 were shown to deplete AP-2γ efficiently compared to other Dharmacon siRNAs.  
Therefore, in this study only these four siRNAs specific for AP-2γ were tested.  
Three siRNA oligonucleotides specific to AP-2α (AP-2α_1, AP-2α_2 and AP-2α_3) 
were also available for RNAi knockdown (see Materials and Methods section 2.2.1).  
All of these siRNA specific to AP-2α and AP-2γ were tested independently in 
transient transfection in T47D cells for their efficiency.  The optimal transfection 
conditions were first compared among three transfection reagents: Oligofectamine 
(Qiagen), INTERFERin (PolyPlus) and DharmaFECT (Thermal Scientific) 
according to the manufacturer’s instructions, followed by testing a range of different 
siRNA final concentrations between 5 and 25nM (see Materials and Methods).  It 
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was found that INTERFERin transfection reagent was the most effective in siRNA 
delivery.  A non-specific random sequence was used as a non-silencing control 
(NSC) and no siRNA i.e. siRNA suspension buffer only, was used as a mock control.  
Cells were harvested after 72 hours and analysed by western blotting.  Figure 34 
shows AP-2α knock down using AP-2α_1 siRNA at 5, 15 and 25nM final 
concentration.  As illustrated, AP-2α expression was efficiently knocked down using 
15nM final siRNA concentration, hence, this concentration was used in later 
experiments in this study.   
 
The next step was to find the best combination to knock down both AP-2α and AP-
2γ expression simultaneously.  Figure 35 shows that, AP-2α_1 siRNA (lane 7) had 
the highest efficiency in knocking down AP-2α expression whereas AP-2γ_3 (lane 5) 
and Dharmacon #07 (lane 6) worked equally well in knocking down AP-2γ 
expression.  For the double knockdown, it seemed that both combinations, AP-
2γ_2/AP-2α_1 (lane 9) and Dharmacon #07/AP-2α_1 (lane 13), knocked down AP-
2α expression equally well, however, the AP-2α protein levels in cells transfected 
with either AP-2γ_2 or AP-2γ_3 siRNA alone were lower than in the mock and NSC 
cells (lane 4 and 5).  In contrast, cells transfected with Dharmacon #07 (lane 6) alone 
showed a similar AP-2α protein level to the mock and NSC cells, which indicated 
that Dharmacon #07 does not interfere with AP-2α expression, therefore Dharmacon 
#07/AP-2α_1 (lane 13) is the better combination to use.  Similarly, Dharmacon 
#07/AP-2α_1 knocked down AP-2γ expression as efficiently as Dharmacon #07/AP-
2α_2 (lane 14), however, AP-2α_2 has a much lower efficiency in knocking down 
AP-2α expression than AP-2α_1.    Therefore, the final conclusion was to use AP-
2α_1 and Dharmacon #07 siRNA to silence both AP-2α and AP-2γ expression 
together in T47D cells at 15nM final concentration of each siRNA using 
INTERFERin transfection reagent.  Figure 36A shows efficient knock down of AP-
2α and AP-2γ protein levels by AP-2α_1 and Dharmacon #07 siRNA after transient 
transfection in T47D cells at 48, 72 and 96 hours. 
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Figure 34. AP-2α knockdown in T47D cells using INTERFERin transfection reagent and final 
siRNA concentrations of 5, 15 and 25nM.  Cells were harvested 72 hours post-transfection with AP-
2α1 siRNA and 10μg whole cell extracts were loaded per lane.  Mock and NSC siRNA were used as 
negative controls.  Blots were probed with primary antibodies against AP-2α before being reprobed 
for Ku70 as a loading control. 
 
 
 
 
 
 
Figure 35. AP-2α and AP-2γ single and double knockdown in T47D cells using different 
combinations of siRNAs.  Lane 1 – Mock, 2 – Non-Silencing, 3 – AP-2γ_1, 4 – AP-2γ_2, 5 – AP-
2γ_3, 6 – Dharmacon #07, 7 – AP-2α_1, 8 – AP-2α_2, 9 – AP-2γ_2/AP-2α_1, 10 – AP-2γ_1/AP-
2α_2, 11 – AP-2γ_2/AP-2α_2, 12 - /AP-2γ_3/AP-2α_2, 13 – Dharmacon #07/AP-2α_1 and 14 – 
Dharmacon #07/AP-2α_2. Cells were harvested 72 hours post-transfection using INTERFERin. 
Whole cell extracts (10μg/lane) from T47D cells were separated by SDS/PAGE and blotted to a 
membrane.  Blots were probed with primary antibodies against AP-2α and AP-2γ before being 
reprobed for Ku70 as a loading control. 
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3.2. AP-2α and AP-2γ silenced T47D cells do not apoptose  
Initial observations in MCF-7 cells transiently transfected with AP-2γ targeting 
siRNAs, suggested that reducing AP-2γ levels in these cells affected cell 
proliferation.  Further Sub-G1 and cell cycle analyses performed on MCF-7 cells 72 
hours after transfection showed a significant increase in G1 and reduced S-phase 
populations in AP-2γ silenced cells.  This indicated that AP-2γ plays a role in the 
control of cell proliferation, particularly at the G1/S transition.  These cells were 
passaged at 48 hours following transfection to ensure that cells were sub-confluent at 
the time of harvest and any observed changes in cell cycle was not due to being over 
confluent, as contact inhibition of growth could become an extra variable in the 
experiments.  Based on these observations in the MCF-7 study, it was hypothesised 
that silencing AP-2α and AP-2γ individually or together would have similar effects 
on cell proliferation in T47D cells.  Indeed, since there were significant numbers of 
floating cells observed in AP-2 silenced samples, compared to the controls, under 
microscopy, it was thought that AP-2 depletion reduced T47D cell viability.  The 
initial experiment looked at the DNA content to give a cell cycle profile, and also 
record the Sub-G1 population of cells with fragmented genomic DNA. 
 
As cells undergoing apoptosis will lose DNA due to DNA fragmentation, these cells 
are detected as a Sub-G1 population.  An increase in Sub-G1 compared to controls 
would indicate an increased rate of apoptosis in silenced cells during G1.  Prior to 
each FACS analysis, knockdown efficiency was checked and confirmed by western 
blotting.  Figure 36A shows three representative western blot analyses to 
demonstrate AP-2α and AP-2γ were depleted successfully at 48, 72 and 96 hours 
following transfection.  Figure 36B shows an increase in the percentage of cells in 
Sub-G1 population following depletion of both AP-2α and AP-2γ.  Cells with either 
AP-2α or AP-2γ single knock down did not have a significant increase in Sub-G1 
population as compared to the controls.  However, inconsistency in the fraction of 
cells in the Sub-G1 populations from AP-2 depleted cells was observed when 
experiments were repeated, which was demonstrated by the large error bars.
 129
 
 
 
 
 
 
No
n-S
ile
nc
ing α
si-
AP
-2
γ
si-
AP
-2 γ/α
si-
AP
-2
0.0
0.5
1.0
1.5
2.0
2.5 48h
72h
96h
Fo
ld
 c
ha
ng
es
 to
 N
on
-S
ile
nc
in
g
 
 
Figure 36.  Sub-G1 analysis showed increased sub-G1 population in AP-2 double silenced T47D 
cells.  Cells transfected with AP-2α and AP-2γ siRNAs were harvested at 48, 72 and 96 hours.  (A) 
Three western blots demonstrated good knock down before samples were subjected to FACS analysis.  
PCNA was used as loading control.  (B) PI staining was used to detect total DNA content.  
Experiments were repeated 3 times independently and results are expressed as mean±s.e., n = 3.  The 
population of cells in SubG1 phase in each sample were normalised to NSC which was set to 1. 
A
B
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A fundamental problem in the experimental design was suggested.  In the initial 
experimental design, cells were transfected with 15nM siRNA final concentration in 
NSC, AP-2α and AP-2γ knockdown.  The same volume of siRNA suspension buffer 
was applied to the mock control.  However, in the double knockdown, cells were 
transfected with 15nM of each of AP-2α and AP-2γ targeting siRNAs, thus the 
resulting siRNA final concentration in these samples was 30nM.  This extra variable 
in the experimental design could lead to the inconsistency observed in the Sub-G1 
analysis with the double knockdown as the extra amount of exogenous molecules 
could be inducing cellular toxicity.  Therefore, a change to the experimental design 
was made, that is an extra 15nM of non-silencing siRNA was transfected into cells 
with 15nM of either AP-2α or AP-2γ siRNA for single knock down experiments.  
For NSC, 30nM of non-silencing siRNA was used and the same volume of siRNA 
suspension buffer was applied to cells as the mock control.  The addition of an extra 
15nM non-silencing siRNA should compensate for the differences between single 
and double knock down samples.  All subsequent experiments were carried out using 
this new experimental design. 
 
Using the new design, western blotting was performed to confirm good knock down 
efficiency and FACS analysis for Sub-G1 population was repeated three times in 
order to obtain means and standard errors.  The effects of AP-2α and AP-2γ 
depletion were assayed at 48 hours post transfection.  Figure 37 shows that the Sub-
G1 levels in AP-2γ knockdown and AP-2α and AP-2γ double knockdown were 
higher than AP-2α knockdown.  However, there was not a significant increase in the 
Sub-G1 population when compared to the NSC.  Due to the fact that the same final 
concentration of siRNA were transfected in all samples, any non-specific effects e.g. 
cyotoxicity, induced by the transfection method per se should be equivalent for all 
samples.  The similar level for the Sub-G1 population in NSC, AP-2γ alone as well 
as double silenced cells suggests that these are non-specific effects due to 
transfection and are not due to depletion of AP-2 factors.  One major disadvantage of 
Sub-G1 FACS analysis is that it can only detect cells that have lost enough DNA in 
order to appear in the Sub-G1 peak, they may not appear in the Sub-G1 area if 
apoptosis occurs during S or G2/M phases of the cell cycle.  In addition, cells that are 
aneuploid, which carry a chromosome number more or less than the diploid number, 
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can temporarily accumulate in the sub-G1 phase.  Sub-G1 analysis can not 
distinguish if cells were dying from apoptosis or another form of accidental cell 
death, i.e. necrosis.  Therefore, in order to verify whether silencing AP-2 in T47D 
cells induces apoptosis and which pathway could be involved, two further assays 
were carried out: TMRE and Caspase activity.   
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Figure 37.  Silencing AP-2α or AP-2γ does not significantly affect the Sub-G1 population in 
T47D cells.  Cells were transfected and harvested for Sub-G1 analysis 48 hours post transfection (see 
Materials and Methods).  Experiments were repeated three times independently and results are 
expressed as mean±s.e., n = 3.  This graph represents the population of cells in Sub-G1 phase that has 
been normalised to NSC which was set to 1. 
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The TMRE assay was chosen to assess apoptosis in T47D cells following AP-2α and 
AP-2γ silencing.  TMRE (tetramethylrhodamine ethyl ester) is a cell permeable 
cationic fluorescent dye that is capable of binding to the inner and outer aspects of 
the inner mitochondrial membrane.  Mitochondria play an important role in 
maintaining cellular functions, and one of the key features is they participate in cell 
survival.  In healthy, non-apoptotic cells, an electrochemical gradient is generated via 
proton pumping across the impermeable inner membrane, this is the so-called 
mitochondrial membrane potential (ΨΔm).  TMRE, bearing a positive charge will 
accumulate inside the negatively charged mitochondrial matrix in proportion to the 
membrane potential, resulting in strong fluorescence intensity.  Upon apoptosis, 
ΨΔm collapses, TMRE is not accumulated in the mitochondria and is released to the 
cytosol resulting in a decrease in TMRE fluorescence intensity.  The intensity of 
fluorescence excited from TMRE can be quantified by FACS in order to assess 
cellular viability.   DAPI was used in this assay to distinguish dead cells, with high 
DAPI staining indicating dead cells.  Non-apoptotic cells with intact mitochondria 
would be expected to have a high TMRE signal but low DAPI staining, whereas, 
early apoptotic cells would have a lower TMRE signal.  
 
Figure 38 shows there were no differences found in the fractions of non-apoptotic 
and apoptotic cells between AP-2α and AP-2γ single and double depletion and the 
two controls.  However, when both AP-2α and AP-2γ were depleted together it 
caused a 2-fold increase in the proportion of dead cells (i.e. DAPI positive) compared 
to the other samples.   
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Figure 38. Silencing for AP-2α or AP-γ does not significantly induce apoptosis in T47D cells but 
increased cell death.  Cells were transfected and harvested for TMRE analysis 48 hours post 
transfection (see Materials and Methods).  Experiments were repeated three times independently and 
results are expressed as mean±s.e., n = 3.  This graph represents the populations of cells in non-
apoptotic, apoptotic and dead at 48 hours post-transfection were normalised to NSC which was set to 
1. 
 
Following mitochondrial depolarization, cytochrome c is translocated into the 
cytosol resulting in the activation of the caspase cascade which subsequently leads to 
cell death.  Therefore, a caspase assay was conducted to investigate whether caspase 
activity was induced following AP-2α or AP-2γ silencing.  As a positive control, 
1μM staurosporine (STS) was added to a separate sample of cells.  Cells transfected 
with 15nM NSC siRNA only were also included to see if caspase activity would vary 
if siRNA concentration was halved.  Figure 39 shows cells treated with 1μM STS 
had the highest caspase activity, whereas the mock control had the lowest caspase 
activity.  All knockdowns and the two NSC samples showed a very similar caspase 
activity at 30 minutes, however, caspase activity in AP-2 double knocked down cells 
was slightly higher than other samples at 1 and 1.5 hours but the difference was not 
significant.  The similarity of caspase activity level between cells with AP-2α and 
AP-2γ single and double knock down and NSC treatment suggested induction of that 
caspase activity is not a consequence of AP-2α or AP-2γ silencing.   
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Based on the results obtained from, Sub-G1, TMRE and caspase assays, I concluded 
that silencing AP-2α and AP-2γ in T47D cells is not associated with apoptosis via 
the mitochondrial-mediated caspase pathway.  Although silencing both AP-2α and 
AP-2γ together appeared to cause a 2-fold induction in cell death, however, due to 
the large error bar present in this sample, the raw data was checked and revealed that 
only one out the of three sets of samples showed a significant increased in cell death. 
Therefore, similar observation with AP-2γ in MCF-7 cells, AP-2 double silencing 
does not induce death of T47D cells. 
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Figure 39. Silencing AP-2 did not induce caspase activity in T47D cells.  Cells were transfected 
and harvested at 48 hours following transfection as indicated in Materials and Methods.  Caspase 
activity was monitored at 30 minutes intervals.  Cells treated with 1μM staurosporine (STS) were used 
as positive control.  Data obtained from a single experiment. 
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3.3. AP-2 silencing increased S and G2/M populations in T47D 
cells 
Cell cycle analysis was performed with the aim of finding out if silencing AP-2 
factors in T47D cells would affect the cell cycle, and which stages of the cell cycle it 
affects.  AP-2α and AP-2γ were silenced individually or together in T47D cells for 
48 hours.  Cells were harvested and fixed for PI staining and analysed for the DNA 
content in each phase of the cell cycle using flow cytometry (see Materials and 
Methods).  Figure 40 shows that, contrary to the previous MCF-7 study, the 
proportion of cells in S-phase and G2/M were slightly higher in AP-2α and AP-2γ 
single and double knockdown cells when compared to the two controls.  However, 
the differences were not statistically significant.  The results obtained from both Sub-
G1 and cell cycle FACS analysis indicated that loss of either AP-2α or AP-2γ alone 
or together did not seem to have the same effect as in MCF-7 cells, that is, AP-2 
depletion does not lead to a partial cell cycle arrest at the G1/S transition in T4D 
cells.  Instead, cell proliferation seemed to increase slightly when AP-2 was silenced, 
therefore, a BrdU assay was used to assess cell proliferation following AP-2 
silencing. 
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Figure 40. Depletion of AP-2 factors increases S-phase and G2/M populations.  Cells were 
transfected as indicated in Materials and Methods.  FACS analysis for cell cycle was performed 48 
hours post transfection.  Experiments were repeated three times independently and results are 
expressed as mean±s.e., n = 3.  Data were normalised to NSC which was set to 1.  Statistical 
significance was not reached. 
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BrdU, bromodeoxyuridine is an analogue of thymidine and will be taken up into the 
DNA of cycling cells.  In vivo and in vitro labelling of cells with BrdU and the 
subsequent detection of BrdU incorporation with a specific anti-BrdU monoclonal 
antibody is an accurate method to quantitate the degree of DNA synthesis.  BrdU is 
incorporated into the newly synthesised DNA of S-phase cells, providing an estimate 
of the fraction of cells in S-phase.  PI staining was used in this assay to separate cells 
in G1 and G2-phase.  AP-2α and AP-2γ expression were silenced independently and 
together in T47D cells and cells were labelled with 10μM BrdU at 48 hours post 
transfection for 30 mins immediately prior to harvest.  As shown in Figure 41 the 
percentage of BrdU-labelled cells was significantly increased in cells silenced for 
both AP-2α and AP-2γ expression indicating there was an induction in the fraction of 
cells actively undergoing S-phase in this sample (p<0.05) compared to the two 
controls.  The increase in S-phase populations was accompanied by a reduction in 
G1-phase and an increase in G2-phase populations.  The increase in cell populations 
in S-phase and G2-phase and reduction in G1-phase were also observed in AP-2α 
and AP-2γ single knockdown samples compared to the controls.  The percentage of 
cells actively undergoing DNA synthesis was consistent with the proportion of cells 
with S-phase DNA content in the cell cycle analysis shown in Figure 40.  This result 
suggested that depleting either AP-2α or AP-2γ or both in T47D cells increased cell 
proliferation which is opposite to the observations in MCF-7 cells. 
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Figure 41. AP-2 silenced T47D cells show an increased S-phase population.   (A)  A timeline of 
the experimental procedure is displayed.  (B) Cells were transfected and harvested for BrdU analysis 
48 hours post transfection (see Materials and Methods). Experiments were repeated three times 
independently and results are expressed as mean±s.e., n = 3.  Data were normalised to NSC which was 
set to 1. *p<0.05, **p<0.01 and ***p<0.001; 2-tailed t-test. Western blot analysis to confirm good 
AP-2 knockdown before samples were subject to FACS analysis. (C) Whole cell extracts (10µg/lane) 
were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies 
against AP-2α and AP-2γ. HSC70 was used as loading control.  This western blot is a representative 
of all three independent experiments  
C
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In order to emphasize the effect of AP-2 silencing on the proliferation rate in this cell 
line and to support the findings of the BrdU assay, T47D cells were subjected to 
synchronisation using aphidicolin after transfection with siRNA.  Aphidicolin was 
chosen because it has been shown to be efficient in synchronising T47D cells 
(Zamora et al., 1998).  Aphidicolin is a potent antiviral and antimitotic agent which 
blocks the cell cycle at G1/early S-phase.  It inhibits the cellular replication of DNA 
by polymerase α allowing cells at G2/M-phase to continue the cell cycle and 
accumulate at the G1/S-border (Lonn and Lonn, 1983).  After treatment with 
aphidicolin, cells will be blocked G1/early S-phase, and if silencing AP-2α and AP-
2γ individually or together in T47D cells increases proliferation, it would be 
expected that AP-2 depleted cells will enter S and G2/M-phase earlier compared to 
mock and NSC treated cells, after the block is released   
 
Initially, T47D cells were treated with aphidicolin at 0.2, 0.5, 1 or 1.5μg/ml for 16 
hours, and cell cycle FACS analysis was performed in order to determine the optimal 
conditions for synchronisation (see Figure 42A).  Once the optimal concentration 
was determined, the cells were synchronised in order to determine a more detailed 
time course (see Figure 42B).  Figure 42A shows a good synchronisation was 
achieved at the lowest aphidicolin concentration, 0.2μg/ml, in which a large 
proportion of cells were at G1-phase at 0 hour, the time when the block was 
removed.  Figure 42B shows a large proportion of cells were blocked in G1 and this 
dropped dramatically upon removal of aphidicolin.  This was followed by a large 
increase in the S-phase population after 3 hours, and the majority of cells reached 
G2/M-phase 5 hours later.  Using these conditions, an experiment was designed to 
knock down AP-2 in T47D cells prior to synchronisation.  Cells were harvested 3 
hours after the block was removed in order to allow enough time for cells to re-enter 
the cell cycle and reach S-phase by the time of harvesting. 
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Figure 42. Cell cycle analysis of synchronised T47D cells using aphidicolin. (A) T47D cells were 
treated with aphidicolin at 0, 0.2, 0.5, 1 or 1.5μg/ml for 16 hours. Cell were then washed and replaced 
with fresh media. Zero, three and six hours after block removal, cells were harvested and fixed for cell 
cycle analysis.  (B) Cells were synchronised with 0.2μg/ml aphidicolin and cell cycle profile was 
assessed by FACS analysis after removal of aphidicolin for the time indicated for a more detailed time 
course analysis. 
B
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Figure 43B shows a significant increase in the fraction of cells actively undergoing 
S-phase in AP-2 silenced and synchronised T47D cells, in particular in AP-2α 
silenced and AP-2 double silenced cells.  The cell population in G2/M-phase in AP-2 
silenced cells was also increased compared to NSC.  The increase in S and G2/M-
phase populations was accompanied by a reduction in G1-phase in AP-2 silenced 
T47D cells.  The differences between AP-2α and AP-2 double silencing and NSC 
populations were statistically significant.  However, the difference between AP-2γ 
silencing and the NSC were not statistically significant but nonetheless an increase in 
S and G2/M and a reduction in G1-phase populations was also seen in AP-2γ 
silenced cells.   
 
Thus, in summary, depletion of AP-2 factors in T47D cells led to increased cell 
populations in S and G2/M phases of the cell cycle.  This contrasts with the partial 
G1/S arrest observed on silencing AP-2γ in MCF-7 cells.  Therefore, it was 
intriguing to investigate whether there was an increase in cell numbers after AP-2 
silencing in T47D cells.  Cell counts were performed on NSC siRNA treated and AP-
2 double silenced T47D cells at 24, 48 and 72 hours following transfection.  As 
illustrated in Figure 44, the number of viable cells in AP-2 double silenced cells was 
significantly higher than for the NSC samples at 72 hours.  This finding is consistent 
with the cell cycle and BrdU analysis. 
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Figure 43.  Silencing AP-2 factors in T47D cells increased S and G2/M phase populations.  (A) A 
timeline of the experimental procedure is displayed.  (B) Cells were transiently transfected with AP-
2α, AP-2γ and NSC siRNA one day prior to synchronisation.   Cells were harvested for cell cycle 
analysis three hours after block removal.  Experiments were repeated three times independently and 
results are expressed as mean±s.e., n = 3.  Data were normalised to NSC which was set to 1.  *p<0.05, 
**p<0.01 and ***p<0.001; One-Way Anova. (C) A representative western blot to demonstrate good 
AP-2α and AP-2γ knock down prior to FACS analysis.  Whole cell extracts (10µg/lane) were 
separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies 
against AP-2α and AP-2γ. HSC70 was used as loading control.  
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Figure 44.  Cell number in AP-2 depleted T47D cells increases compared to controls.  Cells were 
transfected as indicated in Materials and Methods, and cells were counted 24 hours intervals following 
transfection.  Counts were averages and expressed as mean±s.e., n = 3. **p<0.01; 2-tailed t-test.  Cell 
counts were performed using a Casy Cell Counter (Scharfe System). 
 
 
3.4. AP-2α and AP-2γ silencing is accompanied by increased 
p21cip mRNA and protein levels 
Due to the fact that the effect on the cell cycle following AP-2 silencing in MCF-7 
and T47D cells was contradictory, it was intriguing to understand the mechanism 
whereby AP-2α and AP-2γ silencing mediates cell cycle progression in T47D cells.  
In the MCF-7 study, it was found that mRNA and protein levels for the cyclin-
dependent-kinase inhibitor, p21cip, were elevated in AP-2γ depleted cells, and ChIP 
assays showed AP-2γ occupancy at the proximal promoter region of the CDKNIA 
gene encoding p21cip in cycling MCF-7 cells.  This suggested that transcriptional 
repression of p21cip by AP-2γ could be part of its role in cell cycle control in breast 
carcinoma.  It was hypothesised that in T47D cells therefore, levels of p21cip might 
be reduced after AP-2 silencing leading to the increased cell proliferation I have 
observed.  In order to ensure that any changes in p21cip protein level were not due to 
the transfection conditions, cells transfected with 15nM NSC siRNA was also 
included in the western blot analysis with the other samples from cells transfected 
with 30nM siRNA.  Cells were harvested for western blot analysis 48 hours post-
transfection.  Surprisingly, as illustrated in Figure 45, p21cip protein levels in AP-2 
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silenced cells were higher than the controls.  Note that, levels in mock control, and 
cells treated with NSC at 15nM or 30nM siRNA were all very similar, which further 
indicated that p21cip protein levels increased due to AP-2 silencing.  The elevated 
p21cip protein levels in T47D cells with AP-2 double knockdown were observed in 
more than one western blot analysis.  It is known that when cells reach high 
confluency, contact inhibition can induce p21cip levels, and, since the cell cycle and 
BrdU analysis both showed that cells proliferated more when AP-2α and AP-2γ were 
silenced at 48 hours post-transfection, it was possible that the increased p21cip 
protein level was due to the initiation of growth inhibition as a result of over-
confluency.  However, as shown in the cell count study (see Figure 44), AP-2 double 
knocked down T47D cells proliferated more than the NSC between 24 to 72 hours.  
This indicated that the induction in p21cip protein did not lead to cell cycle arrest in 
AP-2 silenced cells, at least not before 72 hours post-transfection.   
 
 
 
  
 
Figure 45. Levels of p21cip increase in AP-2 single and double knocked down T47D cells.  Cells 
were transfected as indicated in Materials and Methods.  Non-silencing x2 indicates 30nM of non-
silencing siRNA was transfected.  Non-silencing = 15nM siRNA was transfected.  Cells were 
harvested for western blot analysis 48 hours post transfection.  Whole cell extracts (10μg/lane) were 
separated by SDS.PAGE and blotted to a membrane.  Blots were probed with primary antibodies 
against AP-2α, AP-2γ and p21.  HSC70 was used as a loading control. 
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The changes in p21cip levels were examined further using additional time 
points.   Figure 46A shows a large reduction in both AP-2α and AP-2γ mRNA and 
protein levels following AP-2 silencing at 48 and 72 hours.  These samples were 
further checked for the changes in p21cip levels.  Figure 46B shows that both the 
mRNA and protein levels of p21cip were increased in AP-2 double silenced cells.  
Interestingly, in contrast to the MCF-7 study, AP-2γ silencing in T47D cells did not 
always lead to p21cip protein induction, as demonstrated by multiple western blot 
analyses and also compare Figure 45 to Figure 46B [Note that Figure 46 is one of the 
most representative western blots].  Instead, AP-2α silencing seemed to induce 
p21cip protein more than AP-2γ silencing at both time points.  However, the p21cip 
mRNA level in AP-2α knockdown was slightly lower than in AP-2γ knockdown, 
which is contradictory to the western blot analysis in which p21cip protein levels 
were higher in AP-2α knockdown than AP-2γ knockdown, although the difference 
was not statistically significant.  The p21cip mRNA and protein levels were higher in 
AP-2 double silenced compared to AP-2α or AP-2γ single silenced cells, and the 
increase in p21cip at mRNA and protein levels in AP-2 double silenced cells was 
always consistent in every AP-2 siRNA transfection experiment.  This might imply 
that silencing of either AP-2α or AP-2γ alone leads to a variable degree of 
compensation by the other or that either are significant, and that the effect on p21cip 
mRNA and protein levels was only consistent when both AP-2α and AP-2γ were 
silenced. 
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Figure 46. Levels of p21cip increase in AP-2 silenced T47D cells.  T47D cells were transfected and 
RNA was extracted to make cDNA (see Materials and Methods). Quantitative PCR analysis of (A)  
AP-2α and AP-2γ mRNA and (B) CDKN1A mRNA levels.  All data were normalised to GAPDH 
mRNA levels and NSC values set as 1 to generate relative mRNA levels.  The graph represents data 
averaged from three PCR replicates, ±standard error.  AP-2α and AP-2γ (A) and p21 (B) protein 
levels were checked.  HSC70 was used as loading control.   
 
 
The western blot analysis illustrated in Figure 46B showed that p21cip protein levels 
were increased in T47D cells following AP-2 silencing, particularly in the AP-2 
double silenced cells.  In the MCF-7 study, Chromatin ImmnunoPrecipitation (ChIP) 
assays had demonstrated that AP-2γ occupancy at the proximal region of the 
CDKN1A promoter in cycling MCF-7 cells, and that the occupancy decreased upon 
AP-2γ silencing (see Figure 22).  This suggested that, at least in MCF-7 cells, AP-2γ 
plays a role in repressing p21cip expression, and that silencing AP-2γ induced 
p21cip.  Therefore, in order to determine whether both AP-2α and AP-2γ also play a 
direct role in CDKN1A transcriptional regulation in T47D cells, ChIP assays were 
carried out to investigate both AP-2α and AP-2γ occupancy at the same proximal 
region of the p21cip promoter.   
 
B
 148
Briefly, T47D cells were transfected with AP-2α and AP-2γ specific siRNA for 48 
hours, and non-silencing siRNA were used as control.  Cells were crosslinked with 
1% formaldehyde for 10 minutes and chromatin was sheared by sonication to an 
average size of 500bp.  Immunoprecipitation reactions for AP-2 factors were carried 
out overnight using predetermined amounts of antibody and washed with optimised 
wash conditions.  The DNA was extracted using Chelex beads.  A ‘no antibody 
control’ was included and treated in the same manner as the other samples and used 
to determine the background level to which qPCR data were normalised.  Three 
primer sets of qPCR primers (which were designed in the MCF-7) study were used in 
order to evaluate the binding of both AP-2α and AP-2γ across the CDKN1A 
promoter.  The locations of these primers on the CDKN1A promoter are summarised 
in Figure 47.  The -21 / +44 primers were designed across a region encompassing the 
start of transcription, which has been described as an important site for 
transcriptional activation by AP-2α (Zeng et al., 1997).  The primer set -2290 / -2185 
was designed against a region flanking the classical p53 binding site (Kaeser and 
Iggo, 2002) and also a region previously shown to be occupied by AP-2α 
(McPherson et al., 2002).  The -4005 / -3931 primer set was designed across a region 
of high species conservation with no potential AP-2 binding sites.  These primers 
were sufficiently spaced across the p21cip promoter region that they would not 
amplify overlapping chromatin fragments, considering the chromatin was sheared to 
an average size of 500bp. 
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Figure 47. A Schematic diagram showing the CDKN1A promoter region.  The locations of the p53 
binding sites (Kaeser and Iggo, 2002) and potential AP-2α and AP-2γ occupancy on the CDKN1A 
promoter region are shown (McPherson et al., 2002; Zeng et al., 1997).  The primers used for the 
qPCR (-21 / +44 and -2990 / -2185) are indicated in Materials and Methods. 
 
 
Figure 48A shows that in the non-silencing siRNA treated T47D cells, both AP-2α 
and AP-2γ occupancy within the CDKN1A endogenous promoter region was 
confined to the region amplified by the -21 / +44 primer set.  Cells transfected with 
AP-2α and/or AP-2γ siRNAs showed a reduced AP-2α and AP-2γ occupancy within 
this region.  An earlier study suggested that AP-2α activated p21cip expression via 
the p53 binding sites at the -2290 / -2185 region (McPherson et al., 2002), however, 
neither AP-2α or AP-2γ were found associated near this classical p53 binding site or 
the region amplified by the other primer set further upstream,  as shown in Figure 
48B and C.  This observation implies that AP-2α could directly regulate p21cip 
expression independently of p53.  These data are consistent with our previous MCF-
7 study, in which AP-2γ occupancy was confined to the proximal promoter region.  
The results of the ChIP suggest that both AP-2α and AP-2γ occupancy are associated 
with CDKN1A gene regulation and highlights the role of both AP-2α and AP-2γ in 
the regulation of transcription from this promoter.  Although AP-2γ silencing did not 
always increase p21cip protein in T47D cells, however, ChIP assays here 
demonstrated the AP-2γ occupancy decreased in silenced cells, which implied AP-2γ 
could repress p21cip expression as we proposed in our MCF-7 study (Williams et al., 
2009), but AP-2γ occupancy in T47D cells may not lead to repression or activation. 
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Due to the fact that the induction of p21cip protein levels was reproducible following 
AP-2α and AP-2α/AP-2γ knockdown, this evidence suggested that AP-2α also 
seems to play a role in repressing p21cip as silencing AP-2α induced p21cip levels.  
Indeed, western blot analysis showed p21cip protein levels increased slightly in AP-
2α or AP-2γ single knockdown but significantly more in AP-2 double knockdown, as 
shown in Figure 46 and Figure 48D.  The ChIP assays demonstrate AP-2α 
occupancy at the same proximal region of the CDKN1A promoter as AP-2γ, 
suggesting AP-2α may have a similar role as AP-2γ in repressing p21cip expression 
in T47D cells.   
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Figure 48.  ChIP assay showing the effect of AP-2 silencing on endogenous AP-2α and AP-2γ 
occupancy at the -21/-44 CDKN1A promoter region.  T47D cells were transient transfected with 
NSC, AP-2α and AP-2γ siRNA as indicated in Materials and Methods.  Cells were harvested for ChIP 
assay 48 hours post-transfection.  Chromatin samples were analysed by qPCR using the (A) -21/+44 
primers; (B) -2290/-2185; and (C) -4005/-3931. Results were presented as a fold change to no 
antibody control and expressed relative to the total input chromatin.  Data averaged from 3 
independent experiments, ±standard error. (D) Whole cell extracts (10μg/lane) were separated by 
SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies against AP-2α, 
AP-2γ, p21cip and HSC70.  This is a representative western blot to show good knock down of AP-2 
proteins and induction of p21 prior to ChIP assays. 
C
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3.5. Difference in p21cip protein levels in T47D and MCF-7 cells 
Western blot analysis showed increased p21cip protein levels following AP-2 
knockdown, and ChIP assays showed both AP-2α and AP-2γ occupancy at the same 
proximal region of CDKN1A as was found for MCF-7 cells.  Based on this evidence, 
silencing AP-2 in T47D cells should have the same effect on the cell cycle as in AP-
2γ silenced MCF-7 cells, namely G1/S arrest.  However, all analyses presented so far 
demonstrated that silencing AP-2 in T47D cells increases the cell proliferation rate 
rather than causing cell cycle arrest.  This led us to investigate further the differences 
following AP-2 silencing between T47D cells and MCF-7 cells. 
 
The first observation highlighted was the difference in p21cip mRNA and protein 
levels between these two cell lines following AP-2 silencing.  When 
comparing Figure 21 and Figure 46B, the p21cip mRNA levels in AP-2γ silenced 
MCF-7 cells increased more than 2-fold compared to mock and NSC samples at 72 
hours.  The p21cip mRNA levels remained similar at 96 hours.  However, the p21cip 
mRNA levels in AP-2α or AP-2γ single silenced T47D cells increased very slightly, 
approximately 20% compared to the controls at 72 hours.  The p21cip mRNA levels 
were higher in the AP-2 double silenced than either AP-2α or AP-2γ single silenced 
T47D cells, which was, at most 1.7-fold compared to the controls.   
 
In the MCF-7 study, cells were transfected with three different AP-2γ siRNAs (AP-
2γ_1; AP-2γ_2 and AP-2γ_3; see Materials and Methods) which are different from 
the siRNA used in T47D cells.  In addition the transfection reagents used in both cell 
lines were different, therefore, in order to ensure all variables were kept constant, 
MCF-7 cells were transfected with the same AP-2γ specific siRNA and transfection 
reagents used for T47D cells for 48 and 72 hours.  Cells were harvested to obtain 
whole cell lysates and the p21cip protein levels were assessed by western blotting.  
As shown in Figure 49, p21cip protein levels elevated significantly in AP-2γ silenced 
MCF-7 cells compared to the controls at both time points.  The induction of p21cip 
protein in AP-2 silenced T47D cells was not as significant as we observed in the AP-
2γ silenced MCF-7 cells (see Figure 45 and Figure 46B).   
 
 154
The p21cip protein was described initially as a universal inhibitor of cyclin-kinase 
complexes.  In human cells there are multiple cyclin-dependent kinases (cdk), and 
their essential activating partner, the cyclins.  They form complexes that are activated 
at specific points during the cell cycle, and they play a specific role in promoting cell 
cycle progression.  Inhibition of cdk-cyclin complex formation by cdk-cyclin 
inhibitors such as p21cip is expected to cause cell cycle arrest leading to an increase 
cell population in G1-phase (or G2/M).  However, it is also known that, p21cip is not 
only an inhibitor of cdk-cyclin kinases activity but also serves as a chaperone, 
promoting the assembly of cdk-cyclin complexes.  When p21cip levels are low, it 
promotes both complex formation and kinase activity, thus it stimulates proliferation.  
However, as the level of p21cip increased further, the kinase activity is inhibited 
leading to growth arrest (LaBaer et al., 1997; Zhang et al., 1994).  As shown 
in Figure 45, Figure 46B and Figure 48D, the increase in p21cip level in AP-2 
silenced T47D cells is much more modest than was observed in MCF-7 cells 
(see Figure 49A).  It suggests that the slight increase in level may boost the 
chaperone activity of p21 but may not be sufficient to inhibit cdk-cyclin activity.  
These different overall levels of p21 in the silenced cells, therefore could explain 
why the effect on the cell cycle in T47D cells following AP-2 knock down was 
contrary to the observations in MCF-7 cells.  Other cell cycle regulators such as 
p27kip did not seem to have an effect on the cell cycle in T47D cells following AP-2 
knockdown (this will be discussed in the following section), and INK4 family 
members but they have not looked at in this study. 
 
 155
 
 
 
 
 
 
 
Figure 49. Analysis of p21 levels in MCF-7 and T47D cells following AP-2γ knocked down.  Cells 
were transfected as indicated using protocol and reagents as used for T47D cells, and harvested at 48 
and 72 hours for western blot.  Whole Cell extracts (10µg/lane) were separated by SDS/PAGE and 
blotted to a membrane. Blots were probed with primary antibodies against AP-2γ, and p21cip.  
HSC70 was used as loading control. (A) MCF-7 cells and (B) T47D cells. 
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Furthermore, it has been shown in AP-2γ silenced MCF-7 cells, that the cyclin-
dependent-kinase inhibitor p27 protein level rose accompanied by a decrease in p27 
phosphorylation at Thr 187.  In cycling cells, p27 is phosphorylated by cyclinE/cdk2 
kinase activity and targeted for proteolysis so the level remains low.  It was possible 
that an induction of p27 was the result of reduced p27 phosphorylation and therefore 
protein stablilisation.  As a consequence, increased p27 protein enhanced the growth 
inhibitory effect in AP-2γ silenced MCF-7 cells.  In addition, the level of 
retinoblastoma (pRb) phosphorylation was reduced in AP-2γ silenced MCF-7 cells 
(data not shown).  pRb is one of the principle cellular targets for cyclin/cdk 
complexes in cell cycle regulation.  pRb phosphorylation relieves its repression of 
E2F factors which are required for S-phase gene expression (Adams and Kaelin, 
1995; Kasten and Giordano, 1998; Pucci et al., 2000).  Since the level of pRb 
phosphorylation was reduced in AP-2γ silenced MCF-7 cells, free pRb was able to 
bind E2F forming a stable pRb/E2F complex resulting in the repression of E2F target 
genes which are required for entry into S-phase.  This was demonstrated by the 
microarray analysis of AP-2γ silenced MCF-7 cells (Williams et al., 2009).  As 
T47D cells, in contrast, increase their rate of proliferation, the effects on p27 and 
pRb in these cells should differ from the observations in MCF-7.  In order to test this 
hypothesis, a panel of western blots were performed to investigate changes in other 
cell cycle regulators following AP-2 single or double silencing in T47D cells and the 
results were compared to AP-2γ silenced MCF-7 cells.  If the hypothesis presented 
here is true, it would be expected that the level of pRb and p27 phosphorylation in 
AP-2 single or double silenced T47D cells will remain similar or be up-regulated 
slightly, thus resulting in the slight increase in proliferation rate. 
 
As shown in Figure 50, little or no change in the levels of cyclin dependent kinase-4 
(cdk4) or pRb was observed following AP-2 single or double knockdowns in T47D 
at 48 and 72 hours.  The levels of ppRb protein increased in AP-2 silenced cells at 48 
hours but remained constant at 72 hours.  The levels of p27 protein were also 
constant at 48 hours, except for AP-2 double knockdown cells where it was slightly 
raised.  The levels decreased in AP-2 silenced cells compared to the controls at 72 
hours.  Moreover, levels of pp27 in AP-2 silenced cells were slightly higher than the 
controls at 48 and 72 hours.  As changes in total pRb and ppRb levels presented here 
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were quite subtle, further western blots were performed using lysates from AP-2 
silenced and synchronised T47D cells.  Figure 51 shows that the levels of total pRB 
increased in AP-2 silenced cells whereas the levels of ppRb remained constant across 
all samples, indicating at least constant if not slightly elevated cdk4 expression but 
this is not reflected in increase ppRb levels in AP-2 silenced cells which is consistent 
with the continued or slightly increased proliferation of T47D cells.  In conclusion, 
the levels of pRb, ppRb, p27 and pp27 proteins in AP-2 silenced T47D cells agree 
with the hypothesis because cells were still proliferating between 48 and 72 hours 
following AP-2 depletion.   
 
Since T47D cells proliferated more when AP-2 factors were depleted, it was 
intriguing to examine the expression of cell cycle regulatory molecules that are 
responsible for cell proliferation.  Therefore, cyclin D1 and cyclin D3 proteins were 
assessed.  It is known that progress through the cell cycle requires cyclins, and these 
cyclins activate cdk and form cyclin/cdk complexes to regulate specific stage of the 
cell cycle.  During G1-phase, the cyclin D family, including cyclin D3, regulates the 
initial G1 to S transition by phosphorylating pRb (Refer to Introduction Chapter 1 
section 1.12).  Over-expression of cyclin D family members shortens G1-phase and 
allows rapid entry to S-phase.  As shown in Figure 50, the cyclin D1 protein levels 
were moderately increased following AP-2 knockdown in T47D cells, whereas 
cyclin D3 protein levels were elevated significantly by 48 hours remained so at 72 
hours.  These western blots analyses were in agreement with findings from my cell 
cycle and BrdU FACS analysis and the cell count study as demonstrated in previous 
sections.  The increase in cell cycle progression to S-phase in T47D cells following 
AP-2α and AP-2γ silencing individually and together is consistent with the increase 
in cyclin D3 protein levels.  To further confirm the different effects on the cell cycle 
seen in MCF-7 and T47D cells, a western blot was used to check cyclin D3 protein 
levels in AP-2γ depleted MCF-7 cells (these were the same lysates used in Figure 
49).  As illustrated in Figure 52, levels of cyclin D3 remained constant and even 
declined in AP-2γ silenced cells by 72 hours, consistent with the growth arrest seen 
in these cells.  Furthermore, in order to ensure that the increase in cyclin D3 in AP-2 
silenced T47D cells was reproducible, AP-2α and AP-2γ expression were transiently 
knocked down in T47D cells for 48 and 72 hours and both cyclin D3 mRNA and 
 158
protein levels were checked.  Figure 53 shows that the mRNA levels of cyclin D3 
increased approximately 25% in AP-2 double silenced cells at both time points, but 
only modestly increased in AP-2 single silenced cells at 48 hours with no change at 
72 hours.  Western blot analysis shows that cyclin D3 protein was up-regulated in 
AP-2 double silenced cells at both time points, which is in agreement with the 
increase in mRNA level.  The protein level was only up-regulated in AP-2 single 
silenced cells at 72 hours, that is after the increase in mRNA level seen at 48 hours.  
The increase in cyclin D3 mRNA and protein levels in AP-2 silenced T47D cells 
suggests that AP-2 factors might regulate cell cycle progression by directly 
regulating the expression of cyclin D3.  This hypothesis was investigated as 
described in the next section. 
 
 
 
Figure 50. Analysis of cell cycle associated proteins in T47D cells following AP-2 silencing.  Cells 
were transfected as indicated, and harvested at 48 and 72 hours for western blot.  Whole Cell extracts 
(10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with 
primary antibodies against, AP-2α, AP-2γ, total pRb, ppRb, Cyclin D1, Cyclin D3, cdk4, p27 pp27.  
HSC70 was used as loading control. 
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Figure 51. Levels of pRb and ppRb in synchronised T47D cells following AP-2 knockdown.  
Cells were transfected with AP-α and AP-2γ specific siRNAs following by synchronisation 24 hours 
after knockdown (refer to Figure 43).  Cells were harvested at 48 hours post-transfection for western 
blotting.  Whole Cell extracts (10µg/lane) were separated by SDS/PAGE and blotted to a membrane. 
Blots were probed with primary antibodies against total pRb and ppRb.  HSC70 was used as loading 
control. 
 
 
 
 
 
 
Figure 52. Levels of cyclin D3 decline in cells following AP-2γ knockdown in MCF-7 cells.  Cells 
were transfected as indicated, and harvested at 48 and 72 hours for western blot.  Whole Cell extracts 
(10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with 
primary antibodies against AP-2γ and Cyclin D3.  HSC70 was used as loading control. 
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Figure 53. Levels of CCND3 mRNA and protein increase following AP-2α and AP-2γ depletion 
in T47D cells.  Cells were transfected and harvested for RNA extraction 48 hours post-transfection 
(refer to Figure 46).  Quantitative PCR analysis of CCND3 mRNA levels.  All data were normalised 
to GAPDH mRNA levels and NSC values set as 1 to generate relative mRNA level.  The graph 
represents data averaged from three PCR replicates, ±standard error.  Whole cell extracts (10µg/lane) 
were separated by SDS/PAGE and blotted to a membrane. Blots were probed with primary antibodies 
against cyclin D3.   
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3.6. AP-2 factors repress the expression of cyclin D3 directly to 
limit proliferation of T47D cells 
As shown previously in Figure 50, Cyclin D3 protein levels were elevated in AP-2 
silenced T47D cells.  Based on the evidence from the western blots and qPCR it is 
plausible to hypothesise that AP-2 factors have a repressive action on cyclin D3 to 
limit its expression, and thereby, control the cell cycle at G1/S-phase.  Therefore, it 
was intriguing to investigate, in addition to p21cip expression, whether AP-2α and 
AP-2γ regulate cell cycle progression in T47D cells via direct regulation of cyclin D3 
expression.  In order to demonstrate the relationship between AP-2 and cyclin D3, I 
first searched for putative AP-2 binding sites in the cyclin D3 promoter region.  
Using the website ‘ECR Browser: Evolutionary Conservation of Genomes’ 
(http://ecrbrowser.dcode.org/), which allows users to visualise and analyse 
evolutionary conserved regions (ECRs) in genomes of sequenced species, human 
(Homo sapiens) chromosome 6 at the genomic position 42015810 to 42022690 was 
aligned with the chimpanzee (Pan troglodytes) genome because they share the most 
conserved homology compared to other species.  Following the instructions, a 
conservation profile was created illustrating sequence elements that are conserved 
above a certain level of sequence identity between the two genomes and were 
highlighted as ECRs.  After alignment, the website provides a link called ‘Mulan 
tool’ which can further identify and annotate evolutionarily conserved transcription 
factor binding sites (TFBS).  In addition, different regions along the genome, for 
example, coding exons, introns, promoters and enhancer regions were also indicated.  
Four putative AP-2 binding sites were found, of which three were located within the 
region (-8 / -107) immediately upstream of the TSS and one was found in an intronic 
region (+642 / +740) downstream of exon 1 (see Figure 54).  To demonstrate that 
AP-2 factors can bind to the CCND3 promoter in cells, I decided to perform a ChIP 
assay on T47D cells for AP-2 factors.  To this end, two sets of primers were designed 
for ChIP assay to amplify the cyclin D3 locus at the proximal promoter region or the 
intronic region predicted to contain consensus AP-2 binding sites (see Figure 54).  In 
addition, as a negative control, a pair of primers was designed to a region without 
predicted AP-2 sites -3307 / -3199 upstream of the ATG initiator codon.  The 
combination of the final primer concentrations for the qPCR reaction was optimised 
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and agarose gel electrophoresis was performed to ensure the presence of a single 
specific PCR product.  A series of qPCR reactions were performed on T47D ChIP 
samples from the control and AP-2α and AP-2γ silenced cells.  Note that, this is the 
same set of ChIP samples used to detect AP-2α and AP-2γ occupancy at the p21cip 
promoter region (see Figure 48). 
 
As shown in Figure 55A, there was higher amplification of cyclin D3 products at the 
-8 / -107 proximal region in AP-2α and AP-2γ immunoprecipitated samples 
compared to the no antibody negative control.  These enrichments were reduced 
when AP-2α and AP-2γ were silenced, strongly suggesting that AP-2 factors bind to 
this region of the CCND3 locus.  Although there was a higher amplification of cyclin 
D3 products at +642 / +740 intronic region in the AP-2α immunoprecipitated NSC 
sample, and a reduction in enrichment was observed upon AP-2α silencing, as shown 
in Figure 55B, however, there was a large variation between the replicates as 
represented by the large error bar.  When compared to the no antibody control, the 
fold enrichment was not as major as at the -8 / -107 region.  Furthermore, it would be 
expected that the AP-2α enrichment level in AP-2γ-silenced cells would be similar to 
the control but, as illustrated, this observation was not seen, therefore, it is believed 
that there was no major AP-2α or AP-2γ occupancy in this region.  No enrichments 
were found at the -3307 / -3199 upstream region, as shown in Figure 55C, further 
suggesting that the binding of AP-2α and AP-2γ to the proximal region of the Cyclin 
D3 promoter is specific.  Notably, AP-2α silencing seems to lead to a reduction of 
AP-2γ recruitment.  This may be that AP-2γ binding dependent on AP-2α but not 
vice versa, however, ChIP assay would be needed in order to confirm. 
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-919 
TCTAGCTTCCGGTAAAACTACAAAGTAACCAAAAGTTTGGGAGGTGGAAGAAATGCAACCAG
ATCGAAGGCCATTTTGATGTTTCATTGGTTTTCAAACCCTCCACCTTCTTTACGTTGG 
-859 
GGTAGATCTCACAGAGTCTGTGCAAGAAACTGATTCAATGAGAATCTAGTTTCTCCGTCC 
CCATCTAGAGTGTCTCAGACACGTTCTTTGACTAAGTTACTCTTAGATCAAAGAGGCAGG 
-799 
ACAGTTTCTCCAAACAGAAACTAAGGCCGACTTTAGGGGCTTGTCCAAACCTAGGCAAGC 
TGTCAAAGAGGTTTGTCTTTGATTCCGGCTGAAATCCCCGAACAGGTTTGGATCCGTTCG 
-739 
AACTTAACAAGGTGAGGCCATGACTCCATGGCCTTTCCGTTCTGTTATATGCTGACTTAG 
TTGAATTGTTCCACTCCGGTACTGAGGTACCGGAAAGGCAAGACAATATACGACTGAATC 
-679 
ACTAAAGCTCTCATACTTTAAAGTGCACAGAAATCTAGTTAAAATGCAGATTCTGATTCA 
TGATTTCGAGAGTATGAAATTTCACGTGTCTTTAGATCAATTTTACGTCTAAGACTAAGT 
-619 
GGTTAGGGGTGGGCCTGAGAGTCTGCATTTCTAACCAGCTCCCAGGCGATGACCACGCAC 
CCAATCCCCACCCGGACTCTCAGACGTAAAGATTGGTCGAGGGTCCGCTACTGGTGCGTG 
-559 
GGGACAGGTCTGGGATCACAGTTTAACTAGCAATGGTGTAGAACACAGAATCTGCAGCAA 
CCCTGTCCAGACCCTAGTGTCAAATTGATCGTTACCACATCTTGTGTCTTAGACGTCGTT 
-499 
GAAGGCCAGCTTCCCAATCCTAGCTCTGCCACGGACCAACTGAATGACAGTTGCCTCGGT 
CTTCCGGTCGAAGGGTTAGGATCGAGACGGTGCCTGGTTGACTTACTGTCAACGGAGCCA 
-439 
TTCCGAGTTTTCGTGAAGATGTAGTGAGTCATTACATCGTGAGGCTTTCGAGCAGCGTTC 
AAGGCTCAAAAGCACTTCTACATCACTCAGTAATGTAGCACTCCGAAAGCTCGTCGCAAG 
-379 
ACTAAGAACTAGCTCTGACATTATTTATCGCATTCCTTAGAGCAAGCAGCCGGTGAAGTA 
TGATTCTTGATCGAGACTGTAATAAATAGCGTAAGGAATCTCGTTCGTCGGCCACTTCAT 
-319 
GGGTTTGACGAATGAATAAGTGAATGAATGACCTTTGGAGAAAAATTGTTTCCTGGGTGA 
CCCAAACTGCTTACTTATTCACTTACTTACTGGAAACCTCTTTTTAACAAAGGACCCACT 
-259  Construct #3 → 
CTAGAGTCCGAGAAGCAAAATGGGAGGGCCCGTGGGTGGGTAGGAGGCCCACCTCCTAGA 
GATCTCAGGCTCTTCGTTTTACCCTCCCGGGCACCCACCCATCCTCCGGGTGGAGGATCT 
-199 Construct #2 → 
AAGTTCTCTGCACCCGGTGGTCCAGAGGGCCTGGAGTGCCCGGAAGCCGGCCGGCTTGCG 
TTCAAGAGACGTGGGCCACCAGGTCTCCCGGACCTCACGGGCCTTCGGCCGGCCGAACGC 
-139          -107 Construct #1 → 
CTCAGCGGCCCAATGGGGCCGCGGGAGGGAGGGGAGAGCGCTCAGCCAACCCTTTCCGTC 
GAGTCGCCGGGTTACCCCGGCGCCCTCCCTCCCCTCTCGCGAGTCGGTTGGGAAAGGCAG 
-79 
CGGGGCGCCGCAGCCCCGCCCCTCGGAGCGTTGCGACGTCCGAGCATTCCACGGTTGCTA 
GCCCCGCGGCGTCGGGGCGGGGAGCCTCGCAACGCTGCAGGCTCGTAAGGTGCCAACGAT 
-19 ← -8    +1 Transcription start site 
CATCGTCGCGAGGGGCGGGGCGCCTGTCAGGGAAGCGGCGCGCGCGCGCGGGCGGCGGGC 
GTAGCAGCGCTCCCCGCCCCGCGGACAGTCCCTTCGCCGCGCGCGCGCGCCCGCCGCCCG 
+42 
GGGCTGGGGATCCGCCGCGCAGTGCCAGCGCCAGCGCCAGACCCGCGCCCCGCGCTCTCC 
CCCGACCCCTAGGCGGCGCGTCACGGTCGCGGTCGCGGTCTGGGCGCGGGGCGCGAGAGG 
+102        ← Reverse primer 
GGCCCGTCGCCTGCCTTGGGACTCGCGAGCCCGCACTCCCGCCCTGCCTGTTCGCTGCCC 
CCGGGCAGCGGACGGAACCCTGAGCGCTCGGGCGTGAGGGCGGGACGGACAAGCGACGGG 
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+162 
Initiator Codon 
GAGTATGGAGCTGCTGTGTTGCGAAGGCACCCGGCACGCGCCCCGGGCCGGGCCGGACCC 
CTCATACCTCGACGACACAACGCTTCCGTGGGCCGTGCGCGGGGCCCGGCCCGGCCTGGG 
+222 
GCGGCTGCTGGGGGACCAGCGTGTCCTGCAGAGCCTGCTCCGCCTGGAGGAGCGCTACGT 
CGCCGACGACCCCCTGGTCGCACAGGACGTCTCGGACGAGGCGGACCTCCTCGCGATGCA 
+282 
ACCCCGCGCCTCCTACTTCCAGTGCGTGCAGCGGGAGATCAAGCCGCACATGCGGAAGAT 
TGGGGCGCGGAGGATGAAGGTCACGCACGTCGCCCTCTAGTTCGGCGTGTACGCCTTCTA 
+342 
GCTGGCTTACTGGATGCTGGAGGTACCGCCCGGACGCGTCCCCCTCCCCCACCGCTCCCG 
CGACCGAATGACCTACGACCTCCATGGCGGGCCTGCGCAGGGGGAGGGGGTGGCGAGGGC 
+402 
GGTCTGGACACACCGGGGCCGCCCTGTCGGGACATCCCGGTCCCCACAGCAATCTGCAGG 
CCAGACCTGTGTGGCCCCGGCGGGACAGCCCTGTAGGGCCAGGGGTGTCGTTAGACGTCC 
+462 
ATGCTCCGAGGCTAAGACTCCCGGGGCCTGGCCTTTCACTAGGGCACCCACGCCAGCTGC 
TACGAGGCTCCGATTCTGAGGGCCCCGGACCGGAAAGTGATCCCGTGGGTGCGGTCGACG 
+522 
CTCCCTTGCTTTCCCGAGCCCTAATCGGCTCCTCCCGACAGTGACTGCCAGTCACTTGGC 
GAGGGAACGAAAGGGCTCGGGATTAGCCGAGGAGGGCTGTCACTGACGGTCAGTGAACCG 
+582 
ACCCTAACTGTGCCTCTCTTCGGGCCGAGCAAACGGGACCAAGGACACTCTCTCCCCTTC 
TGGGATTGACACGGAGAGAAGCCCGGCTCGTTTGCCCTGGTTCCTGTGAGAGAGGGGAAG 
+642  → 
GGCTTCTCACAGCGTCTCCCGCTTCCCTCCGCCTCCCGGCCTTCTCCGGAGAGCGCGCCT 
CCGAAGAGTGTCGCAGAGGGCGAAGGGAGGCGGAGGGCCGGAAGAGGCCTCTCGCGCGGA 
+702       +740 ← 
GGAAAACCCTGGGCTCGGCCGCCCCCGCCCGGGAGCCGGTTCCTGTGTCTTTCGCGGGGT 
CCTTTTGGGACCCGAGCCGGCGGGGGCGGGCCCTCGGCCAAGGACACAGAAAGCGCCCCA 
+762 
TCTGGCGGGGAAGGCGATGGGGGTGGCGCGCGCCCTGTTCCGGCCGACAGGGAAATGAAA 
AGACCGCCCCTTCCGCTACCCCCACCGCGCGCGGGACAAGGCCGGCTGTCCCTTTACTTT 
+822            +882 
AGTGCAGGAGGCAGCGGCAGGAGCCTCCTCCCTTCCCCTCGGGTGTGTGCAGTGGTGGCG 
TCACGTCCTCCGTCGCCGTCCTCGGAGGAGGGAAGGGGAGCCCACACACGTCACCACCGC 
 
 
Figure 54. CCND3 promoter region.  The CCND3 promoter from positions -919 to + 882 is shown 
with potential AP-2 binding sites based on ECR Browser: Evolutionary Conservation of Genomes 
(http://ecrbrowser.dcode.org/) highlighted in green.  Primer sequences used for the ChIP assays (-8 / -
107, and +642 / +740) and PCR for generating luciferase constructs are underlined with the arrow 
indicating the direction.  +1 indicates TSS; Initiator codon ATG is highlighted in bold. Blue colour - 
coding region; Red – 5’ UTR region; Black – Intronic region. 
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Figure 55. ChIP assay showing the effect of AP-2 silencing on endogenous AP-2α and AP-2γ 
occupancy at the CCND3 promoter and intronic region.  Results were presented as a fold change 
to no antibody control and expressed relative to the total input chromatin.  Chromatin samples were 
analysed by qPCR using the (A) -8 / -107; (B) +642 / +740 and (C) –3307/-3199 primers. Data 
averaged from 3 independent experiments, ±standard error (see Figure 48 for further experimental 
details). 
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This evidence strengthened the hypothesis that both AP-2α and AP-2γ might exert an 
inhibitory effect at the proximal region of cyclin D3 promoter, and hence, result in 
increased cell proliferation upon AP-2 silencing.  In order to prove the repressive 
action of AP-2 factors on the CCND3 promoter, I decided to use reporter assays.  
The proximal promoter region was amplified using PCR and was sub-cloned into a 
luciferase reporter plasmid, pGL3 basic.  The ECR Browser website indicated that 
there are three putative AP-2 binding sites between region -234 to -52 immediately 
upstream of the TSS (see Figure 54), hence, three forward primers and one reverse 
primer were designed to generate three different PCR fragments containing these 
sites.  Since the backbone of the pGL3-baisc vector contains the modified coding 
region for firefly luciferase including the ATG initiator codon, thus, when designing 
these primers, I ensured that they would not generate fragments carrying the ATG 
initiator codon from the CCND3 genome (see schematic diagram in Figure 56A).  As 
illustrated in Figure 56A, fragment 1 is the shortest containing only one site, 
fragment 2 contains two sites including fragment 1, and fragment 3 is the longest 
containing all three sites.  These constructs were, named as construct #1, #2 and #3.  
The aim of the experiment was to co-transfect these constructs with AP-2α and AP-
2γ expression constructs into HepG2 cells, which do not express AP-2, to see if AP-2 
co-expression will repress the CCND3 promoter reporter activity.  The pGL3-Basic 
vector alone was used as a negative control.   
 
Prior to co-transfecting these cyclin D3 luciferase reporter constructs with the AP-2 
expression constructs, the transfection conditions for these reporter constructs were 
optimised in order to obtain a reasonable level of basal luciferase activity which 
might be repressed when AP-2 expression constructs were added.  Figure 56B shows 
that the basal luciferase activity was obtained when transfecting 0.25μg of reporter 
construct.  The luciferase activity increased in proportion to the amount of reporter 
transfected into the cells.  Note that, the luciferase activity was the lowest from 
construct #1 for all amounts, whereas the luciferase activity was the highest from 
construct #3 and intermediate from construct #2.  This suggested that construct #3 
contains the functional promoter region and this region might have been deleted in 
construct #1 and #2.  Several transfection experiments were done to scale down the 
total amount of construct being transfected into HepG2 cells due to variation of 
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transfection efficiency between experiments (data not shown).  This could be that an 
excess amount of construct (1μg) was transfected into the cells in the 24-well plate 
format, which exceeded the recommended amount according to the manufacturer’s 
protocol.  The transfection conditions were re-optimised to 500 ng total amount of 
plasmid construct for later experiments. 
 
Using the optimal transfection conditions described above, each of the cyclin D3 
reporter constructs were co-transfected with either AP-2α or AP-2γ expression 
constructs.  A range of expression construct amounts were used to check that any 
effect of AP-2 expression on the reporter luciferase activity was in proportion to the 
dose added.  The results in Figure 56C show that the luciferase activity from 
construct #1 remained constant at all doses of AP-2α or AP-2γ expression constructs, 
indicating that there are no functional AP-2 binding sites in this construct.  However, 
the basal luciferase activities from constructs #2 and #3 were reduced dramatically 
following co-transfection with 50 ng of AP-2α or AP-γ expression constructs.  The 
luciferase activities reduced slightly further as the amount of AP-2 expression 
constructs increased.  These observations suggest that both AP-2α and AP-2γ can 
interact with and mediate transcriptional repression at the CCND3 promoter and that 
the sites of functional binding lie between -108 and -254.  Strategies that could be 
used to identify precise AP-2 binding sites will be discussed in the final Discussion 
chapter. 
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Figure 56. AP-2α and AP-2γ repressed basal activity from the CCND3 promoter.  (A) A 
schematic diagram (not to scale) shows three AP-2 putative binding sites in the proximal promoter 
region of CCND3.  Construct #1 contains one binding site; construct #2 contains two bindings and 
construct #3 contains three binding sites. The initiator codon ATG where AT (red) indicates where the 
primer overlaps but not overlap G (black). (B) HepG2, the AP-2 non-expressing cell line, was 
transiently transfected with 0.25, 0,5 and 1μg of the CCND3 luciferase reporter constructs #1, #2 and 
#3.  Forty-eight hours following transfection cells were assayed for luciferase activity.  (C) HepG2 
cells were transfected with 100 ng of each of the CCND3 reporter constructs and the indicated 
amounts of the AP-2α or AP-2γ expression constructs.  Forty-eight hours following transfection cells 
were assayed for luciferase activity.  A renilla luciferase construct was co-transfected in each 
experiment and the differences in DNA amount were compensated for using a promoterless luciferase 
construct (B) or pcDNA3 plasmid (C).  Luciferase activity were normalised to empty pGL3-Basic 
vector control corrected for Renilla luciferase activity (mean ± SD of two independent experiments).   
C
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Based on the findings of the ChIP and reporter assays as demonstrated here, I 
conclude that both AP-2α and AP-2γ have a repressive effect on cyclin D3 by 
binding to the proximal promoter region, and hence, regulate cell cycle progression 
in T47D cells.  To further demonstrate cyclin D3 expression remains up-regulated in 
AP-2 silenced T47D cells, a synchronisation experiment was repeated following AP-
2 silencing and cells were harvested at 0, 5, 8, 9, 10, 12 and 24 hours after block 
removal and the levels of cyclin D3 protein were assessed by western blotting.  As 
shown in Figure 57, the levels of cyclin D3 in mock and NSC treated cells were up-
regulated from 0 to 5 hours following block removal, and declined from 8 to 24 
hours.  Cyclin D3 protein levels were also up-regulated but then remained at a 
similar level in all AP-2 silenced cells between 0 to 12 hours after block removal.  
This evidence further supports the hypothesis that cyclin D3 expression is repressed 
by AP-2α and AP-2γ, and is up-regulated upon AP-2 silencing.  Moreover, p21cip 
protein levels were also examined in these samples, and they were also found to be 
up-regulated in the controls between 3 to 5 hours.  However, when examined closely, 
the levels were slightly higher in AP-2 silenced cells between 8 to 10 hours.  
Moreover, the loading control in AP-2α silenced cells between 8 to 12 hours 
indicated that these samples were slightly under-loaded, which suggests that both 
p21cip and cyclin D3 protein levels in these samples might be even higher than the 
controls.  Nonetheless, the effect on p21cip proteins following AP-2 silencing seems 
to be more subtle and it is more plausible that the main effect on cell cycle 
progression in T47D cells is due to the release of cyclin D3 repression upon AP-2 
silencing. 
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Figure 57. Analysis of cyclin D3 and p21 expression in synchronised T47D cells.  T47D cells were 
transiently transfected with AP-2α and AP-2γ specific siRNAs and 24 hours following transfection 
cells were synchronised by addition of 0.2μg/ml aphidicolin to the media for 16 hours.  Block was 
removed and cells were harvested at the indicated time points after return to normal growth media.  
Whole cell extracts (10μg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were 
probed with primary antibodies against cyclin D3, p21cip and HSC70. 
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3.7. AP-2 silencing in H3396 and MCF10A cell lines 
Putting all the evidence observed above, the effects of silencing both AP-2α and AP-
2γ in T47D cells were only clearly observed when T47D cells were synchronised.  
This indicated that AP-2 factors may play a relatively minor role regulating the cell 
cycle in this cell line compared to MCF-7 cells which exclusively express AP-2γ.  
This could be due to the fact that T47D cells express both AP-2α and AP-2γ, and that 
silencing of either is compensated for by the other.  Additionally, T47D cells carry 
mutant p53, which may have a dominant effect in terms of cell proliferation 
regardless of AP-2 expression.  Therefore, it was interesting to study the effects of 
both AP-2α and AP-2γ silencing in other breast cell lines.  We chose to investigate 
H3396 and MCF10A cells because they both express AP-2α and AP-2γ and carry 
wild-type p53.  In addition, similarly to MCF-7 cells, H3396 is ERα positive.  In 
contrast, MCF10A is ERα negative and is an immortalised, non-tumourigenic line 
(please see Table 11 for summary).  It would be interesting to determine if silencing 
AP-2 in these cell lines would result in a similar effect to observations made in either 
MCF-7 or T47D cells.  Furthermore, all data obtained in the MCF-7 study were 
collected 96 hours following AP-2γ silencing, whereas here all the observations were 
performed between 48 and 72 hours.  In order to see a prolonged effect on cell 
proliferation in T47D cells following AP-2 silencing, a cell count study was 
performed together with H3396 and MCF10A cells over 120 hours to see whether 
silencing AP-2 for longer periods would have a more pronounced effect on cell 
proliferation. 
 
Using the optimised transfection conditions, both AP-2α and AP-2γ specific siRNAs 
or NSC siRNA were transiently transfected individually or together in T47D, H3396 
and MCF10A cells (see Materials and Methods).  Cells were counted at 24 hour 
intervals from 48 to 120 hours.  As shown in Figure 58A, the numbers of viable cells 
in AP-2 double silenced T47D cells were higher than the NSC cells at 72 hours, 
which is in agreement with the previous cell count study, however, the cell numbers 
for the NSC and AP-2 double silenced cells reached parity at 96 hours.  By 120 hours 
the cell numbers in AP-2 double silenced T47D cells were slightly lower than with 
NSC.  For H3396 cells, AP-2 silencing did not lead to any significant changes in cell 
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proliferation, as demonstrated in Figure 59.  In contrast, Figure 60 shows that when 
AP-2α and AP-2γ were silenced in MCF10A cells, the number of viable cells was 
decreased dramatically by 96 hours.  This was maintained to 120 hours.  Western 
blot analysis demonstrated the knock down in these cell lines remained satisfactory 
throughout the experiment, thus, it is confident that the changes in cell growth were 
due to AP-2 silencing. 
 
In addition, cell cycle analysis was performed on single and double silenced H3396 
and MCF10A cells.  Forty-eight hours post transfection, cells were subjected to 
western blot analysis to ensure good knock down prior to cell cycle analysis.  As 
shown in Figure 61A, there was no statistically significant difference at any stage of 
the cell cycle between AP-2 silenced cells and the controls in H3396 cells.  The 
result of cell cycle analysis is consistent with the cell count study in which AP-2α 
and AP-2γ silencing did not result in any changes in the cell number compared to the 
control. Interestingly, when AP-2γ was silenced in MCF10A cells, the effect on the 
cell cycle was similar to that seen in AP-2γ silenced MCF-7 cells.  As illustrated 
in Figure 62, following AP-2γ single and AP-2 double knockdown, there was a 
reduction in S and G2/M-phase populations accompanied by an increase in G1-phase 
cells.  These changes in the cell cycle were more significant in AP-2 double silenced 
than AP-2γ silenced cells.  This implies that AP-2α might not be responsible in 
regulating cell growth or that AP-2γ can compensate unless both factors are depleted.  
 
Putting together the results of cell count studies and cell cycle analysis suggests that 
AP-2α and AP-2γ might not be the most important factors in terms of cell growth in 
certain cell lines, such as H3396 cells.  In addition, the different effects on the cell 
cycle when silencing either AP-2α or AP-2γ in various cell lines observed in this 
study, implies that AP-2α might be more dominant than AP-2γ in T47D cells but the 
reverse is true in MCF10A.  Interestingly, MCF10A cells predominantly express AP-
2α and a relatively low level of AP-2γ (see Table 11).  The reason there was an effect 
on cell cycle in AP-2γ silenced but not in AP-2α silenced cells was not clear.  It 
could be that AP-2γ in MCF10A has a similar role in controlling cell proliferation as 
in MCF-7 cells.  Nonetheless, when comparing the results obtained from these 
studies across these three breast cell lines, AP-2α and AP-2γ clearly have the greatest 
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effect on MCF10A cell growth, therefore, we decided to focus more on the function 
of AP-2 in this cell line.  A panel of western blots were performed to compare the 
levels of several cell cycle regulators in the control and AP-2 silenced MCF10A cells 
at 48 and 72 hours.  Furthermore, a gene expression profiling experiment across 
Affymetrix GeneChip HG-U133Plus2 microarrays was performed in order to explore 
changes in expression between the controls and AP-2 depleted cells.  The results of 
these analyses are discussed in the next chapter. 
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Figure 58. Cell count study on NSC and AP-2 double silenced T47D cells over 120 hours.  Cells 
were transfected as indicated in Materials and Methods.  (A) Cells were harvested at 24 intervals over 
120 hours following transfection.  Counts were averaged and expressed as mean±s.e., n = 3. Cell 
counts were performed using Casy Cell Counter (Scharfe System). (B) Whole Cell extracts 
(10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with 
primary antibodies against AP-2α and AP-2γ.  HSC70 was used as loading control. 
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Figure 59. Cell count study on NSC and AP-2 double silenced H3396 cells over 120 hours. Cells 
were transfected as indicated in Materials and Methods.  (A) Cells were harvested at 24 intervals over 
120 hours following transfection.  Counts were averaged and expressed as mean±s.e., n = 3. Cell 
counts were performed using Casy Cell Counter (Scharfe System). (B) Whole Cell extracts 
(10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with 
primary antibodies against AP-2α and AP-2γ.  HSC70 was used as loading control. 
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Figure 60. Cell count study on NSC and AP-2 double silenced MCF10A cells over 120 hours.  
Cells were transfected as indicated in Materials and Methods.  (A) Cells were harvested at 24 intervals 
over 120 hours following transfection.  Counts were averaged and expressed as mean±s.e., n = 3. Cell 
counts were performed using Casy Cell Counter (Scharfe System). (B) Whole Cell extracts 
(10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed with 
primary antibodies against AP-2α and AP-2γ.  HSC70 was used as loading control. 
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Figure 61.  Silencing for AP-2 in H3396 cells did not significantly affect the cell cycle. (A)  Cells 
were transfected as indicated and harvest for cell cycle analysis 48 hours post transfection (see 
Materials and Methods).  Experiments were repeated three times independently and results were 
expressed as mean±s.e., n = 3.  Data were normalised to NSC which was set to 1.  No statistically 
significant was found.  (B) Whole Cell extracts (10µg/lane) were separated by SDS/PAGE and blotted 
to a membrane. Blots were probed with primary antibodies against AP-2α and AP-2γ.  HSC70 was 
used as loading control. 
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Figure 62. Silencing for AP-2 in MCF10A cells significantly reduced S and G2/M populations. 
(A) Cells were transfected as indicated and harvest for cell cycle analysis 48 hours post transfection 
(see Materials and Methods).  Experiments were repeated three times independently and results were 
expressed as mean±s.e., n = 3.  Data were normalised to NSC which was set to 1.  No statistically 
significant was found.  (B) Whole Cell extracts (10µg/lane) were separated by SDS/PAGE and blotted 
to a membrane. Blots were probed with primary antibodies against AP-2α and AP-2γ.  HSC70 was 
used as loading control. 
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3.8. p21cip levels vary in different cell lines following AP-2 
silencing 
As demonstrated previously, following AP-2 silencing, T47D cells increased cell 
proliferation and it was hypothesised that this might be due (at least in part) to the 
small increase in p21cip protein in this cell line, which then acts as cyclin-cdk 
promoter (chaperone) rather than inhibitor.  As the initial experiments were carried 
out between 48 to 72 hours post-transfection, it was not clear if prolonged AP-2 
silencing in T47D cells would lead to continuous cell proliferation.  The cell count 
study performed over 120 hours showed that the proliferation of AP-2 double 
silenced cells was slightly higher than the NSC cells but remained similar between 
96 to 120 hours.  Western blot analysis was performed on the cell lysates obtained 
from these cell count samples and showed that p21cip levels were significantly 
increased in AP-2 double silenced cells compared to NSC (see Figure 63) between 
72 to 120 hours.  This evidence further supports the theory that p21cip protein levels 
have to be increased beyond a certain threshold in order to exert a growth inhibitory 
effect (LaBaer et al., 1997).  When the p21cip protein levels were compared between 
T47D, H3396 and MCF10A cell count samples, it was found that the p21cip protein 
levels were very similar in NSC and AP-2 silenced cells throughout the time course 
in H3396 cells and the levels increased gradually from 48 to 120 hours indicating 
higher cell confluency.  The levels of p21cip protein in AP-2 double silenced 
MCF10A cells were up-regulated only at 48 hours compared to NSC, but not 
sustained throughout 120 hours.  This observation was unexpected since the cell 
cycle and cell count studies had shown significant growth inhibition following AP-2 
silencing.  I had expected to see higher p21cip protein levels in AP-2 silenced 
MCF10A cells as observed in AP-2γ silenced MCF-7 cells.  Further experiments 
were performed on AP-2 silenced MCF10A cells to examine p21cip expression more 
closely. 
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Figure 63.  Levels of p21 in T47D, H3396 and MCF10A cells after AP-2 double knock down for 
over 120 hours.  The same sets of samples from in the cell count study of T47D, H3396 and 
MCF10A (refer to Figure 25, 26 and 27 respectively) were used for this western blot.  Whole Cell 
extracts (10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were probed 
with primary antibodies against p21cip.  See Figure 25, 26 and 27 for HSC70 loading control. 
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3.9. Silencing AP-2 in MCF10A does not up-regulate p21cip 
expression 
In order to better understand both p21cip mRNA and protein levels, three 
independent experiments were carried out in which AP-2 factors were silenced for 72 
hours and p21cip mRNA and protein levels were assessed.  These RNA samples 
were later used in Affymetrix Microarray experiments (see Chapter 4).  Prior to 
checking if there were any changes in p21cip expression, qPCR and western blots 
were performed to ensure that AP-2α and AP-2γ expression had been successfully 
knocked down at both the mRNA and protein levels (see Figure 64A).  Figure 64B 
shows that p21cip mRNA levels were not up-regulated following AP-2 silencing, 
instead, the levels were down-regulated by 25% in AP-2 double silenced cells 
compared to NSC.  The p21cip mRNA level in AP-2α silenced cells was similar to 
the NSC, and the level in AP-2γ silenced cells was slightly lower.  However, when 
the protein levels in all the AP-2 silenced samples were compared to NSC cells, a 
moderate increase in AP-2α silenced cells was seen, but no change in AP-2γ or AP-2 
double silenced cells.  This observation is inconsistent with our previous MCF-7 
study as well as the T47D study presented here.  It could be that the regulation of 
p21cip expression by AP-2 varies between different cell lines and that the effect on 
cell proliferation is not just dependent on the level of p21cip expression following 
AP-2 silencing.  Therefore, p21cip expression might not be regulated primarily by 
AP-2 factors in these cells and in addition, the reduction in cell growth in this cell 
line after AP-2 depletion might involve other pathways.  This will be discussed 
further with the expression profile analysis in the next chapter. 
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Figure 64. p21 mRNA and protein levels are not regulated by AP-2 silencing in MCF10A cells.  
Cells were transfected and harvested for RNA extraction 48 hours post-transfection (refer to Materials 
and Methods).  Quantitative PCR analysis of (A) AP-2α and AP-2γ and (B) CDKN1A mRNA levels.  
All data were normalised to GAPDH mRNA levels and NSC values set as 1 to generate relative 
mRNA level.  These graphs represent data averaged from 3 independent experiments, ±standard error. 
Whole cell extracts (10µg/lane) were separated by SDS/PAGE and blotted to a membrane. Blots were 
probed with primary antibodies against (A) AP-2α, AP-2γ and (B) p21.  HSC70 was used as loading 
control.  
B
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Chapter 4 
Results: Gene Expression Profile 
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4. AP-2α and AP-2γ Gene Expression Profiling 
4.1. Choice of cell lines – Why MCF10A? 
Our lab has previously established an AP-2γ dependent gene expression profile 
following RNAi mediated AP-2γ silencing in MCF-7 cells, and it was found that the 
majority of genes that were significantly down-regulated were cell cycle related 
(see Figure 19).  As MCF-7 cells predominantly express high levels of AP-2γ but 
very low AP-2α, it was therefore intriguing to find out the additional breast epithelial 
cell pathways activated by, not only AP-2γ, but also AP-2α specifically.  
Additionally, we wanted to examine to what extent AP-2α and AP-2γ expression 
profiles overlap and whether each family member has its own specific target genes.  
In order to establish which cellular pathways have become activated by AP-2α, AP-γ 
and both AP-2α and AP-2γ in a breast cell line, the research presented in this thesis 
aimed to use Affymetrix GeneChip high-density oligonucleotide microarrays to 
define any changes in gene expression in breast epithelial cells following AP-2 
silencing.   
 
In Chapter 3, I have shown that the effect of AP-2α and AP-2γ silencing in T47D 
cells increased cell proliferation.  The differences in cell growth between the controls 
and AP-2 silenced cells were not significant at 48 hours in either the cell cycle 
analysis or the cell count study (Figure 40 and Figure 44) but became significant 
when cells were silenced for 72 hours, or when cells were synchronised following 
AP-2 targeting siRNA transfection (Figure 43 and Figure 44).  However, prolonged 
AP-2 silencing in this cell line did not cause a further increase in cell proliferation 
rate, instead, cell proliferation was reduced between 96 to 120 hours compared to the 
NSC (Figure 58).   Since the effect of AP-2 silencing on cell growth in T47D cells 
was not as profound as observed in AP-2γ silenced MCF-7 cells (see Figure 20), two 
further cell lines, H3396 and MCF10A, were looked at with the aim of finding out if 
knocking down AP-2α and AP-2γ in these cell lines independently and together 
would have more profound effects on cell growth.  Cell cycle analyses and cell count 
studies showed an increased G1-phase population accompanied by a reduction in S-
phase and a significant reduction in cell proliferation in MCF10A cells following 
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AP-2 silencing (Figure 60 and Figure 62).  In contrast, AP-2 silencing did not have 
an impact on cell growth in H3396 cells (Figure 59 and Figure 61).   
 
Putting together the results obtained in Chapter 3, indicated that AP-2 factors are 
playing an important role in terms of cell growth and survival in MCF10A cells and 
that depleting AP-2 in this cell line led to growth inhibition.  Thus, it has led us to 
pursue the effect of AP-2 on cell growth further using the MCF10A cell line. 
 
4.2. AP-2 silencing did not cause induction of a Sub-G1 
population 
To further elucidate if reduced cell proliferation in MCF10A cells after AP-2 
depletion was due to increased cell death, MCF10A cells were transiently transfected 
with AP-2 targeting siRNAs for 96 hours and Sub-G1 analysis was performed on 
these cells, including the floating cells, to record the Sub-G1 population.  As 
mentioned in Chapter 3 section 3.2, Sub-G1 analysis can detect fragmented genomic 
DNA, which is a typical phenotype of cell death.  As shown in Figure 65, there was 
no significant difference in Sub-G1 population between the controls and AP-2 
silenced MCF10A cells.  This indicated that the effect on cell proliferation was 
independent of cell death following AP-2 silencing. 
 
I have demonstrated using qPCR and western blot analyses (see Figure 64), that 
p21cip expression was not significantly elevated in MCF10A cells following AP-2 
silencing.  This implied that cell cycle arrest in AP-2 silenced MCF10A was not due 
to p21cip up-regulation as we observed in our MCF-7 study, which also implies that 
p21cip was not the major target after AP-2 silencing in MCF10A cells.  It is 
therefore interesting to examine the expression of other cell cycle regulatory 
molecules that are responsible for cell proliferation, in particular those involved in 
G1/S transition: cyclin D, cdk4 and p27.  A panel western blot was performed to 
check if the protein levels of these cell cycle regulators changed after AP-2 was 
knocked down for 72 hours.  Figure 66 illustrates that the protein levels of cyclin D1, 
cyclin D3, cdk4, p27 and p21cip remained constant in all AP-2 silenced samples.  
The absence of marked changes in expression of these cell cycle regulated genes is in 
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agreement with the cell cycle and cell count studies that AP-2 silenced MCF10A 
cells were not actively undergoing S-phase.  Again, this western blot analysis further 
confirms the reduction of cell proliferation in MCF10A cells after AP-2 silencing 
was independent of the p21cip pathway.   
 
At this point it was not clear what caused cell cycle arrest at the G1/S transition in 
AP-2 silenced MCF10A cells, for instance, what other molecules were affected 
following AP-2 silencing that lead to a reduction in cell proliferation.  Nonetheless, 
based on the evidence described above, it is strongly suggesting that it involves a 
mechanism that is different to our previous MCF-7 study.  It is known that both AP-
2α and AP-2 are involved, not only in cell proliferation, but also in differentiation 
during development (see Introduction, section1.8), and their role in regulating the 
proliferation and differentiation of mammary gland epithelial cells has been 
described (see Introduction, section 1.10).  This, therefore, led us to consider if 
silencing AP-2 in MCF10A caused cells to leave the cell cycle and undergo 
differentiation?  Or, if silencing AP-2 in MCF10A reduced cell adhesion which 
eventually causes cell death? To begin to address this, I first observed closely the cell 
morphology after AP-2 depletion and compared to the controls, and as described in 
the next section. 
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Figure 65.  Silencing AP-2α and AP-2γ does not significantly affect the Sub-G1 population in 
MCF10A cells.  Cells were transfected as indicated in Materials and Methods, and harvested at 96 
hours post-transfection.  Cells were fixed and stained with PI for Sub-G1 analysis to detect total DNA 
content. Data obtained from a single experiment and normalised to NSC. 
 
 
 
Figure 66.  Analysis of G1/S-phase associated proteins in MCF10A cells following AP-2 
silencing.  Cells were transfected as indicated in Materials and Methods, and harvested at 72 hours 
post-transfection for western blot analysis.  Whole cell extracts (10μg/lane) were separated by 
SDS/PAGE and blotted to a membrane.  Blots were probed with primary antibodies against AP-2α, 
AP-2γ, cyclin D1, cyclin D3, cdk4, p27 and p21.  HSC70 was used as loading control. 
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4.3. Cell morphology changed following AP-2 silencing in 
MCF10A cells  
MCF10A is a spontaneously immortalised cell line that arose from normal, non-
tumourigenic human mammary epithelial cells which normally grow as monolayers 
on tissue culture plastic (Tait et al., 1990).  Following AP-2 knock down, a marked 
change in the morphology was observed.  As presented in Figure 67, AP-2α and AP-
2 double silenced cells became much rounder and formed looser clusters compared 
to mock and NSC controls.  A morphological change in AP-2γ silenced cells was 
only occasionally observed and it was not as significant as in AP-2α and AP-2 
double silenced cells.  Due to this observation, it was suspected that silencing AP-2, 
in particular AP-2α, caused the cells to become less adherent.  Moreover, the number 
of cells reduced significantly in AP-2 silenced cells compared to the controls, which 
is consistent with the cell count study.  This observation provided a new insight into 
the range of target genes downstream of AP-2α and AP-γ that might be involved in 
cell morphogenesis, however, this needs to be elucidated further.   
 
Additionally, when MCF10A cells are grown on matrigel, these cells form hollow 
spheroid structures which express myoepithelial markers (Debnath et al., 2003).  
However, recently it has been shown that when grown on transwells MCF10A can 
generate multilayer structures, with the upper layers expressing ductal epithelial 
markers (Marshall et al., 2009).  This is similar to observations made in our 
laboratory, where alterations in culture conditions led to the expression of epithelial, 
rather than myoepithelial markers (e.g. keratin18, mucin1; Dr Chiara Berlato, 
Personal communication).  This suggests therefore that MCF10A retain some degree 
of multipotency and are not fully polarised to a myoepithelial/basal phenotype as is 
sometimes suggested and could be used as an informative in vitro model to study the 
role of AP-2 factors in human mammary differentiation.  With this in mind and based 
on the findings described above, I decided to perform Affymetrix GeneChip 
microarrays on AP-2 silenced MCF10A cells in order to generate an AP-2α-
dependent, AP-2γ-dependent as well as an AP-2α/γ-dependent gene expression 
profile. 
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Figure 67.  AP-2α and AP-2 double silencing results in an altered morphological phenotype. 
MCF10A cells were transfected as indicated in Materials and Methods.  Changes in morphology in 
AP-2 silenced cells and controls were observed at 48 hours post-transfection under phase contrast 
microscope at (A) x20 and (B) x40 magnification.   
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4.4. Array processing and quality control 
The Affymetrix Human GeneChip HG-U133 Plus 2 comprises 54,000 probe sets 
representing an estimated 47,000 human transcripts.  A more detailed description of 
the array procedure is given in Materials and Methods in section 2.12.  Briefly, total 
RNA was extracted from MCF10A cells 72 hours following transfection with AP-2α 
and AP-2γ targeting siRNAs, a NSC siRNA and cells treated with transfection 
reagent only (mock).  Four independent silencing experiments were carried out 
(biological replicates) and RNA from each set of experiment was extracted 
independently.  The RNA was treated with DNase to remove any genomic DNA 
contaminants.   
 
Good AP-2 silencing was confirmed at both mRNA and protein levels by qPCR and 
western blotting for each experiment and the best three sets of samples were chosen 
before proceeding further.  Figure 64A in Chapter 3 shows one representative of 
these three experiments.   All three sets (15 samples in total) were prepared at the 
same time for the microarrays in order to minimise variations which might occur 
during preparation.  GeneChip®3’ IVT Express Kit was used for processing the 
samples for microarray expression analysis.  This kit was chosen because it requires 
low RNA input from as little as 50 ng of total RNA, as compared to 10 μg of total 
RNA used in MCF-7 study.  The advantage of using low amount of RNA input was 
because there was no need to scale up the transfection which can lead to reduced 
transfection efficiency and to re-optimise the transfection condition.  Control 
oligonucleotides in known quantities were added to the RNA samples to act as 
hybridisation controls, allowing the signal intensities between chips to be 
normalised.  High yield biotinylated aRNA was achieved for each experimental 
sample.  After all quality controls were checked and reached a satisfactory level (see 
Materials and Methods section 2.14.1), samples were hybridised to Affymetrix HG-
U133 Plus 2 arrays.  The chips were scanned using the GeneArray Scanner 3000 
performed by Tracy Chaplin, Institute of Cancer.  After hybridisation and scanning, 
the data were analysed by a bioinformatician, Dr Claude Chelala (Centre for 
Molecular Oncology and Imaging, Institute of Cancer; see Materials and Methods 
section 2.14).   
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4.5. Data Analysis 
All three sets of data (15 samples in total) were analysed with a False Discovery Rate 
(FDR) adjusted p-value cut-off of <0.01.  In order to reveal the relationship between 
the AP-2 silenced samples and the controls, an unsupervised hierarchical clustering 
of the data was generated based on the top 10,000 differentially expressed genes, 
which is illustrated in a dendrogram in Figure 68.  It was expected that these samples 
would cluster together based on similarities in expression patterns.  For example, all 
AP-2α silenced replicates would be expected to form a subgroup that is distinct from 
AP-2γ and/or AP-2 double silenced replicates.  Mock and NSC would also be 
expected to cluster either together or position next to each other, and further away 
from all AP-2 silenced replicates.  As shown in Figure 68, AP-2α silenced and AP-2 
double silenced replicates from set 2 and 3 fell into the same subgroup, whereas AP-
2γ silenced replicates clustered with the mock and NSC in these sets.  All samples 
obtained from set 1 clustered on their own and failed to fall according to their 
biological subgroups.  It could be that extra variables other than biological effects of 
AP-2 silencing might have affected this set of samples during preparation, 
presumably at the transfection stage when these samples were treated independently 
of the other two sets.   
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Figure 68.  Unsupervised hierarchical clustering of MCF10A cells following AP-2 silencing of 
three independent experiments.  All 15 samples (three mock controls, three non-silencing,controls, 
three AP-2α silenced samples, three AP-2γ silenced samples and three AP-2 double silenced samples) 
were separated into their distinct groups based on the top 10,000 differentially expressed genes.  Mock 
= Mock control; NS = non-silencing control; AP-2a = AP-2α silenced cells; AP-2g = AP-2γ silenced 
cells and AP-2a_g = AP-2 double silenced cells. Number 1, 2 and 3 at the end of each sample name 
distinguishes the three independent experiments. 
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4.6. Identification of ‘AP-2 regulated gene set’ 
We are interested in identifying genes that had changed their expression following 
AP-2 silencing that may explain the reduction in cell proliferation and the change in 
cell morphology.  Therefore, the Affymetrix gene expression data generated for each 
sample: AP-2α, AP-2γ and AP-2 double silenced cells, including the mock control 
were normalised to the NSC.  After normalisation, the most consistently 
differentially expressed genes across the 15 arrays remained and statistically 
significant gene lists were produced specific to each AP-2 silenced group.  Non-
differentially expressed genes were filtered and excluded from the gene lists.  As 
presented in the venn diagram in Figure 69, a number of genes overlapped between 
mock, AP-2α, AP-2γ and AP-2 double silenced samples.  Only those genes that do 
not overlap with the mock control will be studied more closely for future validation.   
 
 
 
Figure 69.  Differentially expressed genes in Mock, NSC and AP-2 silenced cells of all three 
experiments.  Venn diagram shows the numbers of differentially expressed genes that overlap 
between each sample. 
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Prior to preceeding further with the data analysis, it was necessary to check if the 
down-regulation of both AP-2α and AP-2γ expression were among the Affymetrix 
microarray dataset.  Encouragingly, within these significant expression changes, both 
AP-2α and AP-2γ transcript levels were down-regulated in response to AP-2α and 
AP-2γ targeting siRNAs in MCF10A cells and this change was detected by the probe 
sets specific to AP-2α and AP-2γ.   Transcript levels of AP-2α and AP-2γ did not 
change in the mock control.  The changes in both AP-2α and AP-2γ expression 
levels in these samples are summarised in  
Table 12.   
 
 
Probe ID Mock /  NS AP-2α / NS AP-2γ / NS AP-2 
double / NS 
204653_at 
(TFAP2A, 
Transcription factor 
2 alpha) 
0 -1 0 -1 
204654_s_at 
(TFAP2A, 
Transcription factor 
2 alpha) 
0 0 0 -1 
205286_at 
(TFAP2C, 
Transcription factor 
2 gamma) 
0 0 -1 -1 
 
 
Table 12.  Significant changes in AP-2α and AP-2γ gene expression following AP-2 silencing. 
Changes observed in probe sets specific to AP-2α and AP-2γ between NSC and AP-2 silenced groups, 
and between NSC and mock using FDR with adjusted cut-off p-value <0.01. 0 = non-changing; -1 = 
down-regulated and 1 = up-regulated. 
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Further analysis on the differentially expressed genes identified the numbers of genes 
which were up- or down-regulated for each condition and these are summarised 
in Table 13.  Silencing AP-2α resulted in 61 genes being down-regulated genes and 
57 genes being up-regulated.  Silencing both AP-2α and AP-2γ resulted in more than 
twice as many genes being de-regulated (197 genes down-regulated and 247 genes 
up-regulated).  Unfortunately, microarray data analysis could not generate an AP-2γ 
dependent expression profile using p-value at <0.01.  In a less stringent analysis, 
using p-value <0.05, the only gene found to be down-regulated after AP-2γ silencing 
was TFAP2C itself, which implies that it would not be possible to produce a gene 
expression profile showing the biological effects on MCF10A cells when AP-2γ was 
silenced. Nevertheless, analysis on the remaining gene lists was performed using 
FDR adjusted p-value of <0.01.  Since MCF10A cells express very low AP-2γ levels 
compared to AP-2α (see Chapter 3, Table 11), it is likely that silencing AP-2γ alone 
may not lead to significant changes in gene expression as AP-2α may compensate for 
AP-2γ loss.  The lack of overall change in expression profile after loss of AP2γ also 
explains why the AP-2γ silenced replicates clustered with those from mock and NSC 
samples in Figure 68.  Nevertheless, AP-2γ clearly does contribute to the expression 
profile of MCF10A cells since many more genes are de-regulated in double silenced 
cells compared to when AP-2α was depleted. 
 
Unexpectedly, 44 genes were found to be de-regulated in the mock control after 
normalisation to NSC and 24 of these were also de-regulated in AP-2 silenced cells.  
One explanation could be that the siRNA transfection per se changed expression of 
some genes, and these genes have to take into consideration when analysing the gene 
lists for validation.  That is, those de-regulated genes that are common to both mock 
and AP-2 silenced groups will not be considered, and only those genes presented in 
AP-2 silenced groups but not in mock control will be considered as true AP-2-
regulated genes. 
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 No. of genes Mock/NS AP-2α/NS AP-2γ/NS AP-2 
double/NS 
Down 18 61 1 197 
Up 26 57 0 247 
Total 44 118 1 444 
 
Table 13.  Table showing the number of genes that were up or down-regulated following AP-2 
silencing across all three experiments after normalisation to NSC.  Data was analysed with a FDR 
with adjusted cut-off p-value <0.01. Down = down-regulated; Up = up-regulated.   
 
 
4.7. Re-analysis of differentially expressed genes excluding set 1 
data 
Since none of the samples generated from set 1 cluster with the other two sets 
according to their biological subgroups (see Figure 68), this indicates that the 
similarities in gene expression patterns between set 1 and the other 2 sets were not 
significant.  Thus, we were concerned that including set 1 in our data analysis would 
influence the accuracy of the gene lists.  However, if the dendrogram in Figure 68 is 
examined carefully, the clustering pattern within set 1 followed the same trend.  That 
is, data from AP-2α silenced and AP-2 double silenced cells clustered together, 
whereas AP-2γ data formed a separate branch with the two controls.  This might 
indicate that a biological effect was present within this set following AP-2 silencing, 
but the addition of ‘experimental factors’ overwhelmed the effect caused by AP-2 
silencing resulting in this data set forming their own subgroup away from sets 2 and 
3.  Nonetheless, in order to obtain a more stringent gene list, I have decided to 
exclude set 1 and the data was re-analysed by Dr Claude Chelala using same the 
parameters (FDR adjusted p-value of <0.01).   
 
Similar to previous observations, the two replicates of AP-2α silenced and AP-2 
double silenced data clustered to form their own subgroups.  AP-2γ silenced 
replicates again clustered in a separate subgroup along with the mock and NSC 
samples (see dendrogram in Figure 70).  When comparing the expression profiles 
between these groups it was found that the expression changes were very similar to 
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the previous analysis which included set 1, as shown in Figure 71 and Table 14.  I, 
therefore, decided to study these gene lists more closely with the aim of identifying 
which genes might be responsible for the changes in cell proliferation, morphology 
and adhesion observed after AP-2 depletion.   
 
 
 
 
Figure 70.  Unsupervised hierarchical clustering of MCF10A cells following AP-2 silencing 
without set 1.  All 10 samples (two mock controls, two non-silencing,controls, two AP-2α silenced 
samples, two AP-2γ silenced samples and two AP-2 double silenced samples) were separated into 
their distinct groups based on the top 10,000 differentially expressed genes.  Mock = Mock control; 
NS = non-silencing control; AP-2a = AP-2α silenced cells; AP-2g = AP-2γ silenced cells and AP-
2a_g = AP-2 double silenced cells. Number 2 and 3 at the end of each sample name distinguish two 
independent experiments. 
 201
 
 
Figure 71.  Differentially expressed genes in Mock, NSC and AP-2 silenced cells excluding data 
from set 1.  Venn diagram shows the numbers of differentially genes in each sample group and the 
overlap between groups.  
 
 
 
 
No. of genes Mock/NS AP-2α/NS AP-2γ/NS AP-2 
double/NS 
Down 30 61 1 119 
Up 30 61 0 223 
Total 60 122 1 342 
 
Table 14.  Table showing a number of genes that were up-and down-regulated following AP-2 
silencing after normalised to NSC (without set 1). Data was analysed with a FDR with adjusted cut-
off p-value <0.01.  Down = down-regulated; Up = up-regulated.   
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4.8. Ingenuity Pathway Analysis (IPA) 
In order to explore the relationships between the 122 and 342 differentially expressed 
genes following AP-2α single knock down and AP-2α and AP-2γ double knock 
down respectively, I used Ingenuity Pathway Analysis (IPA), a web-based 
application which is increasingly used to analyse array data to identify biologically 
relevant pathways (http://www.ingenuity.com/).  IPA is based on a Knowledge Base 
Database (IPAKB) that consists of the largest curated database with millions of 
computable relationships between genes, proteins, cells, tissues, cellular phenotypes, 
pathways, drugs and disease processes, gathered from the full text of the life sciences 
literature by PhD-level scientists that manually curate the data and assess their 
quality.   
 
Briefly, a dataset containing the Affymetrix probe identifiers (or Gene ID) and their 
corresponding ‘Log-Fold Change’ values was uploaded into the IPA software, and 
compared to the IPAKB to generate biological mechanisms, pathways and functions 
relevant to the dataset.  Only those molecules from the Affymetrix dataset shown to 
interact with other molecules that have at least one functional annotation or disease 
association in the IPAKB are then eligible to be integrated into a network.   
 
The Affymetrix datasets were imported into IPA and the 122 and 342 differentially 
expressed genes obtained after AP-2α silencing and AP-2 double silencing 
respectively were mapped to the IPAKB.  For AP-2α silencing, 24 significant 
networks were generated and the top disease and bio-function of the majority of 
genes involved were ‘Cancer’ and ‘Cellular Movement’ (see Figure 72 and Figure 
73). 
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Figure 72.  IPA analysis of data from AP-2α silenced cells.  A summary of the analysis shows the 
top five diseases which ‘AP-2α regulated genes’ are associated with.  ‘Cancer’ is the most 
significantly associated function involving 33 of the 122 genes in the dataset. 
 
 
 
 
Figure 73.  Molecular networks generated from the‘AP-2α regulated gene set’.  The highest 
scoring 9 out of 24 networks are displayed.  Genes in bold indicate genes identified by Affymetrix 
Microarray analysis, other genes are added by IPAKB.  Red arrows indicate up-regulation and green 
arrows indicate down-regulation.  The column on the right shows the number of molecules in each 
individual network (focus molecule) and their associated functions.  The score shows the likelihood of 
a gene placed in a network due to random chance and a score of 2 or greater was considered 
significant (p<0.01). 
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As shown in Figure 72 and Figure 73, according to IPA, 33 out of the 122 ‘AP-2α 
regulated genes’ are associated with cancer which is the most significantly associated 
disease.  Figure 73 highlights these 21 out of the 122 genes that seem to play a role in 
cellular movement.  Since we are interested if AP-2 has a functional role in cancer, I 
performed further IPA analyse focusing on the 33 ‘Cancer-related genes’.  Of these 
33 genes, 20 of them are associated with cancer followed by cellular movement, cell-
to-cell signalling and interaction, tissue development, cellular growth and 
proliferation, and inflammatory disease (see Figure 74).  These functional modules 
are hallmarks of cancer (Hanahan and Weinberg, 2000).  The top canonical pathway 
revealed by IPA is shown in Figure 75 (the de-regulated signalling pathways that 
most genes from the Affymetrix dataset are shown to be involved in) is the IGF-1 
signalling pathway which plays an important role in cell growth (note, Insulin 
Growth Factor Binding Protein, IGFBP3 and IGFBP6 are up-regulated following 
AP-2α silencing, see Table 15).  This implies that silencing AP-2α could trigger 
cancer-related pathways. 
 
Using the same approach, the dataset from the AP-2 double silenced samples 
containing 342 differentially expressed genes was analysed by IPA.  Similar to AP-
2α single silencing, the majority of the ‘AP-2 double-regulated gene set’ (103 genes) 
were also associated with ‘Cancer’ (see Figure 76).  Molecular network analysis 
revealed 24 networks with highly significant scores, and each individual molecule 
and their associated functions were displayed.   Figure 77 shows seven of these 
networks, in which cancer, molecular transport and genetic disorder were the 
networks with the highest scores.  Further analysis on the 103 ‘cancer-related genes’, 
shows the top three networks include cellular movement, cellular development and 
cell morphology, cellular growth and proliferation (see Figure 78). 
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Figure 74.  IPA functional pathway analyses of the ‘AP-2α-regulated gene set’.  (A) The 
significant functional diseases altered in the common ‘AP-2α-regulated gene set’, with Cancer being 
the most significant.  (B) Canonical pathways showing the top five signalling pathways in which most 
genes from the ‘AP-2α-regulated gene set’ are involved.  The yellow line indicates how many genes 
are involved in the pathway, and the threshold indicates if the interactions between the molecules 
within the same pathway are significant.  Bars that are above the threshold are considered as 
significant. 
 
 
 
Figure 75.  A summary of analysis of 33 out of 122 ‘AP-2α regulated genes’ shown to be 
‘Cancer-related’ genes.  IPA shows among the 33 genes, 20 of them are identified to be mostly 
involved in cellular movement, cell-to-cell signalling interaction, cellular growth and proliferation.  
The column on the right shows the number of molecules in each individual network (focus molecule) 
and their associated functions.  The score shows the likelihood of a gene placed in a network due to 
random chance and a score of 2 or greater was considered significant (p<0.01). 
A
B
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Figure 76.  IPA analysis of data from AP-2 double silenced cells.  A summary of the analysis 
shows the top five diseases which ‘AP-2 double regulated genes’ are associated with.  ‘Cancer’ is the 
most significantly associated function involving 103 of the 342 genes in the dataset. 
 
 
 
 
Figure 77.  Molecular networks generated from the‘AP-2 double regulated gene set’.  The 
highest scoring 7 out of 24 networks are displayed.  Genes in bold indicate genes identified by 
Affymetrix Microarray analysis, other genes are added by IPAKB.  Red arrows indicate up-regulation 
and green arrows indicate down-regulations.  The column on the right shows the number of molecules 
in each individual network (focus molecule) and their associated functions.  The score shows the 
likelihood of a gene placed in a network due to random chance and a score of 2 or greater was 
considered significant (p<0.01). 
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Figure 78.  A summary of analysis of 103 of the 342 ‘AP-2 double-regulated genes’ that 
were shown to be ‘Cancer-related’ genes.  (A) The significant functional diseases altered in the 
common ‘AP-2 double-regulated gene set’, with Cancer being the top of the list. (B) The genes in 
the top three networks are involved in cellular movement, development, proliferation and 
morphology. The column on the right shows the number of molecules in each individual network 
(focus molecule) and their associated functions.  The score shows the likelihood of a gene placed 
in a network due to random chance and a score of 2 or greater was considered significant 
(p<0.01). 
 
A
B
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4.9. Cell Adhesion Molecules are de-regulated in AP-2 silenced 
MCF10A cells 
Cell cycle analysis and the cell count study showed a significant reduction in cell 
proliferation and microscopic observation had revealed cell morphological 
changes following AP-2 silencing.  In addition, AP-2α and AP-2 double silenced 
cells seemed to be less adherent.  It was therefore hypothesised that the 
phenotype of silenced cells was due to reduced cell adhesion (see Figure 
60Figure 62 andFigure 67).  Based on these observations, it was intriguing to 
investigate if silencing AP-2 would affect expression of genes that have a known 
role in cell proliferation, morphology, movement and adhesion, and hence when 
examining the gene expression datasets I focused mainly on genes that are 
involved in these cellular functions.   
 
The initial examination of the AP-2α and AP-2 double expression profiles by 
IPA seems to be in agreement with the experimental findings from the cell cycle 
analysis and cell count study.  Indeed, a number of genes shown to be up-or 
down-regulated following AP-2α and AP-2 double silencing are related to cell 
movement/cell adhesion or encode extracellular matrix (ECM) components, and 
that these genes are significantly enriched in the AP-2 double dataset and to 
lesser extent in AP-2α silenced dataset compared to the mock control.  This 
finding strongly suggested that, at least AP-2α, plays a role in controlling 
adhesion and motility in MCF10A cells, therefore, several cell adhesion, 
migration and invasion molecules were selected as candidates for future 
validation.  Additionally, a number of known breast cancer-related genes were 
also selected.  As expected, the majority of differentially expressed genes from 
the AP-2α silencing dataset was also included in the AP-2 double silencing 
dataset.  The selected genes are summarised in Table 15 and these are discussed 
below. 
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  AP-2α silenced AP-2 double silenced 
Probe ID Gene Description Log Fold Change/p-value Log Fold Change/p-value 
210095_s_at 
212143_s_at 
IGFBP3  insulin-like growth factor binding protein 3 2.963419801 / 2.63E-08 3.54348163 / 3.00E-09 
1.61977955 / 1.57E-05 
203851_at IGFBP6  insulin-like growth factor binding protein 6 1.572360462 / 5.14E-06 1.212110238 / 7.20E-05 
210809_s_at POSTN  periostin, osteoblast specific factor N/A 3.367849641 / 1.14E-05 
214587_at COL8A1  collagen, type VIII, alpha 1 N/A 2.203324398 / 3.40E-07 
211719_x_at 
216442_x_at 
210495_x_at 
212464_s_at 
FN1  fibronectin 1 N/A 2.062665075 / 1.10E-06 
1.932095873 / 3.10E-06 
1.893155202 / 1.35E-06 
1.854414344 / 6.53E-06 
212531_at LCN2  lipocalin 2 N/A 2.68291985 / 4.82E-05 
205767_at EREG  epiregulin 1.714211997 / 7.86E-05 1.634973835 / 0.000122514 
205816_at 
226189_at 
211488_s_at 
ITGB8  integrin, beta 8 
 
N/A 2.037755528 / 8.02E-06 
1.457353127 / 8.64E-05 
1.07323525 / 0.000123908 
226535_at 
 
ITGB6  integrin, beta 6 -1.492560734 / 5.54E-06 -1.409942301 / 1.01E-05 
227314_at ITGA2  integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 
N/A -1.774536412 / 8.26E-06 
201288_at 
1555812_a_at 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta -1.523338463 / 5.37E-05 -1.95993485 / 4.05E-06 
-1.803002922 / 9.08E-06 
200665_s_at 
212667_at 
SPARC  secreted protein, acidic, cysteine-rich 
(osteonectin) 
N/A -1.536917974 / 1.17E-05 
-2.021153506 / 8.20E-07 
209441_at RHOBTB2  Rho-related BTB domain containing 2 -1.296764301 / 3.51E-05 -1.993342224 / 3.43E-07 
 
Table 15.  Significant changes in gene expression following AP-2α and AP-2 double silencing related to AP-2α biology.  Changes observed in probe sets between the 
NSC and AP-2α silenced and AP-2 double silenced groups at the indicated log fold change and FDR adjusted p-value. 
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4.9.1. IGFBP3 and IGFBP6 
Our previous Affymetrix microarray study on AP-2γ silenced MCF-7 cells showed 
that insulin-like growth factor binding protein 3 and 5 (IGFBP3 and IGFBP5) were 
up-regulated, which was confirmed in our validation (Williams et al., 2009).  Here 
in this microarray study IGFBP3 and IGFBP6, were up-regulated following AP-2α 
knock down suggesting that these genes are regulated by AP-2α in MCF10A cells.  
The IGFBPs are known to modulate the actions of IGF, either inhibiting or 
enhancing IGF actions, but they could also function through an IGF-independent 
mechanism (Cohen, 2006; Rajaram et al., 1997).   IGFBP3 and IGFBP6 were 
recognised as growth inhibitory molecules and have been shown to inhibit growth in 
breast cancer (Jogie-Brahim et al., 2009; Schedlich and Graham, 2002), which could 
explain the reduced cell proliferation seen in MCF10A cells following AP-2 knock 
down.  In addition to their anti-proliferative affect, recently it was suggested both 
IGFBP3 and IGFBP6 may also play a role in cell migration (Fu et al., 2010; Fu et 
al., 2007; O'Han et al., 2009).   
 
4.9.2. Periostin 
Periostin (POSTN), is an osteoblast-specific factor, which was first identified as a 
cell adhesion protein in early mouse oesteoblastic cells that are responsible for bone 
formation (Horiuchi et al., 1999).  Human POSTN is a secreted protein that has been 
shown to interact with other ECM proteins such as fibronectin, collagen V and 
integrins to support cell adhesion (Takayama et al., 2006).  Both POSTN and FN1 
are up-regulated in AP-2 silenced MCF10A cells suggesting that these cells might 
have increased their cell adhesiveness, which seems to contradict the observations 
made on the silenced cells.  However, over-expression of POSTN did not promote 
cell proliferation in vitro but enhanced cell invasion and angiogenesis (Kudo et al., 
2006; Shao et al., 2004).  This is consistent with the reduced cell proliferation seen 
in AP-2 silenced cells.  Furthermore, over-expression of POSTN is found in various 
types of cancer, including breast cancer, therefore, it would be interesting to 
investigate the relationship between AP-2 and POSTN (Puglisi et al., 2008; Ruan et 
al., 2009; Zhang et al., 2010).   
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4.9.3. Collagen, type VIII, alpha 1 
Collagen type VIII, alpha1 (COL8A1) is one of the vascular collagen types.  
Vascular collagen is a major component of the extracellular matrix of the vessel wall 
and it is important in maintaining vessel wall integrity and stability.  The functional 
roles of COL8A1 in cellular processes include adhesion, migration, proliferation, 
apoptosis and differentiation (Plenz et al., 2003).  It has been shown that COL8A1 is 
able to stimulate the invasion and migration of smooth muscle cells (Hou et al., 
2000).  Recently, a study demonstrated a role of COL8A1 in liver cancer, in which 
down-regulation of COL8A1 reduced proliferation, metastasis and invasion of 
mouse liver cancer cells (Zhao et al., 2009b).  This suggests that expression of 
COL8A1 may be related to the malignant behaviour of liver cancer cells.  Up-
regulation of COL8A1 expression in AP-2 silenced MCF10A cell implies that the 
invasiveness and motility of these cells may have changed. 
 
4.9.4. Lipocalin 2 
Another secreted protein known as lipocalin 2 (LCN2), that is involved in binding to 
cell surface receptors and transportation of small lipophilic molecules, was found to 
be up-regulated as a result of AP-2 double silencing.  Recently it has been reported 
that up-regulation of LCN2 is associated with more invasive breast cancer in human 
mammary carcinoma cell lines and mouse breast cancer models through its ability to 
promote cell migration and invasion (Fougere et al.; Leng et al., 2009b; Yang et al., 
2009; Yang and Moses, 2009).  Knock down of LCN2 reduced cell migration, 
invasiveness and metastasis in breast cancers (Fougere et al., 2010), thus LCN2 may 
represent a biomarker of invasive breast cancer.  In addition, LCN2 was discovered 
to be expressed predominantly in ERα-negative cells and is a downstream target of 
ERBB2 signalling (Gruvberger et al., 2001; Leng et al., 2009a).  Since AP-2α is 
thought to act as a tumour suppressor, it would be interesting to find out if silencing 
AP-2 would increase expression of genes that are involved in breast cancer 
progression. 
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4.9.5. Epiregulin 
Epiregulin (EREG) is a member of the epidermal growth factor (EGF) family and 
can function as a ligand of epidermal growth factor receptor (EGFR) and in 
particular acts as the ligand for ErbB receptor 4 (ErbB4) (Olayioye et al., 
2000{Komurasaki, 1997 #334)}.  The expression of EREG has recently been 
reported to be positively correlated with ERBB4 in breast tumour samples (Revillion 
et al., 2008).  EREG is found to be expressed particularly in inflammatory breast 
cancer (IBC), a rare but lethal form of primary breast cancer (Bieche et al., 2004).  
Due to its role as an ErbB4 ligand, EREG is able to regulate cell proliferation, 
differentiation, adhesion and migration of several types of epithelial cells including 
those of the mammary gland (Hu et al., 2009; Jones et al., 2003; Zhao et al., 2009a; 
Zhuang et al., 2007).  EREG has also been shown to be involved in breast cancer 
metastasis to the lungs (Eltarhouny et al., 2008; Gupta et al., 2007).  Additionally, 
an early study showed over-expression of EREG induced morphological changes in 
HeLa cells and reduced cell growth in certain epithelial tumour cells.  EREG-
expressing cells became rounder which is consistent with the observations in this 
study (Toyoda et al., 1995).  A more recent study showed that EREG is a direct 
target of the HOXB9 factor.  When HOXB9 was over-expressed in MCF10A cells, 
EREG expression was induced resulting in increased cell motility, angiogenesis and 
epithelial-mesenchymal transition (EMT).  These HOXB9-expressing MCF10A 
cells also displayed morphological changes in which they seemed to lose cell-to-cell 
contact (Hayashida et al., 2010).  Since we find EREG is up-regulated following 
AP-2 silencing, its expression may also contribute to the more rounded phenotype 
we observe.  Interestingly, a recent study showed EREG was also up-regulated after 
AP-2α depletion in HeLa cells (cervix adenocarinoma) (Orso et al., 2008), hence, it 
would be interesting to study this gene further. 
 
4.9.6. Integrins 
The Affymetrix microarray data analysis showed that a subset of genes potentially 
involved in cell adhesion and migration were significantly de-regulated following 
AP-2α and AP-2 double knock down.  Among these, integrins, the well known cell 
adhesion receptors that mediate cell-to-ECM and cell-to-cell adhesive interactions 
and play a major role in the regulation of cell signalling pathways, angiogenesis, 
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metastasis and tumour growth (Rathinam and Alahari; Silva et al., 2008), were 
included.  Integrins are composed of an α-subunit and a β-subunit.   There are 18 α-
subunits and 8 β-subunits in higher mammals and together these two subunits form 
heterodimers in different combinations that result in unique ligand specificities 
(Silva et al., 2008).  Three isoforms of integrins: β6, β8 and α2 (ITGB6 ITGB8 and 
ITGA2, respectively) were shown to be de-regulated in this microarray study.  
Interestingly, integrin β8 was up-regulated whereas integrin β6 and α2 were down-
regulated after AP-2 depletion.  In normal cells the integrin β6 level is low, 
however, numerous studies on integrin β6 (which heterodimerises with the αv 
subunit) showed that the combination of these two subunits is often elevated in more 
aggressive forms of cancer.  Integrin αvβ6 promotes migration and invasion and is 
involved in the increase in other molecules that are important in metastasis and 
proliferation such as cell matrix metalloproteinase (MMP) and transforming growth 
factor β receptor (TGFβ) (Bandyopadhyay and Raghavan, 2009; Munger et al., 
1999; Thomas et al., 2006; Thomas et al., 2001).  Loss of the integrin β6 subunit has 
been shown to reduce cell adhesion and migration (Huang et al., 1998).  The level of 
integrin β6 was down-regulated after AP-2 silencing which could imply that the 
motility of AP-2 silenced MCF10A cells was lowered.  The integrin α2β1 has been 
shown to enhance tumour angiogenesis via the regulation of VEGF (Senger et al., 
2002; Zhang et al., 2008).  In contrast to other integrin subunits, integrin β8 seems 
to have an opposing role in terms of growth-promotion.  Two studies have 
demonstrated that the cytoplasmic domain of β8 cannot mediate cell adhesion, 
instead, over-expression of integrin αvβ8 inhibited cell growth both in vivo and in 
vitro which was independent of apoptosis; reduced cell spreading and mediated cell 
shape changes (Cambier et al., 2000; Nishimura et al., 1994).  Reduction in cell 
proliferation and the changes in cell morphology were observed in AP-2 silenced 
MCF10A cells and the up-regulation of the integrin β8 subunit in the AP-2 double 
silenced Affymetrix gene expression profile seemed to be in agreement with these 
findings.   
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4.9.7. Fibronectin 1 
Another cell adhesion molecule was fibronectin 1 (FN1), an ECM protein that is 
required for binding to certain integrins in order to promote cell adhesion, migration, 
invasion and signal transduction (Akiyama, 1996; Maity et al.; Miyamoto et al., 
1998).  Studies have found that blocking FN1 from binding to integrins reduced cell 
adhesion (Bartsch et al., 2003; Ruoslahti, 1999).  FN1 was up-regulated in this 
microarray study suggesting silencing AP-2 could potentially increase cell 
adhesiveness, invasiveness and motility, however, since integrin β8 was the only 
integrin molecule up-regulated, and its major binding ligand is vitronectin (another 
form of the integrin binding ligand) but not FN1, it could be that, FN1 can bind to 
other fibronectin-binding-receptors and promote cell adhesion, invasion and 
migration.  In addition, although FN1 is known to be an extracellular adhesion 
molecule, the invasiveness of the cells is dependent on the composition of their 
ECM.  A study using human metastatic breast cancer cells (LM2-4) to compare their 
invasive behaviour in the presence of either FN1 or laminin (another ECM protein), 
demonstrated that these breast cancer cells invaded more vigorously towards FN1 
than laminin (Brekhman and Neufeld, 2009).  This implies FN1 may be a more 
potent inducer of invasiveness in certain cells.  Moreover, high expression levels of 
FN1 have been reported to be associated with poor prognosis in breast cancer 
patients (Ioachim et al., 2002; Yao et al., 2007).   
 
4.9.8. ARHGDIB 
ARHGDIB, also known as RhoGDI2, is an inhibitor of RhoGTPases.  ARHGDIB 
has been shown to act as a metastasis suppressor in different cancers, including 
breast cancer (Gildea et al., 2002; Harding and Theodorescu, 2007; Moissoglu et al., 
2009; Said and Theodorescu, 2009; Schunke et al., 2007).  Expression of this gene 
inhibits tumour cells from undergoing metastasis.  Down-regulation of ARHGDIB is 
found in AP-2 silenced MCF10A cells suggesting these cells might potentially 
become more metastatic.   
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4.9.9. SPARC 
SPARC is a secreted protein, acidic and cysteine-rich, also known as osteonectin and 
BM-40, and is recognised as a multifunctional ECM protein.  Its expression is 
required during mammalian development, tissue differentiation, tissue remodelling 
and wound healing (Brekken and Sage, 2001; Podhajcer et al., 2008).  There are 
numerous studies demonstrating that SPARC also plays a critical role in 
tumourigeneis, where SPARC expression has been shown to increase adhesion, 
angiogenesis, migration, proliferation, invasion and metastasis (Arnold and Brekken, 
2009; Framson and Sage, 2004).  However, the role of SPARC in cancer progression 
is not fully understood and remains controversial (Fukunaga-Kalabis and Herlyn, 
2007).  In breast cancer, both SPARC over-expression and down-regulation have 
been shown to be associated with poor prognosis (Helleman et al., 2008; Jones et al., 
2004; Nagai et al., 2010; Watkins et al., 2005). 
  
4.9.10. RhoBTB2 
RhoBTB2, was first named as ‘Deleted in Breast Cancer’ (DBC2) gene because its 
expression was found to be lost in roughly 50% of breast tuoumrs, thus it was 
identified as a tumour suppressor gene (Hamaguchi et al., 2002; Mao et al., 2010; 
Ohadi et al., 2007).  RhoBTB2 belongs to the Rho GTPase family which cycle 
between an active, membrane-bound GTP-associated form and an inactive cytosolic 
GDP-associated form.  Its functions have been suggested to regulate the organisation 
of the actin cytoskeleton, gene transcription, cell cycle, apoptosis and membrane 
trafficking (Siripurapu et al., 2005).  Re-expressing RhoBTB2 in the non-expressing 
T47D cell line led to growth arrest (Hamaguchi et al., 2002).  Since AP-2α has been 
suggested to act as a tumour suppressor, and the expression of RhoBTB2 is down-
regulated in AP-2 silenced MCF10A cells, this suggests that AP-2α may potentially 
control cell survival together with RhoBTB2 in breast cells. 
 
In summary, the observations following AP-2 silencing in MCF10A led to a 
hypothesis that AP-2 silenced cells became less adhesive, however, it was not clear 
if AP-2 silencing might induce cell migration.  Analysis of the Affymetrix 
microarray dataset suggests that a high proportion of AP-2 regulated genes are 
related to cell adhesion, migration and invasion.  Several of these genes have been 
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selected for future validation in order to explore the role of AP-2 in cell adhesion, 
migration and invasion.  Ultimately, further functional assays will be required to 
determine if AP-2 silenced cells are more migratory/invasive (see Discussion). 
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Chapter 5 
Results: KIAA1324 
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5. KIAA1324 as a downstream target of AP-2γ 
KIAA1324 is a protein of unknown function that has features of a membrane-
associated growth factor receptor so may mediate cell growth.  The transcription 
profile generated from Affymetrix microarray analysis of MCF-7 cells found that 
KIAA1324 was the most significantly down-regulated gene following AP-2γ 
silencing.  A ChIP assay showed interaction of AP-2γ at the proximal promoter of 
the endogenous KIAA1324 gene and this interaction was reduced upon AP-2γ knock 
down, which further confirmed that KIAA1324 expression is directly regulated by 
AP-2γ (see Figure 23).  Therefore, it is intriguing to investigate if altering 
KIAA1324 expression would affect cell growth.  In order to answer this, KIAA1324 
expression was induced in non-expressing MCF10A cells and in parallel the 
expression was knocked down in MCF-7 cells which highly express KIAA1324.  A 
specific antibody against KIAA1324 protein was generated to verify the specificity 
of these clones.  Functional assays were performed on these clones and the data is 
presented in this chapter. 
 
5.1. Generation of a specific KIAA1324 antibody  
A polyclonal peptide antibody was raised in rabbits against a 16 amino acid peptide 
that maps near the C-terminus of KIAA1324 (see Materials and Methods 
section 2.19).  Test and final bleeds from the two immunised rabbits were checked 
by western blotting against MCF-7 cell lysates.  Only the final bleed of one of the 
rabbits showed a possible recognition with KIAA1324 (data not shown) and this 
sample was selected for affinity purification to try to reduce non-specific interaction 
(refer to Materials and Methods).  Specificity to KIAA1324 protein was checked 
before using it in further experiments.  To this end, RNAi was used to knock down 
KIAA1324 expression in MCF-7 cells using four siRNAs purchased from 
Dharmacon (Dharmacon #05, 06, 07 and 08) both individually and as a pool.  In 
addition, AP-2γ was also knocked down to confirm that if KIAA1324 levels were 
reduced.  Western blot analysis was performed using the newly purified antibody to 
assess the protein levels in these samples.  Figure 79 shows a clear reduction of AP-
2γ protein when cells were treated with AP-2γ siRNA.  The KIAA1324, antibody 
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detected two polypeptides in lysates from both mock and non-silencing controls.  
The upper band was about 160kDa and the lower band was between 160kDa and 
105kDa.  As the predicted size of KIAA1324 protein is 121kDa, this suggested that 
the lower band may be the true KIAA1324 protein.  Furthermore, because the lower 
band diminished but the upper band remained after KIAA1324 and AP-2γ siRNA 
transfection, this confirms that the lower band represents KIAA1324.  
Moreover, Figure 79 shows that the siRNA pool and the individual Dharmacon 
siRNAs were equally effective at knocking down KIAA1324.  The upper band was 
considered to be due to a non-specific binding of the antibody. 
 
Inducible knock down of AP-2γ expression in MCF-7 cells using the tet-inducible 
system had been established by a senior post-doc, Dr Angelo Scibetta, in the lab 
(Williams et al., 2009).  It was an advantage to use it for assessing the mRNA level 
of KIAA1324 when AP-2γ is stably knocked down in MCF-7 cells.  AP-2γ shRNA-
expressing MCF-7 cells were treated with and without doxycycline for three days to 
ensure expression of the shRNA constructs was sufficient for silencing AP-2γ via 
RNAi before harvesting.  As illustrated in Figure 80A, AP-2γ was successfully 
silenced in doxycycline-induced MCF-7 cells compared to control un-induced cells  
Using the same cDNA samples, the KIAA1324 mRNA level was also checked and 
found to be 25 – 30% lower than that of the non-induced control, as shown in Figure 
80B.  This data is consistent with the microarray data generated in AP-2γ silenced 
MCF-7 cells.  Furthermore, a western blot analysis of lysates from control and 
induced cells demonstrated that the protein level of KIAA1324 was down-regulated 
upon AP-2γ silencing (Figure 80C).  This further confirmed that KIAA1324 is 
directly regulated by AP-2γ, and the specificity of the antibody generated against 
KIAA1324. 
 
In addition, I also checked if KIAA1324 expression was also down-regulated 
following AP-2γ silencing in another cell line.  Thus, qPCR was performed to 
confirm if there was any changes in KIAA1324 mRNA levels in AP-2 silenced 
T47D cells.  The mRNA level of KIAA1324 was reduced in AP-2γ silenced T47D 
cells but not in AP-2α silenced cells compared to the controls (see Figure 81).  This 
evidence further supports that KIAA1324 is a downstream target of AP-2γ. 
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Figure 79.  Silencing KIAA1324 and AP-2γ using RNAi approach in MCF-7 cells.  Four 
Dharmacon siRNAs (#05, #06, #07 and #08) were transfected into MCF-7 cells individually and 
altogether (pool) at 25 nM final siRNA concentration (see Materials and Methods).  AP-2γ was also 
knocked down to assess if it down-regulated KIAA1324 protein.  Mock and non-silencing were 
negaitive controls.  Whole cells extracts (10μg/lane) were separated by SDS/PAGE and blotted to a 
membrane and probed with AP-2γ and KIAA1324 antibodies.  HSC70 was used as a loading control. 
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Figure 80. Silencing of KIAA1324 expression upon AP-2γ knock-down in tet-inducible MCF-7 
cells.  Cells were treated with 1μg of doxycycline for 72 hours and harvested for RNA extraction.  
Quantitative PCR were performed to detect (A) AP-2γ mRNA level and (B) KIAA1324 mRNA level.  
Data were normalised to GAPDH mRNA levels and non-induced control values were set at 1 to 
generate relative mRNA levels. The graphs represent data averaged from three PCR replicates, 
±standard error (C) Whole cells extracts (10μg/lane) were separated by SDS/PAGE and blotted to a 
membrane and probed with AP-2γ and KIAA1324 antibodies.  HSC70 was used as a loading control. 
A
B
C 
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Figure 81.  KIAA1324 is down-regulated in AP-2γ silenced T47D cells.  Cells were transfected as 
indicated in Materials and Methods, and harvested for RNA extraction 48 hours post-transfection.  
qPCR was performed to detect KIAA1324 mRNA level.  Data were normalised to GAPDH mRNA 
levels and non-induced control values were set at 1 to generate relative mRNA levels. The graphs 
represent data averaged from three PCR replicates, ±standard error. 
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5.2. KIAA1324, AP-2γ and ERα expression in a panel of breast 
cell lines 
After confirming the specificity of our KIAA1324 antibody, expression of 
KIAA1324 was checked in a panel of cancer cell lines by western blotting.  Since it 
has been suggested that KIAA1324 is regulated by oestrogen (Deng et al., 2005), the 
expression of ERα was also checked in these cell lines.  As shown in  
Figure 82, KIAA1324 is highly expressed in the ERα and AP-2γ positive cell lines 
MCF-7, T47D and ZR75-1 and also readily detectable in H3396 cells.  
Immortalised, non-tumourigenic lines MCF10A and MTSV1.7neo which are ERα 
negative and have very low AP-2γ levels, do not express KIAA1324.  The liver 
cancer cell line HepG2 was also included as an extra negative control because it 
does not express AP-2γ.  MDA MB 231 cells were the only AP-2γ negative line to 
expressing KIAA1324.  As expected, the non-specific band is seen in extracts from 
all lines running just above the KIAA1324 band.   
 
Additionally, qPCR was performed to further compare the mRNA levels of 
KIAA1324 in three cell lines: MCF-7, T47D and MCF10A cells.  The KIAA1324 
mRNA levels were expected to be significantly higher in MCF-7 and T47D cells 
than MCF10A cells.  As expected, the KIAA1324 expression level was 150 and 100 
fold higher in MCF-7 and T47D cells respectively when compared to MCF10A cells 
(see Figure 83).   
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Figure 82.  KIAA1324 expression in a panel of breast cell lines.  Whole cell extracts (10μg) were 
separated on a 7.5% SDS-PAGE before being transferred to membrane and probed for KIAA1324 
and ERα.  PCNA was used as loading control.  Cell lines expressing both AP-2γ and ERα express 
KIAA1324.  +++ = very high level of expression; ++ = expression readily detectable; +/- = barely 
detectable and - = non expressing.   
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Figure 83.  KIAA1324 mRNA expression in MCF-7, T47D and MCF10A cells.  RNA was 
extracted from MCF-7, T47D and MCF10A cells and reverse transcription was carried out to obtain 
cDNA.  qPCR was performed to detect KIAA1324 mRNA level.  Data were normalised to GAPDH 
mRNA levels and MCF10A values were set at 1 to generate relative mRNA levels. The graphs 
represent data averaged from three PCR replicates, ±standard error. 
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5.3. KIAA1324 is localised to the cytoplasm 
In addition to western blotting, immunohistochemistry on MCF-7 cells was 
performed with and without KIAA1324 and AP-2γ knock down to examine the 
localisation of KIAA1324 in MCF-7 cells.  Figure 84 shows immunofluorescence 
which revealed that KIAA1324 protein was localised to the cytoplasm immediately 
surrounding the nucleus in MCF-7 cells (green fluorescence label).  This finding 
seems to be partly in agreement with Deng et al study where they showed strong 
staining of KIAA1324 protein in the cytoplasm by immunohistochemistry.  In 
addition, they also showed KIAA1324 protein expression on the cell membrane of 
the endometrial cells (both normal and cancer cells).  It can not be determined if 
KIAA1324 protein was expressed on the cell membrane of MCF-7 cells in this 
study, however, since KIAA1324 has a membrane-bound feature, when it is 
activated it becomes internalised and appear as vesicles in the cytoplasm, which 
could explain the observation seen in Figure 84.   
 
Furthermore, the fluorescence intensity reduced in KIAA1324 silenced cells, but it 
could still be seen when examining cells throughout the whole coverslip, suggesting 
the transfection was not highly efficient.  In contrast, AP-2γ (pink fluorescence 
label) was significantly reduced in AP-2γ silenced cells compared to mock control.  
As illustrated, KIAA1324 was still present even when AP-2γ was depleted, which is 
consistent with the previous finding in which KIAA1324 expression level only 
reduced approximately 30% in AP-2γ silenced MCF-7 cells compared to the control 
(see Figure 80B).  Nonetheless, when examined closely, complete depletion of 
KIAA1324 could also be seen in cells with abolished AP-2γ expression (Figure 84, 
bottom panel magnification).   
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Figure 84.  KIAA1324 localises to the cytoplasm in MCF-7 cells.  MCF-7 cells were plated on 
coverslips and transfected with KIAA1324 and AP-2γ siRNA for as indicated in Materials and 
Methods.  After 48 hours cells were fixed and stained with KIAA1324 and AP-2γ antibody.  DAPI 
was used to distinguish the nuclei.  Pictures were taken using confocal microscope. Top panels: 
mock control showing both KIAA1324 and AP-2γ expression (green and pink fluorescence 
respectively). Middle panels: KIAA1324 knocked down and stained with KIAA1324 antibody only.  
Bottom panels: AP-2γ knocked down and stained with both KIAA1324 and AP-2γ antibodies.  
Closer observation of the localisation of KIAA1324 in the cytoplasm is demonstrated in the 
magnified panel. 
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5.4. KIAA1324 expression is not primarily regulated by 
oestrogen in breast cancer cells 
It was shown in a study comparing KIAA1324 RNA expression in endometrial 
samples obtained from postmenopausal women receiving placebo or premarin 
treatments (premarin is a commercial drug that contains a combination of oestrogens 
and is used for hormone therapy in menopausal women), that KIAA1324 expression 
was significantly induced in premarin-treated samples (Deng et al., 2005).  
Furthermore, it was shown that endogenous oestrogen positively regulated 
endometrial expression of KIAA1324, and this expression was elevated in type I 
endometrial carcinomas, which are associated with oestrogen exposure, compared to 
type II which are not associated with oestrogen exposure.  KIAA1324 expression 
was also shown in this study to be highly correlated with ERα and PgR expression, 
suggesting that the regulation of KIAA1324 is predominantly via ERα signalling in 
the uterus.   
 
Based on these findings, it was interesting to determine if KIAA1324 expression is 
also regulated in an ERα positive breast cancer cell line, MCF-7, by oestrogen 
treatment using β-estradiol for 48, 72 and 96 hours.  In addition, MCF-7 cells were 
treated with faslodex, an oestrogen receptor antagonist, which blocks oestrogen 
receptors in a similar way to tamoxifen.  Faslodex treatment can also lead to down-
regulate ER via the proteasome.  It was expected that the expression of KIAA1324 
would increase in β-estradiol treated cells but reduce in faslodex treated cells.  As 
demonstrated in  
Figure 85A, the mRNA levels of KIAA1324 increased about increased transiently 
but fell back to control untreated levels after 48 hours.  However, the induction of 
KIAA1324 mRNA level in β-estradiol-treated sample at 48 hours was not 
significant due to a large error.  Reduction of KIAA1324 mRNA levels was 
observed in faslodex-treated cells but only occurred after 96 hours of treatment.  In  
Figure 85B, the protein levels of KIAA1324 between β-estradial and faslodex 
treated samples and the untreated controls vary greatly which made it difficult to 
interpret.  It could be that the regulation of KIAA1324 by oestrogen is not as 
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pronounced as in endometrial cancer cells and the changes in KIAA1324 expression 
can only be seen if prolonged oestrogen or faslodex treatment is applied. 
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Figure 85. β-estradiol and faslodex treatment on MCF-7 cells did not alter KIAA1324 
expression levels.  MCF-7 cells were treated with 10-8M β-estradiol and 10-7M faslodex for 48, 72 
and 96 hours.  Untreated cells were used as control. (A) Cells were harvested for quantitative PCR to 
detect KIAA1324 mRNA level. Data were normalised to GAPDH mRNA levels and the values of 
untreated controls were set at 1 to generate relative mRNA levels. The graph represents data averaged 
from three independent experiments, ±standard error. (B) Whole cells extracts (10μg/lane) were 
separated by SDS/PAGE and blotted to a membrane and probed with KIAA1324 antibody.  HSC70 
was used as a loading control. 
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5.5. Generation of a KIAA1324 expression clone 
The function of KIAA1324 in cancer cells is not yet clear, however, we have shown 
that KIAA1324 is a novel gene which is directly regulated by AP-2γ in MCF-7 cell, 
and may therefore influence breast carcinogenesis. It would be interesting to study 
the effects of KIAA1324 expression on the growth and survival of breast epithelial 
cells.  In order to do so, a KIAA1324-expression construct was made to over-express 
this gene the non-expressing, immortalised, non-tumourigenic and ERα negative 
MCF10A cell line. 
 
A clone carrying a full length cDNA sequence of KIAA1324 (Clone ID 5297393) 
was ordered from the I.M.A.G.E Consortium.  This clone carried the cDNA insert in 
the pBluescriptR plasmid and the cloning orientation was 5’ SalI/XhoI and BamHI 
3’.  In order to express KIAA1324 effectively in breast-derived cells, the sequence 
had to be subcloned into an expression vector e.g. pcDNA3.1.  As the KIAA1324 
IMAGE clone had a long 5’UTR of approximately 250bp upstream of the ATG start 
codon, in order to increase expression efficiency this was reduced by using PCR to 
introduce a restriction site 20bp 5’ of the initiator ATG as illustrated in the flow 
diagram (see Figure 86).  The final construct was verified by restriction enzyme 
digestion and sequencing (see Materials and Methods section 2.19). 
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Figure 86. Flow diagram of cloning steps to generate a KIAA1324 expression construct.  See 
Materials and Methods for details (see Chapter 2 section 2.19).  BstEII site is a unique site in the 
KIAA!324 sequence 107 bp downstream of the initiator ATG. 
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5.6. Verification of the KIAA1324 expression construct 
Initially I used in vitro transcription/translation (IVT) to try to determine if the 
KIAA1324 expression plasmid was capable of producing the correct protein.  The 
results however were inconclusive (data not shown) and instead I chose to do a short 
term transfection experiment.   
 
The KIAA1324 expression construct were transfected into HepG2 cells, which have 
no endogenous KIAA1324 protein (see Figure 82), for 48 and 72 hours.  Whole cell 
lysates were analysed by western blotting to test the KIAA1324 protein levels.  
MCF10A and MCF-7 lysates were included as negative and positive controls 
respectively in order to distinguish the true positive bands.  Figure 87 shows that 
strong expression of KIAA1324 protein was detected using our antibody in the cell 
lysates that were transfected with the expression construct and in MCF-7 expressing 
cells, but not in the vector control or non-expressing MCF10A cells.  This confirmed 
that the expression construct I generated can work efficiently. 
 
 
 
 
Figure 87. KIAA1324 protein can be expressed from our expression construct.  HepG2 cells 
were transfected with 1 and 2 μg of KIAA1324 expression constructs for 48 and 72 hours.  
Untransfected MCF10A and MCF-7 cell lysates were used as negative and positive controls 
respectively. Whole cells extracts (10μg/lane) was separated by SDS/PAGE and blotted to a 
membrane and probed with our KIAA1324 antibody.  HSC70 was used as a loading control. 
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5.7. Generation of MCF10A sub-clones stably expressing 
KIAA1324 
As mentioned above, KIAA1324 was the most highly AP-2γ regulated gene from the 
microarray analysis of silenced MCF-7 cells.  Expression of this gene has also been 
associated with more aggressive forms of endometrial cancer (Deng et al., 2005).  It 
was therefore intriguing to examine if KIAA1324 expression could alter the growth 
of non-tumorigenic breast cells.   The first step was to establish stable KIAA1324 
expressing cell lines in non-expressing MCF10A cells (a non-tumourigenic 
mammary epithelial line) using the KIAA1324 expression construct.  Transfection 
optimisation was carried out using two transfection methods: Fugene 6 reagent and 
Amaxa electroporation, and the latter seemed to be more efficient (data not shown).  
The pcDNA 3.1- expression vector carries the neomycin resistance gene allowing 
selection of transfected cells in geneticin (G418) containing media (see Material and 
Methods).  Surviving colonies were isolated and transferred to separate wells.  
Colonies were expanded then were harvested for analysis with further samples 
frozen down for future experiments.  KIAA1324 protein expression was checked by 
western blot analysis.  MCF-7 controls were included to confirm the positivity of the 
KIAA1324 signal, and MCF10A wild-type extracts were also run in parallel as a 
negative control.   
 
Unfortunately, colonies that were isolated from the first experiment and survived in 
G418-containing media were not positive for KIAA1324 expression.  This indicated 
that these cells must have taken up the plasmid and integrated into their genome at a 
random position within the plasmids, thus, the coding sequence of KIAA1324 could 
have been destroyed leading to antibiotic resistant clones that do not express 
KIAA1324.  In order to maximise the transfection efficiency and minimise the 
chances of random integration within the plasmid, prior to transfection, the 
expression plasmid was first linearised by restriction digest at PvuI, a single-cut site 
within the ampicillin resistance gene which is not required in mammalian cells.  
Empty vector control was transfected into MCF10A cells along side and treated in 
the same manner as those transfected with the KIAA1324 expression construct.  
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After selection, only four isolated clones survived in G418-containing media.  These 
clones were checked for KIAA1324 expression at the mRNA and protein level. 
 
As shown in Figure 88A, the KIAA1324 mRNA levels in 3 out of the 4 isolated 
MCF10A-KIAA1324 expressing clones were readily detected.  As expected, the 
KIAA1324 mRNA level of the empty vector control was almost undetectable.  
Although these three clones are expressing KIAA1324 higher than the empty vector, 
the mRNA levels of KIAA1324 of these clones are not as high as MCF-7 cells as 
presented in Figure 83.  Using MCF-7 wild-type as a positive control, a western blot 
analysis was carried on these samples and shows that, clone #1, #2 and #3 are 
expressing KIAA1324 protein (the lower band) but not in clone #4 which is 
consistent with the qPCR results, as illustrated in Figure 88B.  Note that, in the 
vector control there is a band at the same position as the true KIAA1324 protein size 
and the non-specific upper band can also be seen after a longer exposure time but 
overall these bands are weaker compared to these seen in clones #1, #2 and #3.  
Clone #4 also displayed the non-specific upper band but not the true KIAA1324 
protein i.e. lower band, thus, I concluded that clone #4 does not express KIAA1324.  
Also, the mRNA level of KIAA1324 in clone #4 was undetectable, therefore, clone 
#4 has the properties of an extra negatve control and was used as such in subsequent 
experiments because the vevtor control clone appeared to sow some expression of 
KIAA1324 protein (Figure 88B) and may have given erroneous results. 
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Figure 88. KIAA1324 expression levels in stable MCF10A transfectants.  MCF10A cells were 
tranfected with 1μg of linearised KIAA1324 expression construct.  Transfected cells were left for 2 
days before being re-plated onto a 15 cm culture plate with G418-containing media, and cultivated 
until distinct colonies formed.  Colonies were isolated and expanded for further analysis.  (A) 
Quantitative PCR of RNA isolated from vector alone or KIAA1324 stable transfectants (#1 – 4). Data 
were normalised to GAPDH mRNA levels and empty vector control values were set at 1 to generate 
relative mRNA levels. (B) Whole cells extracts (10μg/lane) were separated by SDS/PAGE and 
blotted to a membrane and probed with KIAA1324 antibody.  HSC70 was used as a loading control. 
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5.8. KIAA1324 expression does not stimulate growth of MCF10A 
cells 
KIAA1324 has previously been shown to be present in the cytoplasm and at the cell 
membrane by immunohistochemical staining (Deng et al., 2005), suggesting that 
KIAA1324 has features of a membrane-bound growth factor receptor, thus, may 
mediate cell growth.   To test this hypothesis, I compared the growth rates of 
MCF10A G418-selected clones that either did (clone #1 – 3) or did not (clone #4 
and empty vector control) express KIAA1324.  Clones #1 to #4 and empty vector 
control were seeded onto 6 well-plates at 100,000 cells/well and cultivated over 5 
days.  Cell counts were performed at 24 hour intervals.  As demonstrated in Figure 
89, all three KIAA1324-expressing MCF10A clones displayed lower proliferation 
rates compared to the vector control and non-expressing clone #4.   
 
An alternative way to measure cell viability is to perform on MTS assay, is a 
standard colorimetric assay which measures changes in colour to determine the 
number of viable cells in proliferation or cytotoxicity assays.  According to the 
manufacturer’s guide (CellTiter 96® Aqueous One Solution Reagent, Promega), the 
MTS compound is bioreduced by living cells and changes the colour of the tissue 
culture medium following incubation.  The difference in colour change among the 
samples can be determined by measuring the absorbance at 490nm using a 
spectrophotometer, and is directly proportional to the number of living cells in 
culture.  Figure 90 confirms that clones #1 to #3 had lower proliferation rates than 
the vector control throughout 4 days.  Although the cell numbers for clone #4 were 
lower than the vector control from day 1 to 3, it might be that fewer cells were plated 
on day 0 due to inaccuracy, however, the cell number became the same on the day 4 
which indicated that clone #4 proliferated faster than the vector control.  
Nonetheless, all true positive clones showed reduced cell proliferation following 
KIAA1324 expression.  This evidence suggests that expressing KIAA1324 in non-
expressing MCF10A cells might be exerting a growth inhibitory effect, which 
disagrees with the hypothesis proposed by Deng et al.   
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Figure 89. Over-expressing KIAA1324 in MCF10A reduced cell proliferation.  Clones #1 - #4 
and empty vector control were seeded onto 6-well plates at 100,000 cells/well and cells were counted 
over 5 days at 24 hour intervals.  Cells numbers were averaged and expressed as mean±s.e., n = 3.  
Cell counts were performed using Casy Cell Counter (Scharfe System). 
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Figure 90. Over-expressing KIAA1324 in MCF10A reduced cell proliferation assessed by MTS 
assays.  Clones #1 - #4 and empty vector control were seeded onto 96-well plates at 10,000 cells/well 
and MTS reagents were added to the wells each day.  Absorbance values were measured by a 
spectrophotometer every 2 hours until saturation. 
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5.9. Generation of shRNA constructs to stably knock down 
KIAA1324 in MCF-7 cells using a tet-inducible system  
Expressing KIAA1324 in MCF10A immortalised mammary epithelial cells caused 
the cells to cycle more slowly.  One explanation could be that cells that over-express 
KIAA1324 can only do so if they also over-express or silence other genes in the 
pathway.  Therefore MCF-7 cells, which express high levels of KIAA1324 may 
have additional mutations which allow them to ‘tolerate’ KIAA1324.  To test if 
KIAA1324 contributes to growth proliferation in this line, I used a silencing 
strategy.  Tet-repressor expressing MCF-7 cells (MCF-T-Rex) were transfected with 
KIAA1324 shRNA constructs to inducibly knock down KIAA1324 expression.    
Two KIAA1324 targeting siRNA sequences, Dhamarcon #6 and #7, which were 
shown to be efficient in silencing KIAA1324 transiently in MCF-7 cells (see Figure 
79), were chosen to generate KIAA1324 targeting pRetroSuperior shRNA constructs 
for the inducible knock down.  Details of vector construction and sequences used are 
described in Materials and Methods section 2.20.  MCF-T-Rex cells were 
transfected with these shRNA constructs individually and together.  Transfectants 
were selected by using G418 and puromycin-containing media (the selective 
antibiotic for T-Rex and pRetroSuperior plasmids respectively) and expanded for 
later experiments.   
 
To test the efficiency of KIA1324 silencing, doxycycline was added to the cells for 
72 hours in order to induce shRNA expression.  The mRNA and protein levels of 
KIAA1324 were checked by qPCR and western blotting respectively.  Three out of 
eleven clones tested were able to reduce KIAA1324 expression in tet-inducible 
MCF-7 cells.  Of these three clones, two were carrying shRNA constructs which 
express the Dharmacon #6 siRNA sequence (clones #A and #B) and one was 
carrying both shRNA constructs expressing Dharmacon #6 and #7 siRNA sequences 
(clone #C).  Figure 91A demonstrates that the degree of KIAA1324 knock down in 
these three clones was promising compared to non-doxycycline treated counterparts.  
Both mRNA and protein levels of KIAA1324 in the empty vector controls are the 
same with or without doxycycline treatment.  Based on these findings, these 
inducible cell lines were tested in growth assays. 
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Figure 91. Characterisation of three inducible KIAA1324 shRNA transfected cell lines.   Three 
KIAA1324 shRNA transfected clones in MCF-T-Rex cells (clones #A, #B and #C) plus an empty 
vector transfected control line were grown with and without 1μg of doxycycline for 72 hours to 
induce shRNA expression. (A) KIAA1324 mRNA level was analysed by qPCR. Data were 
normalised to GAPDH mRNA levels and the values of no doxycycline controls of each clone were 
set at 1 to generate relative mRNA levels. The graph represents data averaged from three PCR 
replicates, ±standard error. (B) Whole cells extracts (10μg/lane) were separated by SDS/PAGE and 
blotted to a membrane and probed with our KIAA1324 antibody.  HSC70 was used as a loading 
control. 
 
A
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5.10. Cell proliferation rates did not alter when KIAA1324 
was silenced in MCF-7 cells 
To examine if loss of KIAA1324 expression has any impact on the proliferation of 
MCF-7 cells, the three inducible lines were grown with and without doxycycline and 
subjected to cell counting and MTS assays as performed previously with the 
KIAA1324 over-expressing MCF10A lines.  Initially, a cell count study was 
performed on KIAA1324-shRNA expressing MCF-T-Rex clones grown in normal 
media-containing 10% tet-approved FCS over 120 hours.  As shown in Figure 92, 
the cell numbers between doxycycline induced clones and their non-induced 
counterparts were the same up to 96 hours.  Although the doxycycline induced 
clones had lower cell numbers than their non-induced counterparts at 120 hours, this 
observation was also seen in the vector control line.  This might suggest that it could 
due to the toxicity of prolonged doxycycline treatment or cell confluence.  It could 
also be that high serum levels may compensate for loss of KIAA1324 and therefore 
the experiments were repeated using media supplemented with only 1% serum.  
Similar observations were made with these clones which were grown in low serum 
for few days before re-seeding for the cell count study (see Figure 93).  Based upon 
these findings, it suggests that KIAA1324 has a function that is not related to cell 
growth on plastic.   
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Figure 92. Silencing KIAA1324 does not alter the growth rate of MCF-7 cells.  Clones #A - #C 
and empty vector control cells were seeded onto 6-well plates at 150,000 cells/well and treated with 
and without 1 μg doxycycline on the same day. Cells were counted over 5 days at 24 hour intervals.  
Cells numbers were averaged and expressed as mean±s.e., n = 3.  Cell counts were performed using 
Casy Cell Counter (Scharfe System). 
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Figure 93. Silencing KIAA1324 and growing in low serum does not alter the growth rate of 
MCF-7 cells.  Clones #A - #C and empty vector control were seeded onto 6-well plates at 150,000 
cells/well using 1% tet-approved FCS media and treated with and without 1 μg doxycycline on the 
same day. Cells were counted over 6 days at 24 hour intervals.  Cells were averaged and expressed as 
mean±s.e., n = 3.  Cell counts were performed using Casy Cell Counter (Scharfe System). 
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5.11. Does KIAA1324 expression promote anchorage 
independent growth? 
The study by Deng et al suggested that KIAA1324 is associated with more 
aggressive forms of endometrial cancer.  My experiments in MCF01A and MCF-7 
cells suggest that, at least in mammary epithelial cells, KIAA1324 is not directly 
involved in proliferation.  However, growth of cell lines on plastic culture plates 
does not necessarily reveal tumour-like properties.  In order to find out more about 
the function of KIAA1324, KIAA1324-expressing MCF10A and KIAA324-silenced 
MCF-7 cells were grown in soft agar to examine if KIAA1324 can promote a more 
transformed phenotype. 
 
The soft agar colony formation assay is an anchorage independent growth assay 
which assesses the ability of cells to grow in the absence of attachment to a surface.  
The acquisition of anchorage-independent growth is considered to be one of the in 
vitro hallmarks associated with cellular malignancy.  Cells are usually cultured for 3 
to 4 weeks and colonies will form if cells are malignant or undergoing cell 
transformation and able to grow suspended in the agar.  Following this incubation 
period, the colonies can be analysed morphologically using a cell stain such as 
0.005% crystal violet and quantifying the number of colonies formed per well under 
microscopy. 
 
MCF-7 cells are known to be able to grow in an anchorage-independent manner 
(Chen et al., 1998), and in contrast, MCF10A wild-type cells are non-tumourigenic 
and can only be grown when attached to a solid surface.  Therefore wild-type MCF-
7 cells were used as a positive control whereas MCF10A cells were used as a 
negative control for the soft agar assay.  KIAA1324-expressing MCF10A clones and 
KIAA1324-silenced MCF-7 clones (with and without doxycycline treatment) were 
grown in soft agar for 30 days and then stained with 0.005% crystal violet in order to 
visualise viable cells.  Figure 94A shows that MCF-7 cells formed visible colonies 
in soft agar following 30 days incubation, but very few visible colonies were formed 
with MCF10A wild-type cells.  No visible colonies were observed for any of the 
KIAA1324-expressing MCF10A clones including the vector control which, as 
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expected, was very similar to MCF10A wild-type cells, as shown in Figure 
94B.  Figure 94C shows that, when each well was observed under microscopy, there 
was large colony formation with MCF-7 cells with clear staining of crystal violet.  
Large colony formation in MCF10 wild-type, vector control line and KIAA1324-
expressing MCF10A cells (clone #2) was also observed when studied under higher 
magnification.  However, the majority of cells in MCF10 wild-type, vector control 
and KIAA1324-expressing lines were stained only faintly with crystal violet and the 
colony size was too small to be counted as a positive colony.  Although, there were 
positive staining colonies in KIAA1324-expressing line (#clone 2), overall this was 
not significantly different from MCF10A wild type and vector controls, as shown 
in Figure 94D.  This result confirms that MCF10A cells are not able to grow in an 
anchor-independent manner and that expressing KIAA1324 in MCF10A cells does 
not enable them to become anchorage-independent.   
 
Additional, soft agar assays were also performed using KIAA1324-silenced MCF-7 
cells.  Doxycycline was added to the clones to induce KIAA1324 shRNA expression 
for 72 hours in order to allow sufficient reduction of KIAA1324 expression prior to 
the soft agar assay (see Figure 95).  KIAA1324-silenced clones were compared to 
their non-induced counterparts in order to compare the differences in the numbers of 
positive colonies with and without KIAA1324 expression.  The vector control line 
treated with and without doxycycline was included to ensure any changes in the 
number of colonies formed were not due to the addition of doxycycline.  In addition, 
inducible AP-2γ silenced MCF-7 cells using this same tet-inducible system 
(Williams et al., 2009) were included as an extra control as KIAA1324 expression is 
down-regulated when AP-2γ is depleted (see Figure 80 and Figure 95).  As 
demonstrated in Figure 96, the number of stained colonies for the vector control line 
without doxycycline was slightly lower than its doxycycline-induced counterpart, 
therefore, I was confident that doxycycline treatment did not interfere with the assay.  
When colony formation for KIAA1324-silenced clones #A, #B, #C and the AP-2γ 
shRNA line was quantified, it was noted that, with the exception of clone A, all the 
lines showed reduced colony formation in the induced compared to the un-induced 
cells (see Figure 96).  In particular, clone #B which had the lowest KIAA1324 
expression after doxycycline treatment (see Figure 95), had the lowest colony 
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formation, although it is not statistically significant.  This evidence suggested that 
KIAA1324 expression might contribute to the cell malignant phenotype of MCF-7 
cells.  A reduction of colony formation was also observed in AP-2γ-silenced cells, 
however, it is not known whether reduced colony formation was due to AP-2γ 
silencing or KIAA1324 silencing or both.  It might be also due to reduced 
proliferation also observed in AP-2γ silenced cells.  This will therefore need to be 
further verified. 
 
Putting all data obtained in this chapter together, it appears that: 
• KIAA1324 expression is unlikely to be regulated by oestrogen in mammary 
cell lines. 
• KIAA1324 does not have a significant effect on cell proliferation on plastic 
in either high or low serum. 
• KIAA1324 alone does not promote transformation or anchorage independent 
growth in immortalised mammary epithelial cells (MCF10A). 
• KIAA1324 expression may contribute to the ability of MCF-7 cells to show 
anchorage-independent growth but further experiments are required as all 
three shRNA expressing clones showed increased colony formation 
compared to controls in the non-induced (i.e. without doxycycline) condition. 
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Figure 94.  Expression of KIAA1324 does not promote anchorage-independent growth in 
MCF10A cells.  Wild-type MCF-7 (positive control) and MCF10A cells, vector control and 
KIAA1324-expressing clones (#1 – 4) were seeded onto 6-well plates at 30,000 cells/well containing 
agar and 2x media.  Cells were incubated for 30 days then stained with 0.005% crystal violet for 1 
hour. (A) and (B) Representative experiments showing colonies stained with crystal violet.  (C)  Low 
(x10) and high (x40) magnification showing large colony formation for MCF-7 cell line in the top left 
panel. No colony formation for MCF10A wild-type and vector control but one visible colony in 
KIAA1324-expressing MCF10A cells (clone #2).  (D) Visible colonies stained with crystal violet 
were counted manually. The graph represents an average of three replicates ±standard error. 
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Figure 95. Doxycycline-treated cells used for anchorage-independent growth assays showed 
appropriate depletion of KIAA1324 expression.  MCF-T-Rex cells with inducible shRNA 
constructs for KIAA1324 (#A, B and C) and AP-2γ and the empty vector control, were treated with 
and without 1μg of doxycycline for 72 hours prior to re-plating in soft agar.  A portion of cells were 
harvested for qPCR and western blot analysis. (A) qPCR was performed to detect KIAA1324 mRNA 
level. Data were normalised to GAPDH mRNA levels and the values for each un-induced counterpart 
were set at 1 to generate relative mRNA levels. The graph represents data averaged from three PCR 
replicates, ±standard error.  (B) Whole cells extracts (10μg/lane) were separated by SDS/PAGE and 
blotted to a membrane and probed with KIAA1324 antibody.  HSC70 was used as a loading control. 
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Figure 96.  Soft agar assay of KIAA1324-shRNA MCF-7 clones.  Clones and vector control cells 
were treated with and without doxycycline for 72 hours before being re-seeded onto 6-well plates at 
30,000 cells/well containing agar and 2x media.  Cells were incubated for 30 days and stained with 
0.005% crystal violet for 1 hour.  (A) Visible clones stained with crystal violet were counted 
manually.  The graphs represent an average of three replicates ±standard error. (B) Representative 
experiments showing colonies stained with crystal violet.  
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6. Discussion 
According to UK Cancer incidence statistics, the most common cancer in females is 
breast cancer, followed by colorectal, lung and ovarian cancer.  Initial research into 
the mechanisms of tumour formation and progression in breast cancer identified the 
oestrogen receptor and ErbB2 proteins as the major markers for this disease.  
Numerous studies have shown that the expression of AP-2 transcription factors plays 
a critical role during development and suggested that AP-2 family members might 
act as a checkpoint between proliferation and differentiation.  For example:  
 
1. During skin epidermis development, AP-2α expression is required to inhibit 
proliferation by repressing the expression of EGFR as cells exit the basal 
layer, and in the absence of AP-2α the suprabasal cells fail to differentiate 
(Wang et al., 2006).  
2. During gonocyte development, the level of AP-2γ expression is high in early 
proliferating germ cells but is eventually lost in order for cells to 
differentiate.  Ectopic expression of AP-2γ resulted in hyperproliferation and 
prevented differentiation in these cells (Jager et al., 2003; Pauls et al., 2005).  
3. During mammary gland development, AP-2γ over-expression inhibited 
epithelial proliferation in developing alveolar buds resulting in 
hyperproliferation and a failure of the alveolar buds to differentiate into their 
lactating derivatives (Jager et al., 2003).   
 
Overall, these studies suggest that AP-2α expression is required for differentiation, 
and inhibits proliferation, whereas AP-2γ is required for proliferation and must be 
down-regulated for differentiation to occur.  Due to their roles in the control of 
proliferation and differentiation during development, aberrant expression of these 
AP-2 factors might lead to hyperplasia, a proliferative and undifferentiated state and 
eventually contribute to tumour progression in adult tissues.   
 
Indeed, AP-2 factors have been linked with tumour progression in various types of 
cancer, including breast cancer.  In cell lines studies, AP-2α has been shown to 
activate CDNK1A and repress BCL2 transcription (McPherson et al., 2002; 
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Wajapeyee et al., 2006; Zeng et al., 1997).  As described in the introduction, tumour 
studies have correlated high AP-2α expression with reduced proliferation and good 
prognosis in breast cancer patients and have shown that loss or reduction of AP-2α 
is associated with disease progression, supporting a tumour-suppressor-like role for 
AP-2α (Gee et al., 1999; LaBaer et al., 1997; Pellikainen and Kosma, 2007).  
Conversely, AP-2γ expression was shown to be elevated during tumour progression.  
A study from our lab found that high levels of AP-2γ significantly correlated with 
poor prognosis and shortened survival in breast cancer (Gee et al., 2009).  This 
correlation was also found in ERα positive tumours and in ErbB2 negative tumours; 
two tumour types generally considered to have good prognosis.  This indicates that 
AP-2γ in particular may be a useful prognostic indicator in breast cancer and 
therefore the MCF-7 line (which expresses AP-2γ exclusively) was used to 
investigate the cellular pathways regulated by this factor.  It was found that MCF-7 
cells underwent cell cycle arrest at G1/S-phase following AP-2γ knock down and an 
Affymetrix microarray study on the silenced cells revealed the most significantly 
down-regulated genes were involved in cell cycle regulation [see Figure 19 in 
Introduction;(Williams et al., 2009)]. 
 
Since MCF-7 cells predominantly express AP-2γ and carry wild-type p53, it was 
intriguing to go on to investigate the role of AP-2α in other breast cell lines that 
express wild-type or mutant p53.  Several studies have suggested p21cip can be 
activated via either p53-dependent or p53-independent pathways.  In MCF-7 cells 
AP-2γ repressed p21cip expression through direct interaction at the proximal 
promoter (Williams et al., 2009).  Based upon these findings, I, therefore, aimed to 
investigate changes in cell cycle profile following silencing of AP-2α and AP-2γ 
separately and together in cells that express mutant p53 e.g. T47D, or wild-type p53 
e.g. H3396 and MCF10A.  I also aimed to define AP-2α and AP-2γ dependent 
transcriptional changes using Affymetrix oligonucleotide microarrays. 
 
To this end, I successfully used the RNAi technique to knockdown AP-2α and AP-
2γ expression transiently in T47D, H3396 and MCF10A cells.  All variables in the 
experimental design among all samples were held constant.  The major findings 
following AP-2 silencing in these cell lines are summarised below and in Table 16. 
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• Cell Cycle analysis showed a slight increase in the cell population in S-
phase and G2/M phase in all AP-2 silenced T47D cells, but a reduction in S 
and G2/M-phase populations accompanied by an increase in G1-phase in 
AP-2 silenced MCF10A cells.  There were no significant changes in cell 
cycle profile in AP-2 silenced H3396 cells compared to NSC cells. 
• BrdU analysis revealed an increase in the proportion of cells undergoing 
DNA synthesis in AP-2 silenced T47D cells, especially in the double knock 
down.  It also showed a slight increase in G2/M phase but reduced G1-
phase, which agreed with the cell cycle analysis 
• Cell Count studies showed a slight increase in the cell number in AP-2 
double silenced T47D cells at 72 hours but reached parity with NSC cells at 
96 hours; growth arrest did not occur despite induction of p21cip.  In 
contrast, the numbers of AP-2 double silenced MCF10A cells were 
significantly lower than NSC cells between 72 to 120 hours, despite p21cip 
levels remaining low.  No significant differences were observed between 
AP-2 silenced or NSC-treated H3396 cells. 
• TMRE and caspase analyses showed that AP-2 silencing in T47D cells did 
not induce apoptosis.  SubG1 analysis did not reveal an increase in the 
SubG1 population in AP-2 silenced T47D or MCF10A cells indicating that 
silencing AP-2 did not cause apoptosis during G1-phase. 
• ChIP assays showed AP-2α and AP-2γ occupancy at the proximal region of 
the CDNK1A and CCND3 genes in T47D cells.  Reduced AP-2α and AP-2γ 
enrichment at these regions was observed following AP-2 silencing. 
• Luciferase assays demonstrated that both AP-2α and AP-2γ can exert an 
inhibitory effect at the proximal region of the cyclin D3 promoter in T47D 
cells. 
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Table 16.  This table summarises the major differences in protein levels of cell cycle regulators 
observed in MCF-7, T47D and MCF10A cells following AP-2 silencing compared to NSC 
transfected control cells. 
 
 
6.1. AP-2 silencing does not induce apoptosis in T47D cells 
In my initial experiments with T47D cells, a significant number of floating cells 
were observed after transfection with AP-2α and AP-2γ targeted siRNA. Although 
T47D cells are known to carry mutant p53, this mutation (L194F) has been shown to 
bind DNA and induce p53 target genes and T47D cells can still carry out p53-
dependent apoptosis (Kato et al, 2003; Toillon et al, 2002).  I therefore examined if 
silenced cells were undergoing apoptosis. When Sub-G1 analysis was performed, an 
increase in fragmented cells was observed in the AP-2 double knock-down samples, 
however, inconsistencies in the results were noted when experiments were repeated 
and I eventually concluded that the increase in the Sub-G1 population in AP-2 
double knock-down cells was due to the extra amount of siRNA introduced into the 
cells.  When using the new experimental design, where all samples were transfected 
with the same amount of siRNA, the fraction of Sub-G1 population in AP-2 silenced 
T47D cells was similar to the controls (see Figure 37) However, since cells 
undergoing apoptosis during S or G2/M-phase would not appear in the Sub-G1 peak, 
 MCF-7 T47D  MCF10A 
p21 2 to 3-fold increase 1.2-fold increase in 
AP-2α and AP-2γ 
single knockdown 
 
1.75-fold increase 
in AP-2 double 
knockdown 
Constant 
p27 Increased Constant Constant 
pp27 Decreased Constant Not tested 
ppRb Decreased Slightly increased Not tested 
Cyclin D1 Constant Slightly increased Constant 
Cyclin D3 Constant Increased Constant 
Cdk4 Constant Constant Constant 
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to verify whether silencing AP-2 in T47D cells induces apoptosis, two further assays 
were carried out: TMRE and Caspase activity.   
 
As shown in Figure 38, there was a 2-fold increase in the dead cell population in 
AP-2 double silenced cells compared to the controls.  The number of TMRE 
positive, thus, apoptotic cells and the fraction of non-apoptotic cells were also 
reduced slightly. The caspase assay showed similar caspase levels between all 
siRNA treated samples. Although these levels were slightly higher than the mock 
control, very high caspase activity was detected only in STS or cisplatin treated 
positive control cells, indicating that silencing AP-2 transcription factors in T47D 
cells might not be sufficient to induce apoptosis as shown in Figure 39. 
 
Therefore, the increase in the dead cell population in AP-2 double silenced cells 
appears to have occurred in the absence of any hallmarks of apoptosis (decreased 
TMRE staining and increased caspase activity) suggesting that the cells may have 
died though another mechanism [e.g. autophagy or necrosis; (Sasi et al., 2009)]. 
However, there was wide variation between the replicates as represented by the large 
error bar.  The dead cell population in AP-2 double silenced cells could be 
exaggerated due to experimental variations and this did not seem a strong enough 
effect to study further.  Nevertheless, similar to our MCF-7 study (Williams et al, 
2009), I did not find any evidence of apoptosis in AP-2 silenced T47D cells.  
 
6.2. The role of AP-2 in T47D cell cycle regulation 
6.2.1. AP-2 silencing in T47D cells results in increased cell 
proliferation 
My results examining changes to the cell cycle in AP-2 silenced T47D cells have 
given somewhat different results from those previously found using AP-2γ-silenced 
MCF7 cells, as shown in Table 16.  In MCF-7 cells, AP-2γ transcriptionally 
repressed p21cip and a partial cell cycle arrest at G1/S-phase was induced through 
increased p21cip mRNA and protein levels after AP-2γ silencing.  I, therefore 
hypothesised that, at least in AP-2γ silenced T47D cells, the effect on the cell cycle 
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would be similar to observations in MCF-7 cells.  Due to the tumour suppressor-like 
role of AP-2α (as suggested by literature review), I expected there would be more 
cells in S and G/M-phase in AP-2α silenced cells, whereas the differences in the cell 
cycle profile in the double silenced cells would be intermediate between AP-2α and 
AP-2γ single knockdown.  Indeed, in cell cycle and BrdU assays the fraction of cells 
in S and G2/M-phase in AP-2α, and AP-2 double-silenced cells were higher than 
controls.  This finding is in agreement with AP-2α acting as a tumour suppressor.  
However, similar observations were also seen in AP-2γ silenced T47D cells which is 
inconsistent with the MCF-7 study.  Possible explanations for these observations are 
discussed in the following section. 
 
6.2.2. AP-2 silencing results in a slight up-regulation of p21cip 
that contributes to the increase in cell proliferation in 
T47D cells 
In addition to the FACS analyses, changes in cell cycle regulators known to be 
important at the G1/S-phase transition were examined by western blotting following 
AP-2 silencing in T47D cells to try to explain the sustained cell cycle progression 
(see Table 16 for brief summary).  The major similarity between MCF-7 and T47D 
cells was that p21cip protein and mRNA levels were increased following AP-2 
single or double silencing.  As mentioned in Chapter 1, Introduction section 1.12.5, 
p21cip was described initially as a universal inhibitor of cyclin-kinase complexes.  
In human cells there are multiple cyclin-dependent kinases (cdk), and their essential 
activating partner, the cyclins.  They form complexes that are activated at specific 
intervals during the cell cycle in order to promote cell cycle progression.  Inhibition 
of cdk-cyclin complex formation by a cdk-cyclin inhibitor such as p21cip is 
expected to cause cell cycle arrest leading to an increased cell population in G1-
phase.   
 
One explanation for the observed difference between cell types may be that p21cip 
is not only an inhibitor of cdk-cyclin complexes but also serves as an activator, 
promoting the assembly of cdk-cyclin complexes.  Indeed, a study demonstrated that 
p21cip-containing cyclin complexes exist in both catalytically active and inactive 
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forms (Zhang et al., 1994).  This study showed that p21cip was permissive for cdk2 
kinase activity at sub-threshold levels but inhibited kinase activity at saturating 
levels.  Another study also demonstrated that p21cip could promote kinase activity 
in addition to its role as an inhibitor (Cheng et al., 1999; LaBaer et al., 1997).  In the 
Labaer study, they found that the carboxyl terminus of p21cip contains cdk and 
cyclin binding domains, and that both p21cip and p27kip significantly promoted the 
assembly of cdk4/cyclin D1 complexes in a dose-dependent manner.  In the absence 
of p21cip, weak complex assembly and kinase activity were reproducibly detected.  
When p21cip was at an intermediate level it promoted both complex assembly and 
also increased kinase activity, however, as the level of p21cip increased further, the 
kinase activity plateaued and then decreased (as measured by decreased pRb 
phosphorylation), regardless of the maximal complex assembly.  These findings 
suggested that p21cip has two opposing and overlapping effects on the cdk4/cyclin 
D1 complex.  At low concentration it promotes both complex formation and kinase 
activity whereas at higher concentration it inhibits kinase activity.  Complex 
formation also occurred when p21cip was bound to cyclin D1 and cdk4 to form 
ternary complexes in the immortal human mammary epithelial cell line 184A1L5.  
The cyclin D1-associated pRb kinase activity was associated with p21cip as 
demonstrated by the loss of cyclin D1 kinase activity after p21cip was removed from 
the extracts (LaBaer et al., 1997).  A later study, using primary mouse embryo 
fibroblasts (MEF) strains deficient in p21cip or p27kip or both, also demonstrated 
that the assembly of cyclin D1/cdk4 complexes required either p21cip or p27kip.  
Cyclin D1/cdk4 complex formation was significantly reduced in p21cip/p27kip 
double null MEFs compared to the wild-type MEFs (Cheng et al., 1999).  In a 
separate study, repression of p21cip by Notch was shown to prevent nuclear 
translocation and reduced assembly of cyclin D/cdk complexes in human endothelial 
cells (Noseda et al., 2004).  In agreement with Labaer et al, these studies also 
showed cyclin D1/cdk4 dependent pRb kinase activity was no longer detectable, 
which further supports the role of p21cip as a positive cell cycle regulator. 
 
The reason why the effect on the cell cycle in T47D cells following AP-2 silencing 
was contrary to AP-2γ silenced MCF-7 cells could be that initially all FACS and 
western blot analyses performed in this study were at 48 to 72 hours, whereas, in the 
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MCF-7 study all analyses were performed between 72 to 96 hours post-transfection.  
The level of p21cip protein induction in T47D cells might not have reached beyond 
the threshold as proposed by Labaer et al at 48 hours.  Indeed, as noted in Table 16, 
the increase in p21cip level in AP-2-silenced T47D cells is much more modest than 
was observed in MCF-7 cells.  Given the evidence that the p21cip family of proteins 
also have a role as effectors promoting kinase complex assembly and activity, this 
model could explain the increase in S and G2/M-phase populations, as well as the 
increase in cell numbers observed in T47D cells after AP-2 knockdown in this study 
(see Figure 41, Figure 43 andFigure 44).  Following AP-2 single and double 
silencing, p21cip levels increase slightly, and this p21cip protein level promotes 
cdk4/cyclin D1 complex assembly and thus, enhances kinase activity.  This, in turn, 
triggers the downstream pathway (see Figure 12, Introduction) resulting in an 
increase in the proportion of cells undergoing DNA synthesis, which could explain 
an increase in S and G2/M-phase but decreased G1-phase populations in these 
samples.  This hypothesis is illustrated in Figure 97. 
 
 
 
 
 
 
Figure 97.  A schematic diagram suggesting the role of AP-2 factors in the regulation of cell 
cycle via p21, cyclin/cdk and pRb proteins in MCF-7 and T47D cells.  pRb is phosphorylated by 
cdk/cyclin resulting in cells entering S-phase.  In AP-2γ silenced MCF-7 cells, high levels of p21cip 
were induced which inhibited cdk-cyclin kinase activity leading to a reduction in pRb 
phosphorylation and cell cycle arrest.  In AP-2 silenced T47D cells, a modest increase in p21 level 
that acts as a cdk-cyclin kinase activator that may result in more efficient pRb phosphorylation and 
continued cell proliferation 
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6.2.3. ppRb and pp27 protein levels agree with this hypothesis 
Further evidence for this hypothesis came from looking at ppRb levels.  The large 
induction of p21cip level in AP-2γ silenced MCF-7 cells inhibited the cdk/cyclin 
kinase activity leading to a reduction in pRb phosphorylation, as tested by western 
blotting with phospho-specific antibodies.  Indeed, the level of phosphorylated pRb 
(ppRb) in silenced cells was lower than the controls demonstrating that cdk/cyclin 
activity was reduced in these cells (C. Williams, PhD thesis, 2007).  As a 
consequence, hypophosphorylated pRb inactivated E2F by forming a stable 
pRb/E2F complex resulting in the repression of E2F target genes required for entry 
into S-phase.  If the hypothesis presented here is true, the level of ppRb in AP-2 
silenced T47D cells should remain similar to NSC treated cells or be up-regulated 
slightly.  As expected, the levels of pRb phosphorylation in AP-2 silenced T47D 
cells were slightly up-regulated or remained constant compared to the controls 
(see Figure 51).  Consequently, in T47D cells, AP-2 silencing relieved its repressive 
effect on the p21cip promoter region resulting in an increase in p21cip mRNA and 
protein levels, however, the degree of p21cip induction was much more modest 
compared to AP-2γ silenced MCF-7 cells, thus, causing the slight increase in cell 
proliferation observed in this study. 
 
In addition, the p27kip and pp27 protein levels also remained constant across all AP-
2-silenced T47D cells and the controls but in MCF-7 cells p27kip levels rose 
(see Table 16).  It is possible that an induction of p27kip following AP-2γ silencing 
enhances the growth inhibitory effect in MCF-7 cells.  LaBaer et al and Cheng et al 
indicated that p27kip also promoted cdk4/cyclin D1 complex assembly but in the 
LaBaer study, only p21cip was capable of promoting kinase activity, suggesting that 
p27kip may act more as an inhibitor.  The increase in p27kip level was accompanied 
by a decrease in p27kip phosphorylation at Thr 187 in AP-2γ silenced MCF-7 cells.  
In cycling cells, p27kip is phosphorylated by cyclinE/cdk2 kinase activity and 
targeted for proteolysis so the levels remain low.  It was proposed that, upon AP-2γ 
silencing, cdk/cyclin kinase activity was reduced (by the high p21cip level) leading 
to a reduction in p27kip phosphorylation and thus stabilizing p27kip protein 
resulting in p27kip up-regulation.  As the p27kip level does not alter in silenced 
T47D cells and they are still proliferating (increasing cell count), it is reasonable to 
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conclude that while the high p21cip level in MCF-7 cells acts as a cdk/cyclin kinase 
inhibitor, the lower increase in p21cip level acts as a cdk/cyclin kinase activator in 
T47D cells following AP-2 depletion.   
 
6.2.4. Does prolonged AP-2 silencing ever lead to growth 
arrest in T47D cells? 
Two pieces of evidence seemed to be in agreement with the proposed model 
described above for early time points (48 to 72 hours) post transfection.  When AP-
2α and AP-2γ were silenced together over 120 hours in T47D cells, a small increase 
in cell number was observed at 72 hours, but reached parity with NSC cells at 96 
hours and became slightly lower than NSC at 120 hours (see Figure 58).  The levels 
of p21cip protein were examined in these samples and it was found that p21cip 
protein in AP-2 double silenced cells increased significantly compared to NSC cells 
at 72 hours, and remained high at 120 hours.  As I have shown that cell proliferation 
was higher in AP-2 silenced cells compared to NSC cells, initially it was assumed 
that the increased p21cip protein levels may be due to cell contact inhibition.  
However, p21cip protein levels in NSC cells remained significantly lower than in 
AP-2 silenced cells throughout 120 hours despite the cell numbers in both conditions 
being similar between 96 and 120 hours.  Therefore, I was confident that the p21cip 
induction was not the result of cell confluency.  Growth inhibition was not observed 
in AP-2 silenced cells despite the significant p21cip induction, and the growth curve 
was not ‘plateauing’ even at 120 hours.  The possible explanation for this 
observation could be that cyclin D3 protein levels were significantly elevated in AP-
2α and AP-2γ single and double silenced T47D cells.  The mechanism behind the 
induction of cyclin D3 is discussed in more detail below, but it is highly likely that 
this excess cyclin D3 would complex with the newly made p21cip and effectively 
“mop it up” leaving the cyclin D1/cdk4 (whose levels remained largely constant in 
control and silenced cells) to maintain a roughly constant cell cycle rate. This would 
explain why the silenced cells did not arrest even though p21cip was induced.  
 
In this context it is also worth noting that although p21cip induction was only seen 
consistently in AP-2 double knockdown cells, it was also observed to varying 
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degrees for both AP-2α or AP-2γ single knockdown in T47D cells.  It could be that, 
AP-2α and AP-2γ may compensate for the loss of each other, and hence, the effect 
on p21cip expression levels varies between experiments.  Since MCF-7 cells 
predominantly express AP-2γ, thus, the interplay between AP-2 factors and p21cip 
may be more direct than in cells that express both isoforms of AP-2, as reflected by 
the p21cip expression levels following AP-2 silencing. 
 
Since it was not possible to knock down AP-2 expression beyond five days using 
transient transfection, I could not conclude whether silencing AP-2 factors would 
ever led to growth arrest in T47D cells.  Therefore, prolonged silencing of AP-2 in 
T47D cells using a tet-inducible shRNA system could provide a better insight into 
their roles in the regulation of cell growth.  Since, it was possible that these two 
isoforms may compensate for the loss of each other, it would be interesting to 
compare the effect on cell cycle when silencing either of these AP-2 factors or both 
together in long term experiments. Previous attempts in our lab to silence stably AP-
2γ alone in T47D cells resulted in the isolation of just two clones with low AP-2γ 
expression, but after several passages AP-2γ levels were restored (Williams et al, 
2009). This suggests that sustained cell division in T47D cells is not possible 
without AP-2γ expression. 
 
Overall, the functional studies performed on T47D cells following AP-2 silencing 
suggested that, loss of either isoform of AP-2 led to induction of p21cip expression.  
The cell cycle progression in silenced cells was dependent on the level of p21cip 
induction following AP-2 depletion, as low levels seemed to enhance cell 
proliferation, but the proliferation rate slowed down gradually as the p21cip level 
rose after prolonged AP-2 silencing. A summary of these ideas is presented in Figure 
98. 
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Figure 98.  A proposed model for cell cycle regulation by AP-2 in T47D cells.  Following AP-2 
silencing, both p21cip and cyclin D3 protein levels increased which facilitate the assembly of 
cyclin/cdk complexes and enhanced cell proliferation.  At later time points higher levels of p21cip 
accumulate but are sequestered by the increased cyclinD3. However, would prolonged AP-2 silencing 
eventually lead to inhibition of cyclin/cdk kinase activity and cell cycle arrest? 
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6.3. AP-2α and AP-2γ dependent transcriptional repression of 
CDKN1A in T47D cells 
6.3.1. Induction of p21cip is due to de-repression of AP-2 
factors  
Since p21cip up-regulation was observed following AP-2 silencing in T47D cells 
and, given that AP-2γ has previously been shown to directly bind to the p21cip 
promoter, it was intriguing to examine if there is also a direct interaction between 
AP-2α and AP-2γ with the p21cip promoter in T47D cells.  Hence, I performed 
ChIP assays in T47D cells with and without AP-2 silencing, and examined 
enrichment at three discrete CDNK1A loci: the proximal promoter region (-21 / +44) 
; the classical p53 binding site (-2185 / -2290); an upstream region with no putative 
AP-2 binding site as a negative control (-3931 / -4005).  The results showed 
enrichment for AP-2α and AP-2γ binding at the CDNK1A proximal promoter region 
in NSC cells but a reduction in AP-2α or AP-2γ occupancy upon silencing of each 
factor respectively (see Figure 48).   
 
As discussed above, p21cip expression was induced in AP-2 silenced cells, and the 
findings of the ChIP assays suggested that both AP-2α and AP-2γ have a repressive 
effect on the p21cip promoter thus, inhibiting transcription of the CDKN1A gene. 
The result of my AP-2γ ChIP is in agreement with the MCF-7 study (Williams et al., 
2009), but surprisingly, AP-2α also seems to be a repressor of CDKN1A 
transcription in T47D cells.  This finding is inconsistent with other AP-2α studies in 
various cell lines, where over-expression of AP-2α was found to induce p21cip 
expression via both p53-dependent and independent mechanisms (see Introduction. 
section 1.15).  It would therefore be expected that, silencing AP-2α would decrease 
p21cip expression; possible reasons for this difference are discussed in the following 
section. 
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6.3.2. AP-2 repression of p21cip is independent of p53  
It has been reported that the up-regulation of p21cip by over-expression of AP-2α is 
enhanced in the presence of wild-type p53 in lung cancer cells (Wajapeyee and 
Somasundaram, 2003).  Other research has also suggested that AP-2α activation of 
p21cip was entirely dependent on interaction with wild-type p53 at the p53 binding 
site at -2250 of the p21cip promoter in colon cancer cells (McPherson et al., 2002; 
Stabach et al., 2006).   
 
My ChIP analysis of AP-2α and AP-2γ binding to the CDKN1A promoter in T47D 
cells however, only detected interaction at the proximal promoter and not at the p53 
binding site. One possible explanation is that T47D cells carry a mutant p53.  The 
mutation occurs at codon 194 within the central DNA-binding core domain but, as 
discussed above, this does not totally impair the ability of p53 to bind to its target 
DNA sequences (Kato et al., 2003) and p53 binding to the  -2290 / -2185 region can 
be detected by ChIP in T47D cells (Dr Angelo Scibetta, Personal communication). 
Moreover, we found no evidence for an AP-2γ interaction at the -2290 / -2185 
region of the p21cip promoter in our MCF-7 study where again all AP-2 binding was 
located to the proximal promoter and associated with repression of CDKN1A 
(Williams et al., 2009).  
 
Recently, we have begun to study regulation of p21cip in MCF10A cells. When I 
silenced AP-2 factors in these cells there was no change in p21cip expression levels 
despite the fact that silenced MCF10A cells undergo growth arrest.  In order to 
induce p21cip, MCF10A cells were treated with either vinblastine or hydroxyurea.  
These are chemotherapeutic drugs that are known to induce both p53 and p21cip 
expression (Tishler and Lamppu, 1996; Woo et al., 2005; Woo et al., 2006).  
Interestingly, our unpublished ChIP data showed that, upon drug-induction of 
p21cip expression, increased enrichment of AP-2α occurred at both the proximal 
CDKN1A promoter and the p53 binding site in MCF10A cells (Dr Angelo Scibetta, 
Personal communication).  Increased p53 binding to its site on the p21cip promoter 
(but not to the proximal region) also occurred, implying that AP-2α is able to induce 
p21cip expression via both p53-dependent and independent pathways in MCF10A 
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cells as suggested by previous studies (Stabach et al., 2006; Wajapeyee and 
Somasundaram, 2003).  
 
Putting these findings together it suggests that in some cell lines (T47D and MCF-7) 
AP-2 factors (whether α or γ or both) predominantly repress p21cip expression and 
this is achieved by binding to the proximal promoter region only.  However, in other 
lines, such as MCF10A, AP-2 factors (AP-2α in particular) do not repress p21cip 
but can contribute to its induction when cells are stressed by binding to both the 
proximal promoter binding site and to the p53 binding region at -2250.  How these 
different activities of AP-2 factors on the CDKN1A gene are regulated is not clear 
however.  It may reflect which of AP-2α or AP-2γ are at the higher level, i.e. AP-2α 
is higher in MCF10A cells. Alternatively, it may be due to a difference between 
normal and tumour cells, since MCF10A cells are an immortalised, non-
tumourigenic line but the others are tumour lines; acquiring the ability to repress 
p21cip expression would provide tumour cells with a selective advantage. However, 
I also found that the tumour line, H3396, did not induce p21cip expression when 
AP-2 factors were silenced suggesting that p21cip may not be repressed by AP-2 
factors in this line either. Another difference between cells that may decide whether 
AP-2 factors repress or activate p21cip expression may be in relative levels of 
cofactors. Previously our lab has compared breast cell lines for levels of CITED2, 
CITED4 and CBP/p300 and not found any wide differences in expression of these 
AP-2 co-activators (Professor Helen Hurst, personal communication). However, as 
described in the Introduction, much less is understood about AP-2 repression. 
Recent studies in our lab have focussed on the Plu1 demethylase as a potential AP-2 
co-repressor in MCF-7 cells [(Scibetta et al., 2007); Dr Angelo G Scibetta, Personal 
communication], therefore comparing Plu1 levels across the different cell lines may 
be informative.  
 
Nevertheless, it can be concluded that AP-2α seems to act as a transcription 
repressor of CDKN1A gene rather than an activator in T47D cells.  Clearly, the 
relationship between AP-2, p21, and p53 is very complex and seems to be highly 
cell line dependent.  This might explain some of the controversies and discrepancies 
in the literature. For example, our findings in MCF-7 and T47D cells are partially 
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contradicted by a previous study in which p21cip was significantly up-regulated, 
accompanied by a reduction in pRb phosphorylation and cyclin D1 expression 
leading to cell cycle arrest when AP-2α and AP-2γ were over-expressed in colon 
and breast cancer cells (Li et al., 2006a). One needs to take into account that, these 
authors used adenovirus vectors to force over expression of AP-2 proteins in non-
expressing cell lines and this technique often results in non-physiological effects, as 
demonstrated by the control empty vector (only carrying the adenovirus backbone) 
which also induced p21cip expression.  However, it is also possible that the lines 
used in their study resemble MCF10A cells and can only support AP-2 mediated 
induction of p21cip and not repression. 
 
In breast tumour studies, Gee et al (1999) found a positive association between AP-
2α expression and p21cip but a separate study evaluating expression of p21cip, p53 
and AP-2 by IHC in breast tumour samples (Pellikainen et al., 2003) found that 
tumours with high p21cip expression were not related to AP-2 expression.  The 
drawback of this study is that the antibody used against p53 recognised both the 
wild-type and mutated forms, and the antibody used against AP-2 recognised all 
three AP-2 isoforms (α,β and γ), thus, reduced the value of a possible association 
between certain AP-2 isoforms, p21cip, wild-type and mutant p53, although the 
accumulation of p53 in tumours represents a good predictor of the presence of p53 
mutation.  It is likely that tumours carrying non-DNA binding, dominant negative 
mutations in the p53 gene are unable to efficiently activate p21cip expression 
irrespective of AP-2 expression but, as seen from the MCF-7 and T47D studies, AP-
2 expressing tumours with wild-type or less damaging p53 mutations may repress 
p21cip activity and this could have important therapeutic and prognostic 
implications. Therefore, it will be more informative to establish the p53 status in 
future AP-2 tumour studies. 
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6.4. AP-2α and AP-2γ dependent transcriptional repression of 
CCND3 in T47D cells 
6.4.1. Is an increase in cyclin D3 protein level due to 
stabilisation by p21cip? 
As described above, AP-2 silencing in T47D cells led to a significant induction of 
cyclin D3 protein that was not observed in the other lines (Table 16). Initially, it was 
thought that this induction was due to protein stabilisation by the increase in p21cip, 
because it has been suggested that p21cip and p27kip not only facilitate nuclear 
accumulation of D cyclins but also reduce their rate of degradation (Cheng et al., 
1999);(Bagui et al., 2003). Therefore, the slight increase in p21cip protein I 
observed following AP-2 silencing might stabilise cyclin D3 which may result in 
enhanced cyclin D/cdk4 kinase activity and contribute to the increased cell 
proliferation seen at the earlier time points (48 to 72 hours).  However, the protein 
levels of cyclin D1 did not seem to increase as significantly as the cyclin D3 level, 
therefore, the mRNA level of cyclin D3 was looked at to check if the increased 
expression was entirely due to protein stabilisation.  A modest but consistent 
increase in cyclin D3 mRNA levels in AP-2 double silenced cells was observed, 
which implied that AP-2 factors may repress this gene in T47D cells. 
  
6.4.2. Induction in cyclin D3 level is due to de-repression of 
AP-2 factors  
Since AP-2α and AP-2γ have been shown to have a transcriptional repressive effect 
on the CDKN1A gene, it would be interesting to investigate if they also have a direct 
role on cyclin D3 expression.  To this end, I identified four putative AP-2 binding 
sites within the cyclin D3 promoter region using a website with information on all 
evolutionarily conserved TFBS.  ChIP assays showed that enrichment of both AP-
2α and AP-2γ was positive at the proximal region of the cyclin D3 promoter in 
T47D cells but not at regions further upstream of the transcriptional start site.  This 
proximal region contains three out of the four putative binding sites.  Subsequent 
luciferase reporter assays revealed that co-expression of either AP-2α or AP-2γ 
reduced cyclin D3 promoter activity, indicating that both AP-2 isoforms can mediate 
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transcriptional repression at the cyclin D3 promoter and that functional binding lies 
within -108 and -254 bp upstream of the transcriptional start site.   
 
6.4.3. What is the mechanism of AP-2 repression of CCND3? 
A much earlier analysis identified potential activating AP-2 and Sp1 binding sites 
within the human cyclin D2 and cyclin D3 promoters (Brooks et al., 1996).  No 
negative element was identified according to these authors, and all sequences 
required for full CCND3 promoter activity were localised to a region between -206 / 
+1 from the TSS. As no TATA box was identified, they also suggested that Sp1 and 
AP-2 may be responsible for regulating the transcription initiation of the cyclin D3 
gene since sites for both factors lie within the region proximal to the TSS. A 
schematic diagram in Figure 99 shows the potential AP-2 and Sp1 binding sites 
identified within the cyclin D3 promoter. 
 
Two of the potential AP-2 binding sites identified by the Brooks study mapped to 
the same locations I identified within the region of the promoter (-108 / -254) 
repressed by AP-2 in the luciferase reporter assays.  Brook et al also identified an 
additional overlapping Sp1/AP-2 site, but located further downstream from the sites 
identified in my study, lying within the +27 / +51 region between the TSS (+1) and 
the initiator codon ATG (+167). All three of my cyclin D3 reporter constructs 
contained this +27 / +51 region, however, according to the luciferase assays, there 
was very little promoter activity detected from construct 1 when co-transfected with 
or without AP-2α or AP-2γ expression indicating this sequence does not contain a 
positive regulatory element.  
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Figure 99.  A schematic diagram showing potential AP-2 and Sp1 sites within the human 
CCND3 promoter.  Green boxes are putative AP-2 binding sites and red boxes indicate the Sp1 sites 
(Brooks et al., 1996).  The HDAC interaction site at -118 is also shown (Roy et al., 2008).  Arrows 
indicate primer sets used to generate my reporter constructs (see Figure 56 in Chapter 3). 
 
 
From Figure 99, however, it is clear that all the AP-2 sites, including the ones within 
the -108 / -254 region of the promoter lie adjacent to, or overlap with a Sp1 binding 
site. Given that both factors bind to GC rich sequences, this is not surprising. 
However, as described in the Introduction section 1.5, competition by AP-2 for Sp1 
binding sites has been proposed to be a mechanism whereby AP-2 can act as a 
repressor at some promoters, for example the expression of keratin 3 in 
undifferentiated and differentiated corneal epithelial basal cells was shown to be 
dependent on the ratio of Sp1/AP-2 (Chen et al., 1997).  Interestingly, another cyclin 
D3 promoter study identified two AP-2 binding sites between -38 to -150 and two 
Sp1 binding sites between -64 to -129 (Wang et al., 1999), and showed that mutation 
of either of the two Sp1 sites decreased basal promoter activity indicating these Sp1 
sites are critical for cyclin D3 transcription.  It is therefore possible that upon AP-2 
silencing in T47D cells, a significant increase in the ratio of Sp1 to AP-2 DNA 
binding activity occurs which results in activation of certain genes such as CCND3. 
 
The AP-2 site in the proximal CDKN1A promoter also lies in close proximity to a 
series of functional Sp1 sites (see Figure 17 in Introduction) and other work in our 
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lab has examined if repression by AP-2γ acts through competition with Sp1 in MCF-
7 cells (Williams, et al, 2009). However, as mentioned above, our most recent data 
suggests that AP-2γ acts by recruiting the demethylase Plu I (Dr Angelo Scibetta, 
personal communication). Similarly, AP-2 factors may recruit co-repressors to 
directly repress the CCND3 promoter. Interestingly, two recent studies examining 
the transcriptional regulation of mouse cyclin D3 found that expression was 
transcriptionally repressed by HDACs (Kim et al., 2007b; Roy et al., 2008).  
Repression of cyclin D3 by HDAC was not mediated via Sp1 sites, rather, Sp1 sites 
were required for the activation of the cyclin D3 promoter after treatment of cells 
with HDAC inhibitors such as apicidin or TSA.  These findings further support that 
Sp1 binding to the cyclin D3 promoter is required for cyclin D3 transcription.  
Furthermore, Roy et al (2008) showed that HDAC5 interacted within -118 bp 
upstream of the TSS of the cyclin D3 promoter, which is within the functional AP-2 
repressed region (-108 / -254) identified in my study (Roy et al., 2008).   Therefore, 
AP-2 factors may recruit HDACs to exert their repressive effect on the cyclin D3 
promoter though this will have to be further elucidated.  ChIP assays can be done to 
investigate if AP-2 factors and HDACs both bind to this region, and Co-IP can be 
used to check the interaction between AP-2 factors and HDACs.  It is also possible 
that AP-2 may regulate cyclin D2 expression in a similar manner to cyclin D3 since 
AP-2 binding sites were also identified in this promoter (Brooks et al., 1996).  
Furthermore, cell cycle progression induced by c-myc has been shown to involve 
transcriptional activation of cyclin D2 expression (Bouchard et al., 1999).  Co-
transfection of AP-2α resulted in repression of c-myc induced cyclin D2 promoter 
activation, and thereby inhibited myc-mediated cell cycle progression (Hilger-
Eversheim et al., 2000). 
 
Further experiments could be done to define the AP-2 binding site(s) within the -108 
/ -254 region more precisely.  Since site 2 and 3 (highlighted in green in Figure 54) 
contain the AP-2 consensus sequence, the first strategy would be to use double 
stranded oligonucleotides containing either one of these consensus sequences as a 
probe and perform electromobility shift assays (EMSA) using in vitro translated 
human AP-2α or AP-2γ protein.  If these sequences contain a functional binding 
site, AP-2 protein will interact with the probe forming a DNA-protein complex and 
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appear as a ‘shifted band’ on a gel, whereas unbound probe will migrate further 
down.  Competition assays could be done to identify the precise AP-2 binding sites 
using a series of cold competitor oligos carrying point mutations in the half-sites of 
the palindromic potential AP-2 binding sites as competitors for AP-2 binding.  
Specific DNA-protein complex formation will be impaired if the mutated site still 
contains a functional AP-2 binding site, but mutations that no longer support AP-2 
binding will not compete.  The functional importance of each AP-2 site identified 
can then be tested by introducing point mutations that prevent binding into my 
CCND3 reporter construct 3 (using site-directed mutagenesis) and rerunning the 
luciferase assays. Constructs with mutations in the functional AP-2 sites(s) should 
not be repressed when co-transfected with AP-2 expression plasmids. Further 
reporter assays using Sp1 expression constructs to alter the Sp1/AP-2 ratio could 
also be done to investigate if competition between these two factors plays a role in 
regulation of CCND3 expression.  
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6.5. KIAA1324 and its function in breast cell lines is still unclear 
KIAA1324 is an evolutionarily conserved gene which was recently termed 
‘Estrogen-induced gene 121’ (EIG121) in studies in endometrial cancer (Deng et al., 
2005).  It is found on chromosome 1p13.3, which has been reported to be amplified 
in approximately 11% of breast cancer cell lines (Forozan et al., 2000).  The 
function of KIAA1324 is unknown but it has features of a membrane-associated 
growth factor receptor so may mediate cell growth.  My immunofluorescence 
analysis showed that KIAA1324 proteins appeared to be localised to the cytoplasm 
and immediately around the nucleus in MCF-7 cells.  It is known that the 
localisation of transmembrane receptor-like proteins may not appear at the 
membrane when they become activated.  Activated membrane-bound receptors are 
generally internalised and often accumulate in perinuclear vessels as essential steps 
in their signalling pathway (Scita and Di Fiore, 2010).  Affymetrix microarray data 
showed that KIAA1324 expression was found to be significantly down-regulated 
following AP-2γ silencing in MCF-7 cells (Williams et al., 2009).  My western blot 
and qPCR analyses of various breast cell lines revealed that KIAA1324 expression is 
detected solely in ERα-positive breast cell lines, suggesting that KIAA1324 could 
be involved in the ERα-mediated signalling pathway.  As described in the 
introduction section 1.17.2, oestrogen plays an important role in breast 
tumourigensis, this therefore raised the question whether KIAA1324 has any 
implication in breast cancer progression via the oestrogen-ERα pathway?   
 
To this end, I examined if KIAA1324 expression was regulated by oestrogen in 
breast epithelial cells.  After treating MCF-7 cells with β-estradiol or faslodex 
(oestrogen antagonist) for 96 hours, no significant changes in KIAA1324 expression 
at the mRNA or protein levels were observed.  This data suggested that KIAA1324 
may not be regulated by oestrogen, at least not in MCF-7 cells.  Moreover, a close 
homolog of KIAA1324 called KIAA1324-like (KIAA1324L) is also evolutionarily 
conserved and its function is still unknown.  A study examined the function of the 
putative ortholog of KIAA1324-like in Xenopus Laevis (xKIAA1324L), which 
shares 71.9% sequence identity with human KIAA1324L at the protein level (Araki 
et al., 2007).  Expression of xKIAA1324L was down-regulated by Ras in ectodermal 
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explants and had a specific expression pattern during Xenopus development.  This 
suggests that KIAA1324 expression may potentially be regulated by other 
molecules.   
 
The results obtained from the functional assays suggested that KIAA1324 is unlikely 
to be an important factor in regulating ERα-positive MCF-7 cells, despite the high 
level of KIAA1324 expressed in these cells, as silencing KIAA1324 had no affect on 
cell proliferation.  However, when over-expressing KIAA1324 in non-expressing 
MCF10A, a reduction in cell growth was observed over a period of time.  The 
mechanism of growth perturbation was not clear, since only three KIAA1324 
positive clones survived selection.  The level of KIAA1324 expression in all these 
clones was significantly lower than endogenous KIAA1324 expression levels in 
MCF-7 cells.  This suggests that MCF10A cells are unable to support KIAA1324 
expression and therefore only clones modestly expressing KIAA1324 were able to 
grow.  As shown in the cell count and MTS studies, the growth rate of these clones 
remained very low throughout five days suggesting these clones might be 
undergoing cell senescence (G0) or dying.  Eventually these clones failed to attach 
to the plates after trypsinisation and I was no longer able to maintain them in tissue 
culture after a period of time, therefore, it was not possible to perform further 
experiments.  Using a tet-inducible system to express KIAA1324 in MCF10A might 
be a good approach to assess if KIAA1324 expression causes cell senescence or cell 
death.  It would appear that cell lines such as MCF-7 that over-express KIAA1324 
must have activated anti-apoptosis or anti-senescence pathways to combat the effect 
of KIAA1324 seen in the non-tumourigenic MCF10A cells.  
 
In addition, it has been reported that KIAA1324 expression is differentially 
expressed in metastatic, non-metastatic, benign tumour and normal cell lines (Bauer 
et al., 2004).  KIAA1324 was only highly expressed in metastatic cell lines which 
included MCF-7 and NCI-H82 lung tumour cell line.  However, we have to take into 
consideration that MCF-7 cells, although derived from a metastatic breast tumour, 
are not considered to be highly metastatic as suggested by Bauer et al.  It is therefore 
still questionable whether KIAA1324 expression is related to metastasis.  These 
authors also identified two splice variants in other normal epithelial cells and non-
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metastatic carcinoma cell lines, suggesting there might be alternative functions of 
KIAA1324 dependent on the splice forms.  Generation of constructs that carry 
cDNA encoding different splice variants and expressing them in MCF10A cells may 
enable us to find out if these splice variants have different functions.  Also, 
KIAA1324 expression was found in lung tumour cells, which suggested that 
KIAA1324 expression may not be restricted to oestrogenic tissues and the regulation 
of its expression may involve other pathways. 
 
As KIAA1324 has been suggested to be associated with more aggressive forms of 
endometrial cancer (Deng et al., 2005), its expression may promote a more 
transformed phenotype allowing cells to become less contact-inhibited, and exhibit 
anchorage-independent growth and proliferate in the absence of exogenous growth 
factors.  Thus I performed soft agar assays to examine my KIAA1324-expressing 
MCF10A and KIAA1324-silenced MCF-7 clones for anchorage-independent 
growth.  Expressing KIAA1324 in MCF10A cells did not promote anchorage 
independent growth.  However, since KIAA1324 expression levels were not as high 
as the endogenous level in MCF-7 cells, and these clones had low proliferation rates, 
as discussed above, this could explain why there was no colony formation for these 
cells.  KIAA1324 silencing, however, seemed to reduced the malignant potential of 
MCF-7 cells as a slight reduction in colony formation was observed in the soft agar 
assays.  Reduction in colony formation was also seen for AP-2γ silenced cells 
compared to its non-induced counterpart, probably caused by the cell growth arrest 
due to AP-2γ silencing.  Soft agar assays will need to be repeated on these 
KIAA1324-silenced MCF-7 cells as the number of clones for #A, #B and #C were 
all higher than the vector control, with or without doxycycline treatment.  This might 
have been caused by inaccuracy during cell counting.   
 
In summary, KIAA1324 does not seem to be an important factor for cell 
proliferation in MCF-7 cells as no significant changes in cell growth were observed 
despite KIAA1324 silencing.  However, silencing KIAA1324 expression in MCF-7 
cells reduced their tendency to grow in an anchorage-independent manner.  Future 
experiments could focus on the processes of migration and invasion by performing 
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transwell and wound healing assays on induced and un-induced cells in order to test 
further a functional role for KIAA1324 in breast cancer cells. 
 
6.6. Gene expression profiling of AP-2α in MCF10A cells 
The majority of de-regulated genes following AP-2γ silencing in MCF-7 cells were 
shown to be involved in cell cycle regulation (Williams et al., 2009).  As MCF-7 
cells express barely detectable AP-2α levels, it was not possible to assess the AP-2α 
dependent expression profile in this system. One of my initial aims therefore was to 
examine to what extent AP-2α and AP-2γ expression profiles overlap in a breast 
cancer line that expresses both factors.  Expression microarrays were planned for 
T47D cells following AP-2α and AP-2γ silencing, both are expressed at a similar 
level in this cell line.  However, as shown in Chapter 3 Figure 58, the effects of AP-
2 depletion on cell growth in T47D cells were not significant throughout 120 hours 
and only became significant when cells were synchronised.  Thus, we suspected that 
AP-2 factors may play a relatively minimal role in this cell line and I therefore 
optimised AP-2 silencing in two further lines expressing both AP-2 factors, H3396 
and MCF10A.  MCF10A cells, which predominately express AP-2α with low but 
significant levels of AP-2γ, also showed significant growth changes when AP-2 
factors were silenced and therefore, this line was selected for assessment of the AP-2 
dependent gene expression profile.  
 
6.6.1. A Role for AP-2α in the control of cell adhesion and 
migration in MCF10A cells? 
Affymetrix HG-U133 Pus 2 expression microarrays were used to assess the gene 
expression profile of control and AP-2 silenced MCF10A.  Due to the similarity in 
cell cycle changes after AP-2γ silencing in MCF-7 and AP-2γ or AP-2 double 
silencing in MCF10A cells, initially it was expected that the gene expression profiles 
of AP-2γ and AP-2 double silenced cells would be similar, whereas the AP-2α 
profile would be somewhat different since fewer changes in the cell cycle were 
observed following AP-2α single silencing.  However, since p21cip expression was 
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not induced in AP-2 silenced MCF10A cells as we observed in the MCF-7 study, 
some differences in gene expression profile were expected.  
 
Unexpectedly, no AP-2γ dependent gene expression profile was generated despite a 
significant reduction in cell proliferation in AP-2γ single and AP-2 double silenced 
cells (see Figure 62).  It is unclear why the microarray analysis failed to detect any 
changes in gene expression following AP-2γ silencing.  It could be that, although the 
AP-2γ expression level is very low in MCF10A cells, it might still regulate the 
expression of a number of cell cycle related genes., however, loss of AP-2γ in these 
cells may only cause subtle changes in transcript levels that have significant 
biological impact but failed to reach significance in our analysis of the microarray 
data.    
 
In contrast, silencing AP-2α resulted in significant variation of 61 up-regulated and 
61 down-regulated genes.  Silencing both AP-2α and AP-2γ resulted in the 
regulation of more than twice as many genes, 223 up-regulated and 119 down-
regulated genes.  There are a number of genes that were significantly de-regulated in 
AP-2α silenced cells but not in AP-2 double silenced cells and vice versa (see 
appendix).  This suggests that AP-2α and AP-2γ have both redundant and 
antagonistic roles, meaning that in some functions these isoforms can compensate 
for the loss of each other, but they cannot in other functions.  This also indicates that 
there might be a number of genes that were de-regulated following AP-2γ 
knockdown but the presence of AP-2α expression compensated for the loss. 
Moreover, residual AP-2α and AP-2γ expression may also compensate for AP-2α 
silencing at some loci leading to an under estimate of the number of regulated genes. 
 
In order to identify relevant mechanisms, functions and pathways regulated by AP-2 
silencing, the Affymetrix dataset was analysed using IPA.  Although IPA is the most 
widely used pathway analysis tool currently, some genes that might have a 
biological impact may not have appeared in the analysis due to the limitations of 
IPA.  For example, molecules may not be included because they have not been 
entered in the IPKB due to insufficient findings in the literature, and if the 
gene/protein ID corresponds to several loci or more than one gene, such identifiers 
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will not be mapped in the application due to ambiguity of the identity.  In contrast to 
the AP-2γ dependent gene expression profile from the MCF-7 study, only a few cell 
cycle regulated genes were found to be de-regulated in the MCF-10A AP-2α 
dependent gene expression profile, and ‘cell cycle’ function was ranked lower in the 
IPA analysis.  Remarkably, AP-2α and AP-2 double silencing resulted in de-
regulation of a significant number of cancer-related genes, and the majority of these 
are categorised as being involved in cellular movement and cell adhesion.  Among 
these genes, several integrins, adhesion molecules and ECM components as well as 
adhesion/motility signalling molecules were de-regulated following AP-2α or AP-2 
double silencing.  This analysis is in accord with the morphological changes 
observed in AP-2 silenced cells which became rounder and apparently less adherent 
compared to the controls.  Thus, given the elevated number of genes involved in 
adhesion and cellular movement regulated by AP-2α silencing, it gives us a new 
insight that AP-2α may play a role in controlling cell migration, adhesion and 
invasion, rather than as a negative regulator of cell proliferation as suggested by 
previous studies.   
 
The microarray analysis of AP-2α-regulated genes showed that some of the cell 
adhesion-associated genes were up-regulated, whereas some were down-regulated.  
Other genes that have been shown to be involved in metastasis, cell migration and 
invasion were also among the most differentially expressed following AP-2α and 
AP-2 double silencing.  It is known that normal cells require adhesion in order to 
grow and maintain survival in culture: anchorage independence for growth and 
survival is considered a key feature of transformed cells.  Tumour cells are generally 
less adhesive than normal cells and deposit less ECM than normal counterparts.  
Loosened matrix adhesion of tumour cells enables them to migrate from their 
primary site and invade through the surrounding tissues during metastasis.  The 
expression pattern of adhesive molecules is therefore different between normal and 
malignant tissues.  However, a tight balance between the gain and loss of adhesive 
molecule expression in cancer cells must take place as migration can be inhibited if 
cells are too adherent, and cells could die if they totally lose contact or interaction 
with adjacent cells.  Cells must form contacts either to other cells or the ECM to 
allow them to move forward, thus cells must dynamically assemble and disassemble 
 277
their adhesive contacts (Ulrich and Heisenberg, 2009).  The morphological changes 
in AP-2 silenced cells suggested that they may be less adherent.  Since MCF10A 
cells are immortalised normal mammary epithelial cells, the changes in cell 
morphology led us to hypothesise that AP-2 silenced MCF10A cells might resemble 
a more malignant phenotype which would be consistent with the tumour suppressor-
like role proposed for AP-2α.  This could be the reason why some cell adhesion-
related genes were up-regulated and some were down-regulated as shown in the 
microarray analysis.  For example, integrin β8 was found to be up-regulated, 
whereas, integrin β6 and α2 were down-regulated. We have chosen to study 
intergrins for future validation because these proteins are critical for cell adhesion, 
migration and cancer metastasis (Ramsay et al., 2007).  Other molecules have been 
selected for validation not only because they have been shown to play a role in cell 
adhesion, invasion, migration, or metastasis but also because they have been shown 
to be involved in breast cancer progression (see Chapter 4 section 4.9).  In this 
regard it may be informative also to validate expression of these genes (with and 
without AP-2 silencing) in derivatives of the parental MCF10A cell line that have 
been selected with characteristics of premalignancy (MCF-10AT cell lines), 
carcinoma in situ (MCF-10DCIS.com), and invasive carcinoma (MCF-10CA cell 
lines), providing an isogenic model of tumour progression (Santner et al., 2001).   
 
 
A previous study investigated the cell motility, adhesiveness and invasiveness in 
AP-2α and AP-2γ silenced MDA-MB-435 cells and found reduced migration in 
silenced cells compared to the controls (Orso et al., 2008).  Adhesion and invasion 
assays showed that the adhesiveness of AP-2α and AP-2γ silenced cells increased, 
whereas their invasiveness was reduced.  These authors suggested that reduced cell 
migration was due to a reduction in secreted factors that are involved in cell 
migration in AP-2α silenced cells compared to the control cells.  However, in my 
MCF10A study, secreted proteins which have been shown to promote cell adhesion, 
migration and invasion were up-regulated (POSTN and LCN2), and also down-
regulated (SPARC).  Orso et al proposed that expression of both AP-2 factors is 
required for cell migration and invasion but not for cell adhesion.  Also, it is worth 
noting that the MDA-MB-435 cell line used in their study, although originally 
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thought to be derived from breast, has now been shown to be of melanoma origin.  
Their findings seemed to disagree with previous studies on AP-2 factors in 
melanoma, where AP-2α expression has been suggested to be a negative regulator of 
metastasis.  Several cell adhesion-related genes such as MCAM/MUC18, c-KIT and 
E-cadherin whose expression is altered during melanoma progression were found to 
be regulated by AP-2α (Bar-Eli, 2001; Nyormoi and Bar-Eli, 2003; Suyama et al., 
2002).  Over-expression of AP-2α in highly metastatic melanoma cells down-
regulated MCAM/MUC18 but up-regulated c-KIT and inhibited tumour growth and 
metastasis.  Overall, given the complex relationships between genes involved in cell 
adhesion and motility, it is not clear at this stage whether AP-2 silencing in 
MCF10A cells promotes or inhibits cell adhesion, migration and invasion and 
functional assays as described below, need to be performed.   
 
Orso et al also performed microarray analysis to identify AP-2α-regulated genes in 
HeLa cells (cervix adenocarinoma) transiently transfected with AP-2α-targeted 
siRNA or NSC (Orso et al., 2008).  A number of genes involved in cell adhesion and 
motility identified in this report, also agree with the microarray results from my 
MCF10A study.  For example, intergrin β-like 1 (ITGBL1) was down-regulated and 
chemokine ligand 1 and 2 (CXCL1 and CXCL2) were up-regulated.  Both CXCL1 
and CXCL2 were up-regulated in AP-2 double silenced cells in my study (see 
Appendix).  EREG was also found to be up-regulated in both studies, and a number 
of reports have shown that EREG is able to regulate cell proliferation, 
differentiation, adhesion and migration in epithelial cells (see Chapter 4 
section 4.9.5).  Thus, EREG expression might be important in tumour progression.  
Another gene potentially involved in migration that was highly modulated in the 
Orso study but not in mine is endothelial and smooth muscle cell-derived 
neurophilin-like protein (ESDN).  Interestingly, ChIP assays showed AP-2α binding 
to the promoters of ESDN but not to EREG or CXCL2 (Orso et al., 2008).  
Therefore, I cannot rule out that AP-2 could be indirectly regulating some of the 
genes identified in my study.  Surprisingly, Orso et al found that cell migration 
increased after silencing CXCL2, EREG and ESD suggesting these genes act to 
inhibit cell migration at least in HeLa cells.  This disagrees with studies in highly 
aggressive breast cancers, where their expression has been shown to be up-regulated 
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suggesting that they might promote invasion (Eltarhouny et al., 2008; Minn et al., 
2005).  Indeed, EREG and SPARC are among the genes identified in the Minn study 
as a signature of lung metastasis.  When the expression of EREG and SPARC was 
examined in breast tumour samples levels were higher in patients who had 
developed lung metastases, indicating that EREG and SPARC are positively 
correlated with lung metastasis.  Potentially, de-regulation of these genes might 
signal the onset of breast cancer metastasis to the lungs.   
 
Another interesting feature is that several of the genes regulated by AP-2 in 
MCF10A cells have also been suggested to be associated with epithelial-
mesenchymal transition (EMT), including SPARC, FN1, LOX, EREG, POSTN and 
LCN2 (Hayashida et al., 2010; Hollosi et al., 2009; Kaspar et al., 2006; Leng et al., 
2009a; Ruan et al., 2009; Sarrio et al., 2008).  This is the process whereby cells of 
epithelial origin are proposed to lose their epithelial characteristics and polarity and 
acquire a mesenchymal phenotype with increased migratory and invasive behaviour 
(Baum et al., 2008; Tomaskovic-Crook et al., 2009).  EMT is characterised by loss 
of cell-to-cell adhesion, down-regulation of epithelial cytokeratins, up-regulation of 
mesenchymal proteins (e.g. vimentin), reorganisation of the cytoskeleton and 
increased motility and invasiveness.  Several studies have proposed that EMT is a 
critical step in tumour metastasis (Huber et al., 2005; Thiery, 2002).  Gene 
expression profiling of breast cancer patients suggested that activation of EMT 
pathways is correlated with histological grade and associated with poorly 
differentiated tumours (Teschendorff et al., 2007).  A study showed a remarkable 
similarity in the gene expression profiles between premalignant, preinvasive and 
invasive stages of human breast cancer, implying that genes conferring invasion 
could be active in the preinvasive stages (Ma et al., 2003; Sarrio et al., 2008).  
However, the concept of EMT was challenged by another study in which the authors 
did not consider the expression of mesenchymal markers in preinvasive stage was 
due to EMT (Korsching et al., 2005).  Although SPARC is considered as one of the 
EMT markers and its expression has been correlated particularly with poor 
prognosis in breast cancer, there is a debate about the function of SPARC during 
tumourigenesis because of inconsistencies and contradictions in the published data 
(Fukunaga-Kalabis and Herlyn, 2007; Podhajcer et al., 2008).  Therefore, it would 
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be interesting to examine the function of SPARC in terms of breast cancer 
progression in more depth. 
 
An interesting report used MCF10A cells to examined the changes in morphology 
and molecular events when these cells were undergoing the process of EMT (Sarrio 
et al., 2008).  These authors used MCF10A cells because this cell line exhibits a 
basal-like phenotype but shares many features of mesenchymal cancer cell lines 
(Charafe-Jauffret et al., 2006).  When MCF10A cells were grown at low cell density 
they displayed ‘fibroblast-like’ spindle morphology but changed to an ‘epithelial-
like’ compact morphology when cells become confluent.  cDNA microarray analysis 
showed that mesenchymal-associated genes (i.e. genes that are involved in 
cytoskeleton organisation, cell motility, extracellular matrix remodelling and 
invasion) were up-regulated in cells grown under sparse conditions.  In contrast, the 
expression of genes involved in cell-to-cell adhesion, epithelial markers and several 
cytokeratins were up-regulated in confluent cells.  These authors proposed that 
MCF10A cells are intrinsically prone to undergo spontaneous EMT in response to 
low cell density.  The acquisition of the mesenchymal-like phenotype disposes the 
cells to become migratory and invasive.  Since the cell density of AP-2 silenced 
MCF10A cells was significantly lower than NSC (see Figure 60), it could be that 
AP-2 directly regulates certain cell adhesion-related genes as shown in the 
microarray analysis, but the low cell density may in turn enhance a more 
mesenchymal and motile phenotype.    
 
In summary, the microarray analysis indicated that AP-2 factors are involved in the 
regulation of cell adhesion, migration and invasion, rather than just controlling cell 
proliferation as suggested by previous studies including our MCF-7 and T47D 
studies.  Validation using qPCR is underway to identify which genes are consistently 
changed in expression following AP-2 silencing.  ChIP assays will be performed on 
validated genes in order to identify which genes are direct targets of AP-2α.  Further 
functional analyses will be done to investigate the functional consequences of AP-2 
silencing using lentivirus in MCF10A cell models.  For example, 3D growth in 
matrigel assay is a good approach to study the acquisition of an invasive phenotype.  
Since a morphological change was observed upon AP-2 silencing, I predict that the 
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morphology of acini structures formed in 3D will change towards a more invasive 
phenotype compared to the controls.  In parallel, 3D matrigel assays could be 
performed on MCF10AT, MCF10A.DCIA.COM and MCF10A.CA1a cells which 
have been transformed, because it is possible that the normal phenotype of MCF10A 
will suppress the potential pro-tumourigenic activities of AP-2α regulated genes.  
Moreover, matrigel coated transwell filters can be used to assess the 
invasiveness/migratory behaviour of AP-2 silenced cells.  This may help us establish 
whether and to what degree AP-2α regulated genes are involved in migration and 
invasive activity of normal and transformed breast cells.     
 
6.7. Concluding Remarks 
Numerous studies as well as our previous MCF-7 study have suggested that both 
AP-2α and AP-2γ play significant but opposing roles in the regulation of cell 
proliferation.  The functional assays presented within this thesis showed that AP-2α 
and AP-2γ seemed to play similar roles in cell cycle regulation in T47D cells by 
mediating repression of both CDKN1A and CCND3 transcription.  Whether AP-2 
factors induce or repress p21cip may depend on which AP-2 isoform is more 
predominantly expressed in a particular cell line.  However, I have also shown that 
both AP-2 isoforms may not be as significant in terms of cell growth regulation in 
another cell line, H3396. 
 
Also in this study I used gene expression microarray to identify AP-2α and AP-2γ 
regulated genes in MCF10A cells.  A large proportion of cell adhesion, migration 
and invasion related genes were de-regulated in response to AP-2 silencing, 
implying that loss of AP-2 expression in breast epithelial cells may contribute to 
transformation to a more malignant form.  Further investigation is underway to 
understand the functional relevance of these AP-2α dependent regulated targets and 
how AP-2α contributes to the regulation of these genes. 
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7. Appendix 1 
Appendix 1 displays the 122 probe sets that changed their expression significantly (FDR corrected, p value <0.01) between the NSC and AP-2α 
silenced groups.  The table displays the Affymetrix Probe Set ID, Gene Symbol, Gene Name, Long Fold Change and the associated statistical 
significance. 
 
Probe Set ID Gene Symbol Gene Name Log Fold Change p value 
209719_x_at SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 3.280809463 2.30E-05 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 3.112506747 5.71E-07 
209720_s_at SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 3.069590912 5.39E-07 
211906_s_at SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 3.018521523 7.05E-07 
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 2.963419801 2.63E-08 
214199_at SFTPD surfactant protein D 2.848158739 7.13E-08 
203434_s_at MME membrane metallo-endopeptidase 2.704853909 1.72E-05 
219934_s_at SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 2.624412746 1.04E-05 
206026_s_at TNFAIP6 tumor necrosis factor, alpha-induced protein 6 2.42832602 1.26E-06 
222940_at SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 2.384312519 2.32E-06 
209396_s_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 2.342738692 8.15E-05 
220330_s_at SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 2.263285688 4.93E-06 
206025_s_at TNFAIP6 tumor necrosis factor, alpha-induced protein 6 2.222387901 1.09E-07 
207850_at CXCL3 chemokine (C-X-C motif) ligand 3 2.188017014 9.89E-06 
213765_at MFAP5 microfibrillar associated protein 5 2.088508239 9.13E-05 
218990_s_at SPRR3 small proline-rich protein 3 2.04002418 0.00011754 
219869_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 1.976446825 2.53E-07 
205083_at AOX1 aldehyde oxidase 1 1.963447238 1.51E-06 
207014_at GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 1.947635751 1.02E-05 
205082_s_at AOX1 aldehyde oxidase 1 1.824593335 1.03E-06 
218736_s_at PALMD palmdelphin 1.782824898 2.40E-06 
205627_at CDA cytidine deaminase 1.743783902 1.27E-05 
217504_at ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 1.724708645 6.34E-06 
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205767_at EREG epiregulin 1.714211997 0.080201042 
210119_at KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 1.644039842 2.71E-05 
232689_at LOC284561 hypothetical protein LOC284561 1.621109664 6.31E-05 
222853_at FLRT3 fibronectin leucine rich transmembrane protein 3 1.612497352 2.82E-05 
202478_at TRIB2 tribbles homolog 2 (Drosophila) 1.61149354 1.89E-05 
225056_at SIPA1L2 signal-induced proliferation-associated 1 like 2 1.60394396 2.28E-06 
203851_at IGFBP6 insulin-like growth factor binding protein 6 1.572360462 5.14E-06 
202479_s_at TRIB2 tribbles homolog 2 (Drosophila) 1.572142714 2.34E-05 
219250_s_at FLRT3 fibronectin leucine rich transmembrane protein 3 1.544734721 1.33E-05 
243296_at NAMPT nicotinamide phosphoribosyltransferase 1.51730464 7.52E-06 
1555167_s_at NAMPT nicotinamide phosphoribosyltransferase 1.491667117 0.000142707 
242871_at PAQR5 progestin and adipoQ receptor family member V 1.455557406 0.001173431 
1555950_a_at CD55 
CD55 molecule, decay accelerating factor for complement (Cromer blood 
group) 1.451873315 8.00E-06 
201926_s_at CD55 
CD55 molecule, decay accelerating factor for complement (Cromer blood 
group) 1.405400777 0.000111085 
209267_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 1.386812191 1.49E-05 
233737_s_at LOC284561 hypothetical protein LOC284561 1.377378878 5.25E-05 
221447_s_at GLT8D2 glycosyltransferase 8 domain containing 2 1.3581304 5.87E-05 
214321_at NOV nephroblastoma overexpressed gene 1.346632465 8.27E-05 
1555292_at FAM40B family with sequence similarity 40, member B 1.294667424 3.50E-05 
228256_s_at EPB41L4A erythrocyte membrane protein band 4.1 like 4A 1.291303034 0.000184301 
238017_at SDR16C5 short chain dehydrogenase/reductase family 16C, member 5 1.247020355 4.02E-05 
208502_s_at PITX1 paired-like homeodomain 1 1.216000784 4.75E-05 
209699_x_at AKR1C2 aldo-keto reductase family 1, member C2  1.18085128 0.000110808 
  
(dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type III)   
208962_s_at FADS1 fatty acid desaturase 1 1.174397088 7.99E-05 
204469_at PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 1.172718353 8.07E-05 
209587_at PITX1 paired-like homeodomain 1 1.166129363 8.31E-05 
208964_s_at FADS1 fatty acid desaturase 1 1.127788137 0.000931282 
201925_s_at CD55 
CD55 molecule, decay accelerating factor for complement (Cromer blood 
group) 1.105667416 1.41E-05 
210609_s_at TP53I3 tumor protein p53 inducible protein 3 1.079739166 0.000125156 
212973_at RPIA ribose 5-phosphate isomerase A -1.125144778 0.000126339 
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229163_at CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -1.167089567 2.07E-05 
204068_at STK3 serine/threonine kinase 3 (STE20 homolog, yeast) -1.180987186 0.000105565 
202741_at PRKACB protein kinase, cAMP-dependent, catalytic, beta -1.18224626 7.29E-05 
209705_at MTF2 metal response element binding transcription factor 2 -1.195925022 9.45E-05 
221727_at SUB1 SUB1 homolog (S. cerevisiae) -1.202661623 0.000100659 
204011_at SPRY2 sprouty homolog 2 (Drosophila) -1.20545779 6.72E-05 
226261_at ZNRF2 zinc and ring finger 2 -1.211766385 5.23E-05 
215058_at DENND5B DENN/MADD domain containing 5B -1.232635879 0.000129512 
203429_s_at C1orf9 chromosome 1 open reading frame 9 -1.238362121 0.000116063 
219181_at LIPG lipase, endothelial -1.240972207 0.000115807 
218943_s_at DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 -1.243298441 0.000130957 
228933_at NHS Nance-Horan syndrome (congenital cataracts and dental anomalies) -1.281173417 0.000115499 
222557_at STMN3 stathmin-like 3 -1.284451542 2.66E-05 
218309_at CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -1.295461076 9.60E-06 
209441_at RHOBTB2 Rho-related BTB domain containing 2 -1.296764301 3.51E-05 
210869_s_at MCAM melanoma cell adhesion molecule -1.31444023 1.92E-05 
202936_s_at SOX9 SRY (sex determining region Y)-box 9 -1.321541674 0.000142716 
231928_at HES2 hairy and enhancer of split 2 (Drosophila) -1.357936929 0.018727988 
223622_s_at HYI hydroxypyruvate isomerase homolog (E. coli) -1.378068813 0.008012267 
203961_at NEBL nebulette -1.379114256 3.33E-05 
1556499_s_at COL1A1 collagen, type I, alpha 1 -1.406932967 2.46E-05 
229842_at ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) -1.412446804 0.000139675 
206125_s_at KLK8 kallikrein-related peptidase 8 -1.426617704 0.00012719 
219127_at ATAD4 ATPase family, AAA domain containing 4 -1.446165578 3.58E-05 
241541_at MIB2 mindbomb homolog 2 (Drosophila) -1.475289319 3.96E-05 
226535_at ITGB6 integrin, beta 6 -1.492560734 5.54E-06 
201288_at ARHGDIB Rho GDP dissociation inhibitor (GDI) beta -1.523338463 0.000936449 
220346_at MTHFD2L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like -1.537156544 1.03E-05 
228302_x_at CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -1.576441461 7.66E-05 
229616_s_at GRAMD2 GRAM domain containing 2 -1.611964359 2.37E-05 
205180_s_at ADAM8 ADAM metallopeptidase domain 8 -1.631014405 3.28E-05 
204653_at TFAP2A 
transcription factor AP-2 alpha (activating enhancer binding protein 2 
alpha) -1.652095312 3.44E-06 
211668_s_at PLAU plasminogen activator, urokinase -1.759547384 9.32E-06 
215189_at KRT86 keratin 86 -1.767668388 1.54E-05 
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220979_s_at ST6GALNAC5 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5 -1.772928175 2.96E-05 
209772_s_at CD24 CD24 molecule -1.804668898 7.91E-06 
208650_s_at CD24 CD24 molecule -1.825391015 8.19E-06 
205479_s_at PLAU plasminogen activator, urokinase -1.854562158 3.42E-06 
230430_at ENTPD2 ectonucleoside triphosphate diphosphohydrolase 2 -1.887784052 5.65E-06 
227480_at SUSD2 sushi domain containing 2 -1.898122283 0.000114121 
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B -1.93362828 1.28E-05 
209771_x_at CD24 CD24 molecule -1.977401924 3.90E-06 
208651_x_at CD24 CD24 molecule -1.980906582 5.17E-05 
1552797_s_at PROM2 prominin 2 -1.98148095 2.82E-07 
223551_at PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta -2.001708166 1.18E-06 
216379_x_at CD24 CD24 molecule -2.029600265 4.04E-06 
209925_at OCLN occludin -2.040203953 1.69E-06 
39248_at AQP3 aquaporin 3 (Gill blood group) -2.09272301 0.002575194 
204584_at L1CAM L1 cell adhesion molecule -2.252874235 3.53E-07 
266_s_at CD24 CD24 molecule -2.264215314 1.16E-06 
235074_at SPRED1 sprouty-related, EVH1 domain containing 1 -2.283050736 3.90E-07 
226837_at SPRED1 sprouty-related, EVH1 domain containing 1 -2.28318882 3.04E-07 
229385_s_at PLAC2 placenta-specific 2 (non-protein coding) -2.617072656 2.41E-06 
209956_s_at CAMK2B calcium/calmodulin-dependent protein kinase II beta -3.282592827 7.72E-06 
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8. Appendix 2 
Appendix 2 displays the 342 probe sets that changed their expression significantly (FDR corrected, p value <0.01) between the NSC and AP-
2α/γ double silenced groups.  The table displays the Affymetrix Probe Set ID, Gene Symbol, Gene Name, Long Fold Change and the associated 
statistical significance. 
 
Probe Set ID Gene Symbol Gene Name Log Fold Change p value 
220330_s_at SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 5.721938954 8.05E-11 
209395_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 5.333669253 5.71E-07 
209396_s_at CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 4.69255353 9.09E-10 
211906_s_at SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 4.647481734 4.28E-09 
206026_s_at TNFAIP6 tumor necrosis factor, alpha-induced protein 6 4.225577066 1.25E-10 
218723_s_at C13orf15 chromosome 13 open reading frame 15 4.069507823 5.72E-07 
209719_x_at SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 3.781335106 5.25E-06 
1555638_a_at SAMSN1 SAM domain, SH3 domain and nuclear localization signals 1 3.77766272 7.02E-09 
209720_s_at SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 3.755282562 5.16E-08 
203434_s_at MME membrane metallo-endopeptidase 3.666288243 6.40E-07 
206025_s_at TNFAIP6 tumor necrosis factor, alpha-induced protein 6 3.652095926 3.64E-09 
210095_s_at IGFBP3 insulin-like growth factor binding protein 3 3.54348163 3.00E-09 
209829_at FAM65B family with sequence similarity 65, member B 3.518150868 3.97E-06 
219737_s_at PCDH9 protocadherin 9 3.430199617 7.96E-09 
229778_at C12orf39 chromosome 12 open reading frame 39 3.376292 3.76E-06 
210809_s_at POSTN periostin, osteoblast specific factor 3.367849641 1.14E-05 
204818_at HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 3.290395317 9.65E-07 
219934_s_at SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 3.227323698 2.25E-07 
217504_at ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 3.181024477 6.34E-06 
225516_at SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 3.134429412 3.34E-07 
222940_at SULT1E1 sulfotransferase family 1E, estrogen-preferring, member 1 3.113479637 5.62E-07 
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214199_at SFTPD surfactant protein D 3.088092058 2.72E-08 
225056_at SIPA1L2 signal-induced proliferation-associated 1 like 2 3.067748901 1.08E-09 
202376_at SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 3.058864871 2.87E-06 
243296_at NAMPT nicotinamide phosphoribosyltransferase 3.027864169 1.21E-08 
205083_at AOX1 aldehyde oxidase 1 3.000011419 5.06E-08 
1553102_a_at CCDC69 coiled-coil domain containing 69 2.95901615 2.24E-07 
212886_at CCDC69 coiled-coil domain containing 69 2.849552177 2.02E-07 
207432_at BEST2 bestrophin 2 2.83316876 7.46E-06 
206157_at PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 2.773369161 9.29E-07 
203435_s_at MME membrane metallo-endopeptidase 2.767557152 3.42E-06 
206002_at GPR64 G protein-coupled receptor 64 2.754408177 4.44E-07 
210397_at DEFB1 defensin, beta 1 2.687322815 1.73E-06 
212531_at LCN2 lipocalin 2 2.68291985 4.82E-05 
227646_at EBF1 early B-cell factor 1 2.677990558 2.38E-05 
219869_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 2.646473201 7.87E-09 
205207_at IL6 interleukin 6 (interferon, beta 2) 2.625991409 1.26E-07 
216504_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 2.624419037 1.50E-06 
1555167_s_at NAMPT nicotinamide phosphoribosyltransferase 2.618067836 2.38E-08 
233587_s_at SIPA1L2 signal-induced proliferation-associated 1 like 2 2.580574083 1.23E-08 
220014_at PRR16 proline rich 16 2.565279303 1.75E-06 
217738_at NAMPT nicotinamide phosphoribosyltransferase 2.472946108 7.68E-09 
217739_s_at NAMPT nicotinamide phosphoribosyltransferase 2.463830062 4.71E-08 
205082_s_at AOX1 aldehyde oxidase 1 2.450721328 7.13E-09 
207014_at GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 2.38782297 1.12E-06 
201328_at ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 2.379413179 6.36E-07 
204389_at MAOA monoamine oxidase A 2.317761723 0.000101 
206100_at CPM carboxypeptidase M 2.304520164 9.43E-07 
215223_s_at SOD2 superoxide dismutase 2, mitochondrial 2.284958215 1.77E-07 
228570_at BTBD11 BTB (POZ) domain containing 11 2.279502727 1.07E-06 
231880_at FAM40B family with sequence similarity 40, member B 2.248328472 3.70E-05 
222853_at FLRT3 fibronectin leucine rich transmembrane protein 3 2.239157168 3.66E-07 
203921_at CHST2 carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 2.22057145 7.09E-08 
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214587_at COL8A1 collagen, type VIII, alpha 1 2.203324398 3.40E-07 
204388_s_at MAOA monoamine oxidase A 2.19231523 0.000118 
221011_s_at LBH limb bud and heart development homolog (mouse) 2.173167206 5.05E-05 
206707_x_at FAM65B family with sequence similarity 65, member B 2.16865554 2.43E-06 
219250_s_at FLRT3 fibronectin leucine rich transmembrane protein 3 2.167227355 7.54E-07 
219630_at PDZK1IP1 PDZK1 interacting protein 1 2.160791363 1.67E-06 
207850_at CXCL3 chemokine (C-X-C motif) ligand 3 2.128233832 1.32E-05 
238029_s_at SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid transporter 14) 2.119127901 9.23E-07 
238778_at MPP7 membrane protein, palmitoylated 7 (MAGUK p55 subfamily member 7) 2.116268255 2.96E-06 
203608_at ALDH5A1 aldehyde dehydrogenase 5 family, member A1 2.109189683 2.80E-05 
1553589_a_at PDZK1IP1 PDZK1 interacting protein 1 2.095751473 1.04E-06 
204439_at IFI44L interferon-induced protein 44-like 2.074080855 0.000107 
209267_s_at SLC39A8 solute carrier family 39 (zinc transporter), member 8 2.064710623 1.87E-07 
211719_x_at FN1 fibronectin 1 2.062665075 6.53E-06 
205816_at ITGB8 integrin, beta 8 2.037755528 8.02E-06 
1555292_at FAM40B family with sequence similarity 40, member B 2.037360801 2.61E-07 
204105_s_at NRCAM neuronal cell adhesion molecule 2.032172088 4.79E-06 
227697_at SOCS3 suppressor of cytokine signaling 3 2.018651166 2.28E-05 
238017_at SDR16C5 short chain dehydrogenase/reductase family 16C, member 5 1.989948119 2.62E-07 
213948_x_at CADM3 cell adhesion molecule 3 1.952574964 8.72E-05 
221067_s_at C12orf39 chromosome 12 open reading frame 39 1.949319924 3.76E-05 
201739_at SGK1 serum/glucocorticoid regulated kinase 1 1.940759602 4.11E-06 
216442_x_at FN1 fibronectin 1 1.932095873 1.35E-06 
202478_at TRIB2 tribbles homolog 2 (Drosophila) 1.931539046 2.79E-06 
210662_at KYNU kynureninase (L-kynurenine hydrolase) 1.91140672 8.75E-07 
228325_at KIAA0146 KIAA0146 1.909598245 3.86E-06 
210495_x_at FN1 fibronectin 1 1.893155202 3.10E-06 
207096_at SAA4 serum amyloid A4, constitutive 1.877168239 2.53E-06 
223402_at DUSP23 dual specificity phosphatase 23 1.874772323 1.69E-06 
204298_s_at LOX lysyl oxidase 1.87385736 9.53E-06 
223464_at OSBPL5 oxysterol binding protein-like 5 1.867876522 5.76E-06 
203037_s_at MTSS1 metastasis suppressor 1 1.857387412 2.35E-06 
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212464_s_at FN1 fibronectin 1 1.854414344 1.10E-06 
228640_at PCDH7 protocadherin 7 1.850424163 4.34E-05 
227719_at SMAD9 SMAD family member 9 1.850056424 2.74E-06 
209699_x_at AKR1C2 aldo-keto reductase family 1, member C2  1.849969579 1.07E-06 
  
(dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid 
dehydrogenase, type III)   
219316_s_at FLVCR2 feline leukemia virus subgroup C cellular receptor family, member 2 1.845244516 2.37E-05 
204664_at ALPP alkaline phosphatase, placental (Regan isozyme) 1.842000658 2.30E-05 
210119_at KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 1.82920173 9.06E-06 
204604_at PFTK1 PFTAIRE protein kinase 1 1.823306965 1.03E-06 
204470_at CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 1.820738427 8.69E-06 
219795_at SLC6A14 solute carrier family 6 (amino acid transporter), member 14 1.805934343 2.22E-06 
238692_at BTBD11 BTB (POZ) domain containing 11 1.773425629 1.39E-06 
207023_x_at KRT10 keratin 10 1.751116139 4.07E-06 
201943_s_at CPD carboxypeptidase D 1.747691308 3.92E-05 
202436_s_at CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.745788872 1.71E-06 
202437_s_at CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.738759061 2.75E-06 
221122_at HRASLS2 HRAS-like suppressor 2 1.730062066 6.60E-06 
214453_s_at IFI44 interferon-induced protein 44 1.728511388 1.62E-06 
216594_x_at AKR1C1 aldo-keto reductase family 1, member C1  1.708504966 1.34E-05 
  (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)   
207569_at ROS1 c-ros oncogene 1 , receptor tyrosine kinase 1.703965556 9.76E-06 
229584_at LRRK2 leucine-rich repeat kinase 2 1.700610884 1.46E-05 
203708_at PDE4B phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila) 1.693180823 1.14E-05 
202766_s_at FBN1 fibrillin 1 1.692515119 2.67E-06 
211653_x_at AKR1C2 aldo-keto reductase family 1, member C2  1.680981092 3.24E-06 
  
(dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid 
dehydrogenase, type III)   
223618_at FMN2 formin 2 1.676498677 4.09E-05 
202435_s_at CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.674609193 7.63E-07 
202479_s_at TRIB2 tribbles homolog 2 (Drosophila) 1.673178751 1.24E-05 
221477_s_at SOD2 superoxide dismutase 2, mitochondrial 1.658587695 9.78E-06 
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205609_at ANGPT1 angiopoietin 1 1.65560857 0.000307 
203060_s_at PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 1.648177411 2.41E-05 
213287_s_at KRT10 keratin 10 1.644612505 1.02E-05 
205767_at EREG epiregulin 1.634973835 0.000123 
227530_at AKAP12 A kinase (PRKA) anchor protein 12 1.629376968 0.000925 
203066_at CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 1.624033469 4.28E-08 
204457_s_at GAS1 growth arrest-specific 1 1.621802976 6.02E-05 
212143_s_at IGFBP3 insulin-like growth factor binding protein 3 1.61977955 1.57E-05 
210609_s_at TP53I3 tumor protein p53 inducible protein 3 1.61816137 2.03E-06 
212249_at PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 1.61475129 1.72E-05 
216841_s_at SOD2 superoxide dismutase 2, mitochondrial 1.612366437 2.23E-05 
213693_s_at MUC1 mucin 1, cell surface associated 1.608629706 7.97E-06 
219975_x_at OLAH oleoyl-ACP hydrolase 1.608288556 4.48E-06 
231929_at IKZF2 IKAROS family zinc finger 2 (Helios) 1.590502343 5.10E-06 
219115_s_at IL20RA interleukin 20 receptor, alpha 1.583162399 1.13E-05 
210633_x_at KRT10 keratin 10 1.563687278 5.05E-06 
232689_at LOC284561 hypothetical protein LOC284561 1.559495174 9.12E-05 
201942_s_at CPD carboxypeptidase D 1.559121016 2.62E-05 
218736_s_at PALMD palmdelphin 1.554778512 1.04E-05 
218983_at C1RL complement component 1, r subcomponent-like 1.547533874 2.24E-05 
204151_x_at AKR1C1 aldo-keto reductase family 1, member C1  1.534401336 2.37E-06 
  (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase)   
1555950_a_at CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1.531321411 8.00E-06 
206059_at ZNF91 zinc finger protein 91 1.52313937 6.42E-06 
224397_s_at TMTC1 transmembrane and tetratricopeptide repeat containing 1 1.520706318 1.95E-05 
218665_at FZD4 frizzled homolog 4 (Drosophila) 1.511681312 8.14E-05 
201329_s_at ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 1.51016853 1.22E-05 
204546_at KIAA0513 KIAA0513 1.508050243 1.80E-05 
227070_at GLT8D2 glycosyltransferase 8 domain containing 2 1.498776692 4.83E-05 
205627_at CDA cytidine deaminase 1.487062327 6.25E-05 
212239_at PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 1.480495962 0.00011 
242871_at PAQR5 progestin and adipoQ receptor family member V 1.479077724 3.32E-05 
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209676_at TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 1.472727151 9.80E-05 
222945_x_at OLAH oleoyl-ACP hydrolase 1.466537332 1.15E-05 
226189_at ITGB8 integrin, beta 8 1.457353127 8.64E-05 
218546_at C1orf115 chromosome 1 open reading frame 115 1.435109339 1.01E-05 
224463_s_at C11orf70 chromosome 11 open reading frame 70 1.433079786 1.77E-05 
231766_s_at COL12A1 collagen, type XII, alpha 1 1.424861127 3.55E-05 
212912_at RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 1.41824625 0.000109 
201926_s_at CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1.415929922 0.000111 
204748_at PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 1.392229886 7.81E-05 
228256_s_at EPB41L4A erythrocyte membrane protein band 4.1 like 4A 1.385929428 1.55E-05 
209512_at HSDL2 hydroxysteroid dehydrogenase like 2 1.364900281 5.34E-05 
202967_at GSTA4 glutathione S-transferase alpha 4 1.350298663 1.71E-05 
202724_s_at FOXO1 forkhead box O1 1.348899925 2.91E-05 
221447_s_at GLT8D2 glycosyltransferase 8 domain containing 2 1.34404278 6.49E-05 
215997_s_at CUL4B cullin 4B 1.338685788 2.14E-05 
209774_x_at CXCL2 chemokine (C-X-C motif) ligand 2 1.329241343 0.000117 
207601_at SULT1B1 sulfotransferase family, cytosolic, 1B, member 1 1.317583911 0.000116 
241436_at SCNN1G sodium channel, nonvoltage-gated 1, gamma 1.316928967 3.59E-05 
210664_s_at TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 1.313340815 8.06E-05 
226609_at DCBLD1 discoidin, CUB and LCCL domain containing 1 1.309903951 1.62E-05 
206197_at NME5 non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase) 1.309196883 4.04E-05 
242271_at SLC26A9 solute carrier family 26, member 9 1.307898513 5.96E-05 
202729_s_at LTBP1 latent transforming growth factor beta binding protein 1 1.305421836 4.96E-05 
212240_s_at PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 1.288245573 2.44E-05 
225355_at NEURL1B neuralized homolog 1B (Drosophila) 1.278391933 7.01E-05 
228653_at SAMD5 sterile alpha motif domain containing 5 1.272774328 7.48E-05 
226731_at PELO pelota homolog (Drosophila) 1.26998489 4.92E-05 
203665_at HMOX1 heme oxygenase (decycling) 1 1.260388423 5.85E-05 
243582_at SH3RF2 SH3 domain containing ring finger 2 1.239141273 6.75E-05 
1553768_a_at DCBLD1 discoidin, CUB and LCCL domain containing 1 1.235667098 7.93E-05 
217762_s_at RAB31 RAB31, member RAS oncogene family 1.233230366 4.75E-05 
218182_s_at CLDN1 claudin 1 1.231758168 6.00E-05 
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219756_s_at POF1B premature ovarian failure, 1B 1.22953458 6.11E-05 
220528_at VNN3 vanin 3 1.229150785 3.63E-05 
227240_at NGEF neuronal guanine nucleotide exchange factor 1.222243678 5.24E-05 
204797_s_at EML1 echinoderm microtubule associated protein like 1 1.215549245 6.53E-05 
219789_at NPR3 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C) 1.213266269 6.08E-05 
203851_at IGFBP6 insulin-like growth factor binding protein 6 1.212110238 7.20E-05 
209276_s_at GLRX glutaredoxin (thioltransferase) 1.211863432 6.97E-05 
1555471_a_at FMN2 formin 2 1.209458931 2.98E-06 
210166_at TLR5 toll-like receptor 5 1.205394483 0.000121 
241396_at NEDD4L neural precursor cell expressed, developmentally down-regulated 4-like 1.204508274 6.11E-05 
219093_at PID1 phosphotyrosine interaction domain containing 1 1.198533513 0.000129 
222662_at PPP1R3B protein phosphatase 1, regulatory (inhibitor) subunit 3B 1.19305121 6.92E-05 
212311_at KIAA0746 KIAA0746 protein 1.188319779 0.000103 
238121_at GK5 glycerol kinase 5 (putative) 1.182819972 5.70E-05 
219049_at CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 1.166177163 8.23E-05 
223540_at PVRL4 poliovirus receptor-related 4 1.164013468 0.000118 
208510_s_at PPARG peroxisome proliferator-activated receptor gamma 1.163908367 9.37E-05 
226973_at VSTM2L V-set and transmembrane domain containing 2 like 1.149229935 0.000126 
202859_x_at IL8 interleukin 8 1.147923797 0.000113 
222829_s_at IL20RA interleukin 20 receptor, alpha 1.142572983 0.000109 
207469_s_at PIR pirin (iron-binding nuclear protein) 1.140135997 6.93E-05 
202388_at RGS2 regulator of G-protein signaling 2, 24kDa 1.13835295 9.56E-05 
213076_at ITPKC inositol 1,4,5-trisphosphate 3-kinase C 1.127275114 0.000119 
204326_x_at MT1X metallothionein 1X 1.122959712 8.21E-05 
212423_at ZCCHC24 zinc finger, CCHC domain containing 24 1.121067265 0.000127 
211385_x_at SULT1A2 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 1.119345687 9.72E-05 
202087_s_at CTSL1 cathepsin L1 1.117008012 0.000121 
201925_s_at CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group) 1.113823781 1.41E-05 
211488_s_at ITGB8 integrin, beta 8 1.07323525 0.000124 
224302_s_at MRPS36 mitochondrial ribosomal protein S36 -1.112054849 7.77E-05 
226265_at QSER1 glutamine and serine rich 1 -1.12693279 7.86E-05 
210869_s_at MCAM melanoma cell adhesion molecule -1.144343303 7.53E-05 
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223058_at FAM107B family with sequence similarity 107, member B -1.156558243 0.000107 
204011_at SPRY2 sprouty homolog 2 (Drosophila) -1.162748629 9.46E-05 
219165_at PDLIM2 PDZ and LIM domain 2 (mystique) -1.165610126 9.75E-05 
204654_s_at TFAP2A transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) -1.171957638 0.00011 
226608_at C16orf87 chromosome 16 open reading frame 87 -1.187701866 5.61E-05 
222456_s_at LIMA1 LIM domain and actin binding 1 -1.217251352 7.43E-05 
222687_s_at ACER3 alkaline ceramidase 3 -1.227273899 8.02E-05 
235182_at ISM1 isthmin 1 homolog (zebrafish) -1.260094665 5.59E-05 
218793_s_at SCML1 sex comb on midleg-like 1 (Drosophila) -1.26620142 2.94E-05 
1554690_a_at TACC1 transforming, acidic coiled-coil containing protein 1 -1.267215106 4.53E-05 
229664_at MAPK8 mitogen-activated protein kinase 8 -1.278911814 9.08E-05 
227257_s_at C10orf46 chromosome 10 open reading frame 46 -1.283014393 2.73E-05 
201829_at NET1 neuroepithelial cell transforming 1 -1.289034938 5.26E-05 
227776_at ACER3 alkaline ceramidase 3 -1.302789379 2.72E-05 
222688_at ACER3 alkaline ceramidase 3 -1.304427352 0.000104 
202208_s_at ARL4C ADP-ribosylation factor-like 4C -1.316896952 7.45E-07 
209455_at FBXW11 F-box and WD repeat domain containing 11 -1.325420527 2.40E-05 
200696_s_at GSN gelsolin (amyloidosis, Finnish type) -1.339719211 0.000112 
202741_at PRKACB protein kinase, cAMP-dependent, catalytic, beta -1.341864299 2.10E-05 
232914_s_at SYTL2 synaptotagmin-like 2 -1.34642698 0.000116 
219956_at GALNT6 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 
(GalNAc-T6) -1.353037542 6.25E-05 
227266_s_at FYB FYN binding protein (FYB-120/130) -1.357069944 5.95E-05 
240024_at SEC14L2 SEC14-like 2 (S. cerevisiae) -1.364653472 0.00013 
212978_at LRRC8B leucine rich repeat containing 8 family, member B -1.379515115 5.52E-05 
204068_at STK3 serine/threonine kinase 3 (STE20 homolog, yeast) -1.384473158 2.25E-05 
212589_at RRAS2 related RAS viral (r-ras) oncogene homolog 2 -1.390685696 1.23E-05 
231399_at RAB3IP RAB3A interacting protein (rabin3) -1.398638849 2.63E-05 
226535_at ITGB6 integrin, beta 6 -1.409942301 1.01E-05 
212899_at CDC2L6 cell division cycle 2-like 6 (CDK8-like) -1.411596634 2.68E-05 
222557_at STMN3 stathmin-like 3 -1.416480202 9.75E-06 
1555310_a_at PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 -1.438076325 1.98E-05 
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207826_s_at ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein -1.44299339 3.93E-05 
205014_at FGFBP1 fibroblast growth factor binding protein 1 -1.460373909 8.73E-05 
241994_at XDH xanthine dehydrogenase -1.465501223 2.28E-05 
219858_s_at MFSD6 major facilitator superfamily domain containing 6 -1.468150177 4.62E-05 
232020_at SMURF2 SMAD specific E3 ubiquitin protein ligase 2 -1.47954422 7.50E-06 
226961_at PRR15 proline rich 15 -1.492365137 1.29E-05 
229842_at ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) -1.494200838 5.53E-05 
224901_at SCD5 stearoyl-CoA desaturase 5 -1.520897371 1.68E-05 
215189_at KRT86 keratin 86 -1.534864347 6.28E-05 
231928_at HES2 hairy and enhancer of split 2 (Drosophila) -1.536433266 1.07E-05 
200665_s_at SPARC secreted protein, acidic, cysteine-rich (osteonectin) -1.536917974 1.17E-05 
219461_at PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 -1.536973833 1.65E-05 
205870_at BDKRB2 bradykinin receptor B2 -1.539664052 8.39E-06 
210026_s_at CARD10 caspase recruitment domain family, member 10 -1.548281082 2.05E-05 
222835_at THSD4 thrombospondin, type I, domain containing 4 -1.611868781 8.01E-06 
221727_at SUB1 SUB1 homolog (S. cerevisiae) -1.617605637 5.10E-06 
225325_at MFSD6 major facilitator superfamily domain containing 6 -1.61802823 1.53E-05 
205832_at CPA4 carboxypeptidase A4 -1.65768987 7.87E-06 
219995_s_at ZNF750 zinc finger protein 750 -1.662783884 6.56E-05 
209925_at OCLN occludin -1.678290389 1.37E-05 
222858_s_at DAPP1 dual adaptor of phosphotyrosine and 3-phosphoinositides -1.686880827 9.22E-06 
201510_at ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) -1.711695271 2.03E-05 
227862_at TRNP1 TMF1-regulated nuclear protein 1 -1.7198283 1.34E-06 
211668_s_at PLAU plasminogen activator, urokinase -1.721113945 1.60E-05 
223551_at PKIB protein kinase (cAMP-dependent, catalytic) inhibitor beta -1.722485254 6.10E-06 
206125_s_at KLK8 kallikrein-related peptidase 8 -1.724761502 2.02E-05 
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B -1.725714312 4.04E-05 
211795_s_at FYB FYN binding protein (FYB-120/130) -1.731984821 2.27E-06 
204653_at TFAP2A transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) -1.737309164 1.99E-06 
220346_at MTHFD2L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like -1.75441937 2.51E-06 
205479_s_at PLAU plasminogen activator, urokinase -1.759947383 4.35E-06 
229163_at CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -1.763059255 2.07E-05 
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227314_at ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) -1.774536412 8.26E-06 
219181_at LIPG lipase, endothelial -1.779943171 3.00E-06 
206122_at SOX15 SRY (sex determining region Y)-box 15 -1.78302799 9.30E-07 
203798_s_at VSNL1 visinin-like 1 -1.784010138 1.16E-05 
1555812_a_at ARHGDIB Rho GDP dissociation inhibitor (GDI) beta -1.803002922 9.08E-06 
203397_s_at GALNT3 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 
(GalNAc-T3) -1.806334041 1.43E-06 
203797_at VSNL1 visinin-like 1 -1.815541766 5.84E-06 
1552797_s_at PROM2 prominin 2 -1.817392659 7.57E-07 
202998_s_at LOXL2 lysyl oxidase-like 2 -1.824417233 8.64E-06 
216918_s_at DST dystonin -1.826937086 2.98E-06 
222859_s_at DAPP1 dual adaptor of phosphotyrosine and 3-phosphoinositides -1.838793176 2.99E-05 
238439_at ANKRD22 ankyrin repeat domain 22 -1.884113251 3.91E-05 
205180_s_at ADAM8 ADAM metallopeptidase domain 8 -1.905212209 3.28E-05 
204455_at DST dystonin -1.91547427 2.18E-06 
202936_s_at SOX9 SRY (sex determining region Y)-box 9 -1.955022751 1.25E-06 
201288_at ARHGDIB Rho GDP dissociation inhibitor (GDI) beta -1.95993485 4.05E-06 
206517_at CDH16 cadherin 16, KSP-cadherin -1.96760508 3.79E-06 
209441_at RHOBTB2 Rho-related BTB domain containing 2 -1.993342224 3.43E-07 
220979_s_at ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)- -2.006151955 8.32E-06 
  N-acetylgalactosaminide alpha-2,6-sialyltransferase 5   
39248_at AQP3 aquaporin 3 (Gill blood group) -2.016115145 0.0067 
209792_s_at KLK10 kallikrein-related peptidase 10 -2.020638209 1.83E-05 
212667_at SPARC secreted protein, acidic, cysteine-rich (osteonectin) -2.021153506 8.20E-07 
204351_at S100P S100 calcium binding protein P -2.037456796 8.05E-07 
206155_at ABCC2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 -2.045206249 3.52E-07 
223541_at HAS3 hyaluronan synthase 3 -2.11543375 2.27E-05 
235074_at SPRED1 sprouty-related, EVH1 domain containing 1 -2.147476854 6.11E-07 
202206_at ARL4C ADP-ribosylation factor-like 4C -2.188710144 2.90E-05 
202935_s_at SOX9 SRY (sex determining region Y)-box 9 -2.216187541 3.54E-06 
218309_at CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -2.29036123 9.60E-06 
205916_at S100A7 S100 calcium binding protein A7 -2.422917556 0.000112 
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230430_at ENTPD2 ectonucleoside triphosphate diphosphohydrolase 2 -2.451844393 3.10E-07 
209772_s_at CD24 CD24 molecule -2.475058829 7.91E-06 
226837_at SPRED1 sprouty-related, EVH1 domain containing 1 -2.628174097 7.58E-08 
204584_at L1CAM L1 cell adhesion molecule -2.688828298 4.46E-08 
208650_s_at CD24 CD24 molecule -2.726699356 8.19E-06 
229385_s_at PLAC2 placenta-specific 2 (non-protein coding) -2.813438893 1.08E-06 
209771_x_at CD24 CD24 molecule -2.867536617 3.90E-06 
216379_x_at CD24 CD24 molecule -2.910320714 4.04E-06 
228302_x_at CAMK2N1 calcium/calmodulin-dependent protein kinase II inhibitor 1 -2.912953778 7.66E-05 
208651_x_at CD24 CD24 molecule -2.917585122 5.17E-05 
266_s_at CD24 CD24 molecule -2.923268768 1.16E-06 
202207_at ARL4C ADP-ribosylation factor-like 4C -2.95292059 4.05E-07 
203180_at ALDH1A3 aldehyde dehydrogenase 1 family, member A3 -3.051613646 1.25E-07 
204734_at KRT15 keratin 15 -3.102789925 1.98E-06 
210404_x_at CAMK2B calcium/calmodulin-dependent protein kinase II beta -3.578710182 1.52E-06 
209956_s_at CAMK2B calcium/calmodulin-dependent protein kinase II beta -4.123180597 0.000141 
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